| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Amgen Inc.$363.39
-2.01 (-0.55%)
A 92Pipeline Score Fair Value Biotech · Commercial
Market Cap
177.16 B
EPS
14.48
P/E Ratio
22.83 $
Value Trade
768.93 M
SEC Financials
Q1 2026Dilution Risk
Revenue
8.62 B
R&D Expenses
1.72 B
Operating CF
2.19 B
Total Assets
92.50 B
Total Liabilities
92.50 B
Equity
9.19 B
D/E Ratio
12,345
0.91 %
Week
-1.39 %
1 Month
-8.79 %
3 Month
1.32 %
6 Month
33.74 %
5 Year
98,606.32 %
All Time
Cash Data
Cash Position
23.52 B
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 1, 2026
Overview
Volume
1.63 M
52 Week Range
267.83 - 391.29
% held by Insiders
0.23 %
% held by Institutions
83.12 %
Enterprise Value
222.45 B
Total Shares
539.71 M
Short %
2.39 %
Float Shares
537.55 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Amgen Inc.
2404Total events
10Upcoming
974Tier-1 (high impact)
2010 – 2028Coverage
Upcoming catalysts 10
Event history 2394
Jun 14, 2026
▲IP Litigation RulingIP / Competition
Jury finds Amgen willfully infringed Harbour's Grosveld Patent, awards $20.2M damages
Jun 9, 2026
◆Oral PresentationPresentation
Amgen to present at Goldman Sachs 47th Annual Global Healthcare Conference
Jun 7, 2026
▲Oral PresentationRepathaApprovedPresentation
VESALIUS-CV subgroup results for Repatha in high-risk diabetes patients presented at ADA 2026
high-risk diabetes with elevated LDL-Csource ↗
Jun 7, 2026
●Oral PresentationPresentation
Real-world evidence studies on GLP-1 therapy persistence and adherence presented at ADA 2026
obesity and diabetessource ↗
Jun 4, 2026
Jun 3, 2026
▲EU ApprovalIMDYLLTRAApprovedEx-US Regulatory
EC approval of IMDYLLTRA for advanced SCLC
мелкоклеточный рак легкого на запущенной стадииsource ↗
Jun 3, 2026
◆Oral PresentationUPLIZNAApprovedPresentation
Natural History of IgG4-RD: Patterns of Organ Involvement and Flare-associated Biomarker Changes in the Phase 3 MITIGATE Trial (Abstract #OP052) oral presentation at EULAR 2026
IgG4-related diseasesource ↗
Jun 3, 2026
◆Poster PresentationUPLIZNAApprovedPresentation
Long-term Efficacy and Safety of Inebilizumab in IgG4-Related Disease: Primary Results from Year 1 of the Open-Label Period of the Phase 3 MITIGATE Trial (Abstract #POS0440) poster presentation at EULAR 2026
IgG4-related diseasesource ↗
Jun 3, 2026
◆Poster PresentationTAVNEOSApprovedPresentation
Real-world evidence from AQUARIUS analyses (Abstracts #POS0135 and #POS0867) poster presentations at EULAR 2026
ANCA-associated vasculitissource ↗
Jun 1, 2026
▲EU ApprovalIMDYLLTRAApprovedEx-US Regulatory
European Commission grants marketing authorization for IMDYLLTRA as monotherapy for ES-SCLC
extensive-stage small cell lung cancersource ↗
Jun 1, 2026
Drug Pipeline Intelligence
A92
Pipeline Score $105.3B
Pipeline ValueFair Value
Valuation Signal222
Drugs Scored2.0x
rNPV / MCap Top 100%
Large Pharma (rank 1 of 911)
Percentile RankAmgen Inc. earns an A-grade pipeline score (92/100), with $105.3B risk-adjusted pipeline value, led by Maridebart cafraglutide in Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Maridebart cafraglutide Small molecule | Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight | Phase 3 | NCT06858878 | 53% | $13.6B | ACTIVE NOT_RECRUITING | 1,105 | FAST | B (71) | Apr 16, 2027 | LOW_RISK | Dec 31, 2025 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Repatha | high-risk diabetes | Phase 3 | 2026-06-07 | 29%; 21%; 45 mg/dL; 106 mg/dL | AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS Amgen (NASDAQ:AMGN) today announced new data at the American Diabetes Association (ADA) 86th Scientific Sessions reinforcing its commitment to... Read More | |
Repatha | high-risk diabetes | Phase 3 | 2026-06-07 | 29%; 21%; 45 mg/dL; 106 mg/dL | AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS Amgen (NASDAQ:AMGN) today announced new data at the American Diabetes Association (ADA) 86th Scientific Sessions reinforcing its commitment to... Read More | |
Repatha | high-risk diabetes | Phase 3 | 2026-06-07 | 29%; 21%; 45 mg/dL; 106 mg/dL | AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS Amgen (NASDAQ:AMGN) today announced new data at the American Diabetes Association (ADA) 86th Scientific Sessions reinforcing its commitment to... Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in AMGN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
AMGN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-31 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-31 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-31 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
AMGNHarbour BioMed Secures Landmark Victory in U.S. Patent Infringement Case Against Amgen, Reshaping the Global Antibody Patent Landscape
Harbour BioMed achieved a landmark victory in a patent infringement case against Amgen, with a Delaware jury ruling that Amgen willfully infringed Harbour's patent. The jury awarded Harbour $20.2 million in damages, with the possibility of trebling this amount. This ruling affirms the validity of Harbour's innovative antibody technology and sets a precedent in the global antibody patent landscape.
Read more →AMGNAMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS Amgen (NASDAQ:AMGN) today announced new data at the American Diabetes Association (ADA) 86th Scientific Sessions reinforcing its commitment to...
Amgen presented new data at the American Diabetes Association's 86th Scientific Sessions, showcasing the effectiveness of Repatha in reducing major cardiovascular events among patients with high-risk diabetes. The Phase 3 VESALIUS-CV trial results demonstrated a 29% reduction in these events when Repatha was used alongside LDL-C-lowering therapies. Additionally, real-world evidence was shared, emphasizing the need for adherence to diabetes and obesity treatments to achieve better patient outcomes. Amgen's ongoing research aims to address the interconnected challenges of cardiovascular and metabolic diseases.
Read more →AMGNAMGEN TO PRESENT AT THE GOLDMAN SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCE Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 47th Annual Global Healthcare Conference at 9:20 a.m. ET on Tuesday, June 9, 2026. Peter...
Amgen (NASDAQ: AMGN) will present at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026. Executives Peter Griffith and Murdo Gordon will represent the company, and the presentation will be available via webcast. Amgen is known for its innovative medicines and has a robust pipeline aimed at treating various diseases. The company has a long-standing reputation in the biotechnology industry and has been recognized for its workplace culture.
Read more →AMGNЕВРОПЕЙСКАЯ КОМИССИЯ ОДОБРИЛА ПРЕПАРАТ AMGEN IMDYLLTRA® ДЛЯ ЛЕЧЕНИЯ МЕЛКОКЛЕТОЧНОГО РАКА ЛЕГКОГО НА ЗАПУЩЕННОЙ СТАДИИ Компания Amgen (NASDAQ:AMGN) сегодня объявила, что Европейская комиссия (ЕК) выдала регистрационное удостоверение на препарат IMDYLLTRA® (тарлатамаб) ...
Amgen announced that the European Commission has granted regulatory approval for IMDYLLTRA (tarlatamab) as a monotherapy in treating adults with relapsed or refractory small cell lung cancer. This approval is based on results from the phase 3 DeLLphi-304 study, which showed a significant reduction in mortality risk and improved median overall survival compared to standard chemotherapy. The approval marks a critical step forward in tackling a challenging cancer type known for high recurrence rates after first-line treatments.
Read more →AMGNLA CE APRUEBA IMDYLLTRA® DE AMGEN PARA EL CÁNCER DE PULMÓN DE CÉLULAS PEQUEÑAS EN ESTADIO AVANZADO Amgen (NASDAQ:AMGN) anunció hoy que la Comisión Europea (CE) ha otorgado la autorización de comercialización para IMDYLLTRA® (tarlatamab) como...
Amgen announced that the European Commission has approved IMDYLLTRA® (tarlatamab) for the treatment of adults with advanced small cell lung cancer (ES-SCLC) who need systemic therapy after disease progression. The approval is based on the phase 3 DeLLphi-304 trial, which demonstrated a 40% reduction in the risk of death compared to standard chemotherapy. This marks a significant advancement in options for patients facing rapid disease progression. While IMDYLLTRA has shown promise in improving survival, it can cause side effects such as cytokine release syndrome and requires careful patient monitoring during treatment.
Read more →AMGNAMGEN TO PRESENT NEW DATA ACROSS RARE AUTOIMMUNE AND INFLAMMATORY DISEASES AT EULAR 2026 Amgen (NASDAQ:AMGN) today announced the presentation of new data across rare autoimmune and inflammatory diseases at the European Alliance of...
Amgen presented new data on rare autoimmune diseases at the EULAR 2026 Congress, highlighting findings from the Phase 3 MITIGATE trial for UPLIZNA and real-world evidence supporting TAVNEOS. The MITIGATE trial provided insights into immunoglobulin G4-related disease, showcasing UPLIZNA's long-term safety profile and efficacy. Additionally, data from the AQUARIUS analyses confirmed that TAVNEOS helps patients manage ANCA-associated vasculitis while minimizing steroid use. These findings reflect Amgen's ongoing commitment to advancing treatments for challenging medical conditions.
Read more →AMGNLA COMMISSION EUROPÉENNE APPROUVE IMDYLLTRA® D'AMGEN POUR LE TRAITEMENT DU CANCER DU POUMON À PETITES CELLULES DE STADE ÉTENDU Amgen (NASDAQ:AMGN) annonce aujourd'hui que la Commission européenne (CE) a accordé une autorisation de mise sur le marché à IMDYLLTRA® (tarlatamab)...
Amgen has received approval from the European Commission for IMDYLLTRA (tarlatamab) to treat adults with extensive-stage small cell lung cancer (SCLC) requiring systemic treatment after disease progression. This approving decision is based on results from the DeLLphi-304 phase 3 trial, which showed a 40% reduction in the risk of death and extended median overall survival by over five months compared to standard chemotherapy. IMDYLLTRA is now the first T-cell engaging therapy approved for this aggressive form of cancer, providing a new treatment option for European patients facing limited therapeutic alternatives.
Read more →AMGNEURÓPSKA KOMISIA SCHVÁLILA LIEK IMDYLLTRA® SPOLOČNOSTI AMGEN NA LIEČBU POKROČILÉHO ŠTÁDIA MALOBUNKOVÉHO KARCINÓMU PĽÚC Schválenie na základe klinického skúšania fázy 3 DeLLphi-304, ktoré preukázalo 40 % zníženie rizika úmrtia pri použití lieku IMDYLLTRA v porovnaní s...
The European Commission has approved IMDYLLTRA (tarlatamab) for the treatment of adults with advanced small cell lung cancer (ES-SCLC) after disease progression from chemotherapy. This decision is based on phase 3 clinical trial results (DeLLphi-304), which showed a 40% reduction in the risk of death compared to standard chemotherapy. The approval marks a significant advancement in treatment options for patients suffering from this aggressive form of cancer in Europe. While the drug offers promising benefits, it is associated with notable safety concerns that require careful patient monitoring during administration.
Read more →AMGNEUROPÄISCHE KOMMISSION ERTEILT ZULASSUNG FÜR IMDYLLTRA® VON AMGEN FÜR DIE BEHANDLUNG VON KLEINZELLIGEM LUNGENKREBS IM FORTGESCHRITTENEN STADIUM Amgen (NASDAQ:AMGN) gab heute bekannt, dass die Europäische Kommission (EC) die Marktzulassung für IMDYLLTRA® (Tarlatamab) als Monotherapie zur...
Amgen announced that the European Commission has granted marketing authorization for IMDYLLTRA (Tarlatamab) as a monotherapy for adults with advanced small cell lung cancer (ES-SCLC) requiring systemic therapy after failure of platinum-based chemotherapy. This approval is based on results from the Phase-3 DeLLphi-304 study, which showed a 40% reduction in mortality risk compared to chemotherapy. IMDYLLTRA is the first T-cell engager therapy approved for small cell lung cancer, reflecting Amgen's commitment to innovation in cancer treatment. However, patients may experience significant side effects, underscoring the need for close monitoring during administration.
Read more →AMGNEVROPSKÁ KOMISE SCHVÁLILA PŘÍPRAVEK IMDYLLTRA® OD SPOLEČNOSTI AMGEN K LÉČBĚ EXTENZIVNÍHO STADIA MALOBUNĚČNÉHO KARCINOMU PLIC Společnost Amgen (NASDAQ:AMGN) dnes oznámila, že Evropská komise (EK) udělila povolení k uvedení na trh přípravku IMDYLLTRA® (tarlatamab) jako...
Amgen (NASDAQ: AMGN) announced that the European Commission has approved IMDYLLTRA® (tarlatamab) for treating adults with extensive-stage small cell lung cancer (ES-SCLC). This approval is based on the phase III DeLLphi-304 study, demonstrating a 40% reduction in the risk of death compared to traditional chemotherapy and significantly prolonging overall survival. IMDYLLTRA is noted as the first therapy approved to use T-cell activation for this specific indication, marking a significant advancement in treatment options for this aggressive type of cancer.
Read more →AMGNKOMISJA EUROPEJSA ZATWIERDZA PREPARAT IMDYLLTRA® FIRMY AMGEN DO LECZENIA DROBNOKOMÓRKOWEGO RAKA PŁUCA W POSTACI ROZSIANEJ Amgen (NASDAQ:AMGN) ogłosił dzisiaj, że Komisja Europejska (KE) przyznała pozwolenie na dopuszczenie do obrotu produktu leczniczego IMDYLLTRA®...
Amgen's IMDYLLTRA (tarlatamab) has received approval from the European Commission for the treatment of adults with extensive-stage small cell lung cancer after disease progression following platinum-based chemotherapy. The approval is based on positive results from the Phase III DeLLphi-304 trial, which demonstrated a 40% reduction in the risk of death compared to standard chemotherapy. This is the first T-cell engager therapy approved for ES-SCLC and represents a significant advancement for patients in Europe.
Read more →AMGNEUROPEAN COMMISSION APPROVES AMGEN'S IMDYLLTRA® FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has granted marketing authorization for IMDYLLTRA® (tarlatamab) as a...
Amgen announced that the European Commission has granted marketing authorization for its novel treatment IMDYLLTRA (tarlatamab) for extensive-stage small cell lung cancer (ES-SCLC). This approval is based on the results of the DeLLphi-304 Phase 3 trial, which indicated a 40% reduction in the risk of death compared to traditional chemotherapy, along with an extension of median overall survival. Despite the promising results, the treatment does have some associated risks, particularly cytokine release syndrome, requiring careful patient monitoring during administration.
Read more →AMGNAMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE
Amgen will present at the Jefferies Global Healthcare Conference on June 4, 2026, at 9:55 a.m. ET. Key executives, including CFO Peter Griffith, will discuss the company's developments. The presentation will be available via a live webcast, which will also be archived for future access.
Read more →AMGNEmber LifeSciences announces new strategic investments boosting Series A to $27M
Ember LifeSciences has secured strategic investments from Amgen Ventures and TDF Ventures, raising its Series A funding to $27 million. This funding will support the full commercial launch of the Ember Cube 2, a cutting-edge solution for cold chain logistics. The company aims to improve temperature-controlled distribution in the pharmaceutical sector, addressing significant annual losses due to temperature excursions.
Read more →AMGNAMGEN ANNOUNCES RETIREMENT OF CHIEF FINANCIAL OFFICER PETER GRIFFITH
Amgen has announced the retirement of CFO Peter Griffith, who has served since 2020. Thomas Dittrich will return to the company to take over as CFO on September 1, 2026. Griffith's leadership is credited with strengthening Amgen's financial foundation and growth strategy. He will assist in the transition until January 2027.
Read more →AMGNOne Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.Amgen.com AMGEN ANNOUNCES RETIREMENT OF CHIEF FINANCIAL OFFICER PETER GRIFFITH Thomas Dittrich Returning to Amgen as CFO  
Amgen has announced the retirement of its Chief Financial Officer, Peter Griffith, effective September 1, 2026. Thomas Dittrich, who has extensive experience in the financial sector, will return to Amgen to succeed Griffith. Griffith has played a vital role in strengthening the company's financial foundation over his tenure. The transition is designed to be smooth, with Griffith remaining until January 2027 to assist during the period.
Read more →AMGNCNS Drug Delivery Technologies Are Reshaping Alzheimer’s and Biodefense Research
Oncotelic Therapeutics is advancing drug delivery technologies to address the challenges posed by the blood-brain barrier, particularly in treating Alzheimer's disease and biodefense. Their proprietary intranasal delivery system aims to enhance therapeutic access to the central nervous system. This innovation reflects a broader industry trend towards improving CNS drug delivery methods, which is critical given the rising prevalence of neurological disorders.
Read more →AMGNAMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE
Amgen will present at the Bank of America Merrill Lynch Global Healthcare Conference on May 13, 2026. Key executives, including CFO Peter Griffith and EVP of R&D Jay Bradner, will lead the presentation. The event will be available via webcast for media, investors, and the public, with an archived replay accessible for 90 days.
Read more →AMGNAMGEN ANNOUNCES ADDITIONAL $300 MILLION U.S. MANUFACTURING INVESTMENT, TOTALING NEARLY $2 BILLION OVER THE LAST YEAR
Amgen has announced an additional $300 million investment in its U.S. manufacturing network, bringing its total investment to nearly $2 billion over the past year. This expansion aims to enhance production capacity and support the supply of medicines. The investment will particularly focus on the company's biologics manufacturing facility in Puerto Rico, creating jobs and strengthening the local economy.
Read more →AMGN/C O R R E C T I O N -- Amgen/
Amgen has announced its financial results for Q1 2026, highlighting strong performance with 16 brands achieving double-digit growth. The company is optimistic about future growth, supported by new molecules progressing in Phase 3 clinical trials. However, it faces challenges from patent expirations and competition in the market.
Read more →AMGNAMGEN ANNOUNCES WEBCAST OF 2026 FIRST QUARTER FINANCIAL RESULTS
Amgen has announced it will report its first quarter 2026 financial results on April 30, 2026. Following the report, a conference call will be held at 4:30 p.m. ET, featuring CEO Robert A. Bradway and senior management. The call will be broadcast live and archived for future access, reflecting Amgen's commitment to investor communication.
Read more →AMGNOne Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.Amgen.com AMGEN ANNOUNCES RETIREMENT OF DAVID M. REESE, EXECUTIVE VICE PRESIDENT AND CHIEF TECHNOLOGY OFFICER Organizational Cha
Amgen has announced the retirement of David M. Reese, M.D., effective June 30, 2026. Reese, who joined Amgen in 2005, significantly contributed to the approval of numerous innovative therapies and the integration of technology into the company's R&D. His leadership as Chief Technology Officer emphasized the importance of combining biology and technology, which Amgen is now evolving further to enhance its operational capacities. The transition comes as Amgen aims to strengthen its capabilities in convergent innovation.
Read more →AMGNAMGEN ANNOUNCES RETIREMENT OF DAVID M. REESE, EXECUTIVE VICE PRESIDENT AND CHIEF TECHNOLOGY OFFICER
Amgen announced the retirement of David M. Reese, effective June 30, 2026. Reese, who joined Amgen in 2005, played a significant role in advancing the company's innovative medicines and technology integration. Following his retirement, Amgen will appoint new executives to strengthen its focus on convergent innovation, combining biology and technology to enhance drug discovery and patient care.
Read more →AMGNAMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA® IN ADULTS LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE
Amgen announced positive topline results from a Phase 3 trial of TEPEZZA OBI for moderate-to-severe active Thyroid Eye Disease. The trial demonstrated a 77% proptosis response rate and a clinically meaningful reduction in proptosis. This subcutaneous administration method shows comparable efficacy to the intravenous version, potentially increasing patient accessibility. Full study results will be presented at a medical congress.
Read more →AMGNREPATHA® CUTS RISK OF FIRST MAJOR CARDIOVASCULAR EVENTS BY 31% IN HIGH-RISK PATIENTS WITHOUT KNOWN SIGNIFICANT ATHEROSCLEROSIS
Amgen announced that Repatha (evolocumab) significantly reduces the risk of first major cardiovascular events by 31% in high-risk patients without known significant atherosclerosis. This was demonstrated in a subgroup analysis from the Phase 3 VESALIUS-CV trial, which included 3,655 patients with diabetes. The results highlight the importance of early and intensive LDL-C lowering to prevent cardiovascular events.
Read more →AMGNREPATHA® CUTS RISK OF FIRST MAJOR CARDIOVASCULAR EVENTS BY 31% IN HIGH-RISK PATIENTS WITHOUT KNOWN SIGNIFICANT ATHEROSCLEROSIS Amgen (NASDAQ:AMGN) announced today that Repatha® (evolocumab), when added to statins or other low-density lipoprotein cholesterol (LDL-C)-lowering...
Amgen announced that its drug Repatha (evolocumab) has been shown to significantly reduce the risk of first major cardiovascular events by 31% in high-risk patients without significant atherosclerosis. This finding is based on a subgroup analysis from the VESALIUS-CV trial involving 3,655 patients with diabetes, conducted over a median follow-up of 4.8 years. The new results highlight the necessity of early treatment for LDL-C reduction to prevent major cardiovascular issues. Repatha's benefits were consistently observed across multiple secondary endpoints as well.
Read more →AMGNAMGEN TO PRESENT AT THE LEERINK PARTNERS 2026 GLOBAL HEALTHCARE CONFERENCE
Amgen will present at the Leerink Partners 2026 Global Healthcare Conference on March 11, 2026. Key executives, including CFO Peter Griffith and SVP Jasper van Grunsven, will participate in a fireside chat. The event will be available via webcast for media, investors, and the public, with an archive accessible for 90 days post-event.
Read more →AMGNAMGEN ANNOUNCES 2026 SECOND QUARTER DIVIDEND
Amgen announced a dividend of $2.52 per share for the second quarter of 2026, payable on June 5, 2026, to shareholders of record by May 15, 2026. The announcement highlights Amgen's commitment to returning value to shareholders while maintaining a strong pipeline of innovative medicines. The company continues to be recognized for its contributions to the biotechnology industry.
Read more →AMGNAMGEN TO PRESENT AT THE 46TH ANNUAL TD COWEN HEALTH CARE CONFERENCE
Amgen will present at the 46th Annual TD Cowen Health Care Conference on March 2, 2026. Senior executives Kave Niksefat and Justin Claeys will lead the presentation, which will be available via webcast for media and investors. The event underscores Amgen's ongoing commitment to innovation and communication with stakeholders.
Read more →AMGNEUROPÄISCHE KOMMISSION GENEHMIGT UPLIZNA® VON AMGEN FÜR GENERALISIERTE MYASTHENIA GRAVISUSA - DeutschUSA - españolUSA - FrançaisUSA - EnglishUSA - PolskiUSA - češtinaUSA - PусскийUSA - slovenčina
Amgen's UPLIZNA has received approval from the European Commission as a supplementary treatment for adults with generalized Myasthenia Gravis (gMG) who are positive for Anti-AChR or Anti-MuSK antibodies. This marks a significant advancement in treatment options, allowing for biannual administration after initial doses. The approval is supported by data from the MINT study, which demonstrated effective disease control and reduced steroid use among patients.
Read more →AMGNAMGEN TO PRESENT AT CITI'S 2026 VIRTUAL ONCOLOGY LEADERSHIP SUMMIT
Amgen is set to present at Citi's 2026 Virtual Oncology Leadership Summit on February 18, 2026. Jean-Charles Soria, the senior vice president of oncology, will lead the presentation, which will be available via webcast to the media, investors, and the public. The event highlights Amgen's ongoing commitment to oncology and innovation in medicine.
Read more →AMGNEURÓPSKA KOMISIA SCHVÁLILA LIEK UPLIZNA® OD SPOLOČNOSTI AMGEN NA LIEČBU GENERALIZOVANEJ MYASTÉNIE GRAVISUSA - EnglishUSA - EnglishUSA - españolUSA - FrançaisUSA - PolskiUSA - češtinaUSA - Pусский
Amgen's UPLIZNA (inebilizumab) has been approved by the European Commission as an adjunct therapy for adults with generalized myasthenia gravis (gMG) who test positive for anti-AChR or anti-MuSK antibodies. This approval provides a new treatment option aimed at long-term disease control with a convenient dosing schedule. The drug's efficacy is supported by data from the MINT trial, which demonstrated significant improvements in patients' conditions.
Read more →AMGNЕВРОПЕЙСКАЯ КОМИССИЯ ОДОБРИЛА ПРЕПАРАТ AMGEN UPLIZNA ® ДЛЯ ЛЕЧЕНИЯ ГЕНЕРАЛИЗОВАННОЙ МИАСТЕНИИUSA - PусскийUSA - EnglishUSA - españolUSA - FrançaisUSA - PolskiUSA - čeština
Amgen has received approval from the European Commission for UPLIZNA (inebilizumab) as a treatment for adults with generalized Myasthenia Gravis. This approval marks a significant advancement in therapy options for patients suffering from this rare autoimmune condition. UPLIZNA is expected to provide a new treatment pathway that can help manage symptoms effectively while reducing the need for steroids.
Read more →AMGNEVROPSKÁ KOMISE SCHVÁLILA PŘÍPRAVEK UPLIZNA® SPOLEČNOSTI AMGEN PRO GENERALIZOVANOU MYASTENII GRAVISUSA - češtinaUSA - EnglishUSA - españolUSA - FrançaisUSA - PolskiUSA - Pусский
Amgen's UPLIZNA has received approval from the European Commission as a treatment for adults with generalized myasthenia gravis (gMG) who test positive for anti-AChR or anti-MuSK antibodies. This therapy allows for biannual dosing after initial loading doses, potentially improving patient quality of life and reducing reliance on steroids. The approval is backed by the Myasthenia Gravis Inebilizumab Trial (MINT), demonstrating significant efficacy.
Read more →AMGNKOMISJA EUROPEJSKA ZATWIERDZA LEK UPLIZNA® FIRMY AMGEN W LECZENIU UOGÓLNIONEJ MIASTENIIUSA - PolskiUSA - españolUSA - FrançaisUSA - English
The European Commission has approved Amgen's UPLIZNA (inebilizumab) for treating generalized myasthenia gravis (gMG) in adults with positive AChR or MuSK antibodies. This therapy is the first of its kind in Europe, providing a new option for long-term disease management with a convenient dosing schedule. The approval is based on data from the MINT trial, showing significant efficacy in reducing symptoms and steroid use.
Read more →AMGNLA COMMISSION EUROPEENNE APPROUVE UPLIZNA® D'AMGEN DANS LE CADRE DU TRAITEMENT DE LA MYASTHÉNIE GRAVE GÉNÉRALISÉEUSA - FrançaisUSA - EnglishUSA - español
Amgen's UPLIZNA has received approval from the European Commission as an adjunct treatment for adults with generalized myasthenia gravis (MGg) who are positive for anti-AChR or anti-MuSK antibodies. This therapy offers a biannual dosing regimen following initial loading doses, potentially improving long-term disease management and reducing reliance on steroids. The approval is supported by data from the MINT study, which demonstrated significant efficacy.
Read more →AMGNLa Comisión Europea aprueba UPLIZNA® de Amgen para la miastenia gravis generalizadaUSA - españolUSA - EnglishUSA - Français
Amgen's UPLIZNA has received approval from the European Commission as a complementary treatment for adults with generalized myasthenia gravis (gMG) with specific antibodies. This marks the first therapy targeting CD19 approved in Europe, offering a semi-annual dosing regimen after initial loading doses. The approval is based on data from the MINT trial, which demonstrated UPLIZNA's effectiveness in managing gMG symptoms.
Read more →AMGNEUROPEAN COMMISSION APPROVES AMGEN'S UPLIZNA® FOR GENERALIZED MYASTHENIA GRAVIS
The European Commission has approved Amgen's UPLIZNA (inebilizumab) as an add-on treatment for adults with generalized myasthenia gravis (gMG) who are anti-AChR or anti-MuSK positive. This first-in-class therapy offers a new targeted approach with the potential for durable disease control and reduced reliance on steroids. The approval is based on data from the MINT trial, which included a structured steroid-tapering protocol.
Read more →AMGN▲ +8.2%on this news
AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS
Amgen announced its financial results for Q4 and the full year of 2025, showcasing significant growth in revenues and earnings per share. The company highlighted its strong performance and optimistic outlook for 2026, driven by a diverse portfolio of medicines. CEO Robert A. Bradway emphasized the momentum and potential for long-term growth in innovative therapies.
Read more →AMGNAMGEN ANNOUNCES WEBCAST OF 2025 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS
Amgen has announced that it will report its fourth quarter and full year 2025 financial results on February 3, 2026. Following the report, a conference call will be held with key executives, including CEO Robert A. Bradway. The event will be broadcast live and archived for later access, demonstrating Amgen's commitment to investor engagement.
Read more →AMGNAMGEN TO PRESENT AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE Amgen (NASDAQ:AMGN) will present at the 2026 J.P. Morgan Healthcare Conference at 3:45 p.m. PT on Monday, January 12, 2026. Robert A. Bradway,...
Amgen (NASDAQ: AMGN) is set to present at the 2026 J.P. Morgan Healthcare Conference on January 12, 2026. CEO Robert A. Bradway will lead the presentation, which will be webcasted for the general public, investors, and media. The event highlights Amgen's ongoing commitment to transparency and engagement with its stakeholders. Additionally, Amgen has been recognized for its innovative contributions to the biotech industry, further solidifying its position in the market.
Read more →AMGNAMGEN ACQUIRES DARK BLUE THERAPEUTICS, BOLSTERING ONCOLOGY PIPELINE Amgen (NASDAQ: AMGN) today announced its acquisition of Dark Blue Therapeutics Ltd., a privately held biotechnology company based in the United...
Amgen has announced the acquisition of Dark Blue Therapeutics, a UK-based biotechnology firm, for up to $840 million. This strategic move enhances Amgen's oncology pipeline by adding a differentiated investigational small molecule that targets proteins involved in acute myeloid leukemia (AML). Recent preclinical studies indicate strong potential for this therapy to improve treatment outcomes in AML patients. Amgen plans to integrate Dark Blue into its existing research efforts to advance targeted therapies in cancer treatment.
Read more →AMGNAMGEN TAKES ACTION WITH THE U.S. GOVERNMENT TO LOWER THE COST OF MEDICINES FOR AMERICAN PATIENTS
Amgen has announced its commitment to lowering medicine costs for American patients by expanding its direct-to-patient program, AmgenNow™, which will offer significant discounts on medications. This initiative aligns with the U.S. government's pricing requests and underscores Amgen's dedication to innovation and U.S. manufacturing. The company has invested over $40 billion in domestic operations since 2018.
Read more →AMGNAMGEN TAKES ACTION WITH THE U.S. GOVERNMENT TO LOWER THE COST OF MEDICINES FOR AMERICAN PATIENTS Amgen (NASDAQ:AMGN) today announced it is taking action again with the U.S. government to lower medicine costs for American patients, while...
Amgen has announced a new initiative in collaboration with the U.S. government to lower medicine costs for American patients. Under this program, the company will offer its medications Aimovig and Amjevita at significantly reduced prices. Additionally, Amgen plans to expand its AmgenNow program, which previously lowered the price of another medication. The company continues to demonstrate its commitment to domestic innovation and manufacturing, highlighted by substantial investments in the U.S.
Read more →AMGNFDA APPROVES UPLIZNA® FOR ADULTS WITH GENERALIZED MYASTHENIA GRAVIS
Amgen's UPLIZNA has received FDA approval for treating generalized myasthenia gravis (gMG) in adults who are anti-AChR and anti-MuSK antibody positive. This therapy, the first of its kind targeting CD19-positive B cells, allows for deep and durable symptom control with a convenient dosing schedule of twice a year following two initial doses. The approval is based on the MINT trial, which demonstrated significant efficacy in reducing symptoms.
Read more →AMGNAMGEN ANNOUNCES 2026 FIRST QUARTER DIVIDEND
Amgen has announced a dividend of $2.52 per share for the first quarter of 2026, payable on March 6, 2026. This decision underscores the company's robust financial health and commitment to returning value to shareholders. The dividend will benefit all stockholders of record by February 13, 2026.
Read more →AMGNAMGEN TO PRESENT AT CITI'S 2025 GLOBAL HEALTHCARE CONFERENCE
Amgen is scheduled to present at Citi's 2025 Global Healthcare Conference on December 3, 2025. Key executives, including CFO Peter Griffith and EVP of R&D Jay Bradner, will lead the presentation. The event will be available via webcast for media, investors, and the public, with a replay option for 90 days post-event.
Read more →AMGNAMGEN TO PRESENT AT THE 8TH ANNUAL EVERCORE ISI HEALTHCONX CONFERENCE
Amgen is set to present at the 8th Annual Evercore ISI HealthCONx Conference on December 3, 2025. Key executives, including CFO Peter Griffith and EVP of R&D Jay Bradner, will lead the presentation. The event will be available via a live webcast, which will also be archived for later access.
Read more →AMGNFDA GRANTS FULL APPROVAL TO AMGEN'S IMDELLTRA® IN EXTENSIVE STAGE SMALL CELL LUNG CANCER
Amgen's IMDELLTRA has received full FDA approval for treating extensive stage small cell lung cancer (ES-SCLC) after showing a significant survival benefit in the Phase 3 DeLLphi-304 trial. The treatment reduced the risk of death by 40% compared to standard chemotherapy. This approval marks a significant advancement in care options for patients with this aggressive cancer.
Read more →AMGNAMGEN'S REPATHA® CUTS RISK OF FIRST MAJOR ADVERSE CARDIOVASCULAR EVENTS BY 25% IN LANDMARK PHASE 3 VESALIUS-CV TRIAL
Amgen announced that its drug Repatha achieved significant reductions in major adverse cardiovascular events in the Phase 3 VESALIUS-CV trial. The study involved over 12,000 high-risk patients and showed a 25% reduction in major events and a 36% reduction in heart attacks. These results underscore the importance of LDL-C management for patients without prior cardiovascular events.
Read more →AMGN▲ +7.8%on this newsshared move
AMGEN REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS
Amgen reported strong financial results for Q3 2025, highlighting a 12% increase in total product sales year-over-year, driven by significant growth in several key products. The company emphasized its commitment to innovation and expanding access to its medicines. However, some established products, such as Enbrel, saw declines in sales, which could impact future performance.
Read more →AMGNAMGEN'S LANDMARK PHASE 3 REPATHA DATA TO BE PRESENTED AS LATE BREAKER AT THE AMERICAN HEART ASSOCIATION SCIENTIFIC SESSIONS 2025
Amgen announced that new data from the Phase 3 VESALIUS-CV trial of Repatha will be presented at the American Heart Association Scientific Sessions 2025. The trial demonstrated that Repatha significantly reduces the risk of major cardiovascular events in high-risk patients without prior heart attacks or strokes. This positions Repatha as a leading therapy for LDL-C reduction.
Read more →AMGNAMGEN ANNOUNCES 2025 FOURTH QUARTER DIVIDEND Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the fourth quarter of 2025. The dividend will ...
Amgen has announced a dividend of $2.38 per share for the fourth quarter of 2025, which will be paid on December 12, 2025, to stockholders of record by November 21, 2025. The announcement reflects Amgen's continued commitment to returning value to its shareholders. The company has received various accolades for its innovation in the biotechnology sector and continues to advance a broad pipeline of medicines. It is also included in significant stock indices, highlighting its market presence and reputation.
Read more →AMGNAMGEN ANNOUNCES WEBCAST OF 2025 THIRD QUARTER FINANCIAL RESULTS
Amgen has announced it will report its third quarter 2025 financial results on November 4, 2025. Following the report, a conference call will be held at 4:30 p.m. ET with key executives, including CEO Robert A. Bradway. The call will be accessible via a live webcast, which will also be archived for later viewing.
Read more →AMGNFDA APPROVES TEZSPIRE® FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS Amgen (NASDAQ:AMGN) and AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) approved TEZSPIRE® (tezepelumab-ekko) for the...
The FDA has approved TEZSPIRE® (tezepelumab-ekko) for the add-on maintenance treatment of inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP) in patients aged 12 and older. This first-in-class biologic targets thymic stromal lymphopoietin (TSLP) and offers a novel treatment option to over 320 million people worldwide suffering from this condition. Clinical trials demonstrated significant improvements in nasal polyp severity, with a marked reduction in the need for surgery and systemic corticosteroid use. However, potential hypersensitivity and safety concerns in specific populations have been noted.
Read more →AMGNAMGEN MAKES REPATHA® AVAILABLE THROUGH AMGENNOW, A DIRECT-TO-PATIENT PROGRAM IN THE U.S. Amgen (NASDAQ: AMGN) today announced the launch of AmgenNow, a new direct-to-patient program starting with Repatha® (evolocumab). This follows...
Amgen has launched AmgenNow, a direct-to-patient program offering its cholesterol-lowering drug Repatha at a significantly reduced price. The program allows access to Repatha at a monthly cost of $239, nearly 60% lower than the list price, and is available to all patients, including those without insurance. This initiative aligns with efforts to make medications more affordable and accessible for Americans at risk of cardiovascular events. Amgen aims to ease the administrative burden as patients using this program will bypass insurer requirements for step therapy or prior authorization.
Read more →AMGNLANDMARK PHASE 3 TRIAL (VESALIUS-CV) MEETS PRIMARY ENDPOINTS IN A CARDIOVASCULAR PRIMARY PREVENTION STUDY OF 12,000 PATIENTS Amgen (NASDAQ:AMGN) today announced the Phase 3 VESALIUS-CV clinical trial met its dual primary endpoints demonstrating that Repatha® (evolocumab)...
Amgen announced that its Phase 3 VESALIUS-CV trial met its dual primary endpoints, showing that Repatha (evolocumab) significantly reduces cardiovascular events in high-risk patients without prior heart attacks or strokes. Enrolling over 12,000 participants, the study highlighted the drug's potential as a cornerstone treatment in lipid management. Results demonstrated a significant reduction in major adverse cardiovascular events compared to standard therapy, marking a considerable advancement in cardiovascular disease prevention. The full results are set to be presented at the American Heart Association Scientific Sessions in November.
Read more →AMGNAMGEN ANNOUNCES $650M EXPANSION OF U.S. MANUFACTURING, CREATING HUNDREDS OF NEW JOBS Amgen (NASDAQ: AMGN) today announced a $650 million expansion of its U.S. manufacturing network, creating hundreds of new jobs. The planned...
Amgen has announced a $650 million investment to expand its U.S. manufacturing facilities, primarily in Puerto Rico, resulting in the creation of about 750 jobs. This initiative aims to enhance drug production capabilities and integrate advanced technologies into operations, reinforcing the company's commitment to U.S. biomanufacturing. The expansion is part of Amgen's broader strategy to advance its manufacturing network and maintain its leadership in biotechnology.
Read more →AMGNAMGEN AND KYOWA KIRIN ANNOUNCE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 ASCEND LONG-TERM EXTENSION STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS Amgen (NASDAQ: AMGN) and Kyowa Kirin Co., Ltd. (TSE: 4151) today announced preliminary top-line results from the ASCEND study evaluating...
Amgen and Kyowa Kirin have released preliminary top-line results from the ASCEND Phase 3 study of rocatinlimab, a therapy for moderate to severe atopic dermatitis. The study, which involved approximately 2,600 patients, demonstrated positive outcomes regarding the long-term safety and efficacy of the treatment. Results indicated that most participants experienced ongoing therapeutic benefits one year into treatment, with low rates of discontinuation due to adverse events. The findings suggest that rocatinlimab may allow for less frequent dosing after an initial treatment period, potentially improving patient adherence.
Read more →AMGNAMGEN TO PRESENT AT THE MORGAN STANLEY 23RD ANNUAL GLOBAL HEALTHCARE CONFERENCE Amgen (NASDAQ:AMGN) will present at the Morgan Stanley 23rd Annual Global Healthcare Conference at 9:15 a.m. ET on September 9, 2025. Peter Griffith, ...
Amgen will present at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025. The presentation will feature Peter Griffith and Kave Niksefat from Amgen, with a live webcast available for the public. The event will be archived for replay, reflecting Amgen's commitment to transparency with stakeholders. Additionally, the company continues to be recognized for its innovative contributions to healthcare, highlighting its ongoing advancements in the biotech field.
Read more →AMGNAMGEN INVESTING MORE THAN HALF A BILLION DOLLARS IN NEW, STATE-OF-THE-ART CENTER FOR SCIENCE AND INNOVATION AT U.S. GLOBAL HEADQUARTERS Amgen (NASDAQ: AMGN) today announced plans to invest more than $600 million in a new, state-of-the-art center for science and innovation at its...
Amgen announced plans to invest more than $600 million in a new science and innovation center at its headquarters in Thousand Oaks, California. The initiative aims to enhance collaboration among researchers and accelerate the development of new therapeutics. The center will feature advanced technologies to empower scientists and is expected to create hundreds of jobs in the U.S. This investment builds on Amgen's extensive commitment to domestic manufacturing and research since 2017.
Read more →AMGNAMGEN TO PRESENT AT THE 2025 WELLS FARGO HEALTHCARE CONFERENCE Amgen (NASDAQ:AMGN) will present at the 2025 Wells Fargo Healthcare Conference at 10:15 a.m. ET on Wednesday, Sept. 3, 2025. Paul Burton, M.D., Ph.D, ...
Amgen (NASDAQ:AMGN) will present at the 2025 Wells Fargo Healthcare Conference on September 3, 2025. Dr. Paul Burton, the company's Chief Medical Officer, will lead the presentation, highlighting Amgen's innovations and developments. The event will be available via a live webcast, accessible to the public and media. Amgen is well-regarded in the biotechnology sector, with a strong focus on conditions like cancer and heart disease, and has received accolades for its innovative work and corporate culture.
Read more →AMGNREPATHA® NOW INDICATED FOR ADULTS AT INCREASED RISK FOR MAJOR ADVERSE CARDIOVASCULAR EVENTS DUE TO UNCONTROLLED LDL-C Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha® (evolocumab) to...
Amgen's Repatha® (evolocumab) has received expanded FDA approval to treat adults at increased risk for major adverse cardiovascular events due to uncontrolled LDL-C levels. This modification eliminates the previous requirement that patients must have a cardiovascular disease diagnosis to be eligible. The update is aimed at addressing the needs of adults who struggle to meet their LDL-C goals and highlights Repatha's efficacy for patients inadequately managed with statins. This approval acknowledges the significant public health issue as many adults remain at risk for serious cardiovascular events.
Read more →AMGNSINGZYME WINS 2025 AMGEN X NSG GOLDEN TICKET FOR BREAKTHROUGH BIOCONJUGATION PLATFORM Singzyme, a Singapore-based biotech startup pioneering next-generation bioconjugation solutions, has been named the winner of the 2025 Golden Ticket...
Singzyme, a Singapore-based biotech startup, has been awarded the 2025 Golden Ticket Programme, which supports biotech innovation through infrastructure and mentorship. This award includes a one-year residency at NSG BioLabs and access to advanced lab facilities. Singzyme's proprietary Peptide Asparaginyl Ligase platform aims to improve the production of antibody-drug conjugates, showcasing significant potential in targeted therapies.
Read more →AMGNAMGEN REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2025. We're delivering strong performance and reaching more patients ...
Amgen has announced its financial results for the second quarter of 2025, highlighting a solid performance with significant increases in product sales across several key medicines. The company's total product sales reached $8.77 billion, a 9% increase from the previous year. However, some established products saw declines, particularly Enbrel and Prolia. Amgen continues to focus on innovation through investments in medicine and biosimilars, reinforcing its commitment to improving healthcare outcomes.
Read more →AMGNAMGEN ANNOUNCES 2025 THIRD QUARTER DIVIDEND Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the third quarter of 2025. The dividend will...
Amgen has announced a dividend of $2.38 per share for the third quarter of 2025, which will be distributed to stockholders on September 12, 2025. This decision reflects the company's strong financial health and commitment to returning value to its investors. In addition to its dividend announcement, Amgen continues to gain recognition for its innovation in biotechnology and is included in the Dow Jones Industrial Average. The company has a diversified portfolio aimed at addressing various medical needs, including cancer and heart diseases.
Read more →AMGNAMGEN ANNOUNCES WEBCAST OF 2025 SECOND QUARTER FINANCIAL RESULTS Amgen (NASDAQ:AMGN) today announced that it will report its second quarter 2025 financial results on Tuesday, August 5, 2025, after the close of the...
Amgen has announced that it will report its second quarter financial results for 2025 on August 5, 2025, after the market closes. Following the report, a conference call will be conducted with executives from the company, including CEO Robert A. Bradway. The event will be available as a live webcast, providing access to both the investment community and general public. This conference call will also be archived for later access on Amgen's website.
Read more →AMGNAMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR BEMARITUZUMAB IN FIBROBLAST GROWTH FACTOR RECEPTOR 2b (FGFR2b) POSITIVE FIRST-LINE GASTRIC CANCER Amgen (NASDAQ:AMGN) today announced the Phase 3 FORTITUDE-101 clinical trial evaluating first-line bemarituzumab plus chemotherapy (mFOLFOX6) met its ...
Amgen announced that its Phase 3 FORTITUDE-101 trial for bemarituzumab in combination with chemotherapy successfully met the primary endpoint of overall survival in patients with FGFR2b overexpression. This combination therapy demonstrated significant improvement over chemotherapy alone, highlighting its potential to address the unmet needs of advanced gastric cancer patients. While the trial results are promising, there were instances of treatment-emergent adverse events, particularly ocular issues. Further detailed analysis is expected at future medical meetings.
Read more →AMGN▼ -5.8%on this news
RESULTS FROM AMGEN'S PHASE 2 OBESITY STUDY OF MONTHLY MARITIDE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONS MariTide, the First Monthly or Less Frequently Dosed Obesity Treatment, Demonstrated Up to ~20% Average Weight Loss Without a Weight Loss Plateau,...
Amgen presented positive results from the Phase 2 study of MariTide, a monthly obesity treatment, at the ADA 85th Scientific Sessions. The treatment exhibited up to ~20% weight loss without plateau in patients without Type 2 diabetes and notable improvements in hemoglobin A1c in those with the condition. The study highlighted enhanced tolerability through dose escalation, paving the way for further Phase 3 trials targeting various obesity-related conditions. No new safety signals were identified, though gastrointestinal events were reported as common adverse effects.
Read more →AMGNAMGEN'S PHASE 2 MARITIDE DATA TO BE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONS Amgen (NASDAQ:AMGN) today announced full results from Part 1 of the Phase 2 study for MariTide (maridebart cafraglutide, formerly AMG 133) in...
Amgen has announced the full results from Part 1 of its Phase 2 study for MariTide, a peptide-antibody conjugate for obesity and Type 2 diabetes treatment. These results will be presented at the American Diabetes Association Scientific Sessions from June 20-23, 2025. The data demonstrates significant weight loss efficacy without plateau effects, which underlines the potential of MariTide as a therapeutic option. This information is also expected to influence the Phase 3 MARITIME program design.
Read more →AMGNAMGEN AND FOOTBALL LEGEND BARRY SANDERS HIGHLIGHT DANGERS OF BAD CHOLESTEROL IN NEW DOCUMENTARY Amgen (NASDAQ: AMGN) today announced the launch of The Making of a Heart Attack, a documentary that sheds light on the cardiovascular disease crisis...
Amgen has launched a documentary titled 'The Making of a Heart Attack,' which focuses on the dangers of high LDL cholesterol as a major risk factor for cardiovascular disease. Featuring former NFL star Barry Sanders, who himself experienced a heart attack, the documentary aims to educate the public and encourage them to track their cholesterol levels. Amgen's initiative aligns with their 2030 goal to drastically reduce heart attack and stroke rates in the U.S. by promoting early LDL-C testing and increasing awareness of heart health issues.
Read more →AMGNAMGEN TO PRESENT AT GOLDMAN SACHS 46TH ANNUAL GLOBAL HEALTHCARE CONFERENCE Amgen (NASDAQ: AMGN) will present at the Goldman Sachs 46th Annual Global Healthcare Conference at 9:20 a.m. PT on Tuesday, June 10, 2025. Peter...
Amgen (NASDAQ: AMGN) is set to present at the Goldman Sachs 46th Annual Global Healthcare Conference on June 10, 2025. Key executives Peter Griffith and Jay Bradner will lead the presentation, which will be available via a live webcast. This event highlights Amgen's leadership in biotechnology and its ongoing commitment to innovation in fighting serious diseases. The webcast will be archived for at least 90 days for future viewing. Amgen's recognition as one of the world's most innovative companies reflects its industry standing.
Read more →AMGNIMDELLTRA® SIGNIFICANTLY REDUCED RISK OF DEATH BY 40% IN SMALL CELL LUNG CANCER PATIENTS Amgen (NASDAQ:AMGN) today announced new interim results from the global Phase 3 DeLLphi-304 trial showing IMDELLTRA® (tarlatamab-dlle) reduced the...
Amgen announced interim results from the global Phase 3 DeLLphi-304 trial, which showed that IMDELLTRA (tarlatamab-dlle) significantly reduced the risk of death by 40% in small cell lung cancer patients who had previously undergone platinum-based chemotherapy. The trial demonstrated that median overall survival was extended by over five months when compared to standard chemotherapy. Alongside improved survival rates, IMDELLTRA exhibited a favorable safety profile with lower rates of severe adverse events. The findings highlight the drug's potential to transform treatment outcomes for patients with this challenging cancer type.
Read more →AMGNAMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE Amgen (NASDAQ:AMGN) will present at Jefferies Global Healthcare Conference at 9:20 a.m. ET on Wednesday, June 4, 2025. Peter Griffith, executive vice ...
Amgen (NASDAQ: AMGN) is scheduled to present at the Jefferies Global Healthcare Conference on June 4, 2025, at 9:20 a.m. ET. Executive Vice President and CFO Peter Griffith will represent the company alongside Murdo Gordon, EVP of Global Commercial Operations. The conference presentation will be webcasted and accessible to the public, promoting transparency. Amgen is noted for its innovative contributions to biotechnology and has received several accolades, including recognition as one of the 'World's Most Innovative Companies.'
Read more →AMGNAMGEN TO PRESENT AT THE 2025 RBC CAPITAL MARKETS GLOBAL HEALTHCARE CONFERENCE Amgen (NASDAQ:AMGN) will present at the 2025 RBC Capital Markets Global Healthcare Conference at 9:00 a.m. ET on Wednesday, May 21, 2025. Kave...
Amgen (NASDAQ: AMGN) will present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025. Kave Niksefat, senior vice president of Global Marketing and Access, will lead the presentation. The event will be accessible via a live webcast, allowing media and the public to participate. Amgen continues to be recognized for its innovation and contributions to biotechnology, underlining its significant role in healthcare.
Read more →AMGNAMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 9:20 a.m. PT on Wednesday, May 14, 2025. Peter...
Amgen (NASDAQ: AMGN) is scheduled to present at the Bank of America Merrill Lynch Global Healthcare Conference on May 14, 2025. The presentation will feature Peter Griffith and Jay Bradner from Amgen, and it will be broadcast live for media and the public. Amgen is recognized for its innovative approaches in biotechnology, with a strong pipeline addressing multiple diseases. The company has received several accolades recently, emphasizing its position in the industry.
Read more →AMGNAMGEN REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2025. Demand for our products was strong globally in the first...
Amgen reported robust financial results for the first quarter of 2025, highlighting strong global demand and successful outcomes from Phase 3 trials that enhance long-term growth prospects. Notable product sales included substantial increases for treatments like Repatha and TEZSPIRE, although some products, such as TEPEZZA and Enbrel, experienced declines. The company has also seen an increase in total operating expenses by 8% compared to the previous year, reflecting the dynamic nature of the biopharmaceutical landscape as it navigates through challenges and opportunities.
Read more →AMGNAMGEN ANNOUNCES WEBCAST OF 2025 FIRST QUARTER FINANCIAL RESULTS Amgen (NASDAQ:AMGN) today announced that it will report its first quarter 2025 financial results on Thursday, May 1, 2025, after the close of the U.S....
Amgen (NASDAQ: AMGN) has announced that it will report its first quarter 2025 financial results on May 1, 2025, after U.S. markets close. Following the announcement, a conference call will be held with key executives, including CEO Robert A. Bradway. The live audio of the call will be accessible to the public via Amgen's website, and it will be archived for 90 days. Amgen has a long history of innovation in biotechnology and continues to develop treatments for various diseases.
Read more →AMGNAMGEN ANNOUNCES $900 MILLION MANUFACTURING EXPANSION, CREATION OF 350 NEW JOBS IN OHIO Amgen (NASDAQ: AMGN) today announced a $900 million expansion of its Ohio manufacturing facility, bringing the total number of jobs created to 750...
Amgen has announced a $900 million expansion of its manufacturing facility in Ohio, which will create 350 new jobs, bringing the total number of jobs in the state to 750. This investment underscores the company's commitment to U.S. manufacturing and follows its recent investments in other states, enhancing its biomanufacturing capabilities. The expansion aligns with Amgen's broader strategy to leverage technological advancements and operational expertise in biomanufacturing.
Read more →AMGNIMDELLTRA® DEMONSTRATED SUPERIOR OVERALL SURVIVAL IN SMALL CELL LUNG CANCER Amgen (NASDAQ:AMGN) today announced that the global Phase 3 DeLLphi-304 clinical trial evaluating IMDELLTRA® (tarlatamab-dlle) as a treatment for...
Amgen announced positive results from its global Phase 3 DeLLphi-304 trial for IMDELLTRA, an innovative treatment for small cell lung cancer (SCLC) patients who have failed prior chemotherapy. The trial showed a significant improvement in overall survival compared to standard chemotherapy. The safety profile of IMDELLTRA was consistent with known findings, and data will be presented at an upcoming medical event. Amgen aims to further discuss these results with health authorities to bring this therapy to market.
Read more →AMGNUPLIZNA® (INEBILIZUMAB-CDON) IS NOW THE FIRST AND ONLY FDA-APPROVED TREATMENT FOR IGG4-RELATED DISEASE Amgen (NASDAQ:AMGN) announced today that the U.S. Food and Drug Administration (FDA) has approved UPLIZNA as the first and only treatment for adults...
Amgen has received FDA approval for UPLIZNA, making it the first treatment for adults with IgG4-related disease (IgG4-RD). This approval, driven by high unmet medical needs, stems from the promising results of the MITIGATE trial, which showed UPLIZNA's ability to significantly reduce flare risks. Additionally, the therapy's potential to provide corticosteroid-free remission marks a significant advancement in patient care for this debilitating disease. UPLIZNA, already approved for NMOSD, demonstrates Amgen's ongoing commitment to innovative therapies targeting B-cells.
Read more →AMGNUPLIZNA® (INEBILIZUMAB-CDON) SIGNIFICANTLY IMPROVES GENERALIZED MYASTHENIA GRAVIS SYMPTOMS IN ACETYLCHOLINE RECEPTOR AUTOANTIBODY-POSITIVE PATIENTS OVER 52 WEEKS Amgen (NASDAQ:AMGN) today announced new data from the Phase 3, registrational MINT trial evaluating the efficacy and safety of UPLIZNA®...
Amgen announced promising results from the Phase 3 MINT trial of UPLIZNA in patients with generalized myasthenia gravis (gMG), specifically those positive for acetylcholine receptor autoantibodies. The trial highlighted sustained efficacy and significant improvements in daily living activities, reporting 72.3% of patients experiencing symptom relief. These findings will be presented at the upcoming AAN Annual Meeting in April 2025. UPLIZNA is currently under review by the FDA for additional indications and has received Orphan Drug Designation for gMG.
Read more →AMGNAMGEN AND KYOWA KIRIN PROVIDE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 IGNITE STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS Amgen (NASDAQ: AMGN) and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) today announced new results from the ongoing ROCKET Phase 3 clinical trial...
Amgen and Kyowa Kirin reported positive top-line results from the Phase 3 IGNITE study evaluating rocatinlimab for moderate to severe atopic dermatitis. The trial demonstrated statistical significance in achieving key efficacy endpoints with both tested doses. The study involved 769 adults and showed promising improvements in Eczema Area and Severity Index scores. Safety profiles were consistent with prior studies, though some treatment-emergent adverse events were noted, necessitating ongoing evaluation in future trials.
Read more →AMGNAMGEN ANNOUNCES 2025 SECOND QUARTER DIVIDEND Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the second quarter of 2025. The dividend will ...
Amgen (NASDAQ: AMGN) has announced a quarterly dividend of $2.38 per share for Q2 2025, demonstrating its commitment to returning value to shareholders. This dividend will be paid on June 6, 2025, to stockholders of record as of May 16, 2025. The announcement reflects Amgen's strong financial position and recognizes its role as a leading innovator in the biopharmaceutical industry, although the company faces several operational risks and competition challenges.
Read more →AMGNPOSITIVE RESULTS FROM TEZSPIRE® (TEZEPELUMAB-EKKO) PHASE 3 WAYPOINT TRIAL HIGHLIGHT RAPID, SUSTAINED EFFECT IN CHRONIC RHINOSINUSITIS WITH NASAL POLYPS Amgen (NASDAQ:AMGN) and AstraZeneca today announced full results from the Phase 3, registrational WAYPOINT trial demonstrating that TEZSPIRE®...
Amgen (NASDAQ: AMGN) and AstraZeneca have reported positive results from the Phase 3 WAYPOINT trial of TEZSPIRE (tezepelumab-ekko) for chronic rhinosinusitis with nasal polyps (CRSwNP). The trial data demonstrated significant reductions in nasal polyp severity and nasal congestion, as well as a substantial decrease in the need for surgery and corticosteroids. Results were published in the New England Journal of Medicine and highlighted at a major conference, emphasizing TEZSPIRE's potential to improve patient outcomes in a condition often requiring repetitive surgery and medication. The treatment exhibited a favorable safety profile aligned with its use in severe asthma.
Read more →AMGNAMGEN TO PRESENT AT THE 45TH ANNUAL TD COWEN HEALTH CARE CONFERENCE Amgen (NASDAQ: AMGN) will present at the 45th Annual TD Cowen Health Care Conference at 9:10 a.m. ET on Wednesday, March 5, 2025. Jay Bradner,...
Amgen will present at the 45th Annual TD Cowen Health Care Conference on March 5, 2025, with Jay Bradner, EVP of Research and Development, taking part in a fireside chat. The event will be broadcast online, allowing media members, investors, and the public to access the information. Amgen is recognized for its longstanding role in biotechnology and its commitment to innovation in treating various diseases. The webcast will be available for replay for at least 90 days following the event.
Read more →AMGNAMGEN TO PRESENT AT CITI'S 2025 VIRTUAL ONCOLOGY LEADERSHIP SUMMIT Amgen (NASDAQ: AMGN) will present at Citi's 2025 Virtual Oncology Leadership Summit at 3:00 p.m. ET on Wednesday, Feb. 19, 2025. Jean-Charles Soria,...
Amgen (NASDAQ: AMGN) has announced that it will present at Citi's 2025 Virtual Oncology Leadership Summit on February 19, 2025, at 3:00 p.m. ET. Senior vice president Jean-Charles Soria will lead the presentation, which will be available for live streaming and later archived for public access. The announcement underscores Amgen's commitment to advancing its oncology developments and maintaining transparency with investors and the public about its initiatives.
Read more →AMGNAMGEN TO PRESENT AT THE 35th ANNUAL OPPENHEIMER HEALTHCARE LIFE SCIENCES CONFERENCE Amgen (NASDAQ: AMGN) will present at the 35th Annual Oppenheimer Healthcare Life Sciences Conference at 11:20 a.m. ET on Wednesday, Feb. 12, 2025....
Amgen will present at the 35th Annual Oppenheimer Healthcare Life Sciences Conference on February 12, 2025. The presentation will be led by Narimon Honarpour, Amgen's senior vice president of global development, and will be available through a live webcast. This event is part of Amgen's ongoing effort to communicate its innovative developments to investors and the public. In addition to the conference, Amgen holds a substantial reputation in the biotechnology sector as a leading innovator and employer.
Read more →AMGNAMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023. Robust growth...
Amgen (NASDAQ: AMGN) reported its financial results for the fourth quarter and full year of 2024, showing substantial growth in sales and earnings. The company highlighted robust global performance and announced significant investments in its product pipeline. Notable product sales included Repatha and EVENITY, which experienced significant year-over-year growth, while some established products saw declines. Overall, the company's financial health appears strong, with increased cash flow and a reduction in outstanding debt.
Read more →AMGNAMGEN ANNOUNCES WEBCAST OF 2024 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2024 financial results on Tuesday, February 4, 2025, after...
Amgen has announced the release date for its fourth quarter and full year financial results for 2024, set for February 4, 2025, after U.S. market close. This announcement will be accompanied by a conference call featuring key executives, including CEO Robert A. Bradway. The event will be accessible via a live audio webcast, which will also be archived for future access. The company continues to maintain a notable position in the biotechnology industry, recognized for its innovative approaches and extensive therapeutic pipeline.
Read more →AMGNEVROPSKÁ KOMISE SCHVÁLILA PŘÍPRAVEK BLINCYTO® PRO LÉČBU PHILADELPHIA CHROMOZOM NEGATIVNÍ CD19 POZITIVNÍ B-PREKURZOROVÉ AKUTNÍ LYMFOBLASTICKÉ LEUKEMIE VE FÁZI KONSOLIDACE Společnost Amgen (NASDAQ:AMGN) dnes oznámila, že Evropská komise (EK) schválila monoterapii přípravkem BLINCYTO® (blinatumomab) jako součást...
Amgen has announced that the European Commission has approved BLINCYTO® (blinatumomab) for use in consolidating treatment of adults with newly diagnosed Philadelphia chromosome-negative CD19-positive B precursor acute lymphoblastic leukemia (B-ALL). The approval is based on the results from the E1910 study, which demonstrated that adding BLINCYTO significantly improves overall survival compared with traditional chemotherapy alone. Despite this progress, experts note that a substantial number of patients still remain at high risk for relapse.
Read more →AMGNEUROPÄISCHE KOMMISSION GENEHMIGT BLINCYTO® BEI PHILADELPHIA-CHROMOSOM-NEGATIVER CD19-POSITIVER B-ZELL-VORLÄUFER-AKUTER LYMPHOBLASTISCHER LEUKÄMIE IN DER KONSOLIDIERUNGSPHASE Amgen (NASDAQ:AMGN) gab heute bekannt, dass die Europäische Kommission (EK) die Monotherapie BLINCYTO®(Blinatumomab) als Teil der...
Amgen hat bekannt gegeben, dass die Europäische Kommission die Monotherapie BLINCYTO (Blinatumomab) für die Behandlung von Erwachsenen mit neu diagnostizierter Philadelphia-Chromosom-negativer CD19-positiver B-Zell-Vorläufer-Akuter-Lymphoblastischer-Leukämie (B-ALL) in der Konsolidierungsphase genehmigt hat. Diese Genehmigung basiert auf Daten aus der Phase-3-Studie E1910, die eine signifikante Verbesserung der Gesamtüberlebensrate im Vergleich zur traditionellen Chemotherapie zeigt. Die Studie vermittelt die Möglichkeit, dass BLINCYTO tiefere Remissionen und besseres langfristiges Überleben fördern könnte. Zudem hebt Amgen die Bedeutung der Studie und die Unterstützung durch das National Cancer Institute hervor.
Read more →AMGNЕВРОПЕЙСКАЯ КОМИССИЯ ОДОБРЯЕТ BLINCYTO® ДЛЯ НЕГАТИВНОГО ПО ФИЛАДЕЛЬФИЙСКОЙ ХРОМОСОМЕ CD19-ПОЗИТИВНОГО ОСТРОГО ЛИМФОБЛАСТНОГО ЛЕЙКОЗА ИЗ РАННИХ ПРЕДШЕСТВЕННИКОВ B-КЛЕТОК В ФАЗЕ КОНСОЛИДАЦИИ Компания Amgen (NASDAQ:AMGN) сегодня объявила о том, что Европейская комиссия (ЕК) одобрила монотерапию BLINCYTO® (блинатумомаб) в рамках...
Amgen (NASDAQ: AMGN) has announced that the European Commission has approved BLINCYTO® (blinatumomab) for the treatment of adults with first diagnosed negative Philadelphia chromosome acute lymphoblastic leukemia (B-ALL). This significant milestone represents progress in offering patients a novel treatment option that may lead to improved outcomes. The approval is based on data from the E1910 study, which demonstrated BLINCYTO's potential to enhance survival rates. However, clinical challenges remain, particularly the high risk of relapse among patients diagnosed with B-ALL.
Read more →AMGNLA COMMISSION EUROPEENNE APPROUVE BLINCYTO® POUR LA LEUCÉMIE LYMPHOBLASTIQUE AIGUË À PRÉCURSEURS DE CELLULES B, CD19 POSITIF ET CHROMOSOME DE PHILADELPHIE NÉGATIF, EN PHASE DE CONSOLIDATION Amgen (NASDAQ:AMGN) annonce ce jour que la Commission européenne (CE) a approuvé BLINCYTO® (blinatumomab) en monothérapie dans le cadre d'une...
Amgen announced that the European Commission has approved BLINCYTO (blinatumomab) as a monotherapy for adult patients with newly diagnosed B-cell precursor acute lymphoblastic leukemia (B-ALL) who are CD19 positive and Philadelphia chromosome negative. This approval allows for BLINCYTO to be used earlier in the treatment pathway, potentially improving patient survival outcomes. Clinical trial E1910 demonstrated that the addition of BLINCYTO to multi-phase consolidation chemotherapy significantly increased overall survival compared to chemotherapy alone. While the treatment shows promise, many patients still face a high risk of recurrence.
Read more →AMGNEURÓPSKA KOMISIA SCHVÁLILA LIEK BLINCYTO® NA LIEČBU AKÚTNEJ LYMFOBLASTOVEJ LEUKÉMIE NEGATÍVNEJ NA FILADELFSKÝ CHROMOZÓM, POZITÍVNEJ NA CD19 S B-PREKURZOROM VO FÁZE KONSOLIDÁCIE BLINCYTO v kombinácii s viacfázovou konsolidačnou chemoterapiou výrazne znížil riziko úmrtia v porovnaní so samotnou chemoterapiou THOUSAND OAKS,...
Amgen's BLINCYTO (blinatumomab) has been approved by the European Commission as part of the consolidation treatment for adult patients diagnosed with Philadelphia chromosome-negative acute lymphoblastic leukemia (B-ALL). The approval is backed by clinical study E1910, which indicates that the combination of BLINCYTO with multi-phase consolidation chemotherapy significantly improves survival rates compared to chemotherapy alone. Despite these advancements, the risk of relapse remains high in many patients, highlighting ongoing challenges in treatment efficacy.
Read more →AMGNKOMISJA EUROPEJSKA ZATWIERDZA BLINCYTO® W TERAPII KONSOLIDUJĄCEJ STOSOWANEJ U PACJENTÓW Z OSTRĄ BIAŁACZKĄ LIMFOBLASTYCZNĄ Z KOMÓREK PREKURSOROWYCH LINII B BEZ CHROMOSOMU PHILADELPHIA I Z EKSPRESJĄ ANTYGENU CD19. Spółka Amgen (NASDAQ:AMGN) ogłosiła dzisiaj, że Komisja Europejska (KE) zatwierdziła produkt leczniczy BLINCYTO® (blinatumomab) w monoterapii...
The European Commission has approved BLINCYTO (blinatumomab) as a monotherapy for adult patients diagnosed for the first time with Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia (B-ALL). This approval allows for earlier treatment options, potentially improving patient survival rates. Clinical trial results (E1910) indicated a significant increase in overall survival when BLINCYTO was combined with chemotherapy, showcasing an 82.4% five-year survival rate compared to 62.5% for chemotherapy alone. The treatment represents a significant advance in addressing high relapse risks for these patients.
Read more →AMGNLa Comisión Europea aprueba BLINCYTO® Amgen (NASDAQ:AMGN) anunció hoy que la Comisión Europea (CE) ha aprobado la monoterapia con BLINCYTO® (blinatumomab) como parte de la terapia de...
Amgen announced that the European Commission has approved BLINCYTO® (blinatumomab) as a monotherapy in the consolidation therapy for adult patients with newly diagnosed Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL). The approval is based on positive results from the phase 3 E1910 clinical trial, which demonstrated that adding BLINCYTO to multi-agent consolidation chemotherapy significantly reduced the risk of death. This early availability of BLINCYTO may enhance treatment outcomes for patients at high risk of relapse.
Read more →AMGNEUROPEAN COMMISSION APPROVES BLINCYTO® IN PHILADELPHIA CHROMOSOME-NEGATIVE CD19-POSITIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA IN THE CONSOLIDATION PHASE Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has approved BLINCYTO® (blinatumomab) monotherapy as part of consolidation...
Amgen has received approval from the European Commission for BLINCYTO (blinatumomab) as a monotherapy in adult patients with newly diagnosed Philadelphia chromosome-negative CD19-positive B-cell precursor acute lymphoblastic leukemia during the consolidation phase. This approval is based on the Phase 3 E1910 trial, which demonstrated that the addition of BLINCYTO to consolidation chemotherapy significantly improved overall survival rates compared to chemotherapy alone. The approval aims to offer earlier treatment options to patients, potentially improving long-term outcomes in this high-risk patient population.
Read more →AMGNFDA APPROVES LUMAKRAS® (SOTORASIB) IN COMBINATION WITH VECTIBIX® (PANITUMUMAB) FOR CHEMOREFRACTORY KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved LUMAKRAS® (sotorasib) in combination with Vectibix® ...
Amgen announced the FDA's approval of LUMAKRAS (sotorasib) in combination with Vectibix (panitumumab) for adult patients with KRAS G12C-mutated metastatic colorectal cancer. This marks the first targeted treatment for this specific mutation, having demonstrated more than double the progression-free survival compared to the standard-of-care therapies in a pivotal clinical trial. The clinical trial results also showed an overall response rate significantly favoring the combination therapy. The approval highlights the importance of biomarker testing in treating advanced colorectal cancer.
Read more →AMGNAMGEN TO PRESENT AT 43RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE Amgen (NASDAQ:AMGN) will present at the 2025 J.P. Morgan Healthcare Conference at 3:00 p.m. PT on Monday, January 13, 2025. Robert A. Bradway,...
Amgen (NASDAQ: AMGN) is scheduled to present at the 2025 J.P. Morgan Healthcare Conference on January 13, 2025, at 3:00 p.m. PT. CEO Robert A. Bradway will lead the presentation, which will be available via webcast to the media, investors, and the public. The webcast will also be archived for 90 days post-event, underlining Amgen's engagement with stakeholders. This participation reflects Amgen's strategic positioning in the biotechnology industry and its ongoing commitment to innovation in healthcare.
Read more →AMGNAMGEN ANNOUNCES 2025 FIRST QUARTER DIVIDEND Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the first quarter of 2025. The dividend will...
Amgen has declared a dividend of $2.38 per share for the first quarter of 2025, which will be paid on March 7, 2025, to stockholders recorded by February 14, 2025. The announcement reflects Amgen's ongoing commitment to its shareholders, following recognitions as one of the world's most innovative companies. The company continues to advance its portfolio aimed at tackling various serious diseases, and its growing pipeline signifies a proactive approach to innovation in the biopharma sector.
Read more →AMGNBLINCYTO® (BLINATUMOMAB) ADDED TO CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN NEWLY DIAGNOSED PEDIATRIC PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) Amgen (NASDAQ:AMGN) today announced new data demonstrating that adding BLINCYTO® (blinatumomab) to chemotherapy significantly improves disease-free...
Amgen announced positive results from a Phase 3 study showing that adding BLINCYTO to chemotherapy significantly improves disease-free survival in newly diagnosed pediatric patients with B-cell precursor acute lymphoblastic leukemia (B-ALL). The study demonstrated a 96% disease-free survival rate after three years for patients receiving BLINCYTO compared to 87.9% for those on chemotherapy alone. These findings may redefine the standard care for many children with B-ALL. Ongoing discussions with the U.S. FDA will follow as the study highlights BLINCYTO's potential as a first-line treatment.
Read more →AMGNAMGEN ANNOUNCES $1 BILLION MANUFACTURING EXPANSION IN NORTH CAROLINA Amgen (NASDAQ: AMGN) today announced a $1 billion expansion to establish a second drug substance manufacturing facility in North Carolina. This...
Amgen has announced a $1 billion expansion to establish a second drug substance manufacturing facility in Holly Springs, North Carolina. This investment will increase the company's total commitment in the area to over $1.5 billion, following a previous $550 million investment. The new facility is expected to generate 370 jobs and will feature advanced technologies to enhance production efficiency and sustainability. This move positions North Carolina as a pivotal location in Amgen's global manufacturing network to meet rising demand for its innovative therapies.
Read more →AMGNAMGEN TO PRESENT AT CITI'S 2024 GLOBAL HEALTHCARE CONFERENCE Amgen (NASDAQ:AMGN) will present at Citi's 2024 Global Healthcare Conference at 9:30 a.m. ET on Thursday, Dec. 5, 2024. Peter Griffith, executive...
Amgen (NASDAQ: AMGN) will present at Citi's 2024 Global Healthcare Conference on December 5, 2024, with key executives participating in a fireside chat. The webcast will be available for public viewing and will be archived for 90 days post-event. The announcement highlights Amgen's ongoing efforts to engage with investors and the public regarding its innovative medicines and robust development pipeline.
Read more →AMGNAMGEN TO PRESENT AT THE 7th ANNUAL EVERCORE HEALTHCONx CONFERENCE Amgen (NASDAQ:AMGN) will present at the 7th Annual Evercore HealthCONx Conference at 10:00 a.m. ET on Wednesday, Dec. 4, 2024. Peter Griffith,...
Amgen (NASDAQ: AMGN) is set to present at the 7th Annual Evercore HealthCONx Conference on December 4, 2024. The presentation will feature key executives including Peter Griffith, Jay Bradner, and Susan Sweeney. The event will be webcast live and accessible to media and investors. Amgen continues to be recognized for its innovative contributions to the biopharmaceutical sector and will highlight its developments in various therapeutic areas during the conference.
Read more →AMGNAMGEN ANNOUNCES ROBUST WEIGHT LOSS WITH MARITIDE IN PEOPLE LIVING WITH OBESITY OR OVERWEIGHT AT 52 WEEKS IN A PHASE 2 STUDY MariTide Demonstrated up to ~20% Average Weight Loss at 52 Weeks Without a Weight Loss Plateau in People Living With Obesity or Overweight MariTide...
Amgen has announced promising results from a Phase 2 study of MariTide, an investigational treatment for obesity, demonstrating up to 20% average weight loss over 52 weeks without a plateau. Additionally, participants with Type 2 diabetes experienced average weight loss of ~17% and notable reductions in HbA1c levels. The study also showed improvements in various cardiometabolic parameters. Following these positive outcomes, Amgen plans to launch a Phase 3 program named MARITIME to explore further potential benefits of MariTide.
Read more →AMGNAMGEN TO HOST WEBCAST TO DISCUSS MARITIDE PHASE 2 RESULTS AND PROGRESS ON DEVELOPMENT PROGRAM Amgen (NASDAQ:AMGN) will host a webcasted call for the investment community at 5 a.m. PT on Tuesday, Nov. 26, 2024, to discuss data from the 52-week, ...
Amgen has announced a webcast scheduled for 5 a.m. PT on November 26, 2024, to discuss the Phase 2 study results of MariTide and advancements in its development program. The webcast will feature CEO Robert A. Bradway and other senior management, providing insights for the investment community. The session will be available online for both live streaming and subsequent replay for a minimum of 90 days, promoting transparency and accessibility for investors and the public alike.
Read more →AMGNAMGEN ANNOUNCES SENIOR EXECUTIVE RESEARCH APPOINTMENT Amgen (NASDAQ:AMGN) today announced that Howard Chang, M.D., Ph.D., will join the company as senior vice president of Research, effective Dec. 16,...
Amgen has appointed Howard Chang, M.D., Ph.D., as its new senior vice president of Research and chief scientific officer, effective December 16, 2024. Chang, a renowned physician-scientist, will be tasked with leading research priorities across various therapeutic areas including rare diseases and cancer. He brings significant expertise in human genetics and disease biology, which aligns with Amgen's mission to develop innovative therapies. Chang succeeds Ray Deshaies, Ph.D., who has left the company after a distinguished tenure.
Read more →AMGNAMGEN PRESENTS NEW DATA ACROSS RARE INFLAMMATORY DISEASES AT ACR 2024 Amgen (NASDAQ:AMGN) today announced the presentation of new data across its rare disease portfolio and pipeline at the annual American College of...
Amgen presented new data at the ACR Convergence 2024, highlighting the efficacy of UPLIZNA in treating Immunoglobulin G4-Related Disease (IgG4-RD) and improvements in KRYSTEXXA infusion time for uncontrolled gout patients. UPLIZNA-treated patients showed significant reductions in glucocorticoid requirements and received Breakthrough Therapy Designation from the FDA. The AGILE trial for KRYSTEXXA indicated safety and efficacy similar to longer infusion times. However, some adverse effects were noted in participants of these studies.
Read more →AMGNAMGEN PROVIDES STATEMENT ON MARITIDE PHASE 1 DATA Amgen (NASDAQ:AMGN) today issued the following statement on the MariTide (maridebart cafraglutide, formerly AMG 133) Phase 1 data. As previously...
Amgen has issued a statement regarding the Phase 1 data of MariTide (maridebart cafraglutide, formerly AMG 133). The company confirmed that the results do not indicate any safety concerns related to bone mineral density, reaffirming their positive outlook on the drug's potential. They are also looking forward to presenting Phase 2 topline data later this year. This announcement reflects Amgen's confidence in the progress of MariTide's development.
Read more →AMGNAMGEN TO PRESENT AT THE 2024 UBS GLOBAL HEALTHCARE CONFERENCE Amgen (NASDAQ:AMGN) will present at the 2024 UBS Global Healthcare Conference at 10:15 a.m. PT on Wednesday, Nov. 13, 2024. Peter Griffith, executive ...
Amgen (NASDAQ: AMGN) is set to present at the 2024 UBS Global Healthcare Conference on November 13, 2024. Peter Griffith, the company's executive vice president and chief financial officer, will lead the presentation. The event will be webcast live for media, investors, and the general public, with archived access available for 90 days post-event. Amgen continues to be recognized for its innovations and is a notable presence in the biotechnology sector.
Read more →AMGNTEZSPIRE MET BOTH CO-PRIMARY ENDPOINTS IN PHASE 3 TRIAL FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS Amgen (NASDAQ:AMGN) and AstraZeneca today announced positive top-line results from the Phase 3 WAYPOINT trial in patients with chronic rhinosinusitis ...
Amgen and AstraZeneca announced positive top-line results from the Phase 3 WAYPOINT trial for TEZSPIRE in patients with chronic rhinosinusitis with nasal polyps. The trial showed a significant reduction in nasal polyp size and nasal congestion compared to placebo. TEZSPIRE's safety profile was consistent with prior knowledge. The results are indicative of TEZSPIRE's potential to enhance the quality of life for patients suffering from this debilitating condition.
Read more →AMGNAMGEN REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2024. Strong growth in sales and earnings this quarter reflects the...
Amgen (NASDAQ: AMGN) has reported strong financial results for the third quarter of 2024, showcasing significant growth in sales and earnings. The company's total product sales reached $8.15 billion, reflecting a 24% increase year-over-year. Key products like Repatha, EVENITY, and BLINCYTO saw substantial sales growth, contributing to the positive financial trajectory. Amgen continues to invest in its pipeline, aiming to deliver innovative therapies across its core therapeutic areas.
Read more →AMGNAMGEN ANNOUNCES 2024 FOURTH QUARTER DIVIDEND Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.25 per share dividend for the fourth quarter of 2024. The dividend will ...
Amgen (NASDAQ: AMGN) has announced a quarterly dividend of $2.25 per share for the fourth quarter of 2024, set to be paid on December 9, 2024. The dividend reflects the company's positive financial position, as evidenced by its recognition in various industry accolades in 2024. Alongside its commitment to shareholder returns, Amgen emphasizes its dedication to innovative medicines for serious diseases, holding a prominent place in the biotechnology sector. The forward-looking statements in their announcement indicate ongoing strategies for growth and development.
Read more →AMGNAMGEN ANNOUNCES WEBCAST OF 2024 THIRD QUARTER FINANCIAL RESULTS Amgen (NASDAQ:AMGN) today announced that it will report its third quarter 2024 financial results on Wednesday, October 30, 2024, after the close of...
Amgen (NASDAQ: AMGN) announced it will report its third quarter 2024 financial results on October 30, 2024, after the market closes. This announcement will be followed by a conference call featuring CEO Robert A. Bradway and senior management. A live audio broadcast of the conference call will be available online, with a replay accessible for 90 days. The company emphasizes its ongoing commitment to innovation in the biotechnology field.
Read more →AMGNAMGEN PRESENTS POSITIVE PHASE 3 DATA FOR UPLIZNA® (INEBILIZUMAB-CDON) IN GENERALIZED MYASTHENIA GRAVIS (GMG) AT AANEM 2024 Amgen (NASDAQ:AMGN) today announced the presentation of positive top-line results from the Phase 3 MINT trial evaluating the efficacy and safety of...
Amgen has announced positive results from the Phase 3 MINT trial for UPLIZNA (inebilizumab-cdon), aimed at treating adults with generalized myasthenia gravis (gMG). The trial demonstrated statistically significant improvements in the Myasthenia Gravis Activities of Daily Living (MG-ADL) scores. UPLIZNA also showed continued efficacy while allowing for the safe tapering of corticosteroids in patients. With results reinforcing its potential, Amgen plans to seek regulatory approval in the U.S. and other markets.
Read more →AMGNLA LA ANTHONY PARTNERS WITH AMGEN TO SHARE CANDID, BEHIND-THE-SCENES LOOK AT HOW PLAQUE PSORIASIS AFFECTS HER LIFE Amgen (NASDAQ: AMGN) has partnered with multi-talented actress, producer and entrepreneur La La Anthony to share her personal journey living with...
Amgen has joined forces with actress La La Anthony to highlight the personal impact of plaque psoriasis. Through an interactive campaign, Anthony shares her experiences and encourages others to discuss their symptoms with healthcare professionals. The campaign aims to bridge the communication gap between patients and doctors regarding treatment options. Despite the awareness efforts, challenges such as the perception of disease severity and limitations of topical treatments remain prevalent among patients.
Read more →AMGNTEPEZZA® (TEPROTUMUMAB) RECEIVES APPROVAL IN JAPAN FOR THE TREATMENT OF ACTIVE THYROID EYE DISEASE Amgen (NASDAQ:AMGN) today announced TEPEZZA® (JAN: Teprotumumab (Genetical Recombination)) has been approved for the treatment of active or high...
Amgen announced the approval of TEPEZZA (teprotumumab) by Japan's Ministry of Health for the treatment of active Thyroid Eye Disease (TED). This marks TEPEZZA's first approval in Asia, offering a significant treatment option for patients suffering from a disease that can threaten vision. Clinical trial results demonstrated an 89% improvement in proptosis among treated patients. The drug also received orphan drug designation, expediting its regulatory review. However, potential side effects include severe hearing impairment and hyperglycemia.
Read more →AMGNAMGEN TO HOST CONFERENCE CALL TO DISCUSS NEW TOPLINE DATA IN INFLAMMATION AND RARE DISEASE Amgen (NASDAQ:AMGN) will host a webcasted call for the investment community at 1:30 p.m. PT on Tuesday, Sept. 24, 2024, to discuss new topline...
Amgen (NASDAQ: AMGN) will hold a conference call on September 24, 2024, to discuss new topline clinical data related to the Phase 3 programs for rocatinlimab and UPLIZNA. The call will feature executive vice president Jay Bradner and other members of the Amgen team, catering to investors and the media. The event reflects Amgen's ongoing commitment to advancing its innovative medicines and engaging with the investment community. The webcast will also be archived for future access.
Read more →AMGNAMGEN TO PRESENT DATA FROM MULTIPLE EARLY-STAGE CLINICAL TRIALS AT ESMO 2024 Amgen (NASDAQ: AMGN) today announced the presentation of new data across its broad oncology pipeline and portfolio at the European Society for...
Amgen has announced the presentation of new data from its oncology pipeline at the ESMO Congress 2024, scheduled from September 13-17. The abstracts will cover data from studies on various cancers, including colorectal and lung cancers, employing molecularly targeted therapies. However, the FDA's recent complete response letter regarding LUMAKRAS emphasizes the need for further confirmatory studies, which could delay its approval process. Despite these challenges, ongoing trials indicate Amgen's robust commitment to advancing cancer treatment options.
Read more →AMGNAMGEN PRESENTS NEW DATA FOR FIRST-IN-CLASS IMDELLTRA™ (TARLATAMAB-DLLE) IN SMALL CELL LUNG CANCER AT WCLC 2024 Amgen (NASDAQ:AMGN) today announced the presentation of new data showcasing IMDELLTRATM (tarlatamab-dlle), a first-in-class delta-like ligand 3...
Amgen (NASDAQ: AMGN) has presented new promising data for its first-in-class immunotherapy IMDELLTRA (tarlatamab-dlle) at the 2024 World Conference on Lung Cancer. New findings from the DeLLphi-303 and DeLLphi-301 studies indicate the treatment's potential as a first-line maintenance therapy when combined with PD-L1 inhibitors for extensive-stage small cell lung cancer (ES-SCLC). The results demonstrate a manageable safety profile along with sustained efficacy, reinforcing the drug's utility in a patient population that has faced limited therapeutic options. The FDA previously approved IMDELLTRA for patients who have progressed after platinum-based chemotherapy.
Read more →AMGNAMGEN TO PRESENT AT THE 2024 WELLS FARGO HEALTHCARE CONFERENCE Amgen (NASDAQ:AMGN) will present at the 2024 Wells Fargo Healthcare Conference at 9:30 a.m. ET on Thursday, Sept. 5, 2024. Peter Griffith, executive...
Amgen (NASDAQ:AMGN) is set to present at the 2024 Wells Fargo Healthcare Conference on September 5, 2024. Key executives, including Peter Griffith and Jay Bradner, will represent the company during this event. The presentation will be available via webcast, allowing media, investors, and the general public access to the information shared. Amgen continues to be a leader in biopharmaceutical innovation, recognized for its significant contributions to healthcare.
Read more →AMGNAMGEN TO PRESENT AT THE MORGAN STANLEY 22ND ANNUAL GLOBAL HEALTHCARE CONFERENCE Amgen (NASDAQ:AMGN) will present at the Morgan Stanley 22nd Annual Global Healthcare Conference at 9:15 a.m. ET on Wednesday, Sept. 4, 2024. Robert A....
Amgen (NASDAQ: AMGN) is scheduled to present at the Morgan Stanley 22nd Annual Global Healthcare Conference on September 4, 2024. Chairman and CEO Robert A. Bradway will lead the presentation, which will also be broadcasted online. The event aims to inform media, investors, and the public about Amgen's latest developments. Amgen continues to be recognized for its innovation and substantial contributions to the biotechnology industry.
Read more →AMGNOTEZLA® (APREMILAST) NOW AVAILABLE IN THE U.S. FOR MODERATE TO SEVERE PEDIATRIC PLAQUE PSORIASIS Amgen (NASDAQ:AMGN) today announced Otezla® (apremilast) is now available in the U.S. for pediatric use. Earlier this year, the U.S. Food and Drug...
Amgen has announced the U.S. availability of Otezla (apremilast) for pediatric patients aged 6 to 17 with moderate to severe plaque psoriasis. This is the first FDA-approved oral treatment for this demographic, addressing previously limited therapeutic options. The approval follows promising results from a Phase 3 clinical trial that demonstrated Otezla's efficacy compared to placebo. Despite its established safety profile, common side effects such as diarrhea and headaches may pose risks for users.
Read more →AMGNAMGEN TO OPEN NEW SITE IN HYDERABAD, INDIA Amgen (NASDAQ: AMGN) today announced plans to open a new technology and innovation site in Hyderabad, India. The site, known as Amgen India, will...
Amgen has announced plans to open a new technology and innovation site in Hyderabad, India, which will enhance its digital capabilities and accelerate innovation across its global organization. The site, located in HITEC City, is set to accommodate up to 3,000 employees and is expected to be operational by Q4 2024. This expansion reflects Amgen's commitment to leveraging technology and talent in India to advance its pipeline of medicines.
Read more →AMGNAMGEN REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS Amgen (NASDAQ: AMGN) today announced financial results for the second quarter 2024. With a strong, balanced portfolio of in-market products and a...
Amgen has released its financial results for the second quarter of 2024, reporting a 20% increase in total product sales year-over-year. The company emphasizes its strong, balanced product portfolio and advancing pipeline as key drivers for optimistic long-term growth. However, operating expenses have significantly increased, and there were notable declines in sales for specific products such as Neulasta and Enbrel. Amgen’s recognition as one of the 'World's Most Innovative Companies' further underscores its position in the biotechnology industry.
Read more →AMGNAMGEN ANNOUNCES 2024 THIRD QUARTER DIVIDEND Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.25 per share dividend for the third quarter of 2024. The dividend will...
Amgen (NASDAQ: AMGN) has announced a dividend of $2.25 per share for the third quarter of 2024, reflecting its commitment to returning value to shareholders. The dividend will be distributed on September 6, 2024, to stockholders of record by August 16, 2024. The announcement is part of Amgen's ongoing efforts to maintain investor confidence as it continues to innovate in the biopharmaceutical space with a broad pipeline targeting critical health conditions.
Read more →AMGNAMGEN ANNOUNCES WEBCAST OF 2024 SECOND QUARTER FINANCIAL RESULTS Amgen (NASDAQ:AMGN) today announced that it will report its second quarter 2024 financial results on Tuesday, August 6, 2024, after the close of the...
Amgen (NASDAQ: AMGN) announced it will report its second quarter 2024 financial results on August 6, 2024, after U.S. financial markets close. A conference call will follow the announcement, featuring CEO Robert A. Bradway and other senior executives. The event will be accessible via live audio on Amgen's website and will remain available for replay for 90 days. The company continues to maintain a strong reputation for innovation in the biopharmaceutical sector.
Read more →AMGNFDA APPROVES BLINCYTO® (BLINATUMOMAB) IN CD19-POSITIVE PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) IN THE CONSOLIDATION PHASE Amgen (NASDAQ:AMGN) today announced the U.S. Food and Drug Administration (FDA) has approved BLINCYTO® (blinatumomab) for the treatment of adult and...
Amgen has received FDA approval for BLINCYTO (blinatumomab) for treating adult and pediatric patients with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL) during the consolidation phase. This approval is based on successful results from the Phase 3 E1910 clinical trial, which showed that the addition of BLINCYTO to multiphase consolidation chemotherapy significantly improved overall survival compared to chemotherapy alone. This marks the third indication for BLINCYTO, further establishing its role in B-ALL treatment.
Read more →AMGNAMGEN TO PRESENT INNOVATIVE RHEUMATOLOGY RESEARCH AT EULAR 2024 Amgen (NASDAQ:AMGN) today announced the presentation of data across its diverse portfolio and pipeline at the European Alliance of Associations for...
Amgen (NASDAQ: AMGN) is set to showcase its latest research at the EULAR 2024 Congress, highlighting 27 abstracts focused on rheumatic diseases. Key presentations include promising results for dazodalibep in Sjögren's disease and positive outcomes from a post-hoc analysis of KRYSTEXXA in uncontrolled gout. The conference aims to underline Amgen's commitment to advancing treatments for inflammatory conditions, potentially improving patient care and health outcomes significantly.
Read more →AMGNAMGEN ANNOUNCES POSITIVE RESULTS FOR PHASE 3 REGISTRATIONAL TRIAL EVALUATING UPLIZNA® (INEBILIZUMAB-CDON) FOR TREATMENT OF IMMUNOGLOBULIN G4-RELATED DISEASE (IgG4-RD) Amgen (NASDAQ:AMGN) today announced positive topline results from its randomized, double-blind, multicenter, placebo-controlled Phase 3 clinical...
Amgen announced positive topline results from its Phase 3 trial of UPLIZNA (inebilizumab-cdon) for treating Immunoglobulin G4-related disease (IgG4-RD). The trial demonstrated a statistically significant 87% reduction in the risk of disease flares compared to placebo, while also meeting all key secondary endpoints. This trial is notable for being the first randomized, placebo-controlled study to provide class 1 evidence for IgG4-RD treatment. Full trial data will be presented at a future medical meeting, and Amgen plans to file for U.S. approval based on these results.
Read more →AMGNAMGEN TO PRESENT AT GOLDMAN SACHS 45TH ANNUAL GLOBAL HEALTHCARE CONFERENCE Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 45th Annual Global Healthcare Conference at 9:20 a.m. ET on Monday, June 10, 2024. Peter...
Amgen (NASDAQ: AMGN) is set to present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024, at 9:20 a.m. ET. Key executives, including CFO Peter Griffith and R&D Chief Jay Bradner, will feature in the presentation. The event will be available via a webcast for media, investors, and the public. Amgen continues to gain recognition for its innovative contributions to biotechnology and its commitment to developing treatments for serious diseases.
Read more →AMGNAMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE Amgen (NASDAQ:AMGN) will present at Jefferies Global Healthcare Conference at 9:00 a.m. ET on Thursday, June 6, 2024. Peter Griffith, executive vice...
Amgen (NASDAQ: AMGN) is set to present at the Jefferies Global Healthcare Conference on June 6, 2024, led by executives Peter Griffith and Ian Thompson. The presentation will be available via a webcast, providing access to media, investors, and the public. Amgen continues to highlight its innovative approaches in biopharmaceuticals and is recognized for its contributions to healthcare, including being listed as one of the "World's Most Innovative Companies."
Read more →AMGNAMGEN TO PRESENT INNOVATIVE RESEARCH FROM ITS ROBUST ONCOLOGY PORTFOLIO AT ASCO 2024 Amgen (NASDAQ:AMGN) today announced the presentation of new data from its broad oncology portfolio at the American Society of Clinical Oncology...
Amgen has announced the presentation of new data from its oncology portfolio at the ASCO 2024 Annual Meeting, scheduled for May 31 to June 4. The company will showcase 17 abstracts, including one late-breaking oral presentation, highlighting the effectiveness of its therapies targeting difficult cancers. The data will emphasize the potential of T-cell Engager therapies for hematologic and solid tumors, such as IMDELLTRA and the combination of LUMAKRAS with Vectibix for metastatic colorectal cancer. This reflects Amgen's ongoing commitment to improving outcomes for patients with challenging cancer types.
Read more →AMGNNEW DATA PRESENTED AT ATS 2024 SHOW THE POTENTIAL OF TEZSPIRE® TO HELP PATIENTS LIVING WITH COPD Amgen (NASDAQ:AMGN) and AstraZeneca today announced the results of the Phase 2a COURSE trial evaluating Tezspire® (tezepelumab-ekko) in people with...
Amgen and AstraZeneca announced positive results from the Phase 2a COURSE trial of Tezspire (tezepelumab-ekko) for treating chronic obstructive pulmonary disease (COPD). The trial showed a notable reduction in exacerbations for patients with higher eosinophil counts, although the primary result for the overall population was not statistically significant. The companies plan to advance to a Phase 3 clinical program to further evaluate the treatment's efficacy and safety. Improvements in lung function and quality of life measures were also observed among participants, indicating Tezspire's potential impact in COPD management.
Read more →AMGNFDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved IMDELLTRA™ (tarlatamab-dlle) for the treatment of...
Amgen announced the FDA's approval of IMDELLTRA (tarlatamab-dlle), the first and only T-cell engager therapy for extensive-stage small cell lung cancer. This approval is based on the promising results from the DeLLphi-301 study, which showed a 40% objective response rate and a median overall survival of 14.3 months. The therapy targets DLL3-expressing tumor cells and aims to provide an innovative treatment option for patients who have undergone prior chemotherapy. However, there are risks associated, including serious side effects that necessitate health care supervision during treatment.
Read more →AMGNAMGEN TO HOST CONFERENCE CALL FOLLOWING ATS 2024 Amgen (NASDAQ:AMGN) will host a webcasted call for the investment community at 1:00 p.m. PT on Monday, May 20, 2024 following the presentation of new ...
Amgen (NASDAQ: AMGN) will hold a webcasted call for investors at 1:00 p.m. PT on May 20, 2024, to discuss new data regarding TEZSPIRE for chronic obstructive pulmonary disease (COPD). This presentation will take place following the American Thoracic Society (ATS) International Conference. Executive Vice President Jay Bradner and other team members will participate in the call. The webcast will also cover additional programs from Amgen's inflammation portfolio.
Read more →AMGNAMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 9:20 a.m. PT on Tuesday, May 14, 2024. Peter...
Amgen (NASDAQ: AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference on May 14, 2024, at 9:20 a.m. PT. Key executives, including Peter Griffith and Jay Bradner, will participate in the presentation. The event will be accessible via a live webcast, intended for media, investors, and the general public, with archived availability for at least 90 days. Amgen has received multiple accolades, including recognition by Fast Company as one of the world's most innovative companies.
Read more →AMGNAMGEN REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS Amgen (NASDAQ:AMGN) today announced financial results for the first quarter 2024. With many of our innovative products delivering strong growth and...
Amgen (NASDAQ: AMGN) announced its financial results for the first quarter of 2024, reporting a 22% increase in total product sales compared to the same period in 2023. This growth is primarily attributed to a 25% rise in sales volume driven by several innovative products. Despite this positive trend, the company experienced a drop in margins and noted seasonal sales impacts on certain established products. Amgen continues to advance its pipeline of new medicines, contributing to its optimistic outlook for long-term growth.
Read more →AMGNAMGEN HIGHLIGHTS NEW COPD, ASTHMA AND VASCULITIS RESEARCH AT ATS 2024 Amgen (NASDAQ:AMGN) today announced the presentation of new respiratory data at the American Thoracic Society (ATS) 2024 International Conference...
Amgen (NASDAQ:AMGN) announced new findings related to COPD, asthma, and vasculitis at the ATS 2024 International Conference. These include results from the Phase 2a COURSE trial for Tezspire, an investigational therapy for COPD, and a Phase 1 study of AMG104/AZD8630 aimed at asthma treatment. The presentations emphasize Amgen's commitment to addressing severe respiratory diseases with innovative therapies. Additionally, TAVNEOS data focused on patients with severe ANCA-associated vasculitis was highlighted, illustrating the company's broadened research outreach in respiratory drug development.
Read more →AMGNAMGEN ANNOUNCES WEBCAST OF 2024 FIRST QUARTER FINANCIAL RESULTS Amgen (NASDAQ:AMGN) today announced that it will report its first quarter 2024 financial results on Thursday, May 2, 2024, after the close of the U.S....
Amgen has announced that it will report its first quarter 2024 financial results on May 2, 2024, after the U.S. markets close. Following the announcement, the company will hold a conference call with its management team, which will be accessible via a live audio webcast. The webcast will also be archived for replay for 90 days, allowing broader access to this important financial update. Amgen continues to emphasize its innovation in the biopharma sector as evidenced by its recognition from reputable sources.
Read more →AMGNAMGEN TO SUBMIT TEPROTUMUMAB MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY Amgen (NASDAQ:AMGN) today announced the imminent submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ...
Amgen has announced its intention to submit a Marketing Authorization Application (MAA) for teprotumumab to the European Medicines Agency (EMA) for treating moderate to severe Thyroid Eye Disease (TED). If approved, it will be the first medicine authorized for TED in the EU, supported by extensive clinical studies. The treatment offers a significant advancement as it targets the underlying causes of TED, reducing the reliance on steroids or surgery. Teprotumumab is already approved in several other countries, indicating a strong potential for patient impact.
Read more →AMGNAMGEN TO PRESENT TEZSPIRE® PHASE 2A COPD DATA AT ATS 2024 Amgen (NASDAQ:AMGN) today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIRE® (tezepelumab-ekko) in chronic...
Amgen (NASDAQ: AMGN) announced positive results from the Phase 2a COURSE trial for TEZSPIRE® (tezepelumab-ekko) in COPD, with findings accepted for presentation at the ATS 2024 conference. The study showed a 17% reduction in moderate or severe COPD exacerbations compared to placebo, particularly in patients with higher baseline eosinophil counts. Amgen is encouraged by these results and is planning for Phase 3 development of tezepelumab in COPD, addressing a significant unmet medical need. Full data will be shared at the upcoming congress.
Read more →AMGNAMGEN PRESENTS NEW RESEARCH ON OTEZLA® (APREMILAST) AT AAD 2024 Amgen (NASDAQ:AMGN) today announced new, 52-week results from the Phase 3 SPROUT study examining the use of Otezla® (apremilast) in children and...
Amgen has announced promising 52-week results from the Phase 3 SPROUT study, which evaluates the efficacy of Otezla (apremilast) in children with moderate to severe plaque psoriasis. The study shows sustained improvements in psoriasis severity, with over half of patients achieving clear skin. Additionally, findings from a late-breaking study on palmoplantar pustulosis in Japan will also be presented, indicating the treatment's potential in various inflammatory skin conditions.
Read more →AMGNAMGEN ANNOUNCES 2024 SECOND QUARTER DIVIDEND Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.25 per share dividend for the second quarter of 2024. The dividend will ...
Amgen has announced a dividend of $2.25 per share for the second quarter of 2024, which will be payable on June 7, 2024. Shareholders must be on record by May 17, 2024, to qualify for the payout. As a prominent biotechnology company, Amgen emphasizes its commitment to developing innovative therapies and improving health outcomes. Additionally, the company has received various accolades for workplace satisfaction and environmental leadership.
Read more →AMGNAMGEN TO PRESENT AT THE 44TH ANNUAL TD COWEN HEALTH CARE CONFERENCE Amgen (NASDAQ:AMGN) will present at the 44th Annual TD Cowen Health Care Conference at 9:10 a.m. ET on Tuesday, March 5, 2024. Peter Griffith,...
Amgen (NASDAQ: AMGN) announced its participation at the 44th Annual TD Cowen Health Care Conference scheduled for March 5, 2024. Executive Vice President Peter Griffith and Chief Medical Officer Paul Burton will represent the company, presenting the latest developments in their business. The event will include a webcast available to the media, investors, and the general public, with archived access for 90 days post-event. This highlights Amgen's commitment to transparency and investor engagement in the biotech sector.
Read more →AMGNAMGEN OPENS STATE-OF-THE-ART BIOMANUFACTURING SITE IN CENTRAL OHIO Amgen (NASDAQ:AMGN) today announced the opening of its manufacturing site in Central Ohio, the newest in its global operations network and the most...
Amgen has inaugurated its new biomanufacturing facility in Central Ohio, marking a significant expansion in its global operations network. The nearly 300,000-square-foot site aims to deliver safe and reliable medicines while emphasizing sustainability and collaboration among employees. This development is expected to generate 400 jobs, contributing to the state's economy and enhancing the local workforce through an apprenticeship program. The initiative aligns with Amgen's goal of addressing serious diseases globally.
Read more →AMGNAMGEN TO HOST CONFERENCE CALL ON RARE DISEASE Amgen (NASDAQ:AMGN) will host a webcasted call at 1:00 p.m. PT on Thursday, February 22, 2024 to discuss Rare Disease, its newly added fourth pillar...
Amgen (NASDAQ: AMGN) will hold a conference call on February 22, 2024, at 1:00 p.m. PT to discuss its newly added Rare Disease pillar. The call will feature key executives and focus on Amgen's rare disease strategy, including marketed products and pipeline opportunities. Interested parties can access the webcast through Amgen’s website, with the session archived for replay afterwards. This initiative reflects Amgen's ongoing commitment to addressing high unmet medical needs in the biotech field.
Read more →AMGNAMGEN TO PRESENT AT THE 34TH ANNUAL OPPENHEIMER HEALTHCARE LIFE SCIENCES CONFERENCE Amgen (NASDAQ:AMGN) will present at the 34th Annual Oppenheimer Healthcare Life Sciences Conference at 12:00 p.m. ET on Wednesday, Feb. 14, 2024. Jay ...
Amgen (NASDAQ: AMGN) is set to present at the 34th Annual Oppenheimer Healthcare Life Sciences Conference on February 14, 2024, at 12:00 p.m. ET. Key executives, including Jay Bradner and Murdo Gordon, will represent the company during the event. The webcast of the presentation will be available for the media, investors, and the public, with future accessibility for replay. The presentation aligns with Amgen's commitment to showcasing its innovative approaches in addressing serious illnesses.
Read more →AMGNAMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year 2023 versus comparable periods in 2022. 2023 was another...
Amgen (NASDAQ: AMGN) announced its financial results for Q4 and FY 2023, revealing a 20% increase in product sales compared to the same quarter in the previous year. The company reported growth across several products and expects to achieve multiple pipeline milestones in 2024. However, the financial results also highlighted challenges, including higher operating expenses that affected operating margins and a decline in cash flow compared to the prior year.
Read more →AMGNAMGEN ANNOUNCES WEBCAST OF 2023 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2023 financial results on Tuesday, February 6, 2024, after...
Amgen has announced it will report its fourth quarter and full year 2023 financial results on February 6, 2024, followed by a conference call. The call will feature the CEO and other senior management members, providing an opportunity for the investment community to engage directly. The webcast will be available for all stakeholders and archived for future access. This event highlights Amgen's ongoing commitment to transparency and investor relations.
Read more →AMGNAMGEN TO PRESENT AT THE 42ND ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE Amgen (NASDAQ:AMGN) will present at the 2024 J.P. Morgan Healthcare Conference at 9:00 a.m. PT on Monday, January 8, 2024. Robert A. Bradway,...
Amgen (NASDAQ: AMGN) is set to present at the 2024 J.P. Morgan Healthcare Conference on January 8, 2024, featuring CEO Robert A. Bradway. The presentation will be webcast live, allowing accessibility for media members, investors, and the public. Amgen consistently focuses on solving high unmet medical needs through innovative therapeutic solutions, reinforcing its prominent role in biotechnology.
Read more →AMGNAMGEN PROVIDES REGULATORY UPDATE ON STATUS OF LUMAKRAS® (SOTORASIB) Amgen (NASDAQ:AMGN) announced today that the U.S. Food and Drug Administration (FDA) has completed its review of the company's supplemental New Drug...
Amgen announced that the FDA has completed its review of the supplemental New Drug Application for LUMAKRAS (sotorasib), seeking full approval for KRAS G12C-mutated non-small cell lung cancer (NSCLC). This review led to a Complete Response Letter, requiring an additional confirmatory study to support full approval, expected to be finished by February 2028. However, the current dosing of 960 mg once-daily will remain unchanged under accelerated approval. LUMAKRAS was the first KRAS G12C inhibitor approved in the U.S. in May 2021.
Read more →AMGNSUS INCORPORA TRATAMENTO PARA MIELOMA MÚLTIPLO(1) O SUS deverá fornecer, em breve, um novo tratamento para o Mieloma Múltiplo (MM)1, tipo de câncer hematológico que afeta principalmente pessoas acima ...
The Brazilian health system (SUS) is set to provide a new treatment for Multiple Myeloma (MM) soon, which is expected to benefit patients, particularly those over 70. Carfilzomib, developed by Amgen, has demonstrated enhanced clinical outcomes when combined with dexamethasone for patients who have been previously treated. The implementation process involves a maximum of 180 days following the official incorporation decision. This marks a significant advancement in treatment options for patients suffering from this challenging hematological cancer.
Read more →AMGNOne Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.Amgen.com AMGEN ANNOUNCES EXECUTIVE APPOINTMENTS TO ACCELERATE INNOVATION James Bradner, M.D., Joins as Executive Vice President
Amgen has announced new executive appointments, naming James Bradner as Executive Vice President and Chief Scientific Officer, while David M. Reese transitions to Executive Vice President and Chief Technology Officer. This move aims to accelerate innovation within the company, particularly in research and development and technological advancements. Both leaders are expected to enhance Amgen's already strong pipeline, focusing on significant unmet medical needs across various therapeutic areas. This strategic shift highlights Amgen's commitment to integrating technology into biotechnology to improve patient outcomes.
Read more →AMGNAMGEN TO SPONSOR THE IRISH OPEN Amgen (NASDAQ:AMGN) today announced it will serve as the title sponsor of the Irish Open starting in 2024, following the acquisition of Horizon...
Amgen has announced its role as the title sponsor of the 2024 Irish Open, following its acquisition of Horizon Therapeutics. The sponsorship signifies Amgen's ongoing commitment to Ireland, where it has a substantial operational presence and has invested significantly over the years. Prominent Irish golfers will represent Amgen as ambassadors during the tournament, scheduled for September 2024 at the Royal County Down Golf Club. This event is not only a continuation of Horizon's previous sponsorship but also a strategic initiative to bolster Amgen's brand in the region.
Read more →AMGNAMGEN ANNOUNCES EXECUTIVE APPOINTMENTS TO ACCELERATE INNOVATION Amgen (NASDAQ:AMGN) today announced two changes to its senior leadership team in the areas of research and development (R&D) and technology,...
Amgen has announced new executive appointments to strengthen its leadership in research and development and technology. James Bradner joins as Executive Vice President and Chief Scientific Officer, taking over R&D from David M. Reese, who now becomes Executive Vice President and Chief Technology Officer. This transition emphasizes the company's commitment to advancing its drug pipeline and integrating technology and AI into its operations for enhanced efficiency. Both leaders have significant backgrounds that position Amgen well for future innovations in biotechnology.
Read more →AMGNFDA Grants Priority Review to Amgen's Tarlatamab Application for Advanced Small Cell Lung Cancer Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the Company's...
Amgen announced that the FDA has accepted and granted Priority Review for the Biologics License Application (BLA) for tarlatamab, aimed at treating advanced small cell lung cancer (SCLC). This investigational therapy targets DLL3 and proposes a potential first-in-class treatment for patients who have progressed after platinum-based chemotherapy. If approved, tarlatamab will offer a much-needed option in a therapeutic area with limited existing choices. The target action date for the FDA's decision is set for June 12, 2024.
Read more →AMGNAmgen aposta em flexibilização de local de trabalho para melhorar a produtividade e a saúde mental dos colaboradores Em abril de 2021, em meio à pandemia, Ana Arantes começava uma nova etapa de vida. A mudança de São Paulo (SP) para Florianópolis (SC) era o início...
Amgen is implementing a flexible work program aimed at improving employee productivity and mental health. The initiative focuses on employee retention and well-being, allowing employees like Ana Arantes to relocate for better quality of life while continuing to excel professionally. This strategy has resulted in numerous promotions and job assignments within the company, promoting gender equity and nurturing female leadership. The company emphasizes the importance of developing a supportive environment that fosters individual capabilities and team engagement.
Read more →AMGNAMGEN ANNOUNCES 2024 FIRST QUARTER DIVIDEND INCREASE TO $2.25 PER SHARE Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.25 per share dividend for the first quarter of 2024. This is the 12th...
Amgen has announced a dividend increase to $2.25 per share for the first quarter of 2024, reflecting its 12th consecutive yearly increase. This decision comes as the company continues to invest in innovation while managing its balance sheet effectively. The dividend will be paid to stockholders of record on February 16, 2024, with payment scheduled for March 7, 2024. Amgen is recognized as a leading biotechnology company and remains committed to addressing high unmet medical needs in healthcare.
Read more →AMGNAMGEN HIGHLIGHTS HEMATOLOGY PORTFOLIO AT ASH 2023 Amgen (NASDAQ:AMGN) today announced the presentation of new data from its blood cancer portfolio and pipeline at the 65th American Society of...
Amgen presented new data related to its hematology portfolio at the 65th American Society of Hematology Annual Meeting, taking place from December 9-12 in San Diego. The findings emphasized the effectiveness of BLINCYTO and KYPROLIS in treating blood cancers, with statements from Amgen's executive indicating commitment to innovations in hematology treatments. Additionally, analyses on a biosimilar candidate for eculizumab were discussed, positing further options for patients with blood-related conditions.
Read more →AMGNAMGEN TO PRESENT AT THE EVERCORE ISI HEALTHCONX CONFERENCE Amgen (NASDAQ:AMGN) will present at the Evercore ISI HealthCONx Conference at 9:10 a.m. EST on Wednesday, Nov. 29, 2023. Peter H. Griffith, executive ...
Amgen (NASDAQ: AMGN) is scheduled to present at the Evercore ISI HealthCONx Conference on November 29, 2023. Key executives, including CFO Peter H. Griffith and CMO Paul Burton, will lead the presentation, which will be available online for the public and investors. This event highlights Amgen's ongoing commitment to transparency and engagement with stakeholders.
Read more →AMGNAMGEN PRESENTS NEW CARDIOVASCULAR RESEARCH AT AHA 2023 Amgen (NASDAQ:AMGN) today announced new data reinforcing the safety and efficacy of Repatha® (evolocumab) from the FOURIER Open Label Extension (OLE) ...
Amgen presented new research on Repatha® (evolocumab) at AHA 2023, highlighting its safety and efficacy, specifically showing no cognitive decline in patients with low LDL cholesterol levels during long-term treatment. Additionally, new insights from the olpasiran studies suggest a need for further understanding of cardiovascular risks associated with elevated lipoprotein(a). The company aims to significantly reduce heart attack and stroke occurrences by 2030 through improved lipid management initiatives.
Read more →AMGNAMGEN PRESENTS NEW RESEARCH IN EARLY PSORIATIC ARTHRITIS AT ACR 2023 Amgen (NASDAQ:AMGN) today announced results from the global Phase 4 FOREMOST study evaluating Otezla® (apremilast) in patients with early...
Amgen has announced positive results from the global Phase 4 FOREMOST study, evaluating Otezla (apremilast) for early oligoarticular psoriatic arthritis. The study, which is the first placebo-controlled trial of its kind, showed that patients receiving Otezla were twice as likely to achieve minimal disease activity compared to those on placebo. These findings will be presented at the ACR Convergence 2023, indicating a significant advance in the treatment landscape for this common form of psoriatic arthritis. Overall, the study demonstrates promise in addressing unmet needs within this patient population.
Read more →AMGNAMGEN PRESENTS NEW DATA FROM PHASE 2 TRIAL OF DAZODALIBEP IN SJÖGREN'S SYNDROME AT ACR 2023 Amgen (NASDAQ:AMGN) today announced new data from its Phase 2 study evaluating dazodalibep, an investigational medicine, for the treatment of...
Amgen (NASDAQ: AMGN) has presented new data from its Phase 2 study on dazodalibep, an investigational treatment for Sjögren's syndrome, at ACR 2023. The study demonstrated clinical efficacy and safety, achieving its primary endpoint in both patients with systemic disease activity and those with prominent symptoms. Despite the positive findings, there are currently no FDA-approved treatments for Sjögren's syndrome, emphasizing the importance of ongoing clinical development in this area. Amgen is now advancing a Phase 3 trial to further evaluate the benefits of dazodalibep.
Read more →AMGNAMGEN PRESENTS NEW DATA THAT SHOW BLOOD PRESSURE DECREASES FOR ADULTS TREATED WITH KRYSTEXXA® (PEGLOTICASE) Amgen (NASDAQ:AMGN) today announced new data for KRYSTEXXA® (pegloticase) showing a decrease in blood pressure during treatment of adults living with ...
Amgen has presented new research data indicating that KRYSTEXXA (pegloticase) treatment significantly lowers blood pressure in adults with uncontrolled gout, including those with chronic kidney disease. Data from the MIRROR trial demonstrated that patients administered KRYSTEXXA with methotrexate experienced a more pronounced and sustained decrease in blood pressure over 52 weeks compared to the placebo group. Additionally, projections suggest that effective treatment with KRYSTEXXA could prevent numerous cases of uncontrolled gout in patients facing challenges with oral urate-lowering therapies. This research was showcased at the American Society of Nephrology Kidney Week in Philadelphia.
Read more →AMGNAMGEN TO PRESENT DATA AT ACR 2023 ACROSS EXPANDED RHEUMATOLOGY PIPELINE AND PORTFOLIO Amgen (NASDAQ:AMGN) today announced the presentation of new scientific and clinical research across its expanded rheumatology pipeline and portfolio, ...
Amgen (NASDAQ: AMGN) has announced the presentation of new scientific research at the American College of Rheumatology (ACR) Convergence 2023, reflecting its growth in the rheumatology sector, especially following its acquisition of Horizon Therapeutics. The company will present data across various conditions including Sjögren's syndrome and uncontrolled gout, highlighting investigational therapies like dazodalibep for Sjögren's and TAVNEOS for ANCA-associated vasculitis. Over 20 abstracts will be presented, showcasing Amgen's commitment to addressing diverse rheumatological diseases through innovative therapeutic approaches.
Read more →AMGNAMGEN REPORTS THIRD QUARTER FINANCIAL RESULTS Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 20231. We are excited about our pipeline progress and our operating...
Amgen announced its third quarter financial results for 2023, highlighting a 5% increase in total product sales year-over-year. The company's CEO expressed optimism about pipeline advancements and the recent acquisition of Horizon, which enhances their offerings in rare diseases. Despite the positive sales growth, challenges were noted, including decreased selling prices and declining sales for certain products. Additionally, operating expenses rose significantly, potentially impacting profit margins.
Read more →AMGNAMGEN ANNOUNCES WEBCAST OF 2023 THIRD QUARTER FINANCIAL RESULTS Amgen (NASDAQ:AMGN) today announced that it will report its third quarter financial results on Tuesday, October 31, 2023, before the opening of the U....
Amgen (NASDAQ: AMGN) has announced its intention to report third quarter financial results on October 31, 2023, before U.S. market opening. Following the report, a conference call with the investment community will be hosted by CEO Robert A. Bradway and other senior management. The call will be broadcast live over the internet and will also be archived for replay on Amgen's website. This event highlights Amgen's continued commitment to transparency and communication with stakeholders.
Read more →AMGNAMGEN ANNOUNCES 2023 FOURTH QUARTER DIVIDEND Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.13 per share dividend for the fourth quarter of 2023. The dividend will ...
Amgen (NASDAQ: AMGN) has announced a fourth quarter dividend of $2.13 per share, payable on December 8, 2023. This declaration reflects the company’s commitment to delivering shareholder value. Furthermore, Amgen's initiatives and recognition for workplace excellence and climate leadership highlight its positive brand image. However, the company acknowledges inherent risks in its operations and market conditions that could influence its future performance.
Read more →AMGNAMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) PLUS VECTIBIX® (PANITUMUMAB) DATA IN PATIENTS WITH KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER Amgen (NASDAQ:AMGN) today announced data from the global Phase 3 CodeBreaK 300 trial evaluating two doses of LUMAKRAS® (sotorasib) (960 mg or 240 mg) ...
Amgen has announced promising data from the Phase 3 CodeBreaK 300 trial, which evaluated the combination of LUMAKRAS (sotorasib) and Vectibix (panitumumab) in patients with KRAS G12C-mutated metastatic colorectal cancer. The trial demonstrated a statistically significant increase in progression-free survival when compared to standard care. The findings were presented at the ESMO 2023 Congress and published in the New England Journal of Medicine. Amgen plans to submit these results to regulatory authorities for further consideration.
Read more →AMGNAMGEN PRESENTS NEW TARLATAMAB DATA IN SMALL CELL LUNG CANCER Amgen (NASDAQ:AMGN) today announced results from the global Phase 2 DeLLphi-301 study, evaluating tarlatamab, an investigational delta-like ligand 3...
Amgen has announced promising results from its Phase 2 DeLLphi-301 study of tarlatamab, showing a 40% objective response rate and a median overall survival of 14.3 months in patients with advanced small cell lung cancer (SCLC) after previous therapies. The treatment, which utilizes BiTE technology targeting DLL3, displayed an encouraging safety profile with low rates of severe adverse events. These data, presented at the ESMO Congress 2023, suggest tarlatamab's potential as a meaningful therapy in a challenging treatment landscape. Amgen plans to further discuss these findings with regulatory authorities.
Read more →AMGNAMGEN TO WEBCAST INVESTOR CALL AT ESMO 2023 Amgen (NASDAQ:AMGN) today announced that it will host a webcasted call for the investment community at 8:00 a.m. ET on Tuesday, Oct. 24, 2023...
Amgen (NASDAQ: AMGN) has announced a webcast investor call scheduled for October 24, 2023, at 8:00 a.m. ET. This call will follow the presentation of new data from its oncology portfolio, including drugs like AMG 193 and LUMAKRAS (sotorasib), at the ESMO Congress 2023. David M. Reese, M.D., and members of Amgen's team will participate in the call, which aims to engage both media and investors. The webcast will be archived for at least 90 days post-event for those unable to attend live.
Read more →AMGNAMGEN TO PRESENT NEW RESEARCH FROM ONCOLOGY PORTFOLIO AND PIPELINE AT ESMO 2023 Amgen (NASDAQ:AMGN) today announced the presentation of new data across its broad oncology portfolio and pipeline at the European Society for Medical ...
Amgen announced it will present new oncology research at ESMO 2023 from October 20-24 in Madrid. The presentation will include results from pivotal studies focusing on innovative therapies for KRAS G12C-mutated cancers, showcasing the efficacy of combination therapies like LUMAKRAS with Vectibix. Early results of Phase 1 trials for AMG 509 highlight its potential in treating metastatic castration-resistant prostate cancer. Overall, the data reflects Amgen's commitment to advancing cancer treatment options.
Read more →AMGNAMGEN COMPLETES ACQUISITION OF HORIZON THERAPEUTICS PLC Amgen (NASDAQ: AMGN) today announced that it has completed its acquisition of Horizon Therapeutics plc for $116.50 per share in cash, representing a...
Amgen has completed its acquisition of Horizon Therapeutics plc for $116.50 per share, totaling approximately $27.8 billion. This acquisition is expected to enhance Amgen's portfolio in rare disease treatments, allowing the company to better serve patients with serious illnesses. Amgen's CEO expressed optimism regarding the strategic and financial benefits of the merger, stating it positions Amgen as a leader across various diseases. The company plans to provide updated financial guidance in its upcoming third quarter earnings call.
Read more →AMGNOne Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.Amgen.com News Release AMGEN COMPLETES ACQUISITION OF HORIZON THERAPEUTICS PLC Advances Amgen s Mission to Serve Patients With First-in-Class
Amgen has successfully completed its acquisition of Horizon Therapeutics plc, valuing the deal at approximately $27.8 billion. This acquisition is expected to enhance Amgen's capabilities in addressing serious illnesses, particularly in rare and autoimmune diseases. Amgen's chairman emphasized the momentum in their core business and the strategic benefits from this addition, which aims to improve health outcomes for patients worldwide. The company also plans to provide updated financial guidance in their upcoming earnings call.
Read more →AMGNAMGEN LAUNCHES PARTNERS OF CHOICE NETWORK OF EIGHT LEADING ONCOLOGY ACADEMIC CENTERS Amgen (NASDAQ:AMGN) today announced the launch of Amgen Partners of Choice, a new network that brings together Amgen's oncology research and...
Amgen has launched the Amgen Partners of Choice, a collaborative network involving eight leading oncology academic centers globally. This initiative aims to foster partnerships that enhance cancer treatment development and address unmet medical needs. The network will host bi-annual scientific summits to discuss new advancements and prioritize projects, ultimately working towards improved patient outcomes. Key focus areas include thoracic, gastrointestinal, and genitourinary cancers, signaling a significant step in Amgen's commitment to advancing cancer care.
Read more →AMGNAMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 11:40 a.m. BST on Thursday, Sept. 14, 2023....
Amgen (NASDAQ: AMGN) is set to present at the Bank of America Merrill Lynch Global Healthcare Conference on September 14, 2023. CFO Peter H. Griffith will lead the presentation, which will be accessible to media, investors, and the public via webcast. The event aims to showcase Amgen's business developments and commitment to innovation in biotechnology, reflecting its ongoing efforts to address serious illnesses. The webcast will be archived for 90 days for later access.
Read more →AMGNAMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) PLUS CHEMOTHERAPY DATA IN FIRST-LINE KRAS G12C NSCLC AT WCLC Amgen (NASDAQ:AMGN) today announced exciting data from a study arm of the CodeBreaK 101 clinical trial, a Phase 1b study evaluating LUMAKRAS®...
Amgen announced positive results from the Phase 1b CodeBreaK 101 study, evaluating LUMAKRAS plus chemotherapy in KRAS G12C-mutated NSCLC. The combination achieved a 65% confirmed objective response rate and a 100% disease control rate in the first-line setting. With favorable safety data, including common adverse events like neutropenia and anemia, Amgen has started preparations for a Phase 3 study to further investigate this combination treatment. This move reinforces Amgen's commitment to advancing options in cancer treatment, particularly for NSCLC patients with this mutation.
Read more →AMGNAMGEN TO PRESENT AT THE MORGAN STANLEY GLOBAL HEALTHCARE CONFERENCE Amgen (NASDAQ:AMGN) will present at the Morgan Stanley Global Healthcare Conference at 8:50 a.m. ET on Tuesday, Sept. 12, 2023. Robert A. Bradway,...
Amgen (NASDAQ: AMGN) will present at the Morgan Stanley Global Healthcare Conference on September 12, 2023, featuring CEO Robert A. Bradway. The presentation will be accessible to media, investors, and the public via a live webcast. This event is part of Amgen's efforts to communicate advancements in its business and engage with stakeholders. Additionally, the company's achievements in the industry include recognition for its workplace culture and climate initiatives.
Read more →AMGNOne Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.Amgen.com News Release AMGEN AND HORIZON THERAPEUTICS PLC RESOLVE FTC LAWSUIT, CLEARING PATH TO CLOSE ACQUISITION THOUSAND OAKS, Calif., & DU
Amgen has reached a consent order agreement with the FTC, resolving a pending lawsuit that had delayed its acquisition of Horizon Therapeutics. The resolution clears the final steps needed for the acquisition, which both companies expect to finalize in early Q4 2023. The agreement emphasizes that Amgen has no plans to bundle Horizon's products with its own, which is significant for maintaining transparency in their business practices. Amgen aims to leverage this acquisition to better serve patients suffering from rare diseases worldwide.
Read more →AMGNAMGEN AND HORIZON THERAPEUTICS PLC RESOLVE FTC LAWSUIT, CLEARING PATH TO CLOSE ACQUISITION Amgen (NASDAQ:AMGN) and Horizon Therapeutics plc (NASDAQ:HZNP) today announced the entry into a consent order agreement with the Federal Trade...
Amgen and Horizon Therapeutics have entered into a consent order agreement with the FTC, resolving the pending administrative lawsuit. This resolution allows them to finalize their acquisition, which is expected to occur in early Q4 2023. Amgen reassured the FTC that it has no plans to bundle Horizon's products with its own, which is formalized in the consent order. The companies aim to expand their efforts in serving patients with rare diseases following the acquisition approval.
Read more →AMGNAMGEN TO PRESENT AT THE 2023 WELLS FARGO HEALTHCARE CONFERENCE AND THE CITI GLOBAL HEALTHCARE CONFERENCE Amgen (NASDAQ:AMGN) will present at the 2023 Wells Fargo Healthcare Conference at 9:30 a.m. ET on Wednesday, Sept. 6, 2023. Amgen will also present...
Amgen (NASDAQ: AMGN) will present at the 2023 Wells Fargo Healthcare Conference on September 6 and at the Citi Global Healthcare Conference on September 7. Key executives Peter H. Griffith and Murdo Gordon are set to present at both events. Webcasts of the presentations will be available online, ensuring accessibility for media, investors, and the public. Amgen continues its commitment to developing innovative therapeutics for serious illnesses.
Read more →AMGNAMGEN PRESENTS LATE-BREAKING PHASE 2 OLPASIRAN DATA AT ESC 2023 Amgen (NASDAQ:AMGN) today announced data from the final analysis of the Phase 2 OCEAN(a)-DOSE study of olpasiran, a small interfering RNA (siRNA)...
Amgen has presented positive Phase 2 data for olpasiran at the ESC 2023, highlighting its significant and lasting reduction of Lp(a) levels in patients nearly a year after treatment. The study findings suggest olpasiran effectively addresses a major cardiovascular risk factor, with a notable safety profile. This development is expected to lead to the initiation of Phase 3 cardiovascular outcome trials. Additionally, Amgen has formed the LDL Awareness to Action Implementation Consortium aimed at enhancing LDL-C testing and treatment practices.
Read more →AMGNAMGEN TO DISCUSS APPLICATION FOR LUMAKRAS® (SOTORASIB) FOR THE TREATMENT OF KRAS G12C-POSITIVE NSCLC AT FDA ADVISORY COMMITTEE MEETING Amgen (NASDAQ:AMGN) today announced the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) will review data supporting ...
Amgen announced that the FDA Oncologic Drugs Advisory Committee will review the supplemental New Drug Application for LUMAKRAS (sotorasib) for adults with KRAS G12C-positive non-small cell lung cancer. The meeting is scheduled for October 5, 2023. LUMAKRAS, which has already received accelerated approval, aims for full approval by December 24, 2023, and has shown a promising benefit/risk profile in clinical studies for treating advanced lung cancer. Additionally, LUMAKRAS is already available in several international markets, enhancing its global accessibility.
Read more →AMGNAMGEN REPORTS SECOND QUARTER FINANCIAL RESULTS Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2023. We had a very strong quarter, serving more patients across all ...
Amgen announced its financial results for the second quarter of 2023, highlighting significant growth in both revenues and product sales. With a 6% increase in total product sales year-over-year, the company is making strides in serving more patients across its therapeutic categories. Additionally, positive data regarding key products like Tarlatamab and LUMAKRAS was shared, indicating good progress in their development pipeline. The company expects continued strong performance for the remainder of the year, excluding contributions from its upcoming acquisition of Horizon Therapeutics.
Read more →AMGNAMGEN ANNOUNCES 2023 THIRD QUARTER DIVIDEND Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.13 per share dividend for the third quarter of 2023. The dividend will...
Amgen (NASDAQ: AMGN) has announced that its Board of Directors has declared a dividend of $2.13 per share for the third quarter of 2023. The dividend is set to be paid on September 8, 2023, to shareholders of record by August 18, 2023. The company continues to strive for innovations in therapeutics addressing significant medical needs and has been recognized as a leading biotechnology firm globally. Amgen emphasizes its commitment to advancing human health through its diverse pipeline and ongoing collaborations.
Read more →AMGNAMGEN ANNOUNCES WEBCAST OF 2023 SECOND QUARTER FINANCIAL RESULTS Amgen (NASDAQ:AMGN) today announced that it will report its second quarter financial results on Thursday, August 3, 2023, after the close of the U.S. ...
Amgen has announced that it will report its second quarter financial results on August 3, 2023, following the close of U.S. financial markets. A conference call will occur at 1:30 p.m. PT, featuring CEO Robert A. Bradway and senior management. The audio from this call will be available live online and archived for up to 90 days. This disclosure reflects Amgen's ongoing communication with investors and commitment to transparency regarding its financial performance.
Read more →AMGNAMGEN AMPLIA O NÚMERO DE MULHERES NA LIDERANÇA A Amgen anuncia promoções internas que reforçam o compromisso e o objetivo de identificar o potencial dos colaboradores, desenvolver os profissionais ...
Amgen has announced several internal promotions aimed at strengthening women's leadership within the organization. This includes the appointments of Ana Paula Arantes Marques and Luciana Mensor to senior manager roles. Additionally, Leandro Ramos has taken on leadership responsibilities for the Oncology, Hematology and Biosimilars Business Unit. Through these changes, Amgen continues to prioritize gender equity, diversity, inclusion, and belonging within its workforce, particularly in its Brazilian operations, where women represent a significant portion of the team and hold many leadership roles.
Read more →AMGNAMGEN AMPLIA O NÚMERO DE MULHERES NA LIDERANÇA A Amgen anuncia promoções internas que reforçam o compromisso e o objetivo da marca de identificar o potencial dos colaboradores, desenvolver os...
Amgen has announced a series of internal promotions aimed at strengthening its leadership structure, particularly in promoting female executives. Notable appointments include Ana Paula Arantes Marques and Luciana Mensor, who join senior management roles. The company emphasizes gender equity as a key institutional pillar, with initiatives designed to enhance women's leadership representation and career development. Recent statistics show that more than half of Amgen's workforce in Brazil is female, with a significant portion of internal promotions going to women.
Read more →AMGNFDA GRANTS FULL APPROVAL FOR BLINCYTO® (BLINATUMOMAB) TO TREAT MINIMAL RESIDUAL DISEASE-POSITIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application...
Amgen's BLINCYTO (blinatumomab) has received full FDA approval to treat adults and pediatric patients with B-cell precursor acute lymphoblastic leukemia (B-ALL) exhibiting minimal residual disease. This approval converts its previous accelerated approval, confirming its clinical benefits based on extensive Phase 3 studies. Amgen plans to advance further development of BLINCYTO to address additional patient needs and improve treatment methodologies.
Read more →AMGNAMGEN TO PRESENT AT THE GOLDMAN SACHS 44TH ANNUAL GLOBAL HEALTHCARE CONFERENCE Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 44th Annual Global Healthcare Conference at 2:20 p.m. ET on Wednesday, June 14, 2023. Robert A. ...
Amgen (NASDAQ: AMGN) will present at the Goldman Sachs 44th Annual Global Healthcare Conference on June 14, 2023, at 2:20 p.m. ET. CEO Robert A. Bradway will lead the presentation, which will be accessible via a live webcast for media, investors, and the public. This event aims to highlight Amgen's recent developments and ongoing commitment to addressing significant healthcare needs.
Read more →AMGNAMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) CODEBREAK 200 CNS DATA AT ASCO 2023 Amgen (NASDAQ:AMGN) today announced the presentation of new data from the CodeBreaK clinical trial program, the most comprehensive global development ...
Amgen has presented new data from the CodeBreaK clinical trial program at the ASCO Annual Meeting, highlighting the efficacy of LUMAKRAS (sotorasib) in treating KRAS G12C-mutant cancers. Notably, the analysis shows that sotorasib offers delayed CNS progression and longer progression-free survival than docetaxel in patients with advanced NSCLC. Additionally, the combination of sotorasib with Vectibix and FOLFIRI demonstrated a promising response rate in previously treated patients with metastatic colorectal cancer. These findings underline the potential of sotorasib as a significant therapeutic option in these difficult-to-treat cancer types.
Read more →AMGNAMGEN PRESENTS NEW SCIENTIFIC AND CLINICAL RESEARCH ACROSS ITS DIVERSE ONCOLOGY PORTFOLIO AND PIPELINE AT ASCO 2023 New LUMAKRAS® (sotorasib) Data From First Study Evaluating Intracranial Efficacy of a KRAS G12C Inhibitor Versus Docetaxel in Treated KRAS...
Amgen presented its latest oncology research at the ASCO 2023 conference, including advancements in LUMAKRAS for KRAS G12C-mutated cancers. The data highlighted significant efficacy for LUMAKRAS in patients with advanced non-small cell lung cancer and also showcased findings on Tarlatamab for small cell lung cancer. The company is focused on enhancing treatment options within its pipeline, with several ongoing studies aimed at solid tumors. Despite encouraging results, the need for further validation and the potential for adverse reactions were acknowledged.
Read more →AMGNAMGEN PRESENTS NEW RESEARCH ON OTEZLA® (APREMILAST) IN PSORIATIC ARTHRITIS AT EULAR 2023 Amgen (NASDAQ:AMGN) today announced new research examining the use of Otezla® (apremilast) in psoriatic arthritis, including the Phase 4 MOSAIC study ...
Amgen has announced new research on Otezla (apremilast) concerning its effectiveness in treating psoriatic arthritis, particularly through the Phase 4 MOSAIC study. This study uniquely employed MRI to visualize inflammation improvements while assessing Otezla’s impact on structural progression in patients. Results will be presented at the upcoming EULAR 2023 conference, showcasing promising findings related to both inflammatory responses and cardiometabolic health parameters among psoriatic arthritis patients. Amgen aims to enhance understanding and treatment options for this chronic condition.
Read more →AMGNAMGEN TO PRESENT AT THE TD COWEN 4TH ANNUAL ONCOLOGY INNOVATION SUMMIT Amgen (NASDAQ: AMGN) will present at the TD Cowen 4th Annual Oncology Innovation Summit at 11:00 a.m. ET on Wednesday, May 31, 2023. David M. Reese,...
Amgen (NASDAQ: AMGN) will present at the TD Cowen 4th Annual Oncology Innovation Summit on May 31, 2023. David M. Reese, M.D., is scheduled to discuss developments in the company's research and development efforts. The presentation will be available via a live webcast for media, investors, and the general public. Archived recordings will also be accessible for 90 days after the event.
Read more →AMGNMAIO ROXO ALERTA PARA AS DOENÇAS INFLAMATÓRIAS INTESTINAIS (DII) E CÂNCER COLORRETAL De acordo com a Sociedade Brasileira de Coloproctologia (SBCP), as doenças inflamatórias intestinais (DII) são caracterizadas pela inflamação de...
The article discusses the rising prevalence of inflammatory bowel diseases (IBD) as reported by the Sociedade Brasileira de Coloproctologia, indicating a rising rate of cases in Brazil. It emphasizes the importance of early diagnosis and effective treatment options for conditions like Crohn's disease and ulcerative colitis. The article also highlights Amgen's dedication to applying advanced biotechnology in developing innovative treatments for serious illnesses. Colorectal cancer remains a significant health concern in Brazil, underscoring the urgent need for increased public awareness and research efforts.
Read more →AMGNOne Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.Amgen.com News Release AMGEN RESPONDS TO FTC ACTION RE: PROPOSED ACQUISITION OF HORIZON THERAPEUTICS THOUSAND OAKS, Calif. (
Amgen has responded to the FTC's complaint aimed at blocking its proposed acquisition of Horizon Therapeutics, asserting that their products serve different markets with no competitive overlap. The company believes it has sufficiently addressed the FTC's concerns and intends to proceed with the acquisition, targeting a closure by mid-December. Despite their optimistic stance, the FTC's action may complicate the acquisition process, presenting potential delays and legal hurdles.
Read more →AMGNAMGEN RESPONDS TO FTC ACTION RE: PROPOSED ACQUISITION OF HORIZON THERAPEUTICS Amgen (NASDAQ:AMGN) today issued the following statement in response to the U.S. Federal Trade Commission's (FTC) complaint seeking to block the...
Amgen has responded to the FTC's complaint seeking to block its proposed acquisition of Horizon Therapeutics, asserting that the merger presents no legitimate competitive concerns. The company emphasizes that the medications provided by Amgen and Horizon target different diseases and patient populations, with no market overlap. Amgen plans to cooperate with the FTC and aims to finalize the acquisition by mid-December. However, the speculation surrounding potential bundling of products remains a point of contention.
Read more →AMGNAMGEN AND TSCAN THERAPEUTICS ANNOUNCE COLLABORATION TO IDENTIFY NOVEL TARGETS IN CROHN'S DISEASE Amgen (NASDAQ:AMGN) and TScan Therapeutics, Inc. (NASDAQ:TCRX), today announced a multi-year collaboration that will use TScan's proprietary target...
Amgen and TScan Therapeutics have launched a multi-year collaboration aimed at discovering novel targets for Crohn's disease using TScan's TargetScan platform. TScan will receive an initial payment of $30 million, with additional milestone payments possible, totaling over $500 million. Amgen plans to evaluate various therapeutic modalities based on these targets and maintains the rights for global development and commercialization. This partnership reflects a strategic effort to enhance treatment options for inflammatory bowel disease, aiming for first-in-class therapeutic candidates.
Read more →AMGNNEW DATA FROM AMGEN'S PROLIA® (DENOSUMAB) DEMONSTRATES SIGNIFICANT REDUCTION IN OSTEOPOROTIC FRACTURE RISK COMPARED TO ALENDRONATE Amgen (NASDAQ:AMGN) today announced new data from a real-world study of nearly half of a million postmenopausal women with osteoporosis in the U.S....
Amgen announced new real-world study data indicating that Prolia (denosumab) significantly reduces the risk of osteoporotic fractures in postmenopausal women when compared to alendronate. The study, which evaluated nearly half a million Medicare beneficiaries, showed progressively improved fracture risk reduction with longer durations of Prolia treatment. Results were presented at the World Congress on Osteoporosis in Barcelona, emphasizing the need for better management of osteoporosis, particularly in high-risk women. Prolia is already approved in over 80 countries for osteoporosis treatment.
Read more →AMGNAMGEN TO PRESENT AT THE 2023 BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE Amgen (NASDAQ:AMGN) will present at the 2023 Bank of America Merrill Lynch Global Healthcare Conference at 11:00 a.m. ET on Tuesday, May 9, 2023....
Amgen (NASDAQ: AMGN) is set to present at the 2023 Bank of America Merrill Lynch Global Healthcare Conference on May 9, 2023. The presentation will feature Dr. David M. Reese and CFO Peter H. Griffith, catering to media, investors, and the public via a live webcast. Amgen, recognized for its commitment to innovative therapeutics and included in major indices like the Dow Jones, showcases its advancements in biotechnology and dedication to improving health outcomes.
Read more →AMGNAMGEN REPORTS FIRST QUARTER FINANCIAL RESULTS Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2023. We delivered 14% volume growth driven by the breadth of our...
Amgen (NASDAQ:AMGN) reported its financial results for Q1 2023, showcasing a 14% growth in volume, supported by strong demand for its product portfolio. The company indicated a total product sales increase of 2%, despite challenges like a 5% decline in net selling prices and increased operating expenses. Notably, Amgen expects the acquisition of Horizon Therapeutics to be completed in the first half of 2023, which could further enhance its offerings. Certain key products, such as Repatha and Prolia, demonstrated significant increases in sales compared to the previous year.
Read more →AMGNAMGEN ANNOUNCES WEBCAST OF 2023 FIRST QUARTER FINANCIAL RESULTS Amgen (NASDAQ:AMGN) today announced that it will report its first quarter financial results on Thursday, April 27, 2023, after the close of the U.S....
Amgen has announced that it will release its first quarter financial results on April 27, 2023, after the U.S. financial markets close. This announcement will be accompanied by a conference call scheduled for 1:30 PM PT, featuring CEO Robert A. Bradway and other members of the senior management team. The conference call will be broadcast live over the internet and will be accessible to the media, investors, and the general public. Additionally, the webcast will be archived for at least 90 days for later access.
Read more →AMGNAMGEN WINS PATENT APPEAL ON OTEZLA® (APREMILAST) Amgen (NASDAQ:AMGN) today announced that the U.S. Court of Appeals for the Federal Circuit has affirmed the judgment of the U.S. District Court for...
Amgen announced that the U.S. Court of Appeals for the Federal Circuit upheld two of its patents related to Otezla® (apremilast). This ruling affirms the validity of Patent No. 7,427,638 and Patent No. 7,893,101, protecting the pharmaceutical formulations and crystalline forms of Otezla. However, the court ruled against Amgen on Patent No. 10,092,541, which claims treatment methods for psoriasis. The ruling is considered a win for Amgen, solidifying its market position and protecting against generic competition until the patents expire in 2028.
Read more →AMGNFundação AMGEN apoia Ensina Brasil no fomento à formação de cientistas O Ensina Brasil, organização sem fins lucrativos que recruta, seleciona e desenvolve jovens talentos para se tornarem líderes em educação por meio do ...
Amgen Foundation has partnered with Ensina Brasil to enhance educational leadership among young talents in vulnerable public schools. The initiative aims to develop future scientists by investing in STEM education and cultivating qualified educators in Brazil. Since its inception, the program has effectively reached and transformed the education of over 90,000 students, ensuring diverse opportunities and high-quality education for those in need. This partnership aligns with Amgen's commitment to racial equity and community engagement.
Read more →AMGNMULHERES RESPONDEM POR 70%* DAS PROMOÇÕES DE CARGO DENTRO DA AMGEN Uma das principais empresas de biotecnologia do mundo, a Amgen também está comprometida em desenvolver e ampliar ações focadas na equidade de gênero, ...
Amgen is making significant strides in gender equity within its workforce, with women composing 54% of its employees in Brazil and accounting for 68% of internal promotions. Notably, they hold half of the leadership and executive director positions. The company is dedicated to enhancing initiatives for gender equality, including mentorship programs aimed at career development for women. Amgen's commitment to diversity has also earned it recognition as one of the best employers globally.
Read more →AMGNAMGEN TO PRESENT AT THE 33rd ANNUAL OPPENHEIMER HEALTHCARE CONFERENCE Amgen (NASDAQ:AMGN) will present at the 2023 Oppenheimer Healthcare Conference at 2:00 p.m. ET on Monday, March 13, 2023. Susan Sweeney, senior vice...
Amgen (NASDAQ: AMGN) is scheduled to present at the 2023 Oppenheimer Healthcare Conference on March 13, 2023, at 2:00 p.m. ET. Senior Vice President Susan Sweeney will lead the presentation, which will be broadcast live and available for replay on Amgen's website. This participation emphasizes Amgen's commitment to sharing developments with the public and investors. The company is recognized for its innovative approaches to healthcare and has a strong reputation in the biotechnology sector.
Read more →AMGNAMGEN ANNOUNCES 2023 SECOND QUARTER DIVIDEND Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.13 per share dividend for the second quarter of 2023. The dividend will ...
Amgen has announced the declaration of a $2.13 per share dividend for the second quarter of 2023, which will be paid to stockholders on June 8, 2023. This move underscores Amgen's financial health and commitment to returning value to its shareholders, reinforcing its position as a leading biotechnology company. The dividend will benefit all stockholders of record by May 18, 2023. Amgen continues to focus on high unmet medical needs and aims to enhance health outcomes through its innovative therapies.
Read more →AMGNSUS INCORPORA TRATAMENTO PARA MULHERES COM OSTEOPOROSE NA PÓS-MENOPAUSA(1) O Brasil terá um novo tratamento disponível para combater a osteoporose. O Ministério da Saúde confirmou a inclusão do romosozumabe no Sistema Único...
The Brazilian Health Ministry announced the inclusion of romosozumab, a treatment for osteoporosis in postmenopausal women, in the country's public healthcare system (SUS). This decision is aimed at addressing the health needs of the significant population suffering from osteoporosis in Brazil, where many are unaware of their condition. Romosozumab is designed to enhance bone formation and reduce fracture risks, particularly for those with a history of osteoporotic fractures or who have been intolerant to other therapies. The next steps involve completing the Ministry's incorporation protocol for full patient access to the treatment.
Read more →AMGNAMGEN TO PRESENT AT THE 43RD ANNUAL TD COWEN HEALTHCARE CONFERENCE Amgen (NASDAQ:AMGN) will present at the 2023 TD Cowen Healthcare Conference at 11:10 a.m. ET on Wednesday, March 8, 2023. Murdo Gordon, executive...
Amgen (NASDAQ: AMGN) is set to present at the 2023 TD Cowen Healthcare Conference on March 8, 2023. Key executives, including Murdo Gordon and Peter H. Griffith, will lead the presentation. The event will be broadcast online, available for media, investors, and the public, and will be archived for later access. This marks another opportunity for Amgen to share its developments with stakeholders.
Read more →AMGNAMGEN TO PRESENT NEW REPATHA® (EVOLOCUMAB) AND OLPASIRAN DATA AT ACC Amgen (NASDAQ: AMGN) today announced new Repatha® (evolocumab) combined data from the Phase 3 FOURIER and FOURIER Open Label Extension (OLE) studies...
Amgen announced promising data regarding Repatha and olpasiran, with findings showcasing significant reductions in cardiovascular events for patients using Repatha earlier in their treatment. The new results from the Phase 3 FOURIER studies indicate that patients with atherosclerotic cardiovascular disease benefitted greatly. Additionally, olpasiran was shown to reduce lipoprotein(a) by over 90% across various baseline levels, suggesting its potential as an innovative treatment option. The company will present these findings at the upcoming ACC.23/WCC conference in New Orleans, further highlighting their commitment to advancing cardiovascular care.
Read more →AMGNAMGEN ANNOUNCES CARDIOVASCULAR STUDY TO EVALUATE ASSOCIATION BETWEEN LIPOPROTEIN(a) AND CARDIOVASCULAR RISK IN AFRICAN AMERICANS Amgen (NASDAQ:AMGN) today announced the African American Heart Study, in collaboration with the Association of Black Cardiologists (ABC) and the...
Amgen has announced the African American Heart Study, a collaborative effort with the Association of Black Cardiologists and Morehouse School of Medicine. This observational study aims to explore the association between Lipoprotein(a), or Lp(a), levels and atherosclerotic cardiovascular disease (ASCVD) specifically in African Americans, who are often underrepresented in clinical research. The study will enroll 5,000 participants and seeks to understand the genetically influenced higher Lp(a) concentration in this population, potentially improving future therapy strategies.
Read more →AMGNNA CONTRAMÃO DO MERCADO E NA MESMA MÃO DA EMPRESA , AFIRMA DIRETORA PROMOVIDA ÀS VÉSPERAS DE SAIR DE LICENÇA Convicção. Essa é a palavra que resume a reação de Ana Paula Gazzotti, da Amgen, ao receber a notícia de que seria a nova Diretora de Compliance da...
Ana Paula Gazzotti has been appointed as the new Director of Compliance for Amgen in Latin America just as she prepares for maternity leave. Her promotion represents Amgen's commitment to recognizing talent irrespective of familial circumstances, highlighting a shift towards more inclusive corporate practices. Gazzotti expressed that the company's actions have a positive impact on employee morale and workplace culture, enhancing feelings of belonging among staff. Amgen continues to focus on employee well-being and development while combating severe diseases through innovative therapies.
Read more →AMGNAMGEN TO PRESENT AT THE 2023 SVB SECURITIES GLOBAL BIOPHARMA CONFERENCE Amgen (NASDAQ:AMGN) will present at the 2023 SVB Securities Global Biopharma Conference at 10:40 a.m. ET on Tuesday, February 14, 2023. Susan...
Amgen (NASDAQ: AMGN) will present at the 2023 SVB Securities Global Biopharma Conference on February 14, 2023, at 10:40 a.m. ET. The presentation will be led by Susan Sweeney, Senior Vice President of Global Marketing, Access, and Capabilities. The event will be streamed live and made available for replay on Amgen's website, showcasing the company's ongoing developments and commitments in biopharmaceuticals. Amgen continues to emphasize its dedication to addressing unmet medical needs and innovation in human therapeutics.
Read more →AMGNTEZSPIRE® APPROVED FOR SELF-ADMINISTRATION IN THE U.S. WITH A NEW PRE-FILLED PEN Amgen (NASDAQ:AMGN) and AstraZeneca today announced the U.S. Food and Drug Administration (FDA) has approved TEZSPIRE® (tezepelumab-ekko) for...
Amgen and AstraZeneca announced that the FDA has approved TEZSPIRE for self-administration using a pre-filled pen for patients aged 12 and older with severe asthma. This approval allows patients to choose between administering the treatment at home or in a clinical setting. TEZSPIRE is unique as the only biologic approved for severe asthma without phenotype restrictions and has shown a high rate of successful administration in trials. While the treatment offers significant benefits, it is also associated with certain adverse reactions, including hypersensitivity risks.
Read more →AMGNAMJEVITA™ (ADALIMUMAB-ATTO), FIRST BIOSIMILAR TO HUMIRA®, NOW AVAILABLE IN THE UNITED STATES Amgen (NASDAQ:AMGN) today announced AMJEVITA™ (adalimumab-atto), a biosimilar to Humira®* (adalimumab), is now available in the United States....
Amgen has announced that AMJEVITA (adalimumab-atto), the first biosimilar to Humira, is now available in the United States. Approved by the FDA in 2016, AMJEVITA is designed to treat multiple inflammatory diseases and is priced significantly below Humira. The product is also supported by Amgen's comprehensive patient assistance programs. However, potential users must be informed of the associated risks, including serious infections and malignancies.
Read more →AMGNAMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS Amgen (NASDAQ: AMGN) today announced financial results for the fourth quarter and full year 2022 versus comparable periods in 2021. We executed...
Amgen (NASDAQ: AMGN) announced its financial results for the fourth quarter and full year of 2022, showing a strong volume growth and an overall revenue increase. The company delivered effective performance with notable advancements in its pipeline, including the expected acquisition of Horizon Therapeutics. However, the report revealed a decline in GAAP Net Income and Earnings Per Share (EPS) for the fourth quarter, along with a slight decrease in operating margin. Overall, Amgen remains optimistic about its long-term growth strategy and product development.
Read more →AMGNAMGEN POSTS FULL TRANSCRIPT AND AUDIO REPLAY OF FOURTH QUARTER AND FULL YEAR 2022 EARNINGS WEBCAST Amgen (NASDAQ:AMGN) posted the full transcript and audio replay of the company's 2022 fourth quarter and full year financial results webcast from...
Amgen has posted the full transcript and audio replay of its fourth quarter and full year 2022 earnings webcast. This event allows stakeholders to access vital financial information from the company. The details can be found on Amgen's official website, making it easier for investors and analysts to stay informed about the company's developments.
Read more →AMGNAmgen Inc. Recast of 2021 Non-GAAP Financial Information As Reported to Reflect Updated Non-GAAP Policy Beginning
Amgen Inc. has updated its non-GAAP financial reporting policy, effective January 1, 2022. This change entails including upfront license fees, development milestones, and IPR&D expenses from pre-approval programs in their financial statements. The updated policy complies with recent industry guidelines from the U.S. Securities and Exchange Commission. Consequently, Amgen has recast its 2021 financial results to reflect this policy revision, aiming for more accurate performance representation.
Read more →AMGNRule 15(c) Announcement - Rule 15 Proposal to Horizon Equity Award Holders and Participants in the Horizon Employee Share Purchase Plan NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD...
Amgen Inc. has announced a cash offer for Horizon Therapeutics plc through its wholly-owned subsidiary, Pillartree Limited. This proposal, which is governed by Irish corporate law, is intended for Horizon's equity award holders and participants in its employee share purchase plan. The details of the proposal have been sent to relevant stakeholders and made available on both Amgen's and Horizon's websites. Shareholders are encouraged to review the Proxy Statement and related documents for complete information regarding the transaction.
Read more →AMGNAMGEN ANNOUNCES WEBCAST OF 2022 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2022 financial results on Tuesday, Jan. 31, 2023, after the...
Amgen has announced that it will report its fourth quarter and full year 2022 financial results on January 31, 2023, following the close of U.S. markets. The announcement will be accompanied by a conference call at 4:30 p.m. ET, featuring CEO Robert A. Bradway and other executives. The live audio will be accessible to the media, investors, and the public via Amgen's website, and the session will be archived for 90 days for future access.
Read more →AMGNAMGEN AND BIOLABS LA AT THE LUNDQUIST INSTITUTE ANNOUNCE NAMMI THERAPEUTICS TO RECEIVE THE THIRD AMGEN GOLDEN TICKET Amgen (NASDAQ:AMGN) and BioLabs LA at The Lundquist Institute today announced that Nammi Therapeutics has been awarded the third Amgen Golden Ticket...
Amgen and BioLabs LA at The Lundquist Institute announced that Nammi Therapeutics has been awarded the third Amgen Golden Ticket. This award provides Nammi with one year of lab space, additional facility benefits, and connections to Amgen's scientific and business leaders. The selection was made during a virtual pitch event where five finalists presented their business plans. The Amgen Golden Ticket program aims to accelerate life science startups and has awarded 30 Golden Tickets since its inception in 2014.
Read more →AMGNAMGEN TO PRESENT AT THE 41ST ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE Amgen (NASDAQ:AMGN) will present at the 2023 J.P. Morgan Healthcare Conference at 6:45 p.m. ET on Monday, January 9, 2023. Robert A. Bradway,...
Amgen (NASDAQ: AMGN) is scheduled to present at the 2023 J.P. Morgan Healthcare Conference on January 9, 2023, at 6:45 p.m. ET. Robert A. Bradway, Amgen's chairman and CEO, will be presenting. The event will be webcasted live, making it accessible to media, investors, and the public. The presentation aligns with Amgen's mission to deliver innovative therapeutics and improve health outcomes for patients.
Read more →AMGNBLINCYTO® (BLINATUMOMAB) ADDED TO CONSOLIDATION CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN ADULT PATIENTS WITH MEASURABLE RESIDUAL DISEASE-NEGATIVE B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) Amgen (NASDAQ: AMGN) today announced the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) will present results from the E1910 randomized Phase 3 trial....
At 3.5 Years, 83% of Patients on BLINCYTO Plus Chemotherapy Were Alive Versus 65% of Patients on Chemotherapy Alone Trial Design and Conduct Sponsored by the ECOG-ACRIN Cancer Research Group THOUSAND OAKS, Calif. , Dec. 13, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today annou
Read more →AMGNRule 2.7 Announcement: Amgen Inc to Acquire Horizon Therapeutics plc NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF...
THOUSAND OAKS, Calif. , Dec. 12, 2022 /PRNewswire/ -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION THIS ANNOUNCEMENT IS BE
Read more →AMGNNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION THIS ANNOUNCEMENT
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION THIS ANNOUNCEMENT IS BEING MADE PURSUANT TO RULE 2.7 OF THE IRISH TAKEOVER RU
Read more →AMGNAMGEN TO HOST WEBCAST INVESTOR CALL FOLLOWING ANNOUNCED ACQUISITION OF HORIZON THERAPEUTICS Amgen (NASDAQ:AMGN) will host a webcast call for the investment community following the announced acquisition of Horizon Therapeutics at 8:00 a.m. ET ...
THOUSAND OAKS, Calif. , Dec. 12, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will host a webcast call for the investment community following the announced acquisition of Horizon Therapeutics at 8:00 a.m. ET on Monday, December 12, 2022 . Robert A. Bradway , chairman and chief exec
Read more →AMGNAMGEN ANNOUNCES 10% INCREASE IN 2023 FIRST QUARTER DIVIDEND Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.13 per share dividend for the first quarter of 2023. The dividend will...
THOUSAND OAKS, Calif. , Dec. 12, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that its Board of Directors declared a $2.13 per share dividend for the first quarter of 2023. The dividend will be paid on March 8, 2023 , to all stockholders of record as of the close of
Read more →AMGNNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION December 2, 2022 Amgen Inc. ( Amgen ) Possible offer for Horizon Th
Read more →AMGNAMGEN PRESENTS NEW AMG 133 PHASE 1 CLINICAL DATA AT WCIRDC 2022 Amgen (NASDAQ:AMGN) today announced new Phase 1 data from AMG 133, a novel bispecific glucose-dependent insulinotropic polypeptide receptor (GIPR)...
AMG 133 is a First-in-Class Investigational Bispecific Molecule That Activates GLP-1R and Inhibits GIPR Phase 1 Results Showed up to 14.5% Reduction in Body Weight at the Highest Dose After 12 Weeks Initiating Phase 2 Study in Early 2023 THOUSAND OAKS, Calif. , Dec. 1, 2022 /P
Read more →AMGNAMGEN TO WEBCAST INVESTOR CALL AT WCIRDC 2022 Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the World Congress on Insulin Resistance, Diabetes &...
THOUSAND OAKS, Calif. , Nov. 28, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will host a webcast call for the investment community in conjunction with the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) at 8:00 a.m. ET on Monday , Dec. 5, 2022. Dav
Read more →AMGNAMGEN ANNOUNCES WEBCAST OF 2022 EVERCORE ISI HEALTHCARE CONFERENCE Amgen (NASDAQ:AMGN) will present at the Evercore ISI HealthCONx Conference at 11:20 a.m. ET on Tuesday, November 29, 2022. David M. Reese, M.D.,...
THOUSAND OAKS, Calif. , Nov. 23, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Evercore ISI HealthCONx Conference at 11:20 a.m. ET on Tuesday, November 29, 2022 . David M. Reese , M.D., executive vice president of Research and Development at Amgen will present at
Read more →AMGNAMGEN ENTRA EM CONSÓRCIO QUE UNE FARMACÊUTICAS PELA AMPLIAÇÃO DO DIAGNÓSTICO DO CÂNCER DE PULMÃO NO BRASIL A Amgen é a mais nova integrante do Lung Mapping, programa focado em aumentar o acesso ao diagnóstico molecular de câncer de pulmão no Brasil, o que...
Ao lado das farmacêuticas AstraZeneca, Pfizer, Roche, Novartis e Takeda, a companhia passa a fazer parte do programa Lung Mapping, que facilita a identificação dos subtipos do tumor, passo fundamental para determinar o tratamento mais adequado SAO PAULO , 21 de novembro de 2022
Read more →AMGNAMGEN PRESENTS NEW REPATHA® (EVOLOCUMAB) DATA AT AHA 2022 Amgen (NASDAQ:AMGN) today presented a new analysis from the Phase 3 FOURIER and FOURIER open label extension (OLE) studies of Repatha® (evolocumab)...
Very low LDL-C Levels <20 mg/dL Were Well Tolerated With no new Safety Signals and Were Associated With a Reduced Risk of Cardiovascular Outcomes Data Reinforces Long-Term Efficacy and Consistent Safety Profile of Repatha Observed in FOURIER-OLE THOUSAND OAKS, Calif. , Nov. 7,
Read more →AMGNAMGEN TO PRESENT NEW RESEARCH ACROSS SERIOUS INFLAMMATORY AND BONE DISEASES AT ACR 2022 Amgen (NASDAQ:AMGN) today announced that clinical and real-world data across its broad portfolio of established treatments and pipeline assets will...
New Real-World Evidence Highlights AMGEVITA ® Utilization, Treatment Satisfaction and Persistence in European Patients New Data From First-in-Class Treatment TAVNEOS ® , Evaluating Renal Function Among Adults Living With Severe Active ANCA-Associated Vasculitis THOUSAND OAKS, C
Read more →AMGNAMGEN PRESENTS NEW PHASE 2 DATA THAT SHOW OLPASIRAN DELIVERS SIGNIFICANT REDUCTION IN LIPOPROTEIN(A) LEVELS Amgen (NASDAQ:AMGN) today presented end-of-treatment data from its Phase 2 OCEAN(a)-DOSE study of investigational olpasiran (formerly AMG 890) in...
Olpasiran Reduced Lipoprotein(a) Levels by More Than 95% in Patients With Established ASCVD Amgen is Initiating a Phase 3 Cardiovascular Outcomes Trial Based on These Results Data Simultaneously Published in the New England Journal of Medicine THOUSAND OAKS, Calif. , Nov. 6, 2
Read more →AMGNAMGEN ANNOUNCES WEBCAST OF 2022 CREDIT SUISSE GLOBAL HEALTHCARE CONFERENCE Amgen (NASDAQ:AMGN) will present at the Credit Suisse 31st Annual Global Healthcare Conference at 3:50 p.m. ET on Wednesday, November 9, 2022. David...
THOUSAND OAKS, Calif. , Nov. 4, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Credit Suisse 31st Annual Global Healthcare Conference at 3:50 p.m. ET on Wednesday, November 9, 2022 . David M. Reese , M.D., executive vice president of Research and Development and P
Read more →AMGNAMGEN REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2022. Key results include: Total revenues decreased 1% to $6.7 billion ...
THOUSAND OAKS, Calif. , Nov. 3, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced financial results for the third quarter of 2022. Key results include: "Our medicines generated 8% volume growth in the quarter globally, with 11 products achieving record quarterly sales,"
Read more →AMGNAMGEN TO WEBCAST INVESTOR CALL AT AHA 2022 Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the American Heart Association (AHA) Scientific...
THOUSAND OAKS, Calif. , Nov. 2, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will host a webcast call for the investment community in conjunction with the American Heart Association (AHA) Scientific Sessions at 6:00 p.m. ET on Monday , Nov. 7, 2022. David M. Reese , M.D., executive
Read more →AMGNAMGEN ANNOUNCES WEBCAST OF 2022 THIRD QUARTER FINANCIAL RESULTS Amgen (NASDAQ:AMGN) today announced that it will report its third quarter financial results on Thursday, Nov. 3, 2022, after the close of the U.S....
THOUSAND OAKS, Calif. , Oct. 31, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will report its third quarter financial results on Thursday, Nov. 3, 2022 , after the close of the U.S. financial markets. The announcement will be followed by a conference call wi
Read more →AMGNAMGEN ANNOUNCES 2022 FOURTH QUARTER DIVIDEND Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.94 per share dividend for the fourth quarter of 2022. The dividend will ...
THOUSAND OAKS, Calif. , Oct. 28, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that its Board of Directors declared a $1.94 per share dividend for the fourth quarter of 2022. The dividend will be paid on December 8, 2022 , to all stockholders of record as of the clos
Read more →AMGNOne Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.Amgen.com AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX TAVNEOS (avacopan), a First-in-Class Medicine for Patients Wi
AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX TAVNEOS (avacopan), a First-in-Class Medicine for Patients With Severe Active ANCA-Associated Vasculitis, Added to Inflammation Portfolio THOUSAND OAKS, Calif., (Oct. 20, 2022) Amgen (NASDAQ: AMGN) today announced that
Read more →AMGNAMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX Amgen (NASDAQ: AMGN) today announced that it has successfully completed its previously announced acquisition of ChemoCentryx, Inc. (NASDAQ: CCXI), a...
TAVNEOS ® (avacopan), a First-in-Class Medicine for Patients With Severe Active ANCA-Associated Vasculitis, Added to Inflammation Portfolio THOUSAND OAKS, Calif. , Oct. 20, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it has successfully completed its previous
Read more →AMGNAMGEN'S ANNUAL TRENDS REPORT FINDS COMPETITION CREATED BY BIOSIMILARS CONTRIBUTED $21 BILLION IN U.S. HEALTHCARE SYSTEM SAVINGS Amgen (NASDAQ:AMGN) today released the 9th edition of its Biosimilar Trends Report, which examines the current and future state of the U.S....
Ninth Edition of Amgen's Biosimilar Trends Report Examines the U.S. and Global Marketplace with Biosimilars THOUSAND OAKS, Calif. , Oct. 12, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today released the 9 th edition of its Biosimilar Trends Report, which examines the current and
Read more →AMGNESTUDO MOSTRA BENEFÍCIOS DE NOVO TRATAMENTO PARA CÂNCER DE PULMÃO DE CÉLULAS NÃO PEQUENAS A Amgen acaba de anunciar os resultados detalhados do estudo global de fase 3 CodeBreaK 200, apresentados durante o Congresso da Sociedade Europeia...
Trabalho inédito revela que, em um ano, a sobrevida livre de progressão da doença foi de 25% para sotorasibe versus 10% para docetaxel (tipo de quimioterapia intravenosa) SÃO PAULO , 10 de outubro de 2022 /PRNewswire/ -- A Amgen acaba de anunciar os resultados detalhados do estu
Read more →AMGNAMGEN OPENS NEW STATE-OF-THE-ART RESEARCH AND DEVELOPMENT LABORATORY SITE IN SAN FRANCISCO BAY AREA (Oct. 6, 2022) – Amgen (NASDAQ:AMGN) today announced the opening of a new research and development site in San Francisco's Oyster Point, continuing...
245,000 Square Foot Lab Demonstrates Amgen's Continued Commitment to Innovation THOUSAND OAKS, Calif. , Oct. 6, 2022 /PRNewswire/ -- ( Oct. 6, 2022 ) – Amgen (NASDAQ: AMGN ) today announced the opening of a new research and development site in San Francisco's Oyster Point, conti
Read more →AMGNLUMAKRAS® (SOTORASIB) COMBINED WITH VECTIBIX® (PANITUMUMAB) SHOWS CONFIRMED 30% OBJECTIVE RESPONSE RATE IN PATIENTS WITH KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER Amgen (NASDAQ: AMGN) today announced updated data from its Phase 1b CodeBreaK 101 study, one of the most comprehensive global clinical development...
Phase 1b Results Demonstrate Encouraging Median Progression-Free Survival of 5.7 Months in Difficult-to-Treat Patient Population THOUSAND OAKS, Calif. , Sept. 12, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced updated data from its Phase 1b CodeBreaK 101 study, one o
Read more →AMGNAMGEN ANNOUNCES WEBCAST OF 2022 BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE Amgen (NASDAQ:AMGN) will present at Bank of America Merrill Lynch's 2022 Global Healthcare Conference at 4:55 a.m. ET on Thursday, Sept. 15, 2022....
THOUSAND OAKS, Calif. , Sept. 12, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at Bank of America Merrill Lynch's 2022 Global Healthcare Conference at 4:55 a.m. ET on Thursday , Sept. 15, 2022. Peter H. Griffith , executive vice president and chief financial officer at
Read more →AMGNLUMAKRAS®/LUMYKRAS® (SOTORASIB) DEMONSTRATES SUPERIOR PROGRESSION-FREE SURVIVAL OVER DOCETAXEL IN FIRST POSITIVE PHASE 3 TRIAL OF A KRAS G12C INHIBITOR IN NON-SMALL CELL LUNG CANCER Amgen (NASDAQ: AMGN) today announced detailed results from the global Phase 3 CodeBreaK 200 trial, which showed once-daily oral LUMAKRAS®/LUMYKRAS®...
At 1-Year, Progression-Free Survival was 25% for LUMAKRAS Versus 10% for Docetaxel LUMAKRAS Met Key Secondary Endpoint of Objective Response Rate LUMAKRAS Showed Clinically Meaningful Improvements in Patient-Reported Outcomes Compared to Docetaxel THOUSAND OAKS, Calif., Sept.
Read more →AMGNAMGEN ANNOUNCES POSITIVE NEW DATA AT EADV 2022 FOR OTEZLA® (APREMILAST) Amgen (NASDAQ:AMGN) today announced results from two significant Phase 3 clinical studies of oral Otezla® (apremilast), demonstrating efficacy in...
SPROUT Data Show Otezla Resulted in Significant Improvements in Measures of Moderate to Severe Plaque Psoriasis at Week 16 Compared With Placebo in Children Ages 6-17 1 DISCREET 16-week Data Demonstrated Statistically Significant Improvements in Genital Psoriasis, Including Skin
Read more →AMGNAMGEN ANNOUNCES WEBCAST OF 2022 MORGAN STANLEY GLOBAL HEALTHCARE CONFERENCE Amgen (NASDAQ:AMGN) will present at Morgan Stanley's 2022 Global Healthcare Conference at 9:10 a.m. ET on Tuesday, Sept. 13, 2022. Robert A. Bradway, ...
THOUSAND OAKS, Calif. , Sept. 8, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at Morgan Stanley's 2022 Global Healthcare Conference at 9:10 a.m. ET on Tuesday, Sept. 13, 2022 . Robert A. Bradway , chairman and chief executive officer at Amgen will present at the confer
Read more →AMGNAMGEN TO WEBCAST INVESTOR CALL AT ESMO 2022 Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the European Society for Medical Oncology Annual...
THOUSAND OAKS, Calif. , Sept. 7, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will host a webcast call for the investment community in conjunction with the European Society for Medical Oncology Annual Congress (ESMO) at 1:30 p.m. ET on Monday, Sept. 12, 2022 . David M. Reese , M.D.
Read more →AMGNAMGEN ANNOUNCES WEBCAST OF 2022 WELLS FARGO HEALTHCARE CONFERENCE Amgen (NASDAQ:AMGN) will present at Wells Fargo's 2022 Global Healthcare Conference at 9:45 a.m. ET on Thursday, September 8, 2022. David M. Reese, M....
THOUSAND OAKS, Calif. , Sept. 2, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at Wells Fargo's 2022 Global Healthcare Conference at 9:45 a.m. ET on Thursday, September 8, 2022 . David M. Reese , M.D., executive vice president of Research and Development and Peter H. Gr
Read more →AMGNAMGEN ANNOUNCES WEBCAST OF 2022 CITI GLOBAL HEALTHCARE CONFERENCE Amgen (NASDAQ:AMGN) will present at Citi's 2022 Global Healthcare Conference at 8:50 a.m. ET on Wednesday, September 7, 2022. David M. Reese, M.D.,...
THOUSAND OAKS, Calif. , Sept. 2, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at Citi's 2022 Global Healthcare Conference at 8:50 a.m. ET on Wednesday, September 7, 2022 . David M. Reese , M.D., executive vice president of Research and Development and Peter H. Griffith
Read more →AMGNAMGEN ANNOUNCES TOPLINE DATA FROM LUMAKRAS® (SOTORASIB) PHASE 3 TRIAL IN NON-SMALL CELL LUNG CANCER Amgen (NASDAQ: AMGN) today announced that the global Phase 3 CodeBreaK 200 trial evaluating once daily oral LUMAKRAS® (sotorasib) met its primary...
LUMAKRAS Met Primary Endpoint of Progression-Free Survival, Demonstrating Superiority Over Standard of Care Docetaxel Chemotherapy, in KRAS G12C-Mutated Non-Small Cell Lung Cancer Detailed Data to be Presented at an Upcoming Medical Congress THOUSAND OAKS, Calif. , Aug. 30, 202
Read more →AMGNAMGEN TO PRESENT NEW, POSITIVE CLINICAL AND REAL-WORLD DATA ACROSS INFLAMMATION PORTFOLIO AT EADV 2022 Amgen (NASDAQ:AMGN) today announced that clinical and real-world data from across its inflammation portfolio, including both established treatments...
New Positive Data From Phase 3 SPROUT Trial, Studying Otezla (apremilast) in Children Ages 6-17 With Moderate to Severe Plaque Psoriasis Positive Results From the Phase 3 DISCREET Study, Investigating Clinical Efficacy and Safety of Otezla in Patients With Moderate to Severe Gen
Read more →AMGNNEW AMGEN DATA AT ESC 2022 SHOW LONG-TERM LDL-C LOWERING WITH REPATHA® (EVOLOCUMAB) WAS WELL-TOLERATED FOR MORE THAN 8 YEARS Amgen (NASDAQ:AMGN) today presented new compelling data from the Phase 3 FOURIER open label extension (OLE) studies of Repatha® (evolocumab) in...
Earlier Treatment With Repatha Resulted in a Lower Incidence of Major CV Events, Including CV Death 80% of Patients Achieved Guideline Directed LDL-C Levels of <55 mg/dL at Week 12 Data Presented at ESC 2022 and Simultaneously Published in Circulation THOUSAND OAKS, Calif. , A
Read more →AMGNAMGEN ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY OF ABP 959, BIOSIMILAR CANDIDATE TO SOLIRIS® (ECULIZUMAB) Amgen (NASDAQ: AMGN) today announced positive top-line results from the DAHLIA study, a randomized, double-blind, active-controlled, two-period...
Study Evaluated the Efficacy, Safety and Immunogenicity of ABP 959 Compared to Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria THOUSAND OAKS, Calif. , Aug. 23, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced positive top-line results from the DAHLIA st
Read more →AMGNAMGEN TO PRESENT NEW DATA AT ESC CONGRESS 2022 HIGHLIGHTING UP TO 8.5 YEARS OF REPATHA® (EVOLOCUMAB) SAFETY AND TOLERABILITY DATA IN HIGH-RISK ASCVD PATIENT POPULATIONS Amgen (NASDAQ:AMGN) today announced the presentation of eight cardiovascular (CV) scientific research abstracts, including long-term and real-world...
Late-breaking Hot Line Oral Presentation on FOURIER-OLE Data Represents Longest Trials of a PCSK9i to Date New HEYMANS, HAUSER Data to be Presented THOUSAND OAKS, Calif. , Aug. 22, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the presentation of eight cardiovascul
Read more →AMGNAMGEN PRESENTS NEW TARLATAMAB CLINICAL DATA AT WCLC 2022 Amgen (NASDAQ: AMGN) today announced new data from the DeLLphi300 clinical trial, a Phase 1 dose exploration and expansion study evaluating the...
Phase 1 Tarlatamab Study Showed Encouraging Antitumor Activity With Median Duration of Response of 13 Months in Small Cell Lung Cancer No Approved Treatment Options Available to Patients in Third-line Setting THOUSAND OAKS, Calif. , Aug. 8, 2022 /PRNewswire/ -- Amgen (NASDAQ: A
Read more →AMGNAMGEN DATA AT WCLC 2022 HIGHLIGHTS POTENTIAL TO DELIVER TRANSFORMATIVE MEDICINES FOR HISTORICALLY DIFFICULT-TO-TREAT LUNG CANCERS Amgen (NASDAQ: AMGN) today announced three new data sets from its thoracic oncology portfolio that will be presented at the International Association ...
First Data From LUMAKRAS Plus Immunotherapy and LUMAKRAS Plus SHP2 Inhibitor Combinations Show Clinical Activity and Support Ongoing Investigation Updated Phase 1 Tarlatamab Data Reinforce Potential of BiTE ® Therapy in Small Cell Lung Cancer THOUSAND OAKS, Calif. , Aug. 7, 202
Read more →AMGNAMGEN REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2022. Key results include: Total revenues increased 1% to $6.6...
THOUSAND OAKS, Calif. , Aug. 4, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced financial results for the second quarter of 2022. Key results include: "We are focused on delivering our long-term objectives by serving an ever-increasing number of patients around the wo
Read more →AMGNAMGEN TO ACQUIRE CHEMOCENTRYX FOR $4 BILLION IN CASH Amgen (NASDAQ: AMGN) and ChemoCentryx, Inc., (NASDAQ: CCXI), a biopharmaceutical company focused on orally administered therapeutics to treat...
Acquisition Includes TAVNEOS ® (avacopan), a First-in-Class Medicine for Patients With Serious Autoimmune Disease Tavneos Adds to Amgen's Decades-Long Leadership in Inflammation and Nephrology THOUSAND OAKS, Calif. and SAN CARLOS, Calif. , Aug. 4, 2022 /PRNewswire/ -- Amgen (NA
Read more →AMGNAMGEN TO ACQUIRE CHEMOCENTRYX FOR $4 BILLION IN CASH Acquisition Includes TAVNEOS (avacopan), a First-in-Class Medicine for Patients With Serious Autoimmune Disease Tavneos Adds to Amgen s Decades-Long Leade
AMGEN TO ACQUIRE CHEMOCENTRYX FOR $4 BILLION IN Acquisition Includes TAVNEOS (avacopan), a First-in-Class Medicine for Patients With Serious Autoimmune Disease Tavneos Adds to Amgen s Decades-Long Leadership in Inflammation THOUSAND OAKS, Calif. and SAN CARLOS, Calif., Aug. 4
Read more →AMGNAMGEN APPOINTS MICHAEL V. DRAKE TO BOARD OF DIRECTORS Amgen (NASDAQ: AMGN) today announced the appointment of Michael V. Drake, M.D., to its Board of Directors, effective immediately. Dr. Drake will also ...
THOUSAND OAKS, Calif. , Aug. 3, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the appointment of Michael V. Drake , M.D., to its Board of Directors, effective immediately. Dr. Drake will also serve as a member of the Board's Corporate Responsibility and Compliance Co
Read more →AMGNAMGEN ANNOUNCES 2022 THIRD QUARTER DIVIDEND Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.94 per share dividend for the third quarter of 2022. The dividend will...
THOUSAND OAKS, Calif. , Aug. 3, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that its Board of Directors declared a $1.94 per share dividend for the third quarter of 2022. The dividend will be paid on September 8, 2022 , to all stockholders of record as of the close
Read more →AMGNOne Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.Amgen.com News Release
AMGEN APPOINTS MICHAEL V. DRAKE TO BOARD OF DIRECTORS THOUSAND OAKS, Calif., Aug. 3, 2022 Amgen (NASDAQ: AMGN) today announced the appointment of Michael V. Drake, M.D., to its Board of Directors, effective immediately. Dr. Drake will also serve as a member of the Board s Corpo
Read more →AMGNAMGEN TO WEBCAST INVESTOR MEETING AT WCLC 2022 Amgen (NASDAQ: AMGN) will host a webcast call for the investment community in conjunction with the International Association for the Study of Lung...
THOUSAND OAKS, Calif. , Aug. 2, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will host a webcast call for the investment community in conjunction with the International Association for the Study of Lung Cancer (IASLC) 2022 World Conference on Lung Cancer (WCLC) at 12:00 p.m. ET on
Read more →AMGNAMGEN ANNOUNCES WEBCAST OF 2022 SECOND QUARTER FINANCIAL RESULTS Amgen (NASDAQ:AMGN) today announced that it will report its second quarter financial results on Thursday, August 4, 2022, after the close of the U.S. ...
THOUSAND OAKS, Calif. , Aug. 1, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will report its second quarter financial results on Thursday, August 4, 2022 , after the close of the U.S. financial markets. The announcement will be followed by a conference call
Read more →AMGNAMGEN FOUNDATION MORE THAN DOUBLES COMMITMENT TO LABXCHANGE, FREE VIRTUAL SCIENCE EDUCATION PLATFORM The Amgen Foundation today announced an increased commitment to LabXchange, an online science education platform that provides users with access to...
Founding and Lead Sponsor in Collaboration with the Vice Provost of Advances in Learning at Harvard University THOUSAND OAKS, Calif. , June 20, 2022 /PRNewswire/ -- The Amgen Foundation today announced an increased commitment to LabXchange, an online science education platform t
Read more →AMGNAMGEN ANNOUNCES WEBCAST OF GOLDMAN SACHS 43RD ANNUAL HEALTHCARE CONFERENCE Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 43rd Annual Healthcare Conference at 1:40 p.m. ET on Wednesday, June 15, 2022. David M. Reese,...
THOUSAND OAKS, Calif. , June 10, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Goldman Sachs 43 rd Annual Healthcare Conference at 1:40 p.m. ET on Wednesday , June 15, 2022. David M. Reese , M.D., executive vice president of Research and Development and Peter H.
Read more →AMGNFDA APPROVES RIABNI™ (RITUXIMAB-ARRX), A BIOSIMILAR TO RITUXAN® (RITUXIMAB), FOR ADULTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan®, ...
New Indication for Amgen's Fifth FDA-approved Biosimilar Now Approved to Treat All Available Rituxan ® Indications THOUSAND OAKS, Calif. , June 6, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (r
Read more →AMGNNEW HEAD-TO-HEAD DATA SHOW VECTIBIX® (PANITUMUMAB) DEMONSTRATED SUPERIOR OVERALL SURVIVAL COMPARED TO BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN JAPANESE PATIENTS WITH WILD-TYPE RAS COLORECTAL CANCER Amgen (NASDAQ:AMGN) and Takeda Pharmaceutical Company (TSE: 4502) today announced that new data from the Phase 3 PARADIGM clinical trial of Vectibix® ...
First Prospective Study of Treatment in Patients with Wild-Type RAS Colorectal Cancer and Left-Sided Primary Tumor Results From the Phase 3 PARADIGM Trial Being Featured During ASCO 2022 Plenary Session THOUSAND OAKS, Calif. and OSAKA, Japan , June 5, 2022 /PRNewswire/ -- Amgen
Read more →AMGNAMGEN ANNOUNCES WEBCAST OF 2022 JEFFERIES HEALTHCARE CONFERENCE Amgen (NASDAQ:AMGN) will present at the 2022 Jefferies Healthcare Conference at 9:30 a.m. ET on Wednesday, June 8, 2022. Murdo Gordon, executive vice ...
THOUSAND OAKS, Calif. , June 3, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the 2022 Jefferies Healthcare Conference at 9:30 a.m. ET on Wednesday , June 8, 2022. Murdo Gordon , executive vice president of Global Commercial Operations at Amgen will present at the co
Read more →AMGNAMGEN ANNOUNCES POSITIVE TOPLINE PHASE 2 DATA FOR INVESTIGATIONAL OLPASIRAN IN ADULTS WITH ELEVATED LIPOPROTEIN(a) Amgen (NASDAQ:AMGN) today announced positive topline data from the Phase 2 OCEAN(a)-DOSE clinical study, evaluating olpasiran (formerly AMG 890) in...
Study Showed Significant, Sustained Reduction in Lipoprotein(a) During Treatment Period Lipoprotein(a) Reduction was Consistent With Phase 1 Results THOUSAND OAKS, Calif. , May 31, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced positive topline data from the Phase 2
Read more →AMGNNEW DATA SHOWCASES HOW AMGEN IS ADVANCING ALL ANGLES OF CANCER CARE THROUGH INNOVATIVE ONCOLOGY PORTFOLIO AND PIPELINE AT ASCO 2022 Amgen (NASDAQ: AMGN) will present new data from across its broad oncology innovative medicines and biosimilars portfolio and robust pipeline at the...
Results From the PARADIGM Phase 3 Head-to-Head Trial of Vectibix ® (panitumumab) Versus Bevacizumab in Untreated RAS Wild-Type Metastatic Colorectal Cancer* Largest Evaluation of Acquired Resistance to LUMAKRAS ® /LUMYKRAS ® (sotorasib) in KRAS G12C-mutated Cancers Inform Combin
Read more →AMGNAMGEN AND LANCE BASS PARTNER TO ENCOURAGE PEOPLE TO DO A 'DOUBLE TAKE' TO RECOGNIZE THE EARLY SIGNS OF PSORIATIC ARTHRITIS Amgen (NASDAQ:AMGN) and Otezla® (apremilast) have partnered with pop icon and entrepreneur Lance Bass, for the Double Take campaign to empower people ...
Campaign Drives Awareness of Potential Early Symptoms of Psoriatic Arthritis and Empowers People to Take Action THOUSAND OAKS, Calif. , May 12, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and Otezla ® (apremilast) have partnered with pop icon and entrepreneur Lance Bass , for the
Read more →AMGNAMGEN ANNOUNCES WEBCAST OF 2022 BANK OF AMERICA HEALTHCARE CONFERENCE Amgen (NASDAQ:AMGN) will present at the 2022 Bank of America Healthcare Conference at 12:20 p.m. ET on Wednesday, May 11, 2022. David M. Reese, M.D., ...
THOUSAND OAKS, Calif. , May 6, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the 2022 Bank of America Healthcare Conference at 12:20 p.m. ET on Wednesday , May 11, 2022. David M. Reese , M.D., executive vice president of Research and Development and Peter H. Griffith
Read more →AMGNAMGEN RELEASES ANNUAL ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT Amgen (NASDAQ:AMGN) today released its 2021 Environmental, Social & Governance (ESG) report, providing a comprehensive overview of the many ways the...
THOUSAND OAKS, Calif. , May 2, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today released its 2021 Environmental, Social & Governance (ESG ) report, providing a comprehensive overview of the many ways the Company is doing its part to build a better, healthier world. To view the M
Read more →AMGNAMGEN REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS Amgen (NASDAQ: AMGN) today announced financial results for the first quarter of 2022. Key results include: Total revenues increased 6% to $6.2...
THOUSAND OAKS, Calif. , April 27, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced financial results for the first quarter of 2022. Key results include: "We achieved strong, volume-driven growth in the quarter, while launching two very promising first-in-class medicine
Read more →AMGNAMGEN ANNOUNCES RESULTS FROM TWO OPEN LABEL EXTENSION STUDIES OF REPATHA® (EVOLOCUMAB) Amgen (NASDAQ:AMGN) today announced top-line results from two Repatha® (evolocumab) open label extension (OLE) studies to the Phase 3 FOURIER...
Studies Showed Sustained Reduction in LDL-C With no new Safety Findings The Combined Studies Evaluated Safety and Tolerability of Repatha in More Than 6,600 Patients for Over Five Years After Completing the Phase 3 FOURIER Trial Repatha is the Longest Studied PCSK9i THOUSAND O
Read more →AMGNAMGEN ANNOUNCES WEBCAST OF 2022 FIRST QUARTER FINANCIAL RESULTS Amgen (NASDAQ:AMGN) today announced that it will report its first quarter financial results on Wednesday, April 27, 2022, after the close of the U.S. ...
THOUSAND OAKS, Calif. , April 22, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will report its first quarter financial results on Wednesday, April 27, 2022 , after the close of the U.S. financial markets. The announcement will be followed by a conference cal
Read more →AMGNAMGEN ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY OF ABP 654, BIOSIMILAR CANDIDATE TO STELARA® (USTEKINUMAB) Amgen (NASDAQ:AMGN) today announced preliminary results from a Phase 3 study evaluating the efficacy and safety of ABP 654 compared to STELARA®...
Primary Efficacy Analysis Demonstrates no Clinically Meaningful Differences Compared to STELARA THOUSAND OAKS, Calif. , April 18, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced preliminary results from a Phase 3 study evaluating the efficacy and safety of ABP 654 com
Read more →AMGNLUMAKRAS® (SOTORASIB) CODEBREAK 100 STUDY SHOWS TWO-YEAR OVERALL SURVIVAL OF 32.5% IN PATIENTS WITH KRAS G12C-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER Amgen (NASDAQ: AMGN) today announced the presentation of long-term efficacy and safety data from the CodeBreaK 100 Phase 1/2 trial in patients with...
Long-Term Clinical Benefit and Prolonged Tumor Response Seen With 40.7% Objective Response Rate No New Safety Signals Observed Longest Follow-Up of Patients Treated With a KRAS G12C Inhibitor THOUSAND OAKS, Calif. , April 10, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today an
Read more →AMGNAMGEN ANNOUNCES NEW OTEZLA (APREMILAST) DATA AT AAD CONGRESS 2022 Amgen (NASDAQ: AMGN) today announced that new Otezla (apremilast) data, along with findings on the unmet need for patients with plaque psoriasis,...
New data further reinforces clinical benefit of Otezla in mild to moderate plaque psoriasis and in patients with palmoplantar pustulosis Real-world evidence data being presented demonstrates continued burden of disease for patients with mild to moderate plaque psoriasis Otezla
Read more →AMGNAmgen To Present At The 32nd annual Oppenheimer Healthcare Conference Amgen (NASDAQ:AMGN) will virtually present at the 32nd Annual Oppenheimer Healthcare Conference at 11:20 a.m. ET on Wednesday, March 16, 2022. Rob...
THOUSAND OAKS, Calif. , March 10, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will virtually present at the 32 nd Annual Oppenheimer Healthcare Conference at 11:20 a.m. ET on Wednesday , March 16, 2022. Rob Lenz , M.D., Ph.D., senior vice president of Global Development and Peter
Read more →AMGNAMGEN TO PRESENT LONG-TERM OUTCOMES FOR LUMAKRAS® (SOTORASIB) IN KRAS G12C-MUTATED NSCLC AT AACR 2022 Amgen (NASDAQ: AMGN) today announced that new data from across its oncology portfolio and pipeline will be presented at the American Association for...
THOUSAND OAKS, Calif. , March 8, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that new data from across its oncology portfolio and pipeline will be presented at the American Association for Cancer Research (AACR) Annual Meeting from April 8-13 in New Orleans, Louisi
Read more →AMGNGLOBAL BIOTECHNOLOGY LEADER AMGEN BREAKS GROUND ON NEW MANUFACTURING FACILITY IN NORTH CAROLINA Amgen (NASDAQ:AMGN) today announced the groundbreaking of its newest biomanufacturing facility, located in Holly Springs, North Carolina. The...
THOUSAND OAKS, Calif. , March 7, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the groundbreaking of its newest biomanufacturing facility, located in Holly Springs, North Carolina . The facility, expected to be operational by 2025, will support the growing demand for
Read more →AMGNAMGEN TO PRESENT AT THE 42ND ANNUAL COWEN HEALTHCARE CONFERENCE Amgen (NASDAQ:AMGN) will virtually present at the 42nd Annual Cowen Healthcare Conference at 11:10 a.m. ET on Tuesday, March 8, 2022. Murdo Gordon,...
THOUSAND OAKS, Calif. , March 2, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will virtually present at the 42 nd Annual Cowen Healthcare Conference at 11:10 a.m. ET on Tuesday , March 8, 2022. Murdo Gordon , executive vice president of Global Commercial Operations and Peter H. Gri
Read more →AMGNAMGEN ANNOUNCES 2022 SECOND QUARTER DIVIDEND Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.94 per share dividend for the second quarter of 2022. The dividend will ...
THOUSAND OAKS, Calif. , March 2, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that its Board of Directors declared a $1.94 per share dividend for the second quarter of 2022. The dividend will be paid on June 8, 2022 , to all stockholders of record as of the close of
Read more →AMGNNEW DATA FURTHER REINFORCE EFFICACY OF TEZSPIRE™ (TEZEPELUMAB-EKKO) IN A BROAD POPULATION OF SEVERE ASTHMA PATIENTS Amgen (NASDAQ:AMGN) today announced results from a pooled post-hoc analysis of the pivotal NAVIGATOR Phase 3 and PATHWAY Phase 2b trials showed...
THOUSAND OAKS, Calif. , Feb. 26, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced results from a pooled post-hoc analysis of the pivotal NAVIGATOR Phase 3 and PATHWAY Phase 2b trials showed TEZSPIRE™ (tezepelumab-ekko) demonstrated reductions in the annualized asthma ex
Read more →AMGNAMGEN ISSUES INAUGURAL GREEN BOND TO ADVANCE ESG GOALS Amgen (NASDAQ:AMGN) today announced the issuance of its inaugural $750 million green bond, with a 3.000% semi-annual coupon and maturing in 2029, to...
THOUSAND OAKS, Calif. , Feb. 22, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the issuance of its inaugural $750 million green bond, with a 3.000% semi-annual coupon and maturing in 2029, to advance the environmental goals that are part of Amgen's environmental, soc
Read more →AMGNAMGEN RECOGNIZED FOR OUTSTANDING ESG PERFORMANCE Amgen (NASDAQ:AMGN) today announced that it has been named to Newsweek magazine's list of America's Most Responsible Companies for the third...
THOUSAND OAKS, Calif. , Feb. 16, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it has been named to Newsweek magazine's list of "America's Most Responsible Companies" for the third consecutive year; JUST Capital's list of "America's Most JUST Companies" for the
Read more →AMGNLUMAKRAS® (SOTORASIB) SHOWS ENCOURAGING AND CLINICALLY MEANINGFUL ANTICANCER ACTIVITY IN PATIENTS WITH KRAS G12C-MUTATED ADVANCED PANCREATIC CANCER IN CODEBREAK 100 TRIAL Amgen (NASDAQ: AMGN) today announced the presentation of efficacy and safety data from the CodeBreaK 100 Phase 1/2 trial in patients with KRAS...
THOUSAND OAKS, Calif. , Feb. 14, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the presentation of efficacy and safety data from the CodeBreaK 100 Phase 1/2 trial in patients with KRAS G12C-mutated advanced pancreatic cancer who received LUMAKRAS ® (sotorasib)*. The
Read more →AMGN▲ +7.8%on this news
AMGEN OUTLINES GROWTH STRATEGY THROUGH 2030 AT VIRTUAL BUSINESS REVIEW Amgen (NASDAQ:AMGN) today outlined its growth strategy through 2030, a period during which the Company expects to deliver attractive financial...
THOUSAND OAKS, Calif. , Feb. 8, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today outlined its growth strategy through 2030, a period during which the Company expects to deliver attractive financial performance by serving many more patients globally than it does today, both with i
Read more →AMGN▲ +7.8%on this news
AMGEN PROVIDES LONG-TERM GUIDANCE THROUGH 2030 DURING BUSINESS REVIEW MEETING In connection with its virtual business review, Amgen (NASDAQ:AMGN) provided preliminary long-term guidance between 2022 and 2030 in addition to full ...
THOUSAND OAKS, Calif. , Feb. 8, 2022 /PRNewswire/ -- In connection with its virtual business review, Amgen (NASDAQ: AMGN ) provided preliminary long-term guidance between 2022 and 2030 in addition to full year 2022 guidance. In addition, the Company discussed its 2022 share repu
Read more →AMGNAMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year 2021 versus comparable periods in 2020. Key results...
THOUSAND OAKS, Calif. , Feb. 7, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced financial results for the fourth quarter and full year 2021 versus comparable periods in 2020. Key results include: "We realized strong volume growth for many of our key products during la
Read more →AMGNAMGEN TO HOST VIRTUAL BUSINESS REVIEW MEETING Amgen (NASDAQ:AMGN) will host a virtual Business Review Meeting at 8:00 a.m. ET on Tuesday, Feb. 8, 2022. Robert A. Bradway, chairman and chief...
THOUSAND OAKS, Calif. , Feb. 3, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will host a virtual Business Review Meeting at 8:00 a.m. ET on Tuesday , Feb. 8, 2022. Robert A. Bradway , chairman and chief executive officer, along with other members of Amgen's management team, will pr
Read more →AMGNAMGEN AND PLEXIUM ANNOUNCE MULTI-YEAR, DRUG DISCOVERY COLLABORATION TO IDENTIFY NOVEL TARGETED PROTEIN DEGRADATION THERAPIES Amgen (NASDAQ:AMGN) and Plexium, Inc. (Plexium) today announced an exclusive, worldwide, multi-year research collaboration and license agreement to...
THOUSAND OAKS , Calif. and SAN DIEGO, Feb. 3, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and Plexium, Inc. (Plexium) today announced an exclusive, worldwide, multi-year research collaboration and license agreement to identify novel targeted protein degradation therapeutics toward
Read more →AMGNLUMAKRAS® (SOTORASIB) RECEIVES APPROVAL IN JAPAN FOR PATIENTS WITH KRAS G12C-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER Amgen (NASDAQ: AMGN) today announced that LUMAKRAS® (sotorasib) has been approved in Japan for the treatment of KRAS G12C-mutated positive,...
THOUSAND OAKS, Calif. , Jan. 20, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that LUMAKRAS ® (sotorasib) has been approved in Japan for the treatment of KRAS G12C-mutated positive, unresectable, advanced and/or recurrent non-small cell lung cancer (NSCLC) that has
Read more →AMGNTEZSPIRE™ (TEZEPELUMAB-EKKO) NOW AVAILABLE IN THE UNITED STATES FOR THE TREATMENT OF SEVERE ASTHMA Amgen (NASDAQ:AMGN) and AstraZeneca today announced TEZSPIRE™ (tezepelumab-ekko) is now available for shipment to wholesalers in the U.S. TEZSPIRE...
THOUSAND OAKS, Calif. , Jan. 13, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and AstraZeneca today announced TEZSPIRE™ (tezepelumab-ekko) is now available for shipment to wholesalers in the U.S. TEZSPIRE was approved by the U.S. Food and Drug Administration (FDA) on Dec. 17, 2021
Read more →AMGNAMGEN AND ARRAKIS THERAPEUTICS ANNOUNCE MULTI-TARGET COLLABORATION TO IDENTIFY NOVEL RNA DEGRADER SMALL MOLECULE THERAPEUTICS Amgen (NASDAQ:AMGN) and Arrakis Therapeutics today announced a research collaboration focused on the discovery and development of RNA degrader...
THOUSAND OAKS, Calif. and WALTHAM, Mass. , Jan. 11, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and Arrakis Therapeutics today announced a research collaboration focused on the discovery and development of RNA degrader therapeutics against a range of difficult-to-drug targets in m
Read more →AMGNEUROPEAN COMMISSION APPROVES LUMYKRAS® (SOTORASIB) FOR PATIENTS WITH KRAS G12C-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER Amgen (NASDAQ: AMGN) today announced that the European Commission (EC) has granted conditional marketing authorization for LUMYKRAS® (sotorasib), a...
THOUSAND OAKS, Calif. , Jan. 9, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the European Commission (EC) has granted conditional marketing authorization for LUMYKRAS ® (sotorasib), a first-in-class KRAS G12C inhibitor, for the treatment of adults with advanced
Read more →AMGNAMGEN AND BIOLABS LA AT THE LUNDQUIST INSTITUTE ANNOUNCE THAT KARMA BIOTECHNOLOGIES WILL RECEIVE THE SECOND AMGEN GOLDEN TICKET Amgen (NASDAQ:AMGN) and BioLabs LA at the Lundquist Institute today announced that Karma Biotechnologies has been awarded the second Amgen Golden...
THOUSAND OAKS, Calif. , Jan. 10, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and BioLabs LA at the Lundquist Institute today announced that Karma Biotechnologies has been awarded the second Amgen Golden Ticket in Southern California . Karma Biotechnologies will receive one year of
Read more →AMGNAMGEN TO PRESENT AT THE 40TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE Amgen (NASDAQ:AMGN) will virtually present at the 40th Annual J.P. Morgan Healthcare Conference at 11:15 a.m. ET on Tuesday, Jan. 11, 2022. Robert A. ...
THOUSAND OAKS, Calif. , Jan. 6, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will virtually present at the 40 th Annual J.P. Morgan Healthcare Conference at 11:15 a.m. ET on Tuesday , Jan. 11, 2022. Robert A. Bradway , chairman and chief executive officer at Amgen will present at t
Read more →AMGNAMGEN AND GENERATE BIOMEDICINES ANNOUNCE MULTI-TARGET, MULTI-MODALITY RESEARCH COLLABORATION AGREEMENT Amgen (NASDAQ: AMGN) and Generate Biomedicines today announced a research collaboration agreement to discover and create protein therapeutics for...
THOUSAND OAKS, Calif. and CAMBRIDGE, Mass. , Jan. 6, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and Generate Biomedicines today announced a research collaboration agreement to discover and create protein therapeutics for five clinical targets across several therapeutic areas and
Read more →AMGNAMGEN TO PRESENT AT THE GOLDMAN SACHS 14TH ANNUAL HEALTHCARE CEOS UNSCRIPTED CONFERENCE Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 14th Annual Healthcare CEOs Unscripted Conference at 1:00 p.m. ET on Thursday, Jan. 6, 2022....
THOUSAND OAKS, Calif. , Dec. 23, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Goldman Sachs 14th Annual Healthcare CEOs Unscripted Conference at 1:00 p.m. ET on Thursday , Jan. 6, 2022. Robert A. Bradway , chairman and chief executive officer at Amgen will prese
Read more →AMGNFDA APPROVES OTEZLA® (APREMILAST) FOR THE TREATMENT OF ADULT PATIENTS WITH PLAQUE PSORIASIS, REGARDLESS OF SEVERITY LEVEL Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Otezla® (apremilast) for the treatment of adult...
THOUSAND OAKS, Calif. , Dec. 20, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the U.S. Food and Drug Administration (FDA) has approved Otezla ® (apremilast) for the treatment of adult patients with plaque psoriasis who are candidates for phototherapy or systemi
Read more →AMGNFDA APPROVES TEZSPIRE™ (TEZEPELUMAB-EKKO) IN THE U.S. FOR SEVERE ASTHMA Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Amgen and AstraZeneca's Tezspire™...
THOUSAND OAKS, Calif. , Dec. 17, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the U.S. Food and Drug Administration (FDA) has approved Amgen and AstraZeneca's Tezspire ™ (tezepelumab-ekko) for the add-on maintenance treatment of adult and pediatric patients age
Read more →AMGNAmgen Announces New Data Being Presented At ASH 2021 Amgen (NASDAQ: AMGN) today announced new data from its hematology pipeline and marketed portfolio to be presented at the 63rd American Society of...
THOUSAND OAKS, Calif. , Dec. 6, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced new data from its hematology pipeline and marketed portfolio to be presented at the 63 rd American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, Georgia , and virtuall
Read more →AMGNAmgen Announces 10% Increase In 2022 First Quarter Dividend Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.94 per share dividend for the first quarter of 2022. The dividend will...
THOUSAND OAKS, Calif. , Dec. 3, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that its Board of Directors declared a $1.94 per share dividend for the first quarter of 2022. The dividend will be paid on March 8, 2022 , to all stockholders of record as of the close of
Read more →AMGNFDA Approves New KYPROLIS® (carfilzomib) Combination Regimen With DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) and dexamethasone For Patients With Multiple Myeloma At First Or Subsequent Relapse Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the expansion of the KYPROLIS® (carfilzomib) U.S....
THOUSAND OAKS, Calif. , Dec. 1, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the U.S. Food and Drug Administration (FDA) has approved the expansion of the KYPROLIS ® (carfilzomib) U.S. prescribing information to include its use in combination with DARZALEX FASP
Read more →AMGNAmgen Announces Positive Top-Line Results From Otezla® (apremilast) Phase 3 DISCREET Study In Moderate To Severe Genital Psoriasis Amgen (NASDAQ: AMGN) today announced positive top-line results from the DISCREET trial, a Phase 3, multicenter, randomized, placebo-controlled,...
THOUSAND OAKS, Calif. , Dec. 1, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced positive top-line results from the DISCREET trial, a Phase 3, multicenter, randomized, placebo-controlled, double-blind study to assess the efficacy of Otezla ® (apremilast) in adults with
Read more →AMGNAmgen Named To Dow Jones Sustainability World Index For Eighth Consecutive Year Amgen (NASDAQ:AMGN) today announced that it has been named to the Dow Jones Sustainability World Index for the eighth consecutive year, reflecting...
THOUSAND OAKS, Calif. , Nov. 29, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it has been named to the Dow Jones Sustainability World Index for the eighth consecutive year, reflecting the company's enduring commitment to environmental, social, and governance (E
Read more →AMGNAmgen To Present At The 2021 Evercore ISI Healthcare Conference Amgen (NASDAQ:AMGN) will present at the 2021 Evercore ISI Healthcare Conference at 5:10 p.m. ET on Tuesday, Nov. 30, 2021. Rob Lenz, M.D., Ph.D.,...
THOUSAND OAKS, Calif. , Nov. 24, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the 2021 Evercore ISI Healthcare Conference at 5:10 p.m. ET on Tuesday , Nov. 30, 2021. Rob Lenz , M.D., Ph.D., senior vice president of Global Development at Amgen will present at the con
Read more →AMGNAmgen To Present At The 2021 Piper Sandler Healthcare Conference Amgen (NASDAQ:AMGN) will present at the 2021 Piper Sandler Healthcare Conference at 1:00 p.m. ET on Wednesday, Dec. 1, 2021. Murdo Gordon, executive...
THOUSAND OAKS, Calif. , Nov. 24, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the 2021 Piper Sandler Healthcare Conference at 1:00 p.m. ET on Wednesday , Dec. 1, 2021. Murdo Gordon , executive vice president of Global Commercial Operations and Peter H. Griffith , ex
Read more →AMGNAmgen Awards The Bath Institute of Rheumatic Diseases $25,000 Through UPLIFT Innovation Challenge Amgen (NASDAQ:AMGN) today announced the awarding of a one-time $25,000 grant to the Bath Institute of Rheumatic Diseases (BIRD) as part of the...
THOUSAND OAKS, Calif. , Nov. 17, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the awarding of a one-time $25,000 grant to the Bath Institute of Rheumatic Diseases (BIRD) as part of the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Innova
Read more →AMGNLUMYKRAS® (sotorasib) Receives Positive Opinion From EMA CHMP For Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer Amgen (NASDAQ: AMGN) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a...
THOUSAND OAKS, Calif. , Nov. 12, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending conditional marketing authorization of LUMYKRAS ® (
Read more →AMGNAmgen To Present At The 2021 Annual Cowen IO Summit Amgen (NASDAQ:AMGN) will present at the 2021 annual Cowen IO Summit at 2:15 p.m. ET on Monday, Nov. 15, 2021. David M. Reese, M.D., executive vice...
THOUSAND OAKS, Calif. , Nov. 10, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the 2021 annual Cowen IO Summit at 2:15 p.m. ET on Monday , Nov. 15, 2021. David M. Reese , M.D., executive vice president of Research and Development at Amgen will present at the conferen
Read more →AMGNFirst And Only Randomized, Double-blind, Head-to-head Study Comparing Aimovig® (erenumab-aooe), An Anti-CGRP Pathway Therapy, To Topiramate Published In Cephalalgia Amgen (NASDAQ:AMGN) today announced new data from the HER-MES study, the first and only head-to-head study of Aimovig® (erenumab-aooe), a calcitonin...
THOUSAND OAKS, Calif. , Nov. 8, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced new data from the HER-MES study, the first and only head-to-head study of Aimovig ® (erenumab-aooe), a calcitonin gene-related peptide (CGRP) inhibitor, against topiramate for adult patient
Read more →AMGNAmgen Begins Construction On New Biomanufacturing Plant In Central Ohio Amgen (NASDAQ:AMGN) today announced the groundbreaking of its newest biomanufacturing plant, located in New Albany, Ohio. The final product assembly...
THOUSAND OAKS, Calif. , Nov. 5, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the groundbreaking of its newest biomanufacturing plant, located in New Albany, Ohio . The final product assembly and packaging plant will support the growing demand for Amgen's medicines i
Read more →AMGNOne Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.amgen.com AMGEN REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS THOUSAND OAKS, Calif. (
AMGEN REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS THOUSAND OAKS, Calif. (November 2, 2021) - Amgen (NASDAQ AMGN) today announced financial results for the third quarter of 2021. Key results include Total revenues increased 4% to $6.7 billion in comparison to the third quarter
Read more →AMGNAmgen Reports Third Quarter 2021 Financial Results Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2021. Key results include: Total revenues increased 4% to $6.7 billion ...
THOUSAND OAKS, Calif. , Nov. 2, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced financial results for the third quarter of 2021. Key results include: "Our newest product, LUMAKRAS ® , a first-in-class lung cancer treatment, is off to a strong start and our robust pipe
Read more →AMGNAmgen Announces Webcast Of 2021 Third Quarter Financial Results Amgen (NASDAQ: AMGN) today announced that it will report its third quarter financial results on Tuesday, November 2, 2021, after the close of the U.S....
THOUSAND OAKS, Calif. , Oct. 28, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will report its third quarter financial results on Tuesday, November 2, 2021 , after the close of the U.S. financial markets. The announcement will be followed by a conference call
Read more →AMGNFortune and Great Place to Work® Name Amgen One of the World's Best Workplaces™ in 2021 Amgen (NASDAQ: AMGN) today announced that it has been selected as one of the World's Best Workplaces™ for 2021 by Fortune magazine and Great Place to ...
THOUSAND OAKS, Calif. , Oct. 26, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it has been selected as one of the World's Best Workplaces™ for 2021 by Fortune magazine and Great Place to Work ® . Amgen ranked eighth among the 25 companies named to the list. Thos
Read more →AMGNAmgen Announces 2021 Fourth Quarter Dividend Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.76 per share dividend for the fourth quarter of 2021. The dividend will ...
THOUSAND OAKS, Calif. , Oct. 21, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that its Board of Directors declared a $1.76 per share dividend for the fourth quarter of 2021. The dividend will be paid on December 8, 2021 , to all stockholders of record as of the clos
Read more →AMGNAmgen Successfully Completes Acquisition Of Teneobio, Inc. Amgen (NASDAQ: AMGN) today announced that it has successfully completed its previously announced acquisition of Teneobio, Inc. (Teneobio). Effective...
THOUSAND OAKS, Calif. , Oct. 19, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it has successfully completed its previously announced acquisition of Teneobio, Inc. (Teneobio). Effective as of Oct. 19, 2021 , Amgen has acquired all outstanding equity of Teneobio
Read more →AMGNAmgen Announces New LUMAKRAS™ (sotorasib) Combination Data From Phase 1b CodeBreaK 101 Study In Patients With KRAS G12C-mutated Cancers At AACR-NCI-EORTC 2021 Amgen (NASDAQ: AMGN) today announced new combination study results from the Phase 1b CodeBreaK 101 study, a comprehensive global master protocol...
THOUSAND OAKS, Calif. , Oct. 7, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced new combination study results from the Phase 1b CodeBreaK 101 study, a comprehensive global master protocol trial evaluating the safety and efficacy of LUMAKRAS™ (sotorasib), the first and
Read more →AMGNAmgen and Neumora Therapeutics Announce Strategic R&D Collaboration to Accelerate Novel Precision Therapies for Brain Diseases Amgen (NASDAQ: AMGN) and Neumora Therapeutics, Inc. (Neumora), a clinical-stage biopharmaceutical company pioneering precision medicines for brain...
Amgen's deCODE genetics subsidiary is a global leader in analyzing and understanding human health and disease and has been at the forefront of the analysis of human data to enhance drug discovery and development. By leveraging these platform technologies and the complementary cap
Read more →AMGNAmgen Announces New Data Highlighting Global Trends In Hip Fracture Incidence And Treatment Amgen (NASDAQ:AMGN) today announced results from real-world data in Asia, Europe, Oceania, and North and South America on the temporal trends in hip...
THOUSAND OAKS, Calif. , Oct. 4, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced results from real-world data in Asia , Europe , Oceania, and North and South America on the temporal trends in hip fracture incidence, and in post-fracture pharmacological treatment interve
Read more →AMGNAmgen And Kyowa Kirin Present Positive Late-Breaking Data From Phase 2 Study Of AMG 451/KHK4083 In Adult Patients With Moderate-to-Severe Atopic Dermatitis At EADV Congress Amgen (NASDAQ: AMGN) and Kyowa Kirin Co., Ltd. (TSE:4151) today announced that positive data from a Phase 2 study of AMG 451/KHK4083 were presented...
THOUSAND OAKS, Calif. and TOKYO , Oct. 2, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and Kyowa Kirin Co., Ltd. (TSE:4151) today announced that positive data from a Phase 2 study of AMG 451/KHK4083 were presented at the European Academy of Dermatology and Venereology 30 th Virtual
Read more →AMGNAmgen To Webcast Investor Call At EADV 2021 Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the European Academy of Dermatology and Venereology...
THOUSAND OAKS, Calif. , Sept. 29, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will host a webcast call for the investment community in conjunction with the European Academy of Dermatology and Venereology (EADV) 2021 Congress. On Monday, Oct. 4, 2021, at 8:30 a.m. ET, David M. Rees
Read more →AMGNFDA Approves Repatha® (evolocumab) In Pediatric Patients Age 10 And Older With Heterozygous Familial Hypercholesterolemia Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Repatha® (evolocumab) as an adjunct to diet and...
THOUSAND OAKS, Calif. , Sept. 24, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the U.S. Food and Drug Administration (FDA) has approved Repatha ® (evolocumab) as an adjunct to diet and other low-density lipoprotein cholesterol (LDL-C)-lowering therapies for the
Read more →AMGNAmgen To Present At The 2021 Cantor Global Healthcare Conference Amgen (NASDAQ:AMGN) will present at the Cantor Global Healthcare Conference at 2:00 p.m. ET on Monday, Sept. 27, 2021. Susan Sweeney, senior vice...
THOUSAND OAKS, Calif. , Sept. 22, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Cantor Global Healthcare Conference at 2:00 p.m. ET on Monday, Sept. 27, 2021 . Susan Sweeney , senior vice president, Global Marketing, Access and Capabilities and Peter H. Griffith
Read more →AMGNAmgen Releases 8th Edition of Biosimilar Trends Report Amgen (NASDAQ: AMGN) today released the 8th edition of the Biosimilar Trends Report, which examines the current state of the U.S. biosimilars...
THOUSAND OAKS, Calif. , Sept. 22, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today released the 8 th edition of the Biosimilar Trends Report, which examines the current state of the U.S. biosimilars marketplace across inflammation, oncology and nephrology categories, while a new
Read more →AMGNAmgen Wins Patent Case on Otezla® (apremilast) Amgen today announced that the U.S. District Court for the District of New Jersey has upheld patents that protect Amgen's psoriasis therapy Otezla®...
Amgen believes in the value of intellectual property and will continue to vigorously defend its intellectual property rights. In the U.S., Otezla is approved for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for phototherapy or syste
Read more →AMGNLUMAKRAS™ (Sotorasib) Combined With Vectibix® (Panitumumab) Showed Encouraging Efficacy And Safety In Patients With KRAS G12C-Mutated Colorectal Cancer Amgen (NASDAQ: AMGN) today announced the first combination study results from the Phase 1b/2 CodeBreaK 101 study, the most comprehensive global...
THOUSAND OAKS, Calif. , Sept. 16, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the first combination study results from the Phase 1b /2 CodeBreaK 101 study, the most comprehensive global clinical development program in patients with KRAS G12C-mutated advanced colore
Read more →AMGNAmgen And The Lundquist Institute Announce That Diadem Therapeuctics Will Receive The First Amgen Golden Ticket To BioLabs LA Amgen (NASDAQ: AMGN) and The Lundquist Institute today announced that Diadem Biotherapeutics, Inc., has been awarded the first Amgen Golden Ticket in ...
THOUSAND OAKS, Calif. , Sept. 14, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and The Lundquist Institute today announced that Diadem Biotherapeutics, Inc., has been awarded the first Amgen Golden Ticket in Southern California . Diadem will receive one year of lab space at BioLabs
Read more →AMGNAmgen To Present At The 2021 Bank of America Merrill Lynch Global Healthcare Conference Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 11:45 a.m. ET on Friday, Sept. 17, 2021. Peter...
THOUSAND OAKS, Calif. , Sept. 13, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 11:45 a.m. ET on Friday , Sept. 17, 2021. Peter H. Griffith , executive vice president and chief financial officer at Amg
Read more →AMGNAmgen To Webcast Investor Call At ESMO 2021 Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the European Society for Medical Oncology (ESMO) 2021...
THOUSAND OAKS, Calif. , Sept. 13, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will host a webcast call for the investment community in conjunction with the European Society for Medical Oncology (ESMO) 2021 Congress. On Thursday, Sept. 16, 2021, at 8:30 a.m. ET, David M. Reese , M.
Read more →AMGNAmgen To Showcase New Data From Inflammation Portfolio At EADV Virtual Congress 2021 Amgen (NASDAQ: AMGN) today announced that new data from its expanding inflammation pipeline and marketed portfolio will be presented at the European...
THOUSAND OAKS, Calif. , Sept. 13, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that new data from its expanding inflammation pipeline and marketed portfolio will be presented at the European Academy of Dermatology and Venereology (EADV) 30 th Congress, which will ta
Read more →AMGNAmgen to Present at the 19th Annual Morgan Stanley Global Healthcare Conference Amgen (NASDAQ:AMGN) will present at Morgan Stanley's 19th Annual Global Healthcare Conference at 2:45 p.m. ET on Tuesday, Sept. 14, 2021. Robert A....
THOUSAND OAKS, Calif. , Sept. 9, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at Morgan Stanley's 19th Annual Global Healthcare Conference at 2:45 p.m. ET on Tuesday, Sept. 14, 2021 . Robert A. Bradway , chairman and chief executive officer at Amgen will present at the
Read more →AMGNAmgen Presents New Data From Thoracic Oncology Portfolio At WCLC21 Amgen (NASDAQ: AMGN) today announced results from two analyses of the Phase 2 CodeBreaK 100 clinical trial evaluating LUMAKRAS™ (sotorasib), the...
THOUSAND OAKS, Calif. , Sept. 8, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced results from two analyses of the Phase 2 CodeBreaK 100 clinical trial evaluating LUMAKRAS™ (sotorasib), the first and only KRAS G12C inhibitor approved in the U.S., in the treatment of pre
Read more →AMGNNew Tezepelumab Data Show 86% Reduction In Exacerbations In Patients With Severe Asthma And Comorbid Nasal Polyps Amgen (NASDAQ:AMGN) today announced new data from the pivotal NAVIGATOR Phase 3 trial demonstrating that tezepelumab reduced exacerbations and...
THOUSAND OAKS, Calif. , Sept. 5, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced new data from the pivotal NAVIGATOR Phase 3 trial demonstrating that tezepelumab reduced exacerbations and improved lung function and nasal symptoms in patients with severe, uncontrolled a
Read more →AMGNAmgen to Present at the 16th Annual Citi BioPharma Conference Amgen (NASDAQ:AMGN) will present at Citi's 16th Annual BioPharma Conference at 1:25 p.m. ET on Wednesday, Sept. 8, 2021. Murdo Gordon, executive vice ...
THOUSAND OAKS, Calif. , Sept. 3, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at Citi's 16th Annual BioPharma Conference at 1:25 p.m. ET on Wednesday , Sept. 8, 2021. Murdo Gordon , executive vice president of Global Commercial Operations at Amgen will present at the c
Read more →AMGNNew Data At ESC Congress 2021 Shows Repatha® (evolocumab) Improves Features Of Plaque Stability In Patients With Acute Coronary Syndrome (ACS) Amgen (NASDAQ:AMGN) today announced positive data from the HUYGENS Phase 3 study showing that Repatha® (evolocumab) in addition to optimized statin...
THOUSAND OAKS, Calif. , Aug. 27, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced positive data from the HUYGENS Phase 3 study showing that Repatha ® (evolocumab) in addition to optimized statin therapy, in comparison with optimized statin therapy alone, significantly i
Read more →AMGNAmgen Reports Second Quarter 2021 Financial Results Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2021. Key results include: Total revenues increased 5% to $6.5...
THOUSAND OAKS, Calif. , Aug. 3, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced financial results for the second quarter of 2021. Key results include: "We achieved solid, volume-driven growth in the quarter as our business recovered from the effects of the pandemic,"
Read more →AMGNOne Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.amgen.com AMGEN REPORTS SECOND QUARTER 2021 FINANCIAL RESULTS THOUSAND OAKS, Calif. (
AMGEN REPORTS SECOND QUARTER 2021 FINANCIAL RESULTS THOUSAND OAKS, Calif. (August 3, 2021) - Amgen (NASDAQ AMGN) today announced financial results for the second quarter of 2021. Key results include Total revenues increased 5% to $6.5 billion in comparison to the second quarter
Read more →AMGNAmgen Announces 2021 Third Quarter Dividend Amgen (NASDAQ: AMGN) today announced that its Board of Directors declared a $1.76 per share dividend for the third quarter of 2021. The dividend will ...
THOUSAND OAKS, Calif. , July 30, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that its Board of Directors declared a $1.76 per share dividend for the third quarter of 2021. The dividend will be paid on September 8, 2021 , to all stockholders of record as of the clos
Read more →AMGNOne Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.Amgen.com News Release AMGEN APPOINTS S. OMAR ISHRAK TO BOARD OF DIRECTORS THOUSAND OAKS, Calif. (
AMGEN APPOINTS S. OMAR ISHRAK TO BOARD OF DIRECTORS THOUSAND OAKS, Calif. (July 29, 2021) Amgen (NASDAQ:AMGN) today announced the appointment of S. Omar Ishrak to its Board of Directors, effective immediately. Dr. Ishrak will also serve as a member of the Board s Corporate Resp
Read more →AMGNAmgen Appoints S. Omar Ishrak To Board Of Directors Amgen (NASDAQ: AMGN) today announced the appointment of S. Omar Ishrak to its Board of Directors, effective immediately. Dr. Ishrak will also serve...
THOUSAND OAKS, Calif. , July 29, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the appointment of S. Omar Ishrak to its Board of Directors, effective immediately. Dr. Ishrak will also serve as a member of the Board's Corporate Responsibility and Compliance Committee
Read more →AMGNAmgen Announces Webcast Of 2021 Second Quarter Financial Results Amgen (NASDAQ:AMGN) today announced that it will report its second quarter financial results on Tuesday, August 3, 2021, after the close of the U.S....
THOUSAND OAKS, Calif. , July 29, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will report its second quarter financial results on Tuesday, August 3, 2021 , after the close of the U.S. financial markets. The announcement will be followed by a conference call
Read more →AMGNAmgen To Acquire Privately Held Teneobio For $900 Million In Cash With Future Contingent Milestone Payments Amgen (NASDAQ: AMGN) and Teneobio today announced an agreement under which Amgen will acquire Teneobio, a privately held, clinical stage...
THOUSAND OAKS, Calif. and NEWARK, Calif. , July 27, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and Teneobio today announced an agreement under which Amgen will acquire Teneobio, a privately held, clinical stage biotechnology company developing a new class of biologics called Huma
Read more →AMGNAMGEN TO ACQUIRE PRIVATELY HELD TENEOBIO FOR $900 MILLION IN CASH WITH FUTURE CONTINGENT MILESTONE PAYMENTS Acquisition Complements Amgen s Antibody Research Capabilities Across Therapeutic Areas Acquisition
AMGEN TO ACQUIRE PRIVATELY HELD TENEOBIO FOR $900 MILLION IN CASH WITH FUTURE CONTINGENT MILESTONE PAYMENTS Acquisition Complements Amgen s Antibody Research Capabilities Across Therapeutic Areas Acquisition Includes a Portfolio of Early-Stage Oncology Assets, Including a Pha
Read more →AMGNAmgen And The International Federation of Psoriasis Associations Launch UPLIFT Innovation Challenge Amgen (NASDAQ:AMGN), in partnership with the International Federation of Psoriasis Associations (IFPA), announced the launch of the Understanding...
THOUSAND OAKS, Calif. , July 14, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ), in partnership with the International Federation of Psoriasis Associations (IFPA), announced the launch of the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Innovation Challe
Read more →AMGNTezepelumab Granted Priority Review By U.S. FDA Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) and granted...
THOUSAND OAKS, Calif. , July 7, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the U.S. Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) and granted Priority Review for tezepelumab in the treatment of asthma. Tezepelumab is be
Read more →AMGNAmgen Announces Approval Of Aimovig® (Erenumab) In Japan For The Suppression Of Onset Of Migraine Attacks In Adults Amgen (NASDAQ:AMGN) today announced that the Japanese Ministry of Health, Labour and Welfare has granted marketing approval for Aimovig® (erenumab)...
THOUSAND OAKS, Calif. , June 23, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the Japanese Ministry of Health, Labour and Welfare has granted marketing approval for Aimovig ® (erenumab) for the suppression of onset of migraine attacks in adults. Aimovig is the
Read more →AMGNAcclaimed Makeup Artist Allan Avendaño Opens Up About Personal Skin Condition: Provides INSIDE LOOK At Life With Plaque Psoriasis Amgen (NASDAQ:AMGN) and Otezla® (apremilast) have partnered with Allan Avendaño, makeup artist to Hollywood A-listers, for the INSIDE LOOK campaign...
THOUSAND OAKS, Calif. , June 15, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and Otezla ® (apremilast) have partnered with Allan Avendaño, makeup artist to Hollywood A-listers, for the INSIDE LOOK campaign to share his journey living with plaque psoriasis and the difficulties of b
Read more →AMGNAmgen To Present At The Goldman Sachs 42nd Annual Global Healthcare Conference Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 42nd Annual Global Healthcare Conference at 4:40 p.m. ET on Wednesday, June 9, 2021. David M....
THOUSAND OAKS, Calif. , June 4, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Goldman Sachs 42nd Annual Global Healthcare Conference at 4:40 p.m. ET on Wednesday , June 9, 2021. David M. Reese , M.D., executive vice president of Research and Development and Peter
Read more →AMGNResults From Phase 2 CodeBreaK 100 Show LUMAKRAS™ (sotorasib) Is The First And Only KRAS G12C Inhibitor With Overall Survival Data Amgen (NASDAQ: AMGN) today presented data on overall survival, a secondary endpoint, from the Phase 2 results of the CodeBreaK 100 clinical study for ...
THOUSAND OAKS, Calif. , June 4, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today presented data on overall survival, a secondary endpoint, from the Phase 2 results of the CodeBreaK 100 clinical study for LUMAKRAS TM (sotorasib) in previously treated patients with non-small cell l
Read more →AMGNPhase 2 Fight Trial Continues To Show Improved Overall Survival With Bemarituzumab Plus Chemotherapy In Patients With FGFR2b+ Gastric And Gastroesophageal Cancers Amgen (NASDAQ:AMGN) today announced updated results for investigational bemarituzumab in combination with chemotherapy from the Phase 2 FIGHT trial....
THOUSAND OAKS, Calif. , June 4, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced updated results for investigational bemarituzumab in combination with chemotherapy from the Phase 2 FIGHT trial. The trial evaluated bemarituzumab plus chemotherapy (mFOLFOX6) versus chemot
Read more →AMGNOne Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.Amgen.com AMGEN AND KYOWA KIRIN TO JOINTLY DEVELOP AND COMMERCIALIZE KHK4083, A PHASE 3-READY, POTENTIAL FIRST-IN-CLASS TREATMEN
AMGEN AND KYOWA KIRIN TO JOINTLY DEVELOP AND COMMERCIALIZE KHK4083, A PHASE 3-READY, POTENTIAL FIRST-IN-CLASS TREATMENT FOR ATOPIC DERMATITIS Agreement Renews Successful Global Collaboration That led to Several Groundbreaking Therapies in Multiple Disease Areas KHK4083 Deple
Read more →AMGNAmgen to Webcast Investor Meeting at ASCO 2021 Amgen (NASDAQ: AMGN) will host a webcast call for the investment community in conjunction with the American Society of Clinical Oncology (ASCO)...
THOUSAND OAKS, Calif. , June 1, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will host a webcast call for the investment community in conjunction with the American Society of Clinical Oncology (ASCO) Annual Meeting at 4:00 p.m. ET on Friday , June 4, 2021. David M. Reese , M.D., ex
Read more →AMGNAmgen and Kyowa Kirin to Jointly Develop and Commercialize KHK4083, a Phase 3-Ready, Potential First-In-Class Treatment for Atopic Dermatitis Amgen (NASDAQ: AMGN) and Kyowa Kirin Co., Ltd. (TSE: 4151) today announced an agreement to jointly develop and commercialize KHK4083, which is Kyowa...
Agreement Renews Successful Global Collaboration That led to Several Groundbreaking Therapies in Multiple Disease Areas KHK4083 Depletes OX40-Expressing T cells Associated with Atopic Dermatitis and Several Other Inflammatory Diseases Moderate-to-Severe Atopic Dermatitis Affect
Read more →AMGNAmgen To Present At The 2021 Jefferies Healthcare Conference Amgen (NASDAQ:AMGN) will present at the 2021 Jefferies Healthcare Conference at 1:30 p.m. ET on Thursday, June 3, 2021. Murdo Gordon, executive vice...
THOUSAND OAKS, Calif. , May 28, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the 2021 Jefferies Healthcare Conference at 1:30 p.m. ET on Thursday , June 3, 2021. Murdo Gordon , executive vice president of Global Commercial Operations at Amgen will present at the con
Read more →AMGNFDA Approves LUMAKRAS™ (Sotorasib), The First And Only Targeted Treatment For Patients With KRAS G12C-Mutated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved LUMAKRAS™ (sotorasib) for the treatment of adult...
THOUSAND OAKS, Calif. , May 28, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the U.S. Food and Drug Administration (FDA) has approved LUMAKRAS ™ (sotorasib) for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell
Read more →AMGNAmgen To Present At The Cowen 2nd Annual Virtual Oncology Innovation Summit Amgen (NASDAQ: AMGN) will present at the Cowen 2nd Annual Virtual Oncology Innovation Summit at 11:20 a.m. ET on Friday, May 21, 2021. David M....
THOUSAND OAKS, Calif. , May 19, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Cowen 2nd Annual Virtual Oncology Innovation Summit at 11:20 a.m. ET on Friday , May 21, 2021. David M. Reese , M.D., executive vice president of Research and Development at Amgen, will
Read more →AMGNAmgen To Showcase New Data From Oncology Portfolio At ASCO 2021 Amgen (NASDAQ: AMGN) today announced that new data from its expanding oncology pipeline and marketed portfolio will be presented during the 2021...
THOUSAND OAKS, Calif. , May 19, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that new data from its expanding oncology pipeline and marketed portfolio will be presented during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting taking place virtuall
Read more →AMGNNew Tezepelumab Data Continue To Strengthen Profile For A Broad Population Of Severe Asthma Patients Amgen (NASDAQ:AMGN) and AstraZeneca today announced detailed results for tezepelumab, a potential first-in-class treatment, from the pivotal...
THOUSAND OAKS, Calif. , May 13, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and AstraZeneca today announced detailed results for tezepelumab, a potential first-in-class treatment, from the pivotal NAVIGATOR Phase 3 trial demonstrating superiority across every primary and key secon
Read more →AMGNEfficacy Of Repatha® (Evolocumab) Across High-Risk Patient Populations Reinforced At ACC.21 Amgen (NASDAQ:AMGN) today announced the presentation of four cardiovascular research abstracts, including final data from the Repatha® (evolocumab)...
THOUSAND OAKS, Calif. , May 11, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the presentation of four cardiovascular research abstracts, including final data from the Repatha ® (evolocumab) open label extension trial of patients living with HIV who have high cholest
Read more →AMGNAmgen Announces Tezepelumab Biologics License Application Submitted To U.S. FDA Amgen (NASDAQ:AMGN) today announced its partner AstraZeneca (NASDAQ:AZN) submitted a Biologics License Application (BLA) to the U.S. Food and Drug...
THOUSAND OAKS, Calif. , May 10, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced its partner AstraZeneca (NASDAQ: AZN ) submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for tezepelumab, a potential first-in-class medicine in
Read more →AMGNAmgen To Present At The 2021 Bank of America Merrill Lynch Healthcare Conference Amgen (NASDAQ:AMGN) will present at the 2021 Bank of America Merrill Lynch Virtual Healthcare Conference at 11:00 a.m. ET on Tuesday, May 11, 2021....
THOUSAND OAKS, Calif. , May 6, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the 2021 Bank of America Merrill Lynch Virtual Healthcare Conference at 11:00 a.m. ET on Tuesday , May 11, 2021. David M. Reese , M.D., executive vice president of Research and Development,
Read more →AMGNFDA Accepts Amgen's Supplemental New Drug Application For Otezla® (apremilast) For Adults With Mild-To-Moderate Plaque Psoriasis Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application...
THOUSAND OAKS, Calif. , May 5, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for Otezla ® (apremilast) for the treatment of adults with mild-to-moder
Read more →AMGNAmgen Provides Updated Information On LUMAKRAS™ (Sotorasib)¹ Dose Comparison Study Amgen (NASDAQ:AMGN) today announced that it agreed last night with the FDA's proposed post-marketing requirement to conduct, as part of the ongoing...
THOUSAND OAKS, Calif. , April 28, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it agreed last night with the FDA's proposed post-marketing requirement to conduct, as part of the ongoing development program, a multi-center randomized clinical trial to compare th
Read more →AMGNAmgen Reports First Quarter 2021 Financial Results Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2021. Key results include: Total revenues decreased 4% to $5.9 billion ...
THOUSAND OAKS, Calif. , April 27, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced financial results for the first quarter of 2021. Key results include: "While our business continued to be impacted by the COVID-19 pandemic particularly in the first two months of the qu
Read more →AMGNOne Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.amgen.com AMGEN REPORTS FIRST QUARTER 2021 FINANCIAL RESULTS THOUSAND OAKS, Calif. (
AMGEN REPORTS FIRST QUARTER 2021 FINANCIAL RESULTS THOUSAND OAKS, Calif. (April 27, 2021) - Amgen (NASDAQ AMGN) today announced financial results for the first quarter of 2021. Key results include Total revenues decreased 4% to $5.9 billion in comparison to the first quarter of
Read more →AMGNOTEZLA® (apremilast) Significantly Improved Measures Of Disease Severity In Adults With Mild-To-Moderate Plaque Psoriasis Amgen (NASDAQ:AMGN) today announced Otezla® (apremilast) improved measures of disease severity in adults with mild-to-moderate plaque psoriasis...
THOUSAND OAKS, Calif. , April 23, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced Otezla ® (apremilast) improved measures of disease severity in adults with mild-to-moderate plaque psoriasis regardless of their Body Surface Area (BSA) affected by the disease, according
Read more →AMGNAmgen Announces Webcast Of 2021 First Quarter Financial Results Amgen (NASDAQ:AMGN) today announced that it will report its first quarter financial results on Tuesday, April 27, 2021, after the close of the U.S....
THOUSAND OAKS, Calif. , April 22, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will report its first quarter financial results on Tuesday, April 27, 2021 , after the close of the U.S. financial markets. The announcement will be followed by a conference call
Read more →AMGNAmgen's Investigational Targeted Treatment Bemarituzumab Granted Breakthrough Therapy Designation Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for investigational...
THOUSAND OAKS, Calif. , April 19, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for investigational bemarituzumab as first-line treatment for patients with fibroblast growth fac
Read more →AMGNAmgen Launches Biomarker Assist™, a Program To Help More Patients With Non-Small Cell Lung Cancer Gain Access To Biomarker Testing Amgen (NASDAQ: AMGN) today announced the launch of Biomarker Assist™, a program to help more patients with metastatic (stage IV) non-small cell lung...
THOUSAND OAKS, Calif. , April 19, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the launch of Biomarker Assist ™ , a program to help more patients with metastatic (stage IV) non-small cell lung cancer (NSCLC) gain access to biomarker testing. Biomarker testing at the
Read more →AMGNOne Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.Amgen.com AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF FIVE PRIME THERAPEUTICS THOUSAND OAKS, Calif. (
AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF FIVE PRIME THERAPEUTICS THOUSAND OAKS, Calif. (April 16, 2021) Amgen (NASDAQ:AMGN) today announced that it has successfully completed its previously announced tender offer to purchase all outstanding shares of common stock of Five Prim
Read more →AMGNAmgen Successfully Completes Acquisition Of Five Prime Therapeutics Amgen (NASDAQ:AMGN) today announced that it has successfully completed its previously announced tender offer to purchase all outstanding shares of...
THOUSAND OAKS, Calif. , April 16, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it has successfully completed its previously announced tender offer to purchase all outstanding shares of common stock of Five Prime Therapeutics (NASDAQ: FPRX ), a clinical-stage bi
Read more →AMGNAmgen to Acquire Rodeo Therapeutics Corporation Amgen Inc. (NASDAQ:AMGN) and Rodeo Therapeutics Corporation (Rodeo) today announced an agreement under which Amgen will acquire Rodeo, a privately...
THOUSAND OAKS , Calif. and SEATTLE , March 30, 2021 /PRNewswire/ -- Amgen Inc. (NASDAQ: AMGN ) and Rodeo Therapeutics Corporation (Rodeo) today announced an agreement under which Amgen will acquire Rodeo, a privately held biopharmaceutical company based in Seattle that develops s
Read more →AMGNMarço: o mês de conscientização e prevenção câncer colorretal, uma doença recorrente na vida dos brasileiros O câncer colorretal é um tumor maligno que se desenvolve no intestino grosso, especificamente nas regiões do cólon, reto e ânus. No Brasil, a...
SÃO PAULO, 25 de março de 2021 /PRNewswire/ -- O câncer colorretal é um tumor maligno que se desenvolve no intestino grosso, especificamente nas regiões do cólon, reto e ânus. No Brasil, a estimativa para 2020-2022, aponta que ocorrerão 41 mil casos de câncer de colo e reto, send
Read more →AMGNAmgen To Present At The Oppenheimer 31st Annual Healthcare Conference Amgen (NASDAQ:AMGN) will present at the virtual Oppenheimer 31st Annual Healthcare Conference at 2:30 p.m. ET on Tuesday, March 16, 2021. David M....
THOUSAND OAKS, Calif. , March 11, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the virtual Oppenheimer 31st Annual Healthcare Conference at 2:30 p.m. ET on Tuesday, March 16, 2021 . David M. Reese , M.D., executive vice president of Research and Development at Amgen
Read more →AMGNAMGEN TO ACQUIRE FIVE PRIME THERAPEUTICS FOR $1.9 BILLION IN CASH Acquisition Includes Bemarituzumab, A Phase 3 Ready, First-In-Class Program For Gastric Cancer, the Third Leading Cause of Cancer Mortality W
AMGEN TO ACQUIRE FIVE PRIME THERAPEUTICS FOR $1.9 BILLION IN CASH Acquisition Includes Bemarituzumab, A Phase 3 Ready, First-In-Class Program For Gastric Cancer, the Third Leading Cause of Cancer Mortality Worldwide Bemarituzumab is a Strong Strategic Fit With Amgen s Innovati
Read more →AMGNAmgen To Acquire Five Prime Therapeutics For $1.9 Billion in Cash Amgen (NASDAQ: AMGN) and Five Prime Therapeutics (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immuno-oncology and...
THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif. , March 4, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and Five Prime Therapeutics (NASDAQ: FPRX ), a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies, today announced an
Read more →AMGNAmgen Announces 2021 Second Quarter Dividend Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.76 per share dividend for the second quarter of 2021. The dividend will ...
THOUSAND OAKS, Calif. , March 3, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that its Board of Directors declared a $1.76 per share dividend for the second quarter of 2021. The dividend will be paid on June 8, 2021 , to all stockholders of record as of the close of
Read more →AMGNBLINCYTO® (Blinatumomab) Demonstrated Significantly Prolonged Event-Free Survival Compared With Consolidation Chemotherapy In Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia Amgen (NASDAQ:AMGN) today announced that data from a multicenter, randomized Phase 3 study evaluating the efficacy, safety and tolerability of...
THOUSAND OAKS, Calif. , March 2, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that data from a multicenter, randomized Phase 3 study evaluating the efficacy, safety and tolerability of BLINCYTO ® (blinatumomab) compared with consolidation chemotherapy before allogen
Read more →AMGNTezepelumab Is The First Biologic To Significantly Reduce Exacerbations In Broad Population Of Patients With Severe, Uncontrolled Asthma Amgen (NASDAQ:AMGN) and AstraZeneca today announced positive full results from the pivotal NAVIGATOR Phase 3 trial, which showed the potential of...
THOUSAND OAKS, Calif. , Feb. 26, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and AstraZeneca today announced positive full results from the pivotal NAVIGATOR Phase 3 trial, which showed the potential of tezepelumab to be a first-in-class medicine in severe asthma. When added to st
Read more →AMGNAmgen To Present At The Cowen 41st Annual Healthcare Conference Amgen (NASDAQ:AMGN) will present at the Cowen 41st Annual Virtual Healthcare Conference at 12:50 p.m. ET on Thursday, March 4, 2021. Murdo Gordon,...
THOUSAND OAKS, Calif. , Feb. 24, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Cowen 41 st Annual Virtual Healthcare Conference at 12:50 p.m. ET on Thursday , March 4, 2021. Murdo Gordon , executive vice president of Global Commercial Operations and Peter H. Grif
Read more →AMGNAmgen To Webcast Investor Meeting At AAAAI Virtual Annual Meeting Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the 2021 American Academy of Allergy, Asthma &...
THOUSAND OAKS, Calif. , Feb. 22, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will host a webcast call for the investment community in conjunction with the 2021 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting on Friday, Feb. 26 , at 1:00 p.m. ET . David M. R
Read more →AMGNAmgen Submits Supplemental New Drug Application for Otezla® (apremilast) for Adults with Mild-To-Moderate Plaque Psoriasis Amgen (NASDAQ:AMGN) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for...
THOUSAND OAKS, Calif. , Feb. 22, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for Otezla ® (apremilast) for the treatment of adults with mild-to-moderate plaq
Read more →AMGNFDA Grants Sotorasib Priority Review Designation For The Treatment Of Patients With KRAS G12C-Mutated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review for sotorasib for the treatment of...
THOUSAND OAKS, Calif. , Feb. 16, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review for sotorasib for the treatment of patients with KRAS G12C -mutated locally advanced or metastatic non-small ce
Read more →AMGNAmgen To Present At Guggenheim Healthcare Talks Oncology Day Amgen (NASDAQ:AMGN) today announced that Greg Friberg, vice president and global oncology therapeutic area head at Amgen, will participate in a...
THOUSAND OAKS, Calif. , Feb. 9, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that Greg Friberg , vice president and global oncology therapeutic area head at Amgen, will participate in a fireside chat as part of the Guggenheim Healthcare Talks 2021 Oncology Day on Fr
Read more →AMGNAmgen Sponsors Golden Ticket at BioLabs LA at The Lundquist Institute to Help Accelerate Life Science Startups Amgen (NASDAQ:AMGN) today announced a three-year, Golden Ticket sponsorship of the BioLabs LA at The Lundquist Institute (TLI) life sciences...
THOUSAND OAKS, Calif. , Feb. 3, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced a three-year, Golden Ticket sponsorship of the BioLabs LA at The Lundquist Institute (TLI) life sciences co-working space to accelerate the development of new therapies, medical devices, an
Read more →AMGNOne Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.amgen.com AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS THOUSAND OAKS, Calif. (
AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS THOUSAND OAKS, Calif. (February 2, 2021) - Amgen (NASDAQ AMGN) today announced financial results for the fourth quarter and full year 2020 versus comparable periods in 2019. Key results include For the fourth qua
Read more →AMGNAmgen Reports Fourth Quarter And Full Year 2020 Financial Results Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year 2020 versus comparable periods in 2019. Key results...
THOUSAND OAKS, Calif. , Feb. 2, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced financial results for the fourth quarter and full year 2020 versus comparable periods in 2019. Key results include: "In a year marked by the disruption of COVID-19, we served patients arou
Read more →AMGNAmgen Announces Breakthrough Therapy Designation Granted For Sotorasib In China Amgen (NASDAQ: AMGN) today announced that its investigational KRASG12C inhibitor sotorasib was granted Breakthrough Therapy Designation (BTD) by the...
THOUSAND OAKS, Calif. , Jan. 29, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that its investigational KRAS G12C inhibitor sotorasib was granted Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) of the National Medical Products Administr
Read more →AMGNAmgen's Investigational KRAS G12C Inhibitor Sotorasib Demonstrated Rapid, Deep And Durable Responses In Previously Treated Patients With Advanced Non-Small Cell Lung Cancer Amgen (NASDAQ: AMGN) today announced results from the Phase 2 cohort of the CodeBreaK 100 clinical study evaluating investigational sotorasib (AMG...
THOUSAND OAKS, Calif. , Jan. 28, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced results from the Phase 2 cohort of the CodeBreaK 100 clinical study evaluating investigational sotorasib (AMG 510) in 126 patients with KRAS G12C -mutated advanced non-small cell lung canc
Read more →AMGNAmgen Announces Webcast Of 2020 Fourth Quarter And Full Year Financial Results Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2020 financial results on Tuesday, Feb. 2, 2021, after the...
THOUSAND OAKS, Calif. , Jan. 28, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will report its fourth quarter and full year 2020 financial results on Tuesday, Feb. 2, 2021 , after the close of the U.S. financial markets. The announcement will be followed by a
Read more →AMGNAmgen To Webcast Investor Meeting At 2020 World Conference on Lung Cancer Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the 2020 World Conference on Lung Cancer (WCLC) on...
THOUSAND OAKS, Calif. , Jan. 26, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will host a webcast call for the investment community in conjunction with the 2020 World Conference on Lung Cancer (WCLC) on Friday, Jan. 29 , at 8:00 p.m. ET . David M. Reese , M.D., executive vice presi
Read more →AMGNAmgen To Showcase Next Frontier Of Innovation In Lung Cancer Therapies At WCLC 2020 Amgen (NASDAQ:AMGN) today announced new data from its oncology pipeline in lung cancer will be presented during the 2020 World Conference on Lung...
THOUSAND OAKS, Calif. , Jan. 12, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced new data from its oncology pipeline in lung cancer will be presented during the 2020 World Conference on Lung Cancer (WCLC) hosted by the International Association for the Study of Lung Ca
Read more →AMGNAmgen To Achieve Carbon Neutrality By 2027 Amgen (NASDAQ: AMGN) today announced the launch of a new seven-year environmental sustainability plan, which includes a commitment to achieve carbon...
THOUSAND OAKS, Calif. , Jan. 11, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the launch of a new seven-year environmental sustainability plan, which includes a commitment to achieve carbon neutrality, while also reducing water use by 40% and waste disposed by 75%.
Read more →AMGNAmgen To Present At The 39th Annual J.P. Morgan Healthcare Conference Amgen (NASDAQ:AMGN) will present at the 39th Annual J.P. Morgan Healthcare Conference at 11:50 a.m. PT on Monday, Jan. 11, 2021. Robert A. Bradway,...
THOUSAND OAKS, Calif. , Jan. 6, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the 39th Annual J.P. Morgan Healthcare Conference at 11:50 a.m. PT on Monday , Jan. 11, 2021. Robert A. Bradway , chairman and chief executive officer at Amgen, will present at the conferen
Read more →AMGNAmgen presenta all'Agenzia europea per i medicinali richiesta di autorizzazione all'immissione in commercio di Sotorasib La richiesta riguarda i pazienti affetti da carcinoma polmonare non a piccole cellule (NSCLC) precedentemente trattato con mutazione KRAS G12C...
La richiesta riguarda i pazienti affetti da carcinoma polmonare non a piccole cellule (NSCLC) precedentemente trattato con mutazione KRAS G12C L'istanza presentata all'UE fa seguito alla presentazione di una nuova richiesta di autorizzazione per Sotorasib alla FDA statunitense,
Read more →AMGNAmgen reicht Antrag auf Marktzulassung von Sotorasib bei der Europäischen Arzneimittelagentur ein Amgen (NASDAQ: AMGN) gab heute die Einreichung eines Zulassungsantrags (MAA) bei der Europäischen Arzneimittelagentur (EMA) für Sotorasib, einen KRAS ...
Antrag ist für Patienten mit vorbehandeltem nicht-kleinzelligem Lungenkrebs (NSCLC) mit der KRAS G12C Mutation EU-Zulassungsantrag folgt auf den in der vergangenen Woche bekannt gegebenen Antrag auf Zulassung von Sotorasib bei der amerikanischen FDA THOUSAND OAKS, Kalifornien,
Read more →AMGNAmgen envía solicitud de comercialización de Sotorasib a la Agencia Europea del Medicamento Amgen (NASDAQ: AMGN) anunció hoy la presentación de una Solicitud de Autorización de Comercialización (MAA) a la Agencia Europea del Medicamento...
La aplicación es para pacientes con cáncer de pulmón de células no pequeñas previamente tratados (NSCLC) con la mutación KRAS G12C La solicitud de la UE sigue a la solicitud de nuevo medicamento de Sotorasib a la FDA de EE.UU. anunciada la semana pasada THOUSAND OAKS, Californi
Read more →AMGNAmgen soumet une demande d'autorisation de mise sur le marché du sotorasib à l'Agence européenne des médicaments Amgen (NASDAQ: AMGN) a annoncé aujourd'hui la soumission d'une demande d'autorisation de mise sur le marché (AAM) à l'Agence européenne des...
Ce médicament doit être utilisé avec des patients atteints d'un cancer du poumon non à petites cellules déjà traité (CPNPC) et porteurs d'une mutation du gène KRAS G12C La demande d'autorisation dans l'UE fait suite à la demande d'approbation d'un nouveau médicament, le sotorasi
Read more →AMGNAmgen Submits Sotorasib Marketing Authorization Application To The European Medicines Agency Amgen (NASDAQ: AMGN) today announced submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for sotorasib,...
THOUSAND OAKS, Calif. , Dec. 22, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for sotorasib, an investigational KRAS G12C inhibitor, for the treatment of adult patients
Read more →AMGNUpdate On SOURCE Phase 3 Trial For Tezepelumab In Patients With Severe, Oral Corticosteroid-Dependent Asthma Amgen (NASDAQ:AMGN) and AstraZeneca today announced the SOURCE trial did not meet the primary endpoint of a statistically significant reduction in...
THOUSAND OAKS, Calif. , Dec. 21, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and AstraZeneca today announced the SOURCE trial did not meet the primary endpoint of a statistically significant reduction in the daily oral corticosteroid (OCS) dose, without loss of asthma control, wit
Read more →AMGNAmgen Licenses AMG 634, An Investigational Treatment For Tuberculosis And Leprosy, To Medicines Development for Global Health Amgen (NASDAQ:AMGN) and Medicines Development for Global Health (MDGH), a non-profit biopharmaceutical company, today announced that the companies...
THOUSAND OAKS, Calif. and MELBOURNE, Australia , Dec. 22, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and Medicines Development for Global Health (MDGH), a non-profit biopharmaceutical company, today announced that the companies have entered into a license agreement for AMG 634, a
Read more →AMGNFDA Approves Amgen's RIABNI™ (rituximab-arrx), A Biosimilar To Rituxan® (rituximab) Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan®...
THOUSAND OAKS, Calif. , Dec. 17, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan ® (rituximab), for the treatment of adult patients with Non-Hodgkin's Lympho
Read more →AMGNAmgen Awards Two Local Biotech Start-Ups With Golden Ticket To LabCentral Amgen (NASDAQ: AMGN) and LabCentral today announced that Octagon Therapeutics and Seranova Bio have each won an Amgen Golden Ticket to LabCentral,...
Amgen has served as a platinum sponsor of LabCentral since 2014, awarding Golden Tickets to 12 innovative start-ups to date. Each year, Amgen nominates two early-stage companies to take up residence in LabCentral's Kendall Square facilities, which includes one year of free bench
Read more →AMGNAmgen Announces 10% Increase In 2021 First Quarter Dividend Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.76 per share dividend for the first quarter of 2021. The dividend will...
THOUSAND OAKS, Calif. , Dec. 16, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that its Board of Directors declared a $1.76 per share dividend for the first quarter of 2021. The dividend will be paid on March 8, 2021 , to all stockholders of record as of the close of
Read more →AMGNAmgen To Transfer Listing Of Debt Securities To Nasdaq Amgen Inc. (NASDAQ: AMGN) today announced its intention to transfer the securities exchange listing for its 1.250% Senior Notes due 2022 and 2.00%...
THOUSAND OAKS, Calif. , Dec. 16, 2020 /PRNewswire/ -- Amgen Inc. (NASDAQ: AMGN ) today announced its intention to transfer the securities exchange listing for its 1.250% Senior Notes due 2022 and 2.00% Senior Notes due 2026 (the "Debt Securities") from the New York Stock Exchange
Read more →AMGNAmgen Submits Sotorasib New Drug Application To U.S. FDA For Advanced Or Metastatic Non-Small Cell Lung Cancer With KRAS G12C Mutation Amgen (NASDAQ:AMGN) today announced submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for sotorasib, an...
THOUSAND OAKS, Calif. , Dec. 16, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for sotorasib, an investigational KRAS G12C inhibitor for the treatment of patients with KRAS G12C
Read more →AMGNAmgen's Sotorasib Granted Breakthrough Therapy Designation For Advanced Or Metastatic Non-Small Cell Lung Cancer Patients With KRAS G12C Mutation Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for its...
THOUSAND OAKS, Calif. , Dec. 8, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for its investigational KRAS G12C inhibitor, sotorasib, for the treatment of patients with locally
Read more →AMGNAmgen And Novartis Partner With Karamo Brown To Support And Empower People Living With Migraine Amgen (NASDAQ:AMGN) today announced a partnership with Karamo Brown, Emmy-nominated host from Netflix's hit show Queer Eye, to support and empower...
THOUSAND OAKS, Calif. , Dec. 7, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced a partnership with Karamo Brown , Emmy-nominated host from Netflix's hit show "Queer Eye," to support and empower people living with migraine. Karamo, who is known for helping people open u
Read more →AMGNAmgen To Present First Clinical Data For BCMA-Targeted Half-Life Extended BiTE® Therapy AMG 701 At ASH 2020 Amgen (NASDAQ:AMGN) today announced the first presentation of clinical safety and efficacy data from the Phase 1 study of AMG 701 in heavily...
THOUSAND OAKS, Calif. , Dec. 5, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the first presentation of clinical safety and efficacy data from the Phase 1 study of AMG 701 in heavily pre-treated patients with relapsed/refractory multiple myeloma (R/R MM). AMG 701 is
Read more →AMGNAmgen To Webcast Investor Call At ASH 2020 Amgen (NASDAQ:AMGN) will host a webcast call for the investment community on Tuesday, Dec. 8, at 4:00 p.m. ET following the 62nd American Society of...
THOUSAND OAKS, Calif. , Dec. 3, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will host a webcast call for the investment community on Tuesday, Dec. 8 , at 4:00 p.m. ET following the 62nd American Society of Hematology (ASH) Annual Meeting & Exposition. David M. Reese , M.D., execut
Read more →AMGNAmgen Announces New Data Being Presented At ASH 2020 Amgen (NASDAQ:AMGN) today announced several upcoming data presentations from its oncology and hematology pipeline and marketed product portfolio at...
THOUSAND OAKS, Calif. , Nov. 30, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced several upcoming data presentations from its oncology and hematology pipeline and marketed product portfolio at the 62 nd American Society of Hematology (ASH) Annual Meeting & Exposition,
Read more →AMGNAmgen To Present At The Evercore ISI Virtual HealthCONx Conference Amgen (NASDAQ:AMGN) will present at the Evercore ISI Virtual HealthCONx Conference at 1:50 p.m. ET on Tuesday, Dec. 1, 2020. David M. Reese, M.D.,...
THOUSAND OAKS, Calif. , Nov. 25, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Evercore ISI Virtual HealthCONx Conference at 1:50 p.m. ET on Tuesday , Dec. 1, 2020. David M. Reese , M.D., executive vice president of Research and Development and Peter H. Griffith
Read more →AMGNAmgen To Transition Development And Commercial Rights For Omecamtiv Mecarbil And AMG 594 To Cytokinetics Amgen (NASDAQ:AMGN) today announced the Company has provided notice to Cytokinetics of termination of its collaboration and its intention to...
THOUSAND OAKS, Calif. , Nov. 23, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the Company has provided notice to Cytokinetics of termination of its collaboration and its intention to transition the development and commercialization rights for omecamtiv mecarbil and
Read more →AMGNAmgen To Present At The Jefferies Virtual London Healthcare Conference Amgen (NASDAQ:AMGN) will present at the Jefferies Virtual London Healthcare Conference at 12:00 p.m. ET on Wednesday, Nov. 18, 2020. Peter H....
THOUSAND OAKS, Calif. , Nov. 13, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Jefferies Virtual London Healthcare Conference at 12:00 p.m. ET on Wednesday , Nov. 18, 2020. Peter H. Griffith , executive vice president and chief financial officer at Amgen will pre
Read more →AMGNAmgen To Present At The Cowen 4th Annual IO Summit Amgen (NASDAQ:AMGN) will present at the Cowen 4th Annual Virtual IO Summit at 3:30 p.m. ET on Friday, November 13, 2020. David M. Reese, M.D.,...
THOUSAND OAKS, Calif. , Nov. 10, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Cowen 4 th Annual Virtual IO Summit at 3:30 p.m. ET on Friday, November 13, 2020 . David M. Reese , M.D., executive vice president of Research and Development at Amgen will present at
Read more →AMGNTezepelumab NAVIGATOR Phase 3 Trial Met Primary Endpoint Of A Statistically Significant And Clinically Meaningful Reduction In Exacerbations In A Broad Population Of Patients With Severe Asthma Amgen (NASDAQ:AMGN) and AstraZeneca today announced positive topline results from the Phase 3 NAVIGATOR trial in which the investigational medicine...
THOUSAND OAKS, Calif. , Nov. 9, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and AstraZeneca today announced positive topline results from the Phase 3 NAVIGATOR trial in which the investigational medicine tezepelumab demonstrated a statistically significant reduction in exacerbatio
Read more →AMGNAmgen Showcases New Data Across Cardiovascular Portfolio At AHA Scientific Sessions 2020: A Virtual Experience Amgen (NASDAQ:AMGN) today announced that data from its cardiovascular (CV) portfolio will be presented at the American Heart Association (AHA)...
THOUSAND OAKS, Calif. , Nov. 9, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that data from its cardiovascular (CV) portfolio will be presented at the American Heart Association (AHA) Scientific Sessions 2020: A Virtual Experience, Nov. 13-17, 2020 . Amgen will pre
Read more →AMGNAmgen Presents First Clinical Data for AMG 757 at SITC 2020 Amgen (NASDAQ: AMGN) today announced the first presentation of AMG 757 Phase 1 clinical safety and efficacy data in relapsed or refractory small cell ...
THOUSAND OAKS, Calif. , Nov. 9, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the first presentation of AMG 757 Phase 1 clinical safety and efficacy data in relapsed or refractory small cell lung cancer (SCLC). AMG 757 is an investigational half-life extended (HLE) b
Read more →AMGNAmgen To Present At The 29th Annual Credit Suisse Healthcare Conference Amgen (NASDAQ:AMGN) will present at the 29th Annual Credit Suisse Virtual Healthcare Conference at 4:15 p.m. ET on Monday, Nov. 9, 2020, in...
THOUSAND OAKS, Calif. , Nov. 4, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the 29th Annual Credit Suisse Virtual Healthcare Conference at 4:15 p.m. ET on Monday , Nov. 9, 2020, in Scottsdale, Ariz. Murdo Gordon , executive vice president of Global Commercial Opera
Read more →AMGNAmgen fomenta doação de medula óssea entre seus colaboradores em prol dos pacientes com leucemia De acordo com o relatório semestral da ABTO (Associação Brasileira de Transplante Órgãos), entre janeiro e junho de 2020, o número de transplantes de ...
SÃO PAULO, 28 de outubro de 2020 /PRNewswire/ -- De acordo com o relatório semestral da ABTO (Associação Brasileira de Transplante Órgãos), entre janeiro e junho de 2020, o número de transplantes de medula óssea realizados no país diminuiu 19,67% em relação ao mesmo período de 20
Read more →AMGNAmgen Reports Third Quarter 2020 Financial Results Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2020. Key results include: Total revenues increased 12% to $6.4...
THOUSAND OAKS, Calif. , Oct. 28, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced financial results for the third quarter of 2020. Key results include: "Amgen continues to deliver strong, volume-driven growth in a challenging environment, while also advancing new medi
Read more →AMGNOne Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.amgen.com AMGEN REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS THOUSAND OAKS, Calif. (
AMGEN REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS THOUSAND OAKS, Calif. (October 28, 2020) - Amgen (NASDAQ AMGN) today announced financial results for the third quarter of 2020. Total revenues increased 12% to $6.4 billion in comparison to the third quarter of 2019 driven by h
Read more →AMGNAmgen Announces Webcast Of 2020 Third Quarter Financial Results Amgen (NASDAQ:AMGN) today announced that it will report its third quarter financial results on Wednesday, October 28, 2020, after the close of the...
THOUSAND OAKS, Calif. , Oct. 27, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will report its third quarter financial results on Wednesday, October 28, 2020 , after the close of the U.S. financial markets. The announcement will be followed by a conference ca
Read more →AMGNAmgen Announces Participation Of Systemic Lupus Erythematosus (SLE) Adaptive Clinical Trial In The FDA Complex Innovative Trial Designs (CID) Pilot Program Amgen (NASDAQ:AMGN) today announced that it has completed trial design discussions through two Complex Innovative Trial Designs (CID) Pilot Program...
THOUSAND OAKS, Calif. , Oct. 27, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it has completed trial design discussions through two Complex Innovative Trial Designs (CID) Pilot Program meetings with the U.S. Food and Drug Administration (FDA) for its planned Ph
Read more →AMGNAmgen Announces 2020 Fourth Quarter Dividend Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.60 per share dividend for the fourth quarter of 2020. The dividend will ...
THOUSAND OAKS, Calif. , Oct. 21, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that its Board of Directors declared a $1.60 per share dividend for the fourth quarter of 2020. The dividend will be paid on December 8, 2020 , to all stockholders of record as of the clos
Read more →AMGNAmgen, Cytokinetics And Servier Announce Topline Results From GALACTIC-HF, A Phase 3 Trial Of Omecamtiv Mecarbil In Patients With Heart Failure Amgen (NASDAQ:AMGN), Cytokinetics, Incorporated (NASDAQ:CYTK) and Servier today announced topline results from GALACTIC-HF, a Phase 3 pivotal...
THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif. and SURESNES, France, Oct. 8, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ), Cytokinetics, Incorporated (NASDAQ: CYTK ) and Servier today announced topline results from GALACTIC-HF, a Phase 3 pivotal clinical trial of omecamtiv m
Read more →AMGNAmgen Announces Positive Topline Phase 2 Results For Investigational KRAS G12C Inhibitor Sotorasib In Advanced Non-Small Cell Lung Cancer Amgen (NASDAQ: AMGN) today announced positive topline Phase 2 results from the CodeBreaK 100 clinical study, evaluating sotorasib (proposed INN for...
THOUSAND OAKS, Calif. , Oct. 5, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced positive topline Phase 2 results from the CodeBreaK 100 clinical study, evaluating sotorasib (proposed INN for AMG 510) in 126 patients with KRAS G12C -mutant advanced non-small cell lung c
Read more →AMGNAmgen Announces Five-Year Data That Reinforce The Safety And Efficacy Profile Of Aimovig® (erenumab-aooe) In Adult Patients With Episodic Migraine Amgen (NASDAQ:AMGN) today announced that results reinforcing the long-term safety and efficacy profile of Aimovig® (erenumab-aooe) in patients with...
THOUSAND OAKS, Calif. , Oct. 3, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that results reinforcing the long-term safety and efficacy profile of Aimovig ® (erenumab-aooe) in patients with episodic migraine (EM) are being presented at the Migraine Trust Virtual Sym
Read more →AMGNClinical Data From Full Phase 1 Cohort Of Investigational Sotorasib Published In New England Journal Of Medicine Amgen (NASDAQ: AMGN) today announced that updated data from the full Phase 1 cohort of the CodeBreaK 100 clinical study, evaluating sotorasib...
THOUSAND OAKS, Calif. , Sept. 20, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that updated data from the full Phase 1 cohort of the CodeBreaK 100 clinical study, evaluating sotorasib (proposed INN for AMG 510) in 129 patients across multiple advanced solid tumors,
Read more →AMGNAmgen To Webcast Investor Calls At ESMO 2020 Amgen (NASDAQ:AMGN) will host two webcast calls for the investment community in conjunction with the European Society for Medical Oncology (ESMO)...
THOUSAND OAKS, Calif. , Sept. 16, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will host two webcast calls for the investment community in conjunction with the European Society for Medical Oncology (ESMO) 2020 Virtual Congress. On Sunday, Sept. 20, 2020, at 11:00 a.m. PDT, David M.
Read more →AMGNAmgen To Showcase Data From Oncology Pipeline During ESMO Virtual Congress 2020 Amgen (NASDAQ:AMGN) announced today that data from its oncology pipeline in solid tumors will be presented during the European Society of Medical...
THOUSAND OAKS, Calif. , Sept. 16, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) announced today that data from its oncology pipeline in solid tumors will be presented during the European Society of Medical Oncology (ESMO) Virtual Congress 2020, Sept. 19-21, 2020 . Amgen will presen
Read more →AMGNAmgen And MBC BioLabs Announce Winners Of The Amgen Golden Ticket Amgen (NASDAQ:AMGN) and MBC BioLabs today announced that BigHat Biosciences and Trilo Therapeutics have each been awarded an Amgen Golden Ticket to...
SAN FRANCISCO , Sept. 15, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and MBC BioLabs today announced that BigHat Biosciences and Trilo Therapeutics have each been awarded an Amgen Golden Ticket to MBC BioLabs. The companies will receive priority admission or renewal for one year
Read more →AMGNAmgen To Present At The 2020 Bank of America Virtual Global Healthcare Conference Amgen (NASDAQ:AMGN) will present at the Bank of America Virtual Global Healthcare Conference at 12:35 p.m. ET on Thursday, Sept. 17, 2020. Peter H....
THOUSAND OAKS, Calif. , Sept. 14, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Bank of America Virtual Global Healthcare Conference at 12:35 p.m. ET on Thursday , Sept. 17, 2020. Peter H. Griffith , executive vice president and chief financial officer at Amgen,
Read more →AMGNAmgen To Present At The 18th Annual Morgan Stanley Global Healthcare Conference Amgen (NASDAQ:AMGN) will present at Morgan Stanley's 18th Annual Virtual Global Healthcare Conference at 11:45 a.m. ET on Wednesday, Sept. 16, 2020....
THOUSAND OAKS, Calif. , Sept. 11, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at Morgan Stanley's 18 th Annual Virtual Global Healthcare Conference at 11:45 a.m. ET on Wednesday , Sept. 16, 2020. Robert A. Bradway , chairman and chief executive officer at Amgen will p
Read more →AMGNAmgen To Present At The 15th Annual Citi BioPharma Conference Amgen (NASDAQ:AMGN) will present at Citi's 15th Annual Virtual BioPharma Conference at 2:25 p.m. ET on Thursday, Sept. 10, 2020. Murdo Gordon,...
THOUSAND OAKS, Calif. , Sept. 4, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at Citi's 15th Annual Virtual BioPharma Conference at 2:25 p.m. ET on Thursday, Sept. 10, 2020 . Murdo Gordon , executive vice president of Global Commercial Operations at Amgen and Peter H.
Read more →AMGNAmgen Announces Positive Data From Phase 3B Study Of Repatha® (Evolocumab) In Pediatric Patients With Heterozygous Familial Hypercholesterolemia At ESC Congress 2020 Amgen (NASDAQ:AMGN) today announced positive data from the HAUSER-RCT Phase 3b study evaluating the safety and efficacy of Repatha® (evolocumab) in...
THOUSAND OAKS, Calif. , Aug. 29, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced positive data from the HAUSER-RCT Phase 3b study evaluating the safety and efficacy of Repatha ® (evolocumab) in pediatric patients, 10-17 years of age, with heterozygous familial hypercho
Read more →AMGNNew Amgen Data To Be Presented At ESC Congress 2020 Highlighting Repatha® (evolocumab) Efficacy In High-Risk Patient Populations Amgen (NASDAQ:AMGN) today announced the presentation of 12 cardiovascular scientific research abstracts, including clinical trial and real-world...
THOUSAND OAKS, Calif. , Aug. 25, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the presentation of 12 cardiovascular scientific research abstracts, including clinical trial and real-world evidence studies of Repatha ® (evolocumab), that add to the growing body of evi
Read more →AMGNFDA Approves New KYPROLIS® (carfilzomib) Combination Regimen With DARZALEX® (daratumumab) And Dexamethasone In Both Once- And Twice-Weekly Dosing Regimens Amgen (NASDAQ:AMGN) today announced the U.S. Food and Drug Administration (FDA) has approved the expansion of the KYPROLIS® (carfilzomib) U.S....
THOUSAND OAKS, Calif. , Aug. 20, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the U.S. Food and Drug Administration (FDA) has approved the expansion of the KYPROLIS ® (carfilzomib) U.S. prescribing information to include its use in combination with DARZALEX ® (darat
Read more →AMGNAmgen Announces Early Tender Results Of Senior Notes Exchange Offers Amgen Inc. (NASDAQ:AMGN) announced today the early tender results of its previously announced nine separate private offers to exchange (each, an...
THOUSAND OAKS, Calif. , Aug. 13, 2020 /PRNewswire/ -- Amgen Inc. (NASDAQ: AMGN ) announced today the early tender results of its previously announced nine separate private offers to exchange (each, an "Exchange Offer" and, collectively, the "Exchange Offers") certain specified se
Read more →AMGNOne Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.Amgen.com AMGEN ANNOUNCES EARLY TENDER RESULTS OF SENIOR NOTES EXCHANGE OFFERS THOUSAND OAKS, Calif. (
AMGEN ANNOUNCES EARLY TENDER RESULTS OF SENIOR NOTES EXCHANGE OFFERS THOUSAND OAKS, Calif. (August 13, 2020) Amgen Inc. (NASDAQ:AMGN) announced today the early tender results of its previously announced nine separate private offers to exchange (each, an Exchange Offer and, coll
Read more →AMGNAmgen Announces Pricing Terms For Senior Notes Exchange Offers, Increases The Maximum Notes Exchange Cap And Accepts Tendered Notes Amgen Inc. (NASDAQ:AMGN) announced today the pricing terms of its previously announced nine separate private offers to exchange (each, an Exchange...
THOUSAND OAKS, Calif. , Aug. 13, 2020 /PRNewswire/ -- Amgen Inc. (NASDAQ: AMGN ) announced today the pricing terms of its previously announced nine separate private offers to exchange (each, an "Exchange Offer" and, collectively, the "Exchange Offers") certain specified series of
Read more →AMGNDia Nacional de Combate ao Colesterol: brasileiros negligenciam as doenças cardiovasculares durante a pandemia Ficar atento à saúde, principalmente no período de quarentena, é essencial. Incluindo o monitoramento do colesterol, pois se alto, pode ser perigoso. ...
SÃO PAULO, 6 de agosto de 2020 /PRNewswire/ -- Ficar atento à saúde, principalmente no período de quarentena, é essencial. Incluindo o monitoramento do colesterol, pois se alto, pode ser perigoso. O Dia Nacional de Combate ao Colesterol, 08 de agosto, visa conscientizar sobre a i
Read more →AMGNAmgen Commences Exchange Offers For Certain Series Of Outstanding Senior Notes From Exchange Eligible Holders Amgen Inc. (NASDAQ: AMGN) announced today the commencement of nine separate private offers to exchange (each, an Exchange Offer and, collectively,...
THOUSAND OAKS, Calif. , July 30, 2020 /PRNewswire/ -- Amgen Inc. (NASDAQ: AMGN ) announced today the commencement of nine separate private offers to exchange (each, an "Exchange Offer" and, collectively, the "Exchange Offers") certain specified series of its outstanding senior no
Read more →AMGNOne Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.Amgen.com AMGEN COMMENCES EXCHANGE OFFERS FOR CERTAIN SERIES OF OUTSTANDING SENIOR NOTES FROM EXCHANGE ELIGIBLE HOLDERS THOUSAND
AMGEN COMMENCES EXCHANGE OFFERS FOR CERTAIN SERIES OF OUTSTANDING SENIOR NOTES FROM EXCHANGE ELIGIBLE HOLDERS THOUSAND OAKS, Calif. (July 30, 2020) Amgen Inc. (NASDAQ: AMGN) announced today the commencement of nine separate private offers to exchange (each, an Exchange Offer a
Read more →AMGNAmgen Reports Second Quarter 2020 Financial Results Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2020. Key results include: Despite the impact of the COVID-19...
THOUSAND OAKS, Calif. , July 28, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced financial results for the second quarter of 2020. Key results include: "As our strong results demonstrate, we continue to reliably supply patients as we navigate the COVID-19 pandemic,"
Read more →AMGNOne Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.amgen.com AMGEN REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS THOUSAND OAKS, Calif. (
AMGEN REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS THOUSAND OAKS, Calif. (July 28, 2020) - Amgen (NASDAQ AMGN) today announced financial results for the second quarter of 2020. Despite the impact of the COVID-19 pandemic, total revenues increased 6% to $6.2 billion in comparis
Read more →AMGNANVISA aprova autoinjetor para diminuir exposição hospitalar de pacientes em tratamento oncológico A ANVISA (Agência Nacional de Vigilância Sanitária) aprovou um autoinjetor, o Neulastim® On-Body Injector (OBI), desenvolvido pela Amgen, uma das...
SÃO PAULO, 27 de julho de 2020 /PRNewswire/ -- A ANVISA (Agência Nacional de Vigilância Sanitária) aprovou um autoinjetor, o Neulastim® On-Body Injector (OBI), desenvolvido pela Amgen, uma das líderes de biotecnologia, que tem potencial de diminuir a exposição hospitalar de brasi
Read more →AMGNAmgen Announces Webcast Of 2020 Second Quarter Financial Results Amgen (NASDAQ:AMGN) today announced that it will report its second quarter financial results on Tuesday, July 28, 2020, after the close of the U.S....
THOUSAND OAKS, Calif. , July 23, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will report its second quarter financial results on Tuesday, July 28, 2020 , after the close of the U.S. financial markets. The announcement will be followed by a conference call w
Read more →AMGNAmgen Announces 2020 Third Quarter Dividend Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.60 per share dividend for the third quarter of 2020. The dividend will...
THOUSAND OAKS, Calif. , July 23, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that its Board of Directors declared a $1.60 per share dividend for the third quarter of 2020. The dividend will be paid on September 8, 2020 , to all stockholders of record as of the clos
Read more →AMGNAmgen Appoints Amy E. Miles To Board Of Directors Amgen today announced the appointment of Amy E. Miles to its Board of Directors, effective July 23, 2020. Ms. Miles will serve as a member of the...
THOUSAND OAKS, Calif. , July 23, 2020 /PRNewswire/ -- Amgen today announced the appointment of Amy E. Miles to its Board of Directors, effective July 23 , 2020. Ms. Miles will serve as a member of the Board's Audit Committee and Governance and Nominating Committee. Following the
Read more →AMGNAmgen Foundation Awards Khan Academy An Additional $3 Million To Support Science Learning And Educational Equity Amid COVID-19 The Amgen Foundation today announced the renewal of a $3 million grant to Khan Academy to support several key learning initiatives, including virtual ...
THOUSAND OAKS , Calif. and MOUNTAIN VIEW, Calif., July 21, 2020 /PRNewswire/ -- The Amgen Foundation today announced the renewal of a $3 million grant to Khan Academy to support several key learning initiatives, including virtual biology lessons; partnerships with school district
Read more →AMGNAmgen Announces Additional Investment In BeiGene Amgen (NASDAQ:AMGN) today announced an additional investment of approximately $421 million in BeiGene's registered direct offering of ordinary...
THOUSAND OAKS, Calif. , July 12, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced an additional investment of approximately $421 million in BeiGene's registered direct offering of ordinary shares, which maintains Amgen's current pro rata ownership of BeiGene at approxim
Read more →AMGNAppeals Court Affirms Validity Of Enbrel® (etanercept) Patents Injunction Against Sandoz's Infringement Stands Amgen today announced that the United States Court of Appeals for the Federal Circuit has held in Amgen's favor on the validity of two patents that...
THOUSAND OAKS, Calif. , July 1, 2020 /PRNewswire/ -- Amgen today announced that the United States Court of Appeals for the Federal Circuit has held in Amgen's favor on the validity of two patents that describe and claim Enbrel® (etanercept) and methods for making it. The patent
Read more →AMGNPermanecer sem fraturas é essencial para pacientes com osteoporose durante a pandemia A osteoporose afeta homens e mulheres, geralmente, após os 50 anos. De acordo com a IOF (International Osteoporosis Foundation), a doença é...
Indivíduos com doença osteoporótica podem sofrer com a progressão da doença não tenham os cuidados necessários SÃO PAULO, 25 de junho de 2020 /PRNewswire/ -- A osteoporose afeta homens e mulheres, geralmente, após os 50 anos. De acordo com a IOF (International Osteoporosis Found
Read more →AMGNAmgen Is Supporting Advancement Of AMG 634 For Global Health Diseases In Developing Countries Amgen (NASDAQ: AMGN) today announced it is supporting the further study of AMG 634, a phosphodiesterase type 4 (PDE4) inhibitor, for the treatment of ...
THOUSAND OAKS, Calif. , June 22, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced it is supporting the further study of AMG 634, a phosphodiesterase type 4 (PDE4) inhibitor, for the treatment of tuberculosis (TB) and erythema nodosum leprosum (ENL), an inflammatory cuta
Read more →AMGNAmgen To Present At The BMO Capital Markets 2020 Prescriptions for Success Healthcare Conference Amgen (NASDAQ: AMGN) will present at the BMO Capital Markets 2020 Prescriptions for Success Healthcare Conference at 4:00 p.m. ET on Tuesday, June...
THOUSAND OAKS, Calif. , June 18, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the BMO Capital Markets 2020 Prescriptions for Success Healthcare Conference at 4:00 p.m. ET on Tuesday , June 23, 2020. Elliott Levy , senior vice president of R&D Strategy and Operations
Read more →AMGNAmgen To Present At The Goldman Sachs 41st Annual Global Healthcare Conference Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 41st Annual Virtual Global Healthcare Conference on Wednesday, June 10, 2020 at 1:20 p.m. ET....
THOUSAND OAKS, Calif. , June 5, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Goldman Sachs 41st Annual Virtual Global Healthcare Conference on Wednesday, June 10, 2020 at 1:20 p.m. ET . Peter H. Griffith , executive vice president and chief financial officer, an
Read more →AMGNAmgen Presents New AMG 510 Clinical Data Across Multiple Solid Tumors During ASCO20 Virtual Scientific Program Amgen (NASDAQ:AMGN) today announced new data from the CodeBreaK 100 clinical development program evaluating investigational AMG 510 (proposed INN...
THOUSAND OAKS, Calif. , May 29, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced new data from the CodeBreaK 100 clinical development program evaluating investigational AMG 510 (proposed INN sotorasib) in heavily pretreated patients with a range of KRAS G12C -mutant sol
Read more →AMGNAmgen To Present At The Jefferies 2020 Virtual Healthcare Conference Amgen (NASDAQ: AMGN) will present at the Jefferies 2020 Virtual Healthcare Conference at 4:00 p.m. ET on Tuesday, June 2, 2020. David M. Reese, M.D., ...
THOUSAND OAKS, Calif. , May 28, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Jefferies 2020 Virtual Healthcare Conference at 4:00 p.m. ET on Tuesday , June 2, 2020. David M. Reese , M.D., executive vice president of Research and Development at Amgen, will be lea
Read more →AMGNAmgen To Webcast Investor Meeting At 56th Annual Meeting Of The American Society Of Clinical Oncology (ASCO) Amgen (NASDAQ: AMGN) will host a webcast call for the investment community in conjunction with the ASCO20 Virtual Scientific Program on Friday, May...
THOUSAND OAKS, Calif. , May 26, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will host a webcast call for the investment community in conjunction with the ASCO20 Virtual Scientific Program on Friday, May 29 , at 1:00 p.m. PT . David M. Reese , M.D., executive vice president of Rese
Read more →AMGNAmgen Announces Voting Results Of Annual Meeting Of Stockholders Amgen (NASDAQ:AMGN) today announced voting results from the Company's Annual Meeting of Stockholders on May 20, 2020, held virtually this year due to ...
THOUSAND OAKS, Calif. , May 20, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced voting results from the Company's Annual Meeting of Stockholders on May 20, 2020 , held virtually this year due to the COVID-19 pandemic. More than 88 percent of outstanding shares were rep
Read more →AMGNAmgen Showcases Oncology Pipeline At ASCO 2020 Amgen (NASDAQ:AMGN) today announced that data from its oncology pipeline and marketed portfolio will be presented during the ASCO20 Virtual...
THOUSAND OAKS, Calif. , May 13, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that data from its oncology pipeline and marketed portfolio will be presented during the ASCO20 Virtual Scientific Program taking place May 29 - 31, 2020 . Notable data from the oncology p
Read more →AMGNAmgen To Present At The Bank Of America Merrill Lynch Virtual Global Healthcare Conference Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Virtual Global Healthcare Conference at 1:40 p.m. ET on Thursday, May 14. Peter ...
THOUSAND OAKS, Calif. , May 12, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Bank of America Merrill Lynch Virtual Global Healthcare Conference at 1:40 p.m. ET on Thursday , May 14. Peter H. Griffith , executive vice president and chief financial officer, and Mu
Read more →AMGNFDA Grants Fast Track Designation For Omecamtiv Mecarbil In Heart Failure Amgen (NASDAQ:AMGN) and Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast...
THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif. , May 8, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and Cytokinetics, Incorporated (NASDAQ: CYTK ) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for omecamtiv mecarbil, a n
Read more →AMGNAmgen Announces Positive Top-Line Results From Otezla® (apremilast) Phase 3 ADVANCE Study In Mild-To-Moderate Plaque Psoriasis Amgen (NASDAQ:AMGN) today announced positive top-line results from the ADVANCE trial, a Phase 3, multicenter, randomized, placebo-controlled,...
THOUSAND OAKS, Calif. , May 6, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced positive top-line results from the ADVANCE trial, a Phase 3, multicenter, randomized, placebo-controlled, double-blind study to assess the efficacy of Otezla ® (apremilast) in adults with mi
Read more →AMGNKYPROLIS® (carfilzomib) Patents Upheld Against Generic Manufacturer Amgen (NASDAQ:AMGN) today announced that the U.S. District Court in Delaware issued a decision upholding the validity of patent claims from three...
KYPROLIS® (carfilzomib) is indicated in combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy. KYPROLIS® is indicated as a single agent for
Read more →AMGNAmgen To Present At The SunTrust Robinson Humphrey Life Sciences Summit Virtual Meeting Series Amgen (NASDAQ:AMGN) today announced that the Company will participate in the SunTrust Robinson Humphrey Life Sciences Summit Virtual Meeting Series....
THOUSAND OAKS, Calif. , May 4, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the Company will participate in the SunTrust Robinson Humphrey Life Sciences Summit Virtual Meeting Series. David M. Reese, M.D., executive vice president of Research and Development at
Read more →AMGNAmgen Reports First Quarter 2020 Financial Results Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2020 and discussed the company's response to the COVID-19 pandemic....
THOUSAND OAKS, Calif. , April 30, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced financial results for the first quarter of 2020 and discussed the company's response to the COVID-19 pandemic. First Quarter Performance Key results include: "I am inspired by the many
Read more →AMGNOne Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.amgen.com AMGEN REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS THOUSAND OAKS, Calif. (
Exhibit 99.1 News Release One Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.amgen.com AMGEN REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS THOUSAND OAKS, Calif. (April 30, 2020) - Amgen (NASDAQ:AMGN) today announced financial results for the first
Read more →AMGNAmgen Announces Webcast Of 2020 First Quarter Financial Results Amgen (NASDAQ:AMGN) today announced that it will report its first quarter financial results on Thursday, April 30, 2020, after the close of the U.S....
THOUSAND OAKS, Calif. , April 27, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will report its first quarter financial results on Thursday, April 30, 2020 , after the close of the U.S. financial markets. The announcement will be followed by a conference call
Read more →AMGNAmgen e Adaptive Biotecnologies anunciam parceria para desenvolver anticorpos com potencial de prevenir ou tratar a COVID-19 A Amgen, empresa de biotecnologia, e a Adaptive Biotechnologies anunciaram uma colaboração que visa ajudar a combater a pandemia da COVID-19. As...
SÃO PAULO, 9 de abril de 2020 /PRNewswire/ -- A Amgen, empresa de biotecnologia, e a Adaptive Biotechnologies anunciaram uma colaboração que visa ajudar a combater a pandemia da COVID-19. As empresas combinarão suas expertises para descobrir e desenvolver anticorpos neutralizante
Read more →AMGNAmgen And Adaptive Biotechnologies To Participate In Webinar On COVID-19 Strategic Collaboration Amgen (NASDAQ:AMGN) and Adaptive Biotechnologies Corporation (NASDAQ:ADPT) will participate in a webinar hosted by Bernstein on Thursday, April 9 at...
THOUSAND OAKS, Calif. , and SEATTLE , April 7, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and Adaptive Biotechnologies Corporation (NASDAQ: ADPT ) will participate in a webinar hosted by Bernstein on Thursday, April 9 at 8 a.m. PT ( 11 a.m. ET ) where David M. Reese , M.D., execu
Read more →AMGNAmgen And Adaptive Biotechnologies Announce Strategic Partnership To Develop A Therapeutic To Prevent Or Treat COVID-19 Amgen (NASDAQ:AMGN) and Adaptive Biotechnologies (NASDAQ:ADPT) today announced a collaboration aimed at helping address the COVID-19 pandemic. The...
THOUSAND OAKS, Calif. , and SEATTLE , April 2, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and Adaptive Biotechnologies (NASDAQ: ADPT ) today announced a collaboration aimed at helping address the COVID-19 pandemic. The companies will combine expertise to discover and develop full
Read more →AMGNAmgen Establishes Wholly-Owned Affiliate In Japan Amgen (NASDAQ:AMGN) today announced that it has consummated the purchase from Astellas of 49% of shares of Amgen Astellas BioPharma K.K. (AABP), a...
THOUSAND OAKS, Calif. , March 31, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it has consummated the purchase from Astellas of 49% of shares of Amgen Astellas BioPharma K.K. (AABP), a joint venture between Amgen and Astellas established in 2013. AABP, which is
Read more →AMGNAmgen Update Regarding COVID-19 For Media
Amgen Update Regarding COVID-19 For Media As the COVID-19 pandemic continues to evolve, we are committed to doing everything we can to keep our staff and their families safe and to help the communities where we live and work reduce the number of people exposed to the virus. We a
Read more →AMGNAmgen Announces Positive Results At ACC.20/WCC From Phase 3B Study Of Repatha® (Evolocumab) In People Living With HIV Who Have High LDL-Cholesterol Amgen (NASDAQ:AMGN) today announced positive results from the EvolocumaB Effect on LDL-C LowerIng in SubJEcts with Human Immunodeficiency ViRus and...
THOUSAND OAKS, Calif. , March 28, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced positive results from the Evolocuma B E ffect on LDL-C Lower I ng in Sub JE cts with Human Immunodeficiency Vi R us and IN creased C ardiovascular Ris K (BEIJERINCK) study evaluating the
Read more →AMGNAmgen And The Amgen Foundation Commit Up To $12.5 Million To Support COVID-19 Relief Efforts Amgen (NASDAQ:AMGN) and the Amgen Foundation today announced an initial commitment of up to $12.5 million to support U.S. and global relief efforts...
THOUSAND OAKS, Calif. , March 23, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and the Amgen Foundation today announced an initial commitment of up to $12.5 million to support U.S. and global relief efforts to address critical needs in communities impacted by the COVID-19 pandemic.
Read more →AMGNAmgen Announces 2020 Second Quarter Dividend Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.60 per share dividend for the second quarter of 2020. The dividend will ...
THOUSAND OAKS, Calif. , March 4, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that its Board of Directors declared a $1 .60 per share dividend for the second quarter of 2020. The dividend will be paid on June 8, 2020 , to all stockholders of record as of the close o
Read more →AMGNAmgen To Present At The Cowen 40th Annual Healthcare Conference Amgen (NASDAQ:AMGN) will present at the Cowen 40th Annual Healthcare Conference at 11:20 a.m. ET on Monday, March 2, 2020 in Boston. Peter H....
THOUSAND OAKS, Calif. , Feb. 27, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Cowen 40 th Annual Healthcare Conference at 11:20 a.m. ET on Monday, March 2, 2020 in Boston. Peter H. Griffith , executive vice president and chief financial officer, and Murdo Gordon
Read more →AMGNAmgen, Cytokinetics And Servier Announce Continuation Of GALACTIC-HF Following Planned Interim Analysis Amgen (NASDAQ:AMGN), Cytokinetics, Incorporated (NASDAQ:CYTK) and Servier today announced that the Data Monitoring Committee (DMC) for GALACTIC-HF...
THOUSAND OAKS, Calif. , SOUTH SAN FRANCISCO, Calif. , and SURESNES, France, Feb. 26, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ), Cytokinetics, Incorporated (NASDAQ: CYTK ) and Servier today announced that the Data Monitoring Committee (DMC) for GALACTIC-HF recently completed the
Read more →AMGNAmgen lança biossimilar para tratamento de doenças inflamatórias A Amgen, uma das maiores empresas de biotecnologia do mundo, anuncia o lançamento e comercialização do primeiro medicamento biossimilar da molécula...
SÃO PAULO, 3 de fevereiro de 2020 /PRNewswire/ -- A Amgen, uma das maiores empresas de biotecnologia do mundo, anuncia o lançamento e comercialização do primeiro medicamento biossimilar da molécula adalimumabe disponível no Brasil. AMGEVITA® foi aprovado pela Agência Nacional de
Read more →AMGNOne Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.amgen.com AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS THOUSAND OAKS, Calif. (
Exhibit 99.1 News Release One Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.amgen.com AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS THOUSAND OAKS, Calif. (Jan. 30, 2020) - Amgen (NASDAQ:AMGN) today announced financial results
Read more →AMGNAmgen Reports Fourth Quarter And Full Year 2019 Financial Results Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year 2019 versus comparable periods in 2018. Key results...
THOUSAND OAKS, Calif. , Jan. 30, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced financial results for the fourth quarter and full year 2019 versus comparable periods in 2018. Key results include: "We are entering a period of new product driven revenue growth," said R
Read more →AMGNAmgen Announces Webcast Of 2019 Fourth Quarter And Full Year Financial Results Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2019 financial results on Thursday, Jan. 30, 2020, after the ...
THOUSAND OAKS, Calif. , Jan. 27, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will report its fourth quarter and full year 2019 financial results on Thursday, Jan. 30, 2020 , after the close of the U.S. financial markets. The announcement will be followed by
Read more →AMGNFree LabXchange Science Education Accelerator Launched By Amgen Foundation And Harvard's Faculty Of Arts And Sciences The Amgen Foundation and the Faculty of Arts and Sciences at Harvard University (Harvard FAS) today announced the global launch of LabXchange™, a...
THOUSAND OAKS, Calif. and CAMBRIDGE, Mass. , Jan. 22, 2020 /PRNewswire/ -- The Amgen Foundation and the Faculty of Arts and Sciences at Harvard University (Harvard FAS) today announced the global launch of LabXchange™, a free online science education platform that provides users
Read more →AMGNAmgen Announces Global Diagnostic Collaborations To Expand Molecular Testing For Patients With Non-Small Cell Lung Cancer Amgen (NASDAQ: AMGN) today announced strategic collaborations with leading diagnostic companies Guardant Health, Inc. and QIAGEN N.V. to develop...
THOUSAND OAKS, Calif. , Jan. 13, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced strategic collaborations with leading diagnostic companies Guardant Health, Inc. and QIAGEN N.V. to develop blood- and tissue-based companion diagnostics (CDx), respectively, for investiga
Read more →AMGNAmgen To Present At The 38th Annual J.P. Morgan Healthcare Conference Amgen (NASDAQ:AMGN) will present at the 38th Annual J.P. Morgan Healthcare Conference at 8:30 a.m. PT on Tuesday, Jan. 14, 2020, in San Francisco....
THOUSAND OAKS, Calif. , Jan. 9, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the 38 th Annual J.P. Morgan Healthcare Conference at 8:30 a.m. PT on Tuesday, Jan. 14, 2020, in San Francisco. Robert A. Bradway, chairman and chief executive officer at Amgen, will presen
Read more →AMGNAmgen To Present At The Goldman Sachs 12th Annual Healthcare CEOs Unscripted Conference Amgen (NASDAQ:AMGN) will present via video conference at the Goldman Sachs 12th Annual Healthcare CEOs Unscripted Conference at 1 p.m. PT on...
THOUSAND OAKS, Calif. , Jan. 7, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present via video conference at the Goldman Sachs 12 th Annual Healthcare CEOs Unscripted Conference at 1 p.m. PT on Thursday, Jan. 9, 2020 . Robert A. Bradway , chairman and chief executive officer a
Read more →AMGNNova combinação terapêutica diminui 37% do risco de progressão ou morte em pacientes com Mieloma Múltiplo Pacientes e profissionais de saúde que enfrentam a alta taxa de mortalidade do mieloma múltiplo, um tipo agressivo de câncer do sangue, receberam...
SÃO PAULO, 6 de janeiro de 2020 /PRNewswire/ -- Pacientes e profissionais de saúde que enfrentam a alta taxa de mortalidade do mieloma múltiplo, um tipo agressivo de câncer do sangue, receberam notícias promissoras sobre novas formas de tratar a doença durante o 61º congresso anu
Read more →AMGNOne Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.Amgen.com News Release AMGEN COMMENCES STRATEGIC COLLABORATION WITH BEIGENE TO EXPAND ONCOLOGY PRESENCE IN CHINA Strategic Collaboration Will
AMGEN COMMENCES STRATEGIC COLLABORATION WITH BEIGENE TO EXPAND ONCOLOGY PRESENCE IN CHINA Strategic Collaboration Will Accelerate Amgen s Expansion in China THOUSAND OAKS, Calif. (Jan. 2, 2020) Amgen (NASDAQ:AMGN) today announced the successful closing of the transaction to en
Read more →AMGNAmgen Commences Strategic Collaboration With BeiGene to Expand Oncology Presence in China Amgen (NASDAQ: AMGN) today announced the successful closing of the transaction to enter into a strategic collaboration with BeiGene that will...
THOUSAND OAKS, Calif. , Jan. 2, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the successful closing of the transaction to enter into a strategic collaboration with BeiGene that will significantly accelerate Amgen's plans to expand its oncology presence in China , th
Read more →AMGNAmgen And Allergan Submit Biologics License Application For ABP 798, Biosimilar Candidate To Rituxan® (rituximab), To U.S. Food And Drug Administration Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug...
THOUSAND OAKS, Calif. , Dec. 19, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and Allergan plc. (NYSE: AGN ) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ABP 798, a biosimilar candidate to Rituxan ® (ritu
Read more →AMGNEuropean Commission Approves EVENITY® (romosozumab) For The Treatment Of Severe Osteoporosis In Postmenopausal Women At High Risk Of Fracture Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced that the European Commission (EC) has granted marketing authorization for...
THOUSAND OAKS, Calif. and BRUSSELS , Dec. 11, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and UCB (Euronext Brussels: UCB) today announced that the European Commission (EC) has granted marketing authorization for EVENITY ® (romosozumab) for the treatment of severe osteoporosis in
Read more →AMGNAmgen Announces 10% Increase In 2020 First Quarter Dividend Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.60 per share dividend for the first quarter of 2020. The dividend will...
THOUSAND OAKS, Calif. , Dec. 11, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that its Board of Directors declared a $1 .60 per share dividend for the first quarter of 2020. The dividend will be paid on March 6, 2020 , to all stockholders of record as of the close o
Read more →AMGNAmgen Data From Phase 3 CANDOR Study Combining KYPROLIS® (carfilzomib) And DARZALEX® (daratumumab) To Be Presented During Late-Breaking Session At American Society Of Hematology Annual Meeting Amgen (NASDAQ:AMGN) today announced additional results from the primary analysis of the Phase 3 CANDOR study evaluating KYPROLIS® (carfilzomib) in...
THOUSAND OAKS, Calif. , Dec. 10, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced additional results from the primary analysis of the Phase 3 CANDOR study evaluating KYPROLIS ® (carfilzomib) in combination with dexamethasone and DARZALEX ® (daratumumab) (KdD) compared t
Read more →AMGNAmgen Selects Location For R&D Facility In The South San Francisco Biotechnology Hub Amgen (NASDAQ:AMGN) today announced the signing of a lease with BioMed Realty for a new 240,000-square-foot Leadership in Energy and Environmental...
THOUSAND OAKS, Calif. , Dec. 9, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the signing of a lease with BioMed Realty for a new 240,000-square-foot Leadership in Energy and Environmental Design (LEED) candidate facility in the Gateway of Pacific campus development
Read more →AMGNFDA Approves Amgen's AVSOLA™ (infliximab-axxq), For The Same Indications As Remicade® (infliximab) Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved AVSOLA™ (infliximab-axxq) for all approved...
THOUSAND OAKS, Calif. , Dec. 6, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the U.S. Food and Drug Administration (FDA) has approved AVSOLA™ (infliximab-axxq) for all approved indications of the reference product, Remicade ® (infliximab): for the treatment of
Read more →AMGNAmgen Announces Data Being Presented At ASH 2019 Amgen (NASDAQ:AMGN) today announced new clinical data from its oncology in-line products and pipeline that will be presented at the 61st American...
THOUSAND OAKS, Calif. , Dec. 2, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced new clinical data from its oncology in-line products and pipeline that will be presented at the 61 st American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando , Dec. 7-10
Read more →AMGNOne Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.Amgen.com News Release AMGEN COMPLETES ACQUISITION OF OTEZLA (APREMILAST) Differentiated Therapy Strengthens Amgen s Long-Standing Expertise
AMGEN COMPLETES ACQUISITION OF OTEZLA (APREMILAST) Differentiated Therapy Strengthens Amgen s Long-Standing Expertise in Inflammation THOUSAND OAKS, Calif. (Nov. 21, 2019) - Amgen (NASDAQ:AMGN) today announced the successful completion of its acquisition of worldwide rights to
Read more →AMGNAmgen Completes Acquisition Of Otezla® (apremilast) Amgen (NASDAQ:AMGN) today announced the successful completion of its acquisition of worldwide rights to Otezla® (apremilast), the only oral,...
THOUSAND OAKS, Calif. , Nov. 21, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the successful completion of its acquisition of worldwide rights to Otezla ® (apremilast), the only oral, non-biologic treatment for moderate-to-severe plaque psoriasis and psoriatic arthr
Read more →AMGNNew Results From COSMIC-HF Presented At AHA 2019 Show Treatment Of Heart Failure Patients With Omecamtiv Mecarbil Was Associated With Neutral Or Improved Measures Of Diastolic Function Amgen (NASDAQ: AMGN), Cytokinetics, Incorporated (NASDAQ: CYTK) and Servier announced that new results from COSMIC-HF (Chronic Oral Study of Myosin...
THOUSAND OAKS, Calif. , SOUTH SAN FRANCISCO, Calif. , and SURESNES, France, Nov. 18, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ), Cytokinetics, Incorporated (NASDAQ: CYTK ) and Servier announced that new results from COSMIC-HF ( C hronic O ral S tudy of M yosin Activation to I ncr
Read more →AMGNAmgen Announces New FOURIER Analysis Showing Benefit Of Repatha® (evolocumab) In High-Risk Patients Who Have Experienced A Recent Heart Attack Amgen today announced a new analysis from the Repatha® (evolocumab) cardiovascular outcomes (FOURIER) study that evaluates the effectiveness of...
THOUSAND OAKS, Calif. , Nov. 16, 2019 /PRNewswire/ -- Amgen today announced a new analysis from the Repatha ® (evolocumab) cardiovascular outcomes (FOURIER) study that evaluates the effectiveness of Repatha in patients who have suffered a recent myocardial infarction (MI). The an
Read more →AMGNAmgen And The Duke Clinical Research Institute Announce Initiation Of First Large-Scale Registry To Evaluate Real-World Lipid Management And The Effectiveness Of PCSK9 Inhibitors Amgen (NASDAQ:AMGN) in collaboration with the Duke Clinical Research Institute (DCRI) today announced plans to initiate the Cardiovascular...
THOUSAND OAKS, Calif. , Nov. 15, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) in collaboration with the Duke Clinical Research Institute (DCRI) today announced plans to initiate the C ardio v ascular M ulti-dimensional Ob servational I nvestigation of the U se of PC S K9 inhibitors
Read more →AMGNAmgen Highlights Data To Be Presented At AHA 2019 Across Cardiovascular Portfolio Amgen (NASDAQ:AMGN) today announced that new data from its cardiovascular portfolio will be presented at the American Heart Association (AHA)...
THOUSAND OAKS, Calif. , Nov. 11, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that new data from its cardiovascular portfolio will be presented at the American Heart Association (AHA) Scientific Sessions 2019 in Philadelphia , Nov. 16-18 . This includes new clinical
Read more →AMGNAmgen To Present At The 28th Annual Credit Suisse Healthcare Conference Amgen (NASDAQ:AMGN) will present at the 28th Annual Credit Suisse Healthcare Conference at 9:45 a.m. MT on Tuesday, Nov. 12, 2019, in Scottsdale,...
THOUSAND OAKS, Calif. , Nov. 7, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the 28 th Annual Credit Suisse Healthcare Conference at 9:45 a.m. MT on Tuesday , Nov. 12, 2019, in Scottsdale, Ariz. David W. Meline, executive vice president and chief financial officer a
Read more →AMGNAmgen Enters Into Strategic Collaboration With BeiGene To Expand Oncology Presence In China Amgen (NASDAQ:AMGN) announced today that it has entered into a strategic collaboration with BeiGene that will significantly accelerate Amgen's plans...
THOUSAND OAKS, Calif. , Oct. 31, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) announced today that it has entered into a strategic collaboration with BeiGene that will significantly accelerate Amgen's plans to expand its oncology presence in China , the world's second-largest pharm
Read more →AMGNAmgen entra no mercado de biossimilares com o lançamento de KANJINTI™ para câncer de mama e outros tumores A Amgen, uma das empresas líderes em biotecnologia no mundo, lança no mercado brasileiro seu primeiro biossimilar para o tratamento de câncer. O...
SÃO PAULO, 31 de outubro de 2019 /PRNewswire/ -- A Amgen, uma das empresas líderes em biotecnologia no mundo, lança no mercado brasileiro seu primeiro biossimilar para o tratamento de câncer. O KANJINTI™ 1,2 (trastuzumabe) foi aprovado pela ANVISA (Agência Nacional de Vigilância
Read more →AMGNOne Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.Amgen.com AMGEN ENTERS INTO STRATEGIC COLLABORATION WITH BEIGENE TO EXPAND ONCOLOGY PRESENCE IN CHINA Amgen to Acquire 20.5% Sta
AMGEN ENTERS INTO STRATEGIC COLLABORATION WITH BEIGENE TO EXPAND ONCOLOGY PRESENCE IN CHINA Amgen to Acquire 20.5% Stake in BeiGene for Approximately $2.7 Billion in Cash BeiGene to Commercialize XGEVA (denosumab), KYPROLIS (carfilzomib) and BLINCYTO (blinatumomab) in China
Read more →AMGNThe Discovery Of Amgen's Novel Investigational KRAS(G12C) Inhibitor AMG 510 Published In Nature Amgen (NASDAQ: AMGN) today announced a publication in Nature unveiling the discovery of AMG 510, a small molecule inhibitor of KRASG12C being...
THOUSAND OAKS, Calif. , Oct. 30, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced a publication in Nature unveiling the discovery of AMG 510, a small molecule inhibitor of KRAS G12C being investigated as a treatment for a variety of solid tumors with KRAS G12C mutation.
Read more →AMGNAmgen Reports Third Quarter 2019 Financial Results Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2019. Key results include: Total revenues decreased 3% to $5.7 billion ...
THOUSAND OAKS, Calif. , Oct. 29, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced financial results for the third quarter of 2019. Key results include: "Amgen continues to execute well in a dynamic environment, with many of our innovative medicines delivering double-di
Read more →AMGNAmgen Announces Webcast of 2019 Third Quarter Financial Results Amgen (NASDAQ:AMGN) today announced that it will report its third quarter financial results on Tuesday, Oct. 29, 2019, after the close of the U.S....
THOUSAND OAKS, Calif. , Oct. 24, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will report its third quarter financial results on Tuesday, Oct. 29, 2019 , after the close of the U.S. financial markets. The announcement will be followed by a conference call wi
Read more →AMGNAmgen To Make Repatha® (evolocumab) Available Exclusively At Its Lower List Price Option In 2020 Amgen (NASDAQ:AMGN) today announced that effective Dec. 31, 2019, Repatha® (evolocumab), an innovative treatment for patients with high cholesterol...
THOUSAND OAKS, Calif. , Oct. 24, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that effective Dec. 31, 2019 , Repatha ® (evolocumab), an innovative treatment for patients with high cholesterol and cardiovascular disease proven to reduce heart attacks and strokes, wil
Read more →AMGNAmgen Recommends Rejection Of 'Mini-Tender' Offer From TRC Capital Corporation Amgen (NASDAQ:AMGN) today announced that it has been notified of an unsolicited mini-tender offer dated Oct. 11, 2019, made by TRC Capital...
THOUSAND OAKS, Calif. , Oct. 23, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it has been notified of an unsolicited "mini-tender" offer dated Oct. 11, 2019 , made by TRC Capital Corporation, a private Canadian investment company, to purchase up to 500,000 shar
Read more →AMGNDavid Meline, Amgen s Chief Financial Officer, to Retire Peter Griffith to Assume CFO Role in 2020
David Meline, Amgen s Chief Financial Officer, to Retire Peter Griffith to Assume CFO Role in 2020 THOUSAND OAKS, Calif., October 22, 2019 Amgen (NASDAQ: AMGN) today announced the planned retirement of David W. Meline, who has served as the company s executive vice president an
Read more →AMGNAmgen Announces 2019 Fourth Quarter Dividend Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.45 per share dividend for the fourth quarter of 2019. The dividend will ...
THOUSAND OAKS, Calif. , Oct. 22, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that its Board of Directors declared a $1 .45 per share dividend for the fourth quarter of 2019. The dividend will be paid on Dec. 6, 2019 , to all stockholders of record as of the close o
Read more →AMGNNplate® (romiplostim) Now Approved For Earlier Use In Adults With Immune Thrombocytopenia Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) approved Amgen's Supplemental Biologics License Application...
THOUSAND OAKS, Calif. , Oct. 18, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the U.S. Food and Drug Administration (FDA) approved Amgen's Supplemental Biologics License Application (sBLA) for Nplate ® (romiplostim) to include new data in its U.S. prescribing i
Read more →AMGNEVENITY® (Romosozumab) Receives Positive CHMP Opinion For The Treatment Of Severe Osteoporosis In Postmenopausal Women At High Risk Of Fracture Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced that following a re-examination procedure, the Committee for Medicinal Products...
THOUSAND OAKS, Calif. and BRUSSELS , Oct. 17, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and UCB (Euronext Brussels: UCB) today announced that following a re-examination procedure, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) ha
Read more →AMGNSports Anchor And Multiple Myeloma Patient Rod Gilmore Joins Amgen's Myeloma MVP™ Team Amgen (NASDAQ:AMGN) today announced the expansion of Myeloma MVP™, a national initiative to help myeloma patients and their care teams create their...
THOUSAND OAKS, Calif. , Oct. 15, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the expansion of Myeloma MVP ™ , a national initiative to help myeloma patients and their care teams create their M ost V aluable P lan. In its second year, Myeloma MVP now includes an upd
Read more →AMGNAmgen Foundation Launches Amgen Biotech Experience In Pittsburgh The Amgen Foundation today announced the launch of the Amgen Biotech Experience (ABE) program in Pittsburgh, Pa. Through a grant from the Richard...
THOUSAND OAKS, Calif. and PITTSBURGH , Oct. 9, 2019 /PRNewswire/ -- The Amgen Foundation today announced the launch of the Amgen Biotech Experience (ABE) program in Pittsburgh, Pa. Through a grant from the Richard King Mellon Foundation, the region's students will become a part o
Read more →AMGNAmgen Announces New Clinical Data Evaluating Novel Investigational KRAS(G12C) Inhibitor In Patients With Solid Tumors At ESMO 2019 Amgen (NASDAQ: AMGN) today announced new data from the ongoing Phase 1 study evaluating AMG 510 in patients with previously treated KRAS G12C-mutant...
THOUSAND OAKS, Calif. , Sept. 27, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced new data from the ongoing Phase 1 study evaluating AMG 510 in patients with previously treated KRAS G12C -mutant solid tumors. The data include the first evidence of anti-tumor activity r
Read more →AMGNHeart Attack Survivors Are Taking Steps To Reduce Their Cardiovascular Risk. But Are They The Right Ones? In recognition of World Heart Day on Sunday, September 29, Amgen (NASDAQ:AMGEN) today released findings from a global survey that evaluated worldwide ...
THOUSAND OAKS, Calif. , Sept. 26, 2019 /PRNewswire/ -- In recognition of World Heart Day on Sunday, September 29 , Amgen (NASDAQ: AMGEN ) today released findings from a global survey that evaluated worldwide heart attack survivors' perceptions and awareness of the connection betw
Read more →AMGNAmgen To Webcast Investor Call At ESMO 2019 Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the European Society for Medical Oncology (ESMO) 2019...
THOUSAND OAKS, Calif. , Sept. 25, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will host a webcast call for the investment community in conjunction with the European Society for Medical Oncology (ESMO) 2019 Congress on Saturday, Sept. 28 , at 10 a.m. PT . David M. Reese , M.D., exe
Read more →AMGNAmgen Announces Positive Results From Two Phase 3 BLINCYTO® (blinatumomab) Studies In Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia Amgen (NASDAQ:AMGN) today announced that the results of a prespecified interim analysis of an open-label, randomized, controlled global multicenter...
THOUSAND OAKS, Calif. , Sept. 24, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the results of a prespecified interim analysis of an open-label, randomized, controlled global multicenter Phase 3 trial (20120215) showed that the primary endpoint of event-free sur
Read more →AMGNAmgen Showcases New Data From Oncology Pipeline And Portfolio At ESMO 2019 Amgen (NASDAQ:AMGN) today announced that new data from its oncology pipeline and marketed product portfolio will be presented at the European Society ...
THOUSAND OAKS, Calif. , Sept. 17, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that new data from its oncology pipeline and marketed product portfolio will be presented at the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain , Sept. 27-
Read more →AMGNAmgen To Present At The Bank of America Merrill Lynch Global Healthcare Conference Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 9:45 a.m. British Summer Time on Wednesday,...
THOUSAND OAKS, Calif. , Sept. 13, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 9:45 a.m. British Summer Time on Wednesday, Sept. 18, 2019 , in London . David W. Meline , executive vice president and c
Read more →AMGNAmgen Announces Phase 3 CANDOR Study Combining KYPROLIS® (carfilzomib) And DARZALEX® (daratumumab) Meets Primary Endpoint Of Progression-Free Survival Amgen (NASDAQ:AMGN) today announced the Phase 3 CANDOR study evaluating KYPROLIS® (carfilzomib) in combination with dexamethasone and DARZALEX®...
THOUSAND OAKS, Calif. , Sept. 13, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the Phase 3 CANDOR study evaluating KYPROLIS ® (carfilzomib) in combination with dexamethasone and DARZALEX ® (daratumumab) (KdD) compared to KYPROLIS and dexamethasone alone (Kd) met its
Read more →AMGNAmgen Highlights New Data From KYPROLIS® (carfilzomib) And Oncology Pipeline At IMW 2019 Amgen (NASDAQ:AMGN) today announced that new data from its oncology portfolio and pipeline will be presented at the 17th International Myeloma...
THOUSAND OAKS, Calif. , Sept. 12, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that new data from its oncology portfolio and pipeline will be presented at the 17 th International Myeloma Workshop (IMW) 2019 in Boston , Sept. 12-15, 2019 . Data featured from Amgen's
Read more →AMGNAmgen Announces New Clinical Data Evaluating Novel Investigational KRAS(G12C) Inhibitor In Larger Patient Group At WCLC 2019 Amgen (NASDAQ:AMGN) today announced new data from the ongoing Phase 1 study evaluating AMG 510 in patients with previously treated KRAS G12C-mutated...
THOUSAND OAKS, Calif. , Sept. 8, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced new data from the ongoing Phase 1 study evaluating AMG 510 in patients with previously treated KRAS G12C -mutated solid tumors. AMG 510 is a first-in-class investigational oral therapy tha
Read more →AMGNAmgen To Present At The Morgan Stanley Global Healthcare Conference Amgen (NASDAQ: AMGN) will present at the Morgan Stanley Global Healthcare Conference at 9:10 a.m. ET on Tuesday, Sept. 10, 2019, in New York City....
THOUSAND OAKS, Calif. , Sept. 5, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Morgan Stanley Global Healthcare Conference at 9:10 a.m. ET on Tuesday, Sept. 10, 2019 , in New York City . Robert A. Bradway , chairman and chief executive officer at Amgen, will pres
Read more →AMGNAmgen To Webcast Investor Call At IASLC 2019 World Conference on Lung Cancer Amgen (NASDAQ:AMGN) will host a webcast call for the investment community at the International Association for the Study of Lung Cancer (IASLC) 2019...
THOUSAND OAKS, Calif. , Sept. 4, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will host a webcast call for the investment community at the International Association for the Study of Lung Cancer (IASLC) 2019 World Conference on Lung Cancer (WCLC) on Sunday, Sept. 8 , at 8 a.m. PT .
Read more →AMGNNew Amgen Data To Be Presented At ESC Congress 2019 Highlight Additional Evidence For Repatha® (Evolocumab) Effectiveness In Cardiovascular Disease Across Multiple Patient Groups Amgen (NASDAQ: AMGN) today announced the presentation of 14 cardiovascular scientific research abstracts, including studies evaluating the safety and ...
THOUSAND OAKS, Calif. , Aug. 28, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the presentation of 14 cardiovascular scientific research abstracts, including studies evaluating the safety and efficacy of Repatha ® (evolocumab) by race and ethnicity and further examin
Read more →AMGNAmgen To Acquire Otezla® For $13.4 Billion In Cash, Or Approximately $11.2 Billion Net Of Anticipated Future Cash Tax Benefits Amgen (NASDAQ: AMGN) announced today that it has entered into an agreement with Celgene Corporation (NASDAQ: CELG) in connection with its previously...
THOUSAND OAKS, Calif. , Aug. 26, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) announced today that it has entered into an agreement with Celgene Corporation (NASDAQ: CELG ) in connection with its previously announced merger with Bristol-Myers Squibb Company (NYSE: BMY ) to acquire
Read more →AMGNOne Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.amgen.com News Releaser AMGEN TO ACQUIRE OTEZLA FOR $13.4 BILLION IN CASH, OR APPROXIMATELY $11.2 BILLION NET OF ANTICIPATED FUTURE CASH TAX
AMGEN TO ACQUIRE OTEZLA FOR $13.4 BILLION IN CASH, OR APPROXIMATELY $11.2 BILLION NET OF ANTICIPATED FUTURE CASH TAX BENEFITS Innovative Therapy Will Strengthen Amgen s Inflammation Portfolio for Patients Around the World Acquisition Expected to Accelerate Growth and Enhance Va
Read more →AMGNAmgen And Allergan Announce Positive Top-Line Results From Comparative Clinical Study Of ABP 798, Biosimilar Candidate To Rituxan® (Rituximab) Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced positive top-line results from a comparative clinical study evaluating the efficacy...
THOUSAND OAKS, Calif. , Aug. 22, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and Allergan plc. (NYSE: AGN ) today announced positive top-line results from a comparative clinical study evaluating the efficacy and safety of ABP 798, a biosimilar candidate to Rituxan ® (rituximab), c
Read more →AMGNAmgen Wins Patent Case On Enbrel® (etanercept) Amgen (NASDAQ:AMGN) today announced that the U.S. District Court for the District of New Jersey has ruled in Amgen's favor on validity of the two...
THOUSAND OAKS, Calif. , Aug. 9, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the U.S. District Court for the District of New Jersey has ruled in Amgen's favor on validity of the two patents that describe and claim Enbrel ® (etanercept) and methods for making it
Read more →AMGNAmgen Announces 2019 Third Quarter Dividend Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.45 per share dividend for the third quarter of 2019. The dividend will...
THOUSAND OAKS, Calif. , Aug. 2, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that its Board of Directors declared a $1.45 per share dividend for the third quarter of 2019. The dividend will be paid on Sept. 6, 2019 , to all stockholders of record as of the close of
Read more →AMGNAmgen Reports Second Quarter 2019 Financial Results Amgen (NASDAQ: AMGN) today announced financial results for the second quarter of 2019. Key results include: Total revenues decreased 3% to $5.9...
THOUSAND OAKS, Calif. , July 30, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced financial results for the second quarter of 2019. Key results include: "With our newer products generating strong volume gains globally and many first-in-class medicines advancing through
Read more →AMGNOne Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.amgen.com AMGEN REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS THOUSAND OAKS, Calif. (
Exhibit 99.1 News Release One Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.amgen.com AMGEN REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS THOUSAND OAKS, Calif. (July 30, 2019) - Amgen (NASDAQ:AMGN) today announced financial results for the second
Read more →AMGNAmgen kontroluje 98% udziałów w Nuevolution po zakończeniu przedłużonego okresu przyjęcia Niniejsza oferta nie jest kierowana do, niniejszy komunikat prasowy nie może być publikowany pośrednio lub bezpośrednio w lub do, a oferty na akcje...
THOUSAND OAKS , Kalifornia, 29 lipca 2019 r. /PRNewswire/ -- Niniejsza oferta nie jest kierowana do, niniejszy komunikat prasowy nie może być publikowany pośrednio lub bezpośrednio w lub do, a oferty na akcje nie będą przyjmowane od ani w imieniu akcjonariuszy w Australii, Kanad
Read more →AMGNSpolečnost Amgen po ukončení prodlouženého akceptačního období vlastní 98 % akcií společnosti Nuevolution Nabídka není učiněná a tato tisková zpráva nesmí být distribuována, přímo ani nepřímo, ani nebude přijímána žádná nabídka akcií od jejich držitelů...
THOUSAND OAKS , Kalifornie, 28. července 2019 /PRNewswire/ -- Nabídka není učiněná a tato tisková zpráva nesmí být distribuována, přímo ani nepřímo, ani nebude přijímána žádná nabídka akcií od jejich držitelů nebo v jejich zastoupení v Austrálii, Kanadě, Hongkongu, Japonsku, Nov
Read more →AMGNSpoločnosť Amgen získala na konci predĺženej lehoty na akceptáciu kontrolu nad 98% akcií firmy Nuevolution Táto ponuka nebude realizovaná a táto tlačová správa nesmie byť distribuovaná, priamo ani nepriamo, v krajine alebo do krajiny, ani nebude...
THOUSAND OAKS , Kalifornia, 27. júla 2019 /PRNewswire/ -- Táto ponuka nebude realizovaná a táto tlačová správa nesmie byť distribuovaná, priamo ani nepriamo, v krajine alebo do krajiny, ani nebude akceptovaná žiadna ponuka akcií od alebo v mene vlastníkov akcií v Austrálii, Kana
Read more →AMGNAmgen hält nach Ablauf der verlängerten Annahmefrist 98% der Anteile an Nuevolution Das Angebot gilt nicht für Australien, Kanada, Hongkong, Japan, Neuseeland und Südafrika, und diese Pressemitteilung darf weder direkt noch indirekt...
THOUSAND OAKS , Kalifornien, 27. Juli 2019 /PRNewswire/ -- Das Angebot gilt nicht für Australien, Kanada, Hongkong, Japan , Neuseeland und Südafrika, und diese Pressemitteilung darf weder direkt noch indirekt in diesen Ländern veröffentlicht werden, ebenso werden keine Anteilsan
Read more →AMGNAmgen controla el 98% de las acciones de Nuevolution una vez finalizado el plazo de aceptación La oferta no se realiza, y el presente comunicado de prensa no se distribuirá, directa o indirectamente, en, ni se aceptarán ofertas de acciones...
THOUSAND OAKS, California , 27 de julio de 2019 /PRNewswire/ -- La oferta no se realiza, y el presente comunicado de prensa no se distribuirá, directa o indirectamente, en, ni se aceptarán ofertas de acciones desde o en nombre de titulares en Australia , Canadá, Hong Kong , Japó
Read more →AMGNAmgen contrôle 98 % des actions de Nuevolution à la fin de la période d'acceptation prolongée L'Offre n'est pas faite et le présent communiqué ne peut pas être distribué, directement ou indirectement, dans ou vers les pays mentionnés...
THOUSAND OAKS , Californie, 27 juillet 2019 /PRNewswire/ -- L'Offre n'est pas faite et le présent communiqué ne peut pas être distribué, directement ou indirectement, dans ou vers les pays mentionnés ci-dessous. De plus, aucune offre d'actions ne sera acceptée de la part ou pour
Read more →AMGNПо окончании продленного периода рассмотрения заявок компания Amgen контролирует 98% акций Nuevolution Данное предложение не распространяется на акционеров, заявки на покупки или продажу акций от акционеров не принимаются, а данный пресс-релиз не может ...
ТАУЗАНД-ОКС ( THOUSAND OAKS ), Калифорния, 26 июля 2019 г. /PRNewswire/ -- Данное предложение не распространяется на акционеров, заявки на покупки или продажу акций от акционеров не принимаются, а данный пресс-релиз не может напрямую или опосредованно распространяться в Австрали
Read more →AMGNAmgen Controls 98% Of The Shares In Nuevolution After The End Of The Extended Acceptance Period The Offer is not being made, and this press release may not be distributed, directly or indirectly, in or into, nor will any tender of shares be...
THOUSAND OAKS, Calif. , July 26, 2019 /PRNewswire/ -- The Offer is not being made, and this press release may not be distributed, directly or indirectly, in or into, nor will any tender of shares be accepted from or on behalf of holders in, Australia , Canada , Hong Kong , Japan
Read more →AMGNAmgen Announces Webcast Of 2019 Second Quarter Financial Results Amgen (NASDAQ:AMGN) today announced that it will report its second quarter financial results on Tuesday, July 30, 2019, after the close of the U.S....
THOUSAND OAKS, Calif. , July 25, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will report its second quarter financial results on Tuesday, July 30, 2019 , after the close of the U.S. financial markets. The announcement will be followed by a conference call w
Read more →AMGNAmgen And Allergan's MVASI™ (bevacizumab-awwb) And KANJINTI™ (trastuzumab-anns) Now Available In The United States Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) today announced that MVASI™ (bevacizumab-awwb), a biosimilar to Avastin® (bevacizumab), and...
THOUSAND OAKS, Calif. , July 18, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and Allergan plc (NYSE: AGN ) today announced that MVASI™ (bevacizumab-awwb), a biosimilar to Avastin ® (bevacizumab), and KANJINTI TM (trastuzumab-anns), a biosimilar to Herceptin ® (trastuzumab), are no
Read more →AMGNAmgen, Novartis And Banner Alzheimer's Institute Discontinue Clinical Research Program With BACE Inhibitor CNP520 For Alzheimer's Prevention Amgen (NASDAQ:AMGN), Novartis and Banner Alzheimer's Institute today announced the collective decision to discontinue investigation of the BACE1...
The Generation Program was designed to research the safety and efficacy of CNP520 for the prevention or delay of the onset of Alzheimer's disease in people at high risk for developing symptoms based on age and their genetic status. Alzheimer's is a complex disease and one of the
Read more →AMGNAmgen annonce le résultat de l'offre publique d'achat recommandée aux actionnaires de Nuevolution, déclare l'offre inconditionnelle et l'exécute L'Offre n'est pas proposée, et le présent communiqué ne peut pas être distribué, directement ou indirectement, dans ou vers les pays mentionnés...
THOUSAND OAKS , Californie, 9 juillet 2019 /PRNewswire/ -- L'Offre n'est pas proposée, et le présent communiqué ne peut pas être distribué, directement ou indirectement, dans ou vers les pays mentionnés ci-dessous. De plus, aucune offre d'actions ne sera acceptée de la part de o
Read more →AMGNAmgen gibt das Ergebnis des empfohlenen öffentlichen Barangebots bekannt, das den Anteilseignern der Nuevolution unterbreitet wurde, erklärt das Angebot für unwiderruflich und schließt es ab Das Angebot wird nicht direkt oder indirekt durch Anteilseigner in Australien, Kanada, Hongkong, Japan, Neuseeland oder Südafrika ausgesprochen....
THOUSAND OAKS , Kalifornien, 9. Juli 2019 /PRNewswire/ -- Das Angebot wird nicht direkt oder indirekt durch Anteilseigner in Australien, Kanada, Hongkong, Japan , Neuseeland oder Südafrika ausgesprochen. Diese Pressemitteilung darf in diesen Ländern nicht veröffentlicht werden.
Read more →AMGNAmgen ogłasza wyniki rekomendowanej publicznej oferty gotówkowej dla akcjonariuszy Nuevolution, deklaruje ofertę bezwarunkową i dopełnia ofertę Niniejsza oferta nie jest kierowana do, niniejszy komunikat prasowy nie może być publikowany pośrednio lub bezpośrednio w lub do, a oferty na akcje...
THOUSAND OAKS , Kalifornia, 9 lipca 2019 r. /PRNewswire/ -- Niniejsza oferta nie jest kierowana do, niniejszy komunikat prasowy nie może być publikowany pośrednio lub bezpośrednio w lub do, a oferty na akcje nie będą przyjmowane od ani w imieniu akcjonariuszy w Australii, Kanadz
Read more →AMGNAmgen anuncia el resultado de la oferta pública en efectivo consensuada a los accionistas de Nuevolution La Oferta no se está realizando y este comunicado de prensa no puede ser distribuido, directa o indirectamente, en o hacia, ni se aceptará ninguna...
- Amgen anuncia el resultado de la oferta pública en efectivo consensuada a los accionistas de Nuevolution, declara la oferta incondicional y completa la oferta THOUSAND OAKS, California, 9 de julio de 2019 /PRNewswire/ -- La Oferta no se está realizando y este comunicado de pr
Read more →AMGNSpolečnost Amgen oznámila výsledky veřejné nabídky na hotovostní odkup všech akcií od akcionářů společnosti Nuevolution, uznala tuto nabídku za bezpodmínečnou a uzavřela ji Nabídka není učiněná a tato tisková zpráva nesmí být distribuována, přímo ani nepřímo, ani nebude přijímána žádná nabídka akcií od jejich držitelů...
THOUSAND OAKS , Kalifornie, 9. července 2019 /PRNewswire/ -- Nabídka není učiněná a tato tisková zpráva nesmí být distribuována, přímo ani nepřímo, ani nebude přijímána žádná nabídka akcií od jejich držitelů nebo v jejich zastoupení v Austrálii, Kanadě, Hongkongu, Japonsku, Nové
Read more →AMGNAmgen обнародовала результаты публичного предложения выкупа акций Nuevolution, заявив о полном и безоговорочном завершении процесса Данное предложение не распространяется на акционеров, заявки на покупки или продажу акций от акционеров не принимаются, а данный пресс-релиз не может ...
ТАУЗАНД-ОКС ( THOUSAND OAKS ), Калифорния, 9 июля 2019 г. /PRNewswire/ -- Данное предложение не распространяется на акционеров, заявки на покупки или продажу акций от акционеров не принимаются, а данный пресс-релиз не может напрямую или опосредованно распространяться в Австралии
Read more →AMGNSpoločnosť Amgen oznamuje výsledok Odporúčanej verejnej ponuky predaja akcionárom spoločnosti Nuevolution za hotovostnú protihodnotu, vyhlasuje Ponuku za bezpodmienečnú a uzatvára Ponuku Táto ponuka nebude realizovaná a táto tlačová správa nesmie byť distribuovaná, priamo ani nepriamo, v krajine alebo do krajiny, ani nebude...
THOUSAND OAKS , Kalifornia, 9. júla 2019 /PRNewswire/ -- Táto ponuka nebude realizovaná a táto tlačová správa nesmie byť distribuovaná, priamo ani nepriamo, v krajine alebo do krajiny, ani nebude akceptovaná žiadna ponuka akcií od alebo v mene vlastníkov akcií v Austrálii, Kanad
Read more →AMGNAmgen Announces The Outcome Of The Recommended Public Cash Offer To The Shareholders Of Nuevolution, Declares The Offer Unconditional And Completes The Offer The Offer is not being made, and this press release may not be distributed, directly or indirectly, in or into, nor will any tender of shares be...
THOUSAND OAKS, Calif. , July 8, 2019 /PRNewswire/ -- The Offer is not being made, and this press release may not be distributed, directly or indirectly, in or into, nor will any tender of shares be accepted from or on behalf of holders in, Australia , Canada , Hong Kong , Japan
Read more →AMGNAmgen and UCB Provide Regulatory Update on Status of EVENITY™ (romosozumab) in the EU Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced that the companies have been informed the Committee for Medicinal Products for...
THOUSAND OAKS, Calif. and BRUSSELS , June 27, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and UCB (Euronext Brussels: UCB) today announced that the companies have been informed the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has ado
Read more →AMGNAmgen And MBC BioLabs Announce Winners Of The Amgen Golden Ticket Amgen (NASDAQ:AMGN) and MBC BioLabs (formerly QB3@953) today announced that Regencor and Nitrome Biosciences have each been awarded an Amgen Golden...
SAN FRANCISCO , June 25, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and MBC BioLabs (formerly QB3@953) today announced that Regencor and Nitrome Biosciences have each been awarded an Amgen Golden Ticket to MBC BioLabs. The companies receive priority admission or renewal for one y
Read more →AMGNAmgen And The Institute For Protein Design (IPD) At University Of Washington Announce Unique Strategic Research Partnership Amgen (NASDAQ:AMGN) and the University of Washington's Institute for Protein Design (IPD), which is revolutionizing its field of science by creating...
THOUSAND OAKS, Calif. and SEATTLE , June 19, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and the University of Washington's Institute for Protein Design (IPD), which is revolutionizing its field of science by creating custom-designed proteins from scratch to improve human health,
Read more →AMGNAmgen Announces BLINCYTO® (blinatumomab) Five-Year Overall Survival Data At EHA 2019 Amgen (NASDAQ:AMGN) today announced the five-year overall survival (OS) analysis from the single-arm, Phase 2 BLAST study that evaluated BLINCYTO®...
THOUSAND OAKS, Calif. , June 15, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the five-year overall survival (OS) analysis from the single-arm, Phase 2 BLAST study that evaluated BLINCYTO ® (blinatumomab) in patients with minimal residual disease (MRD)-positive acut
Read more →AMGNAmgen publie le document d'offre concernant l'offre publique d'achat au comptant recommandée aux actionnaires de Nuevolution L'offre n'est pas faite et le présent communiqué de presse ne peut être distribué, directement ou indirectement, en Afrique du Sud, en Australie, au...
THOUSAND OAKS , Californie, 14 juin 2019 /PRNewswire/ -- L'offre n'est pas faite et le présent communiqué de presse ne peut être distribué, directement ou indirectement, en Afrique du Sud, en Australie, au Canada , à Hong Kong , au Japon ou en Nouvelle-Zélande ou dans toute autr
Read more →AMGNFDA Approves Amgen And Allergan's KANJINTI™ (trastuzumab-anns), A Biosimilar To Herceptin® (trastuzumab) Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved KANJINTI™...
THOUSAND OAKS, Calif. , June 13, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and Allergan plc (NYSE: AGN ) today announced that the U.S. Food and Drug Administration (FDA) has approved KANJINTI ™ (trastuzumab-anns) for all approved indications of the reference product, Herceptin ®
Read more →AMGNAmgen publica el Documento de Oferta con respecto a la oferta pública en efectivo para los accionistas de Nuevolution La Oferta no se está realizando y este comunicado de prensa no puede ser distribuido, directa o indirectamente, en o hacia, ni se aceptará ninguna...
THOUSAND OAKS, California, 13 de junio de 2019 /PRNewswire/ -- La Oferta no se está realizando y este comunicado de prensa no puede ser distribuido, directa o indirectamente, en o hacia, ni se aceptará ninguna oferta de acciones de o en nombre de titulares en, Australia , Canadá
Read more →AMGNAmgen veröffentlicht Angebotsunterlagen zum empfohlenen öffentlichen Barangebot an die Aktionäre von Nuevolution In Australien, Kanada, Hongkong, Japan, Neuseeland oder Südafrika oder in irgendeiner Gerichtsbarkeit, in der das Vorlegen des Angebots, der Vertrieb ...
THOUSAND OAKS , Kalifornien, 13. Juni 2019 /PRNewswire/ -- In Australien, Kanada, Hongkong, Japan , Neuseeland oder Südafrika oder in irgendeiner Gerichtsbarkeit, in der das Vorlegen des Angebots, der Vertrieb dieser Pressemitteilung oder die Annahme irgendeines Kaufangebots für
Read more →AMGNSpolečnost Amgen zveřejnila nabídkový dokument pro doporučenou veřejnou nabídku na hotovostní odkup všech akcií od akcionářů společnosti Nuevolution Nabídka není učiněná a tato tisková zpráva nesmí být distribuována, přímo ani nepřímo, ani nebude přijímána žádná nabídka akcií od jejich držitelů...
THOUSAND OAKS , Kalifornie, 13. června 2019 /PRNewswire/ -- Nabídka není učiněná a tato tisková zpráva nesmí být distribuována, přímo ani nepřímo, ani nebude přijímána žádná nabídka akcií od jejich držitelů nebo v jejich zastoupení v Austrálii, Kanadě, Hongkongu, Japonsku, Novém
Read more →AMGNSpoločnosť Amgen zverejňuje dokument ponuky s ohľadom na Odporúčanú verejnú ponuku predaja akcionárom spoločnosti Nuevolution za hotovostnú protihodnotu Táto ponuka nebude realizovaná a táto tlačová správa nesmie byť distribuovaná, priamo ani nepriamo, v krajine alebo do krajiny, ani nebude...
THOUSAND OAKS , Kalifornia, 12. júna 2019 /PRNewswire/ -- Táto ponuka nebude realizovaná a táto tlačová správa nesmie byť distribuovaná, priamo ani nepriamo, v krajine alebo do krajiny, ani nebude akceptovaná žiadna ponuka akcií od alebo v mene vlastníkov akcií v Austrálii, Kana
Read more →AMGNAmgen publikuje ofertę dotyczącą rekomendowanej publicznej oferty gotówkowej dla akcjonariuszy Nuevolution Niniejsza oferta nie jest kierowana do, niniejszy komunikat prasowy nie może być publikowany pośrednio lub bezpośrednio w lub do, a oferty na akcje...
THOUSAND OAKS , Kalifornia, 12 czerwca 2019 r. /PRNewswire/ -- Niniejsza oferta nie jest kierowana do, niniejszy komunikat prasowy nie może być publikowany pośrednio lub bezpośrednio w lub do, a oferty na akcje nie będą przyjmowane od ani w imieniu akcjonariuszy w Australii, Kana
Read more →AMGNКомпания Amgen обнародовала официальное предложение покупки акций Nuevolution Данное предложение не распространяется на акционеров, заявки на покупки или продажу акций от акционеров не принимаются, а данный пресс-релиз не может ...
ТАУЗАНД-ОКС ( THOUSAND OAKS ), Калифорния, 12 июня 2019 г. /PRNewswire/ -- Данное предложение не распространяется на акционеров, заявки на покупки или продажу акций от акционеров не принимаются, а данный пресс-релиз не может напрямую или опосредованно распространяться в Австрали
Read more →AMGNAmgen Publishes Offer Document With Respect To The Recommended Public Cash Offer To The Shareholders Of Nuevolution The Offer is not being made, and this press release may not be distributed, directly or indirectly, in or into, nor will any tender of shares be...
THOUSAND OAKS, Calif. , June 12, 2019 /PRNewswire/ -- The Offer is not being made, and this press release may not be distributed, directly or indirectly, in or into, nor will any tender of shares be accepted from or on behalf of holders in, Australia , Canada , Hong Kong , Japan
Read more →AMGNAmgen To Present At The Goldman Sachs 40th Annual Global Healthcare Conference Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 40th Annual Global Healthcare Conference at 11:20 a.m. PT on Wednesday, June 12, 2019, in...
THOUSAND OAKS, Calif. , June 7, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Goldman Sachs 40 th Annual Global Healthcare Conference at 11:20 a.m. PT on Wednesday , June 12, 2019, in Rancho Palos Verdes, Calif. David M. Reese , M.D., executive vice president of
Read more →AMGNAmgen Announces First Clinical Data Evaluating Novel Investigational KRASG12C Inhibitor AMG 510 At ASCO 2019 Amgen (NASDAQ: AMGN) today announced the first clinical results from a Phase 1 study evaluating investigational AMG 510, the first KRASG12C inhibitor ...
AMG 510 is the First KRASG12C Inhibitor to Reach Clinical Stage After Three Decades of RAS Research First-In-Human Results Show Preliminary Safety, Tolerability Data and Anti-Tumor Activity in KRAS Mutant Solid Tumors FDA Grants AMG 510 Orphan Drug Designation for KRASG12C-Posi
Read more →AMGNAmgen Highlights The Versatility Of The BiTE® Immuno-Oncology Platform In Multiple Tumor Types At ASCO 2019 Amgen (NASDAQ: AMGN) today announced new data from Phase 1 studies evaluating investigational bispecific T cell engager (BiTE®) molecules were...
THOUSAND OAKS, Calif. , June 2, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced new data from Phase 1 studies evaluating investigational bispecific T cell engager (BiTE ® ) molecules were presented at the 55 th Annual Meeting of the American Society of Clinical Oncolog
Read more →AMGNDodatkowe nieodwołalne zobowiązania do przyjęcia zalecanej publicznej oferty gotówkowej Amgen dla akcjonariuszy Nuevolution Niniejsza oferta nie jest kierowana do, niniejszy komunikat prasowy nie może być publikowany pośrednio lub bezpośrednio w lub do, a oferty na akcje...
THOUSAND OAKS , Kalifornia, 30 maja 2019 r. /PRNewswire/ -- Niniejsza oferta nie jest kierowana do, niniejszy komunikat prasowy nie może być publikowany pośrednio lub bezpośrednio w lub do, a oferty na akcje nie będą przyjmowane od ani w imieniu akcjonariuszy w Australii, Kanadz
Read more →AMGNCompromisos irrevocables para aceptar la oferta pública en efectivo recomendada de Amgen a accionistas de Nuevolution La Oferta no se está haciendo en, y este comunicado de prensa no se puede distribuir, directa o indirectamente, en o a, ni se aceptará ninguna oferta ...
THOUSAND OAKS, California , 29 de mayo de 2019 /PRNewswire/ -- La Oferta no se está haciendo en, y este comunicado de prensa no se puede distribuir, directa o indirectamente, en o a, ni se aceptará ninguna oferta de acciones de o en nombre de los titulares en, Australia , Canadá
Read more →AMGNDodatočné neodvolateľné záväzky spoločnosti Amgen vzťahujúce sa na akceptáciu odporúčanej verejnej ponuky predaja akcionárom spoločnosti Nuevolution za hotovostnú protihodnotu Táto ponuka nebude realizovaná a táto tlačová správa nesmie byť distribuovaná, priamo ani nepriamo, v krajine alebo do krajiny, ani nebude...
THOUSAND OAKS , Kalifornia, 29. mája 2019 /PRNewswire/ -- Táto ponuka nebude realizovaná a táto tlačová správa nesmie byť distribuovaná, priamo ani nepriamo, v krajine alebo do krajiny, ani nebude akceptovaná žiadna ponuka akcií od alebo v mene vlastníkov akcií v Austrálii, Kana
Read more →AMGNZusätzliche unwiderrufliche Verpflichtungserklärungen zur Annahme von Amgens empfohlenem öffentlichem Barangebot an die Aktionäre von Nuevolution In Australien, Kanada, Hongkong, Japan, Neuseeland oder Südafrika oder in irgendeiner Gerichtsbarkeit, in der das Vorlegen des Angebots, die...
THOUSAND OAKS , Kalifornien, 29. Mai 2019 /PRNewswire/ -- In Australien, Kanada, Hongkong, Japan , Neuseeland oder Südafrika oder in irgendeiner Gerichtsbarkeit, in der das Vorlegen des Angebots, die Verbreitung dieser Pressemitteilung oder die Annahme irgendeines Kaufangebots f
Read more →AMGNОт акционеров Nuevolution получены дополнительные обязательства в отношении публичного предложения покупки акций компанией Amgen Данное предложение не распространяется на акционеров, заявки на покупки или продажу акций от акционеров не принимаются, а данный пресс-релиз не может ...
ТАУЗАНД-ОКС ( THOUSAND OAKS ), Калифорния, 29 мая 2019 г. /PRNewswire/ -- Данное предложение не распространяется на акционеров, заявки на покупки или продажу акций от акционеров не принимаются, а данный пресс-релиз не может напрямую или опосредованно распространяться в Австралии
Read more →AMGNEngagements à caractère irrévocable supplémentaires, en vue d'accepter l'offre publique d'achat au comptant, recommandée par Amgen aux actionnaires de Nuevolution L'offre n'est pas faite et le présent communiqué de presse ne peut être distribué, directement ou indirectement, en Afrique du Sud, en Australie, au...
THOUSAND OAKS , Californie, 29 mai 2019 /PRNewswire/ -- L'offre n'est pas faite et le présent communiqué de presse ne peut être distribué, directement ou indirectement, en Afrique du Sud, en Australie, au Canada , à Hong Kong , au Japon ou en Nouvelle-Zélande ou dans toute autre
Read more →AMGNAmgen To Webcast Investor Meeting At 55th Annual Meeting Of The American Society Of Clinical Oncology (ASCO) Amgen (NASDAQ: AMGN) will host a webcast investor meeting at ASCO 2019 on Monday, June 3 at 6:30 p.m. CT. David M. Reese, M.D., executive vice...
THOUSAND OAKS, Calif. , May 29, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will host a webcast investor meeting at ASCO 2019 on Monday, June 3 at 6:30 p.m. CT . David M. Reese , M.D., executive vice president of Research and Development at Amgen, along with members of Amgen's cli
Read more →AMGNDalší neodvolatelné závazky k přijetí doporučené veřejné nabídky společnosti Amgen na hotovostní odkup všech akcií od akcionářů společnosti Nuevolution Nabídka není učiněná a tato tisková zpráva nesmí být distribuována, přímo ani nepřímo, ani nebude přijímána žádná nabídka akcií od jejich držitelů...
THOUSAND OAKS , Kalifornie, 30. května 2019 /PRNewswire/ -- Nabídka není učiněná a tato tisková zpráva nesmí být distribuována, přímo ani nepřímo, ani nebude přijímána žádná nabídka akcií od jejich držitelů nebo v jejich zastoupení v Austrálii, Kanadě, Hongkongu, Japonsku, Novém
Read more →AMGNAdditional Irrevocable Undertakings To Accept Amgen's Recommended Public Cash Offer To The Shareholders Of Nuevolution The Offer is not being made, and this press release may not be distributed, directly or indirectly, in or into, nor will any tender of shares be...
THOUSAND OAKS, Calif. , May 28, 2019 /PRNewswire/ -- The Offer is not being made, and this press release may not be distributed, directly or indirectly, in or into, nor will any tender of shares be accepted from or on behalf of holders in, Australia , Canada , Hong Kong , Japan
Read more →AMGNAmgen Joins With Community Oncology Networks For New Research Collaboration Amgen (NASDAQ: AMGN), along with leading community oncology networks, today announced the launch of Amgen Community Oncology Research Collaborators...
THOUSAND OAKS, Calif. , May 28, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ), along with leading community oncology networks, today announced the launch of Amgen Community Oncology Research Collaborators (ACORC), a new initiative to enhance access by community centers to innovative
Read more →AMGNAmgen anuncia una oferta pública en efectivo consensuada a los accionistas de Nuevolution La Oferta no se está realizando y este comunicado de prensa no puede ser distribuido, directa o indirectamente, en o hacia, ni se aceptará ninguna...
THOUSAND OAKS, California, 25 de mayo de 2019 /PRNewswire/ -- La Oferta no se está realizando y este comunicado de prensa no puede ser distribuido, directa o indirectamente, en o hacia, ni se aceptará ninguna oferta de acciones de o en nombre de titulares en, Australia , Canadá,
Read more →AMGNAmgen annonce une offre publique d'achat au comptant recommandée aux actionnaires de Nuevolution L'offre n'est pas faite et le présent communiqué de presse ne peut être distribué, directement ou indirectement, en Afrique du Sud, en Australie, au...
THOUSAND OAKS , Californie, 24 mai 2019 /PRNewswire/ -- L'offre n'est pas faite et le présent communiqué de presse ne peut être distribué, directement ou indirectement, en Afrique du Sud, en Australie, au Canada , à Hong Kong , au Japon ou en Nouvelle-Zélande ou dans toute autre
Read more →AMGNAmgen gibt empfohlenes öffentliches Barangebot an die Aktionäre von Nuevolution bekannt In Australien, Kanada, Hongkong, Japan, Neuseeland oder Südafrika oder in irgendeiner Gerichtsbarkeit, in der das Vorlegen des Angebots, die...
THOUSAND OAKS , Kalifornien, 24. Mai 2019 /PRNewswire/ -- In Australien, Kanada, Hongkong, Japan , Neuseeland oder Südafrika oder in irgendeiner Gerichtsbarkeit, in der das Vorlegen des Angebots, die Verbreitung dieser Pressemitteilung oder die Annahme irgendeines Kaufangebots f
Read more →AMGNAmgen publikuje rekomendowaną ofertę gotówkową dla akcjonariuszy Nuevolution Niniejsza oferta nie jest kierowana do, niniejszy komunikat prasowy nie może być publikowany pośrednio lub bezpośrednio w lub do, a oferty na akcje...
THOUSAND OAKS , Kalifornia, 24 maja 2019 r. /PRNewswire/ -- Niniejsza oferta nie jest kierowana do, niniejszy komunikat prasowy nie może być publikowany pośrednio lub bezpośrednio w lub do, a oferty na akcje nie będą przyjmowane od ani w imieniu akcjonariuszy w Australii, Kanadz
Read more →AMGNSpoločnosť Amgen oznamuje akcionárom spoločnosti Nuevolution verejnú ponuku predaja za hotovostnú protihodnotu Táto ponuka nebude realizovaná a táto tlačová správa nesmie byť distribuovaná, priamo ani nepriamo, v krajine alebo do krajiny, ani nebude...
THOUSAND OAKS , Kalifornia, 23. mája 2019 /PRNewswire/ -- Táto ponuka nebude realizovaná a táto tlačová správa nesmie byť distribuovaná, priamo ani nepriamo, v krajine alebo do krajiny, ani nebude akceptovaná žiadna ponuka akcií od alebo v mene vlastníkov akcií v Austrálii, Kana
Read more →AMGNSpolečnost Amgen oznamuje doporučenou veřejnou nabídku na hotovostní odkup všech akcií od akcionářů společnosti Nuevolution Nabídka není učiněná a tato tisková zpráva nesmí být distribuována, přímo ani nepřímo, ani nebude přijímána žádná nabídka akcií od jejich držitelů...
THOUSAND OAKS , Kalifornie, 23. května 2019 /PRNewswire/ -- Nabídka není učiněná a tato tisková zpráva nesmí být distribuována, přímo ani nepřímo, ani nebude přijímána žádná nabídka akcií od jejich držitelů nebo v jejich zastoupení v Austrálii, Kanadě, Hongkongu, Japonsku, Novém
Read more →AMGNAmgen обнародовала публичное предложение о выкупе акций Nuevolution Данное предложение не распространяется на акционеров, заявки на покупки или продажу акций от акционеров не принимаются, а данный пресс-релиз не может ...
ТАУЗАНД-ОКС ( THOUSAND OAKS ), Калифорния, 22 мая 2019 г. /PRNewswire/ -- Данное предложение не распространяется на акционеров, заявки на покупки или продажу акций от акционеров не принимаются, а данный пресс-релиз не может напрямую или опосредованно распространяться в Австралии
Read more →AMGNAmgen announces a recommended public cash offer to the shareholders of Nuevolution The Offer is not being made, and this press release may not be distributed, directly or indirectly, in or into, nor will any tender of shares be...
THOUSAND OAKS, Calif. , May 21, 2019 /PRNewswire/ -- The Offer is not being made, and this press release may not be distributed, directly or indirectly, in or into, nor will any tender of shares be accepted from or on behalf of holders in, Australia , Canada , Hong Kong , Japan
Read more →AMGNAmgen Announces Voting Results Of Annual Meeting Of Stockholders Amgen (NASDAQ:AMGN) today announced voting results from the Company's Annual Meeting of Stockholders, held in Westlake Village, Calif. Approximately...
THOUSAND OAKS, Calif. , May 21, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced voting results from the Company's Annual Meeting of Stockholders, held in Westlake Village , Calif. Approximately 89 percent of outstanding shares were represented at the meeting. The dire
Read more →AMGNAmgen To Present At The RBC Healthcare Conference And The UBS Global Healthcare Conference Amgen (NASDAQ:AMGN) will present at the RBC Health Care Conference at 8:30 a.m. ET and at the UBS Global Healthcare Conference at 2 p.m. ET on...
THOUSAND OAKS, Calif. , May 16, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the RBC Health Care Conference at 8:30 a.m. ET and at the UBS Global Healthcare Conference at 2 p.m. ET on Tuesday, May 21, 2019 , in New York City . Elliott M. Levy , M.D., senior vice pre
Read more →AMGNAmgen Showcases Oncology Pipeline At ASCO 2019 Amgen (NASDAQ: AMGN) today announced that data from its oncology pipeline will be presented at the 55th Annual Meeting of the American Society of...
THOUSAND OAKS, Calif. , May 15, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that data from its oncology pipeline will be presented at the 55 th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago , May 31-June 4, 2019 . Seven investigation
Read more →AMGNAmgen To Present At The Bank of America Merrill Lynch 2019 Health Care Conference Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch 2019 Health Care Conference at 10 a.m. PT on Wednesday, May 15, 2019. David W....
THOUSAND OAKS, Calif. , May 10, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Bank of America Merrill Lynch 2019 Health Care Conference at 10 a.m. PT on Wednesday, May 15, 2019 . David W. Meline , executive vice president and chief financial officer at Amgen, wil
Read more →AMGNAmgen To Highlight Extensive Long-Term Safety And Efficacy Data Of Aimovig® (erenumab-aooe) Across The Spectrum Of Migraine At AAN Annual Meeting Amgen (NASDAQ:AMGN) today announced that it will present new long-term data of Aimovig® (erenumab-aooe) across the migraine spectrum at the 2019...
THOUSAND OAKS, Calif. , May 2, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will present new long-term data of Aimovig ® (erenumab-aooe) across the migraine spectrum at the 2019 American Academy of Neurology (AAN) Annual Meeting in Philadelphia . Data from a
Read more →AMGNAmgen And Syapse Enter Precision Medicine Collaboration In Oncology Amgen (NASDAQ:AMGN), a world leader in biotechnology, and Syapse, a company powering precision medicine insights through its global provider network, ...
Under the terms of the agreement, Amgen and Syapse will develop observational research analytics to assess treatment outcomes for areas of unmet need in oncology. This effort will identify existing patients within the Syapse Learning Health Network that could be eligible for Amge
Read more →AMGNAmgen Ignites A Social Fitness Movement To Support The Fight Against Heart Disease And Cancer Amgen (NASDAQ:AMGN) today launched the Breakaway Challenge initiative, a national social fitness program to motivate individuals to take action in...
THOUSAND OAKS, Calif. , May 1, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today launched the Breakaway Challenge initiative, a national social fitness program to motivate individuals to take action in their health and to support the fight against heart disease and cancer. Amgen's
Read more →AMGNAmgen Reports First Quarter 2019 Financial Results Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2019. Key results include: Total revenues were unchanged at $5.6...
THOUSAND OAKS, Calif. , April 30, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced financial results for the first quarter of 2019. Key results include: "We continue to generate strong, volume-driven growth for our newer products, while effectively defending our mature
Read more →AMGNOne Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.amgen.com AMGEN REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS THOUSAND OAKS, Calif. (
Exhibit 99.1 News Release One Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.amgen.com AMGEN REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS THOUSAND OAKS, Calif. (April 30, 2019) - Amgen (NASDAQ:AMGN) today announced financial results for the first
Read more →AMGNAmgen Announces Webcast of 2019 First Quarter Financial Results Amgen (NASDAQ:AMGN) today announced that it will report its first quarter financial results on Tuesday, April 30, 2019, after the close of the U.S....
THOUSAND OAKS, Calif. , April 25, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will report its first quarter financial results on Tuesday, April 30, 2019 , after the close of the U.S. financial markets. The announcement will be followed by a conference call
Read more →AMGNAmgen Foundation Launches Amgen Biotech Experience In Tampa, Florida The Amgen Foundation, together with the University of South Florida (USF), today announced the launch of the Amgen Biotech Experience (ABE) program...
TAMPA, Fla. , April 17, 2019 /PRNewswire/ -- The Amgen Foundation, together with the University of South Florida (USF), today announced the launch of the Amgen Biotech Experience (ABE) program in Tampa, Florida , as part of its long-standing science education program. Globally, A
Read more →AMGNEVENITY™ (romosozumab-aqqg) Now Available In The United States For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture Amgen (NASDAQ: AMGN) today announced that EVENITY™ (romosozumab-aqqg) is now available for shipment to wholesalers in the U.S. EVENITY was approved...
THOUSAND OAKS, Calif. , April 15, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that EVENITY™ (romosozumab-aqqg) is now available for shipment to wholesalers in the U.S. EVENITY was approved by the U.S. Food and Drug Administration (FDA) on April 9, 2019 , for the tr
Read more →AMGNFDA Approves EVENITY™ (romosozumab-aqqg) For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today announced that the U.S. Food and Drug Administration (FDA) has approved EVENITY™...
THOUSAND OAKS, Calif. and BRUSSELS , April 9, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and UCB (Euronext Brussels: UCB) today announced that the U.S. Food and Drug Administration (FDA) has approved EVENITY™ (romosozumab-aqqg) for the treatment of osteoporosis in postmenopausal
Read more →AMGNAmgen Presents New Data At WCO-IOF-ESCEO 2019 Revealing Osteoporosis Treatment Gap In Europe Amgen (NASDAQ:AMGN) today announced new data presented from a cross-sectional study revealing a gap in the diagnosis and treatment of osteoporosis in ...
THOUSAND OAKS, Calif. , April 7, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced new data presented from a cross-sectional study revealing a gap in the diagnosis and treatment of osteoporosis in Europe . The real-world study of osteoporosis management in primary care r
Read more →AMGNAmgen, Cytokinetics And Servier Announce Continuation Of GALACTIC-HF Following Planned Interim Analysis Amgen (NASDAQ: AMGN), Cytokinetics, Incorporated (NASDAQ: CYTK) and Servier today announced that the Data Monitoring Committee (DMC) for GALACTIC-HF...
THOUSAND OAKS, Calif. , and SOUTH SAN FRANCISCO, Calif. , and SURESNES, France, March 20, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ), Cytokinetics, Incorporated (NASDAQ: CYTK ) and Servier today announced that the Data Monitoring Committee (DMC) for GALACTIC-HF recently completed
Read more →AMGNAmgen Announces New Four-Year Outcomes Study To Examine Long-Term Effects Of Repatha® (evolocumab) In High-Risk Cardiovascular Disease (CVD) Patients Without Prior Heart Attack Or Stroke Amgen (NASDAQ:AMGN) today announced plans to conduct VESALIUS-CV, a multinational clinical outcomes study for Repatha® (evolocumab) which will...
THOUSAND OAKS, Calif. , March 15, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced plans to conduct VESALIUS-CV, a multinational clinical outcomes study for Repatha ® (evolocumab) which will involve at least 13,000 patients worldwide at high risk of experiencing a first
Read more →AMGNAmgen and Jay Leno Partner to Sound the Alarm on High Cholesterol and its Link to Heart Attack and Stroke in Patients Most at Risk Amgen (NASDAQ:AMGN) today launched Cholesterol 911, a national initiative urging high-risk cardiovascular disease patients to reduce their risk of...
THOUSAND OAKS, Calif. , March 12, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today launched Cholesterol 911 , a national initiative urging high-risk cardiovascular disease patients to reduce their risk of another heart attack or stroke by addressing their continued high LDL-C, or
Read more →AMGNAmgen Announces 2019 Second Quarter Dividend Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.45 per share dividend for the second quarter of 2019. The dividend will ...
THOUSAND OAKS, Calif. , March 7, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that its Board of Directors declared a $1 .45 per share dividend for the second quarter of 2019. The dividend will be paid on June 7, 2019 , to all stockholders of record as of the close o
Read more →AMGNAmgen To Present At The Cowen and Company 39th Annual Healthcare Conference Amgen (NASDAQ:AMGN) will present at the Cowen and Company 39th Annual Healthcare Conference at 9:20 a.m. ET on Tuesday, March 12, 2019, in Boston....
THOUSAND OAKS, Calif. , March 7, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Cowen and Company 39 th Annual Healthcare Conference at 9:20 a.m. ET on Tuesday, March 12, 2019 , in Boston . David W. Meline , executive vice president and chief financial officer at
Read more →AMGNNew Data From Amgen To Be Presented At ACC.19 Continues To Build Evidence For Repatha® (evolocumab) Across Multiple Patient Populations Amgen (NASDAQ:AMGN) today announced the presentation of nine cardiovascular scientific research abstracts, including safety and efficacy results from ...
THOUSAND OAKS, Calif. , March 6, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the presentation of nine cardiovascular scientific research abstracts, including safety and efficacy results from the largest and longest open label study of homozygous familial hyperchole
Read more →AMGNAmgen Highlights Progress Of Innovative Early Oncology Pipeline With New Data At AACR 2019 Amgen (NASDAQ:AMGN) today announced that new data from its early-stage oncology pipeline will be presented at the American Association for Cancer...
THOUSAND OAKS, Calif. , Feb. 28, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that new data from its early-stage oncology pipeline will be presented at the American Association for Cancer Research (AACR) Annual Meeting in Atlanta , March 29 – April 3, 2019 . "At Am
Read more →AMGNJury Upholds Amgen's Patents On Repatha® (evolocumab) Amgen (NASDAQ:AMGN) today announced that a Delaware jury delivered a verdict in Amgen's favor upholding the validity of two Amgen patents related to...
About Repatha ® (evolocumab) Repatha ® (evolocumab) is a human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). Repatha binds to PCSK9 and inhibits circulating PCSK9 from binding to the low-density lipoprotein (LDL) receptor (LDLR), preven
Read more →AMGNAmgen, Cytokinetics And Servier Announce Start Of METEORIC-HF, The Second Phase 3 Clinical Trial Of Omecamtiv Mecarbil In Patients With Heart Failure Amgen (NASDAQ: AMGN), Cytokinetics, Incorporated (NASDAQ: CYTK) and Servier today announced that METEORIC-HF (Multicenter Exercise Tolerance...
THOUSAND OAKS, Calif. , SOUTH SAN FRANCISCO, Calif. , and SURESNES, France, Feb. 21, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ), Cytokinetics, Incorporated (NASDAQ: CYTK ) and Servier today announced that METEORIC-HF ( M ulticenter E xercise T olerance E valuation of O mecamtiv M
Read more →AMGNAmgen Reports Fourth Quarter And Full Year 2018 Financial Results Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year 2018 in comparison to comparable periods in 2017. Key...
THOUSAND OAKS, Calif. , Jan. 29, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced financial results for the fourth quarter and full year 2018 in comparison to comparable periods in 2017. Key results include: "Through our continued solid operating performance in 2018, w
Read more →AMGNOne Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.amgen.com AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS THOUSAND OAKS, Calif. (
Exhibit 99.1 News Release One Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.amgen.com AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS THOUSAND OAKS, Calif. (Jan. 29, 2019) - Amgen (NASDAQ:AMGN) today announced financial results
Read more →AMGNAmgen Announces Webcast of 2018 Fourth Quarter and Full Year Financial Results Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2018 financial results on Tuesday, Jan. 29, 2019, after the...
THOUSAND OAKS, Calif. , Jan. 24, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will report its fourth quarter and full year 2018 financial results on Tuesday, Jan. 29, 2019 , after the close of the U.S. financial markets. The announcement will be followed by
Read more →AMGNAmgen Receives NMPA Approval For Repatha® (evolocumab) In China To Reduce The Risk Of Cardiovascular Events Amgen (NASDAQ:AMGN) today announced that the National Medical Products Administration (NMPA) has approved a new indication for Repatha® (evolocumab)...
THOUSAND OAKS, Calif. , Jan. 24, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the National Medical Products Administration (NMPA) has approved a new indication for Repatha ® (evolocumab) as the first PCSK9 inhibitor in China for adults with established atherosc
Read more →AMGNAmgen And Allergan Announce Positive Top-Line Results From Phase 1/ Phase 3 Study Of ABP 798, Biosimilar Candidate To Rituximab Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced positive top-line results from a Phase 1/ Phase 3 study evaluating the...
THOUSAND OAKS, Calif. , Jan. 24, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and Allergan plc. (NYSE: AGN ) today announced positive top - line results from a Phase 1/ Phase 3 study evaluating the pharmacokinetics, efficacy and safety of biosimilar candidate ABP 798, a biosimilar
Read more →AMGNEuropean Commission Approves BLINCYTO® (blinatumomab) In Patients With Philadelphia Chromosome Negative Minimal Residual Disease-Positive B-cell Precursor Acute Lymphoblastic Leukemia Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has approved an expanded indication for BLINCYTO® (blinatumomab) monotherapy to ...
THOUSAND OAKS, Calif. , Jan. 22, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the European Commission (EC) has approved an expanded indication for BLINCYTO ® (blinatumomab) monotherapy to include adult patients with Philadelphia chromosome negative (Ph-) CD19 p
Read more →AMGNAmgen And UCB Receive Positive Vote From FDA Advisory Committee In Favor Of Approval For EVENITY™ (romosozumab) Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced strong support from the U.S. Food and Drug Administration (FDA) Bone,...
THOUSAND OAKS, Calif. and BRUSSELS , Jan. 16, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and UCB (Euronext Brussels: UCB) today announced strong support from the U.S. Food and Drug Administration (FDA) Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) for the appr
Read more →AMGNEVENITY™ (romosozumab) Receives Approval In Japan For The Treatment Of Osteoporosis In Patients At High Risk Of Fracture Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced that the Japanese Ministry of Health, Labor and Welfare has granted a marketing...
THOUSAND OAKS, Calif. and BRUSSELS, Belgium , Jan. 8, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and UCB (Euronext Brussels: UCB) today announced that the Japanese Ministry of Health, Labor and Welfare has granted a marketing authorization for EVENITY™ (romosozumab) for the treat
Read more →AMGNAmgen Makes All Repatha® (evolocumab) Device Options Available In The US At A 60 Percent Reduced List Price Amgen (NASDAQ:AMGN) today announced that as part of the Company's commitment to improve patient affordability for an innovative biologic medicine for ...
THOUSAND OAKS, Calif. , Jan. 7, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that as part of the Company's commitment to improve patient affordability for an innovative biologic medicine for people with high cholesterol who are at risk for heart attacks and strokes,
Read more →AMGNAmgen To Present At The 37th Annual J.P. Morgan Healthcare Conference Amgen (NASDAQ:AMGN) will present at the 37th Annual J.P. Morgan Healthcare Conference at 8:30 a.m. PT on Tuesday, Jan. 8, 2019, in San Francisco....
THOUSAND OAKS, Calif. , Jan. 3, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the 37 th Annual J.P. Morgan Healthcare Conference at 8:30 a.m. PT on Tuesday, Jan. 8, 2019, in San Francisco. Robert A. Bradway, chairman and chief executive officer at Amgen, will present
Read more →AMGNAmgen Submits Supplemental Biologics License Application For Nplate® (romiplostim) Amgen (NASDAQ:AMGN) today announced the submission of a Supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration...
THOUSAND OAKS, Calif. , Dec. 19, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the submission of a Supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Nplate ® (romiplostim) to include the treatment of adult patients w
Read more →AMGNAmgen And Molecular Partners Announce Strategic Collaboration In Immuno-Oncology Amgen (NASDAQ:AMGN) and Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company pioneering the use of DARPin® therapeutics, today...
THOUSAND OAKS, Calif. and ZURICH -SCHLIEREN, Switzerland , Dec. 18, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company pioneering the use of DARPin ® therapeutics, today announced a collaboration and license agreemen
Read more →AMGNAmgen Engages Cambridge Biotech Community To Select 2018 LabCentral Golden Ticket Winners Amgen (NASDAQ:AMGN) and LabCentral today announced that Kernal Biologics and PanTher Therapeutics have each won the Amgen Golden Ticket at LabCentral....
As a LabCentral platinum sponsor, Amgen nominates two early-stage companies annually to take up residence in LabCentral's Kendall Square facilities in Cambridge . The Golden Ticket represents one year of free bench space for one scientist, including benefit of LabCentral's shared
Read more →AMGNAmgen Submits Biologics License Application for ABP 710 (Biosimilar Infliximab) To US Food And Drug Administration Amgen (NASDAQ:AMGN) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ABP...
THOUSAND OAKS, Calif. , Dec. 17, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ABP 710, a biosimilar candidate to REMICADE ® (infliximab). "At Amgen, we have s
Read more →AMGNFDA Approves Nplate® (Romiplostim) For Use In Pediatric Patients With Immune Thrombocytopenia Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application...
THOUSAND OAKS, Calif. , Dec. 14, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Nplate ® (romiplostim) for the treatment of pediatric patients one y
Read more →AMGNAmgen And Direct Relief Partner To Aid Cancer Patients In 18 Developing Countries Amgen (NASDAQ:AMGN) and Direct Relief today announced a joint initiative in which Direct Relief will distribute $93 million worth of Amgen donated...
THOUSAND OAKS, Calif. and SANTA BARBARA, Calif. , Dec. 13, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and Direct Relief today announced a joint initiative in which Direct Relief will distribute $93 million worth of Amgen donated cancer treatments and supportive care medicines. Th
Read more →AMGNAmgen And Magellan Rx Management Collaborate To Improve Patient Care For Chronic, Difficult-To-Treat Conditions Amgen (NASDAQ:AMGN) today announced a novel multi-year collaboration with Magellan Rx Management, the pharmacy benefit management division of...
THOUSAND OAKS, Calif. , Dec. 11, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced a novel multi-year collaboration with Magellan Rx Management, the pharmacy benefit management division of Magellan Health, that will leverage each company's capabilities and resources to i
Read more →AMGNAmgen And Lazarex Cancer Foundation Team Up To Allow More Diversity In Clinical Trials Amgen (NASDAQ:AMGN) and the Lazarex Cancer Foundation, a non-profit organization focused on improving patient access to cancer clinical trials, today ...
THOUSAND OAKS, Calif. and SAN FRANCISCO , Dec. 10, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and the Lazarex Cancer Foundation, a non-profit organization focused on improving patient access to cancer clinical trials, today announced that they have teamed up to support more equit
Read more →AMGNAmgen Announces 10 Percent Increase In 2019 First Quarter Dividend Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.45 per share dividend for the first quarter of 2019. The dividend will...
THOUSAND OAKS, Calif. , Dec. 7, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that its Board of Directors declared a $1 .45 per share dividend for the first quarter of 2019. The dividend will be paid on March 8, 2019 , to all stockholders of record as of the close of
Read more →AMGNAmgen Announces First-In-Human Data Evaluating Investigational Novel BiTE® Immunotherapies AMG 420 And AMG 330 At ASH 2018 Amgen (NASDAQ:AMGN) today announced the first clinical results from studies evaluating investigational novel bispecific T cell engager (BiTE®)...
THOUSAND OAKS, Calif. , Dec. 3, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the first clinical results from studies evaluating investigational novel bispecific T cell engager (BiTE ® ) immunotherapies AMG 420 and AMG 330. In two separate Phase 1 dose escalation stu
Read more →AMGNAmgen To Present At The Citi Global Healthcare Conference Amgen (NASDAQ:AMGN) will present at the Citi Global Healthcare Conference at 12:35 p.m. ET on Thursday, Dec. 6, 2018, in New York City. Elliott M....
THOUSAND OAKS, Calif. , Dec. 3, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Citi Global Healthcare Conference at 12:35 p.m. ET on Thursday , Dec. 6, 2018, in New York City . Elliott M. Levy , M.D., senior vice president of Global Development at Amgen, will pres
Read more →AMGNAmgen And UCB Announce FDA Advisory Committee Meeting To Review EVENITY™ (romosozumab) For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced the U.S. Food and Drug Administration (FDA) Bone, Reproductive and Urologic...
THOUSAND OAKS, Calif. and BRUSSELS , Nov. 30, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and UCB (Euronext Brussels: UCB) today announced the U.S. Food and Drug Administration (FDA) Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) will review data supporting the
Read more →AMGNAmgen To Webcast Investor Call At ASH 2018 Amgen (NASDAQ:AMGN) will host a webcast call for the investment community at the 60th American Society of Hematology (ASH) Annual Meeting &...
THOUSAND OAKS, Calif. , Nov. 28, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will host a webcast call for the investment community at the 60th American Society of Hematology (ASH) Annual Meeting & Exposition on Monday, Dec. 3, 2018 , at 8 p.m. PT. David M. Reese, M.D., executive v
Read more →AMGNAmgen To Present At the Piper Jaffray And Evercore ISI Healthcare Conferences Amgen (NASDAQ:AMGN) will present at the Piper Jaffray Healthcare Conference at 8:30 a.m. ET on Tuesday, Nov. 27, 2018, in New York City and at the...
THOUSAND OAKS, Calif. , Nov. 21, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Piper Jaffray Healthcare Conference at 8:30 a.m. ET on Tuesday , Nov. 27, 2018, in New York City and at the Evercore ISI Healthcare Conference at 11 a.m. ET on Wednesday, Nov. 28, 2018
Read more →AMGNAmgen Receives CHMP Positive Opinion To Expand Use Of BLINCYTO® (Blinatumomab) In Patients With Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted ...
THOUSAND OAKS, Calif. , Nov. 16, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion to expand the current indication for BLINCYTO ® (blinat
Read more →AMGNAmgen Presents Results Highlighting The Long-Term Safety And Efficacy Of Repatha® (Evolocumab) In The Longest Duration Study Of A PCSK9 Inhibitor To Date At AHA Scientific Sessions 2018 Amgen (NASDAQ:AMGN) today announced the final report of the Open-Label Study of Long-TERm Evaluation Against LDL-C (OSLER-1), demonstrating long-term ...
THOUSAND OAKS, Calif. , Nov. 12, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the final report of the O pen-Label S tudy of L ong-T ER m Evaluation Against LDL-C (OSLER-1), demonstrating long-term treatment with Repatha ® (evolocumab) was associated with robust and
Read more →AMGNAmgen Foundation Pledges $500,000 In Relief To Victims Of Ventura And Los Angeles County Wildfires Amgen (NASDAQ:AMGN) today announced that the Amgen Foundation has pledged $500,000 to support victims of the local wildfires in Ventura and Los...
THOUSAND OAKS, Calif. , Nov. 12, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the Amgen Foundation has pledged $500,000 to support victims of the local wildfires in Ventura and Los Angeles Counties. The Amgen Foundation will select recipient non-profit organiza
Read more →AMGNAmgen Announces Presentation Of Research Reinforcing The Long-Term Safety And Efficacy Of Repatha® (Evolocumab) In High-Risk Patients At AHA Scientific Sessions 2018 Amgen (NASDAQ:AMGN) today announced the presentation of 10 scientific research abstracts, including the final report of the OSLER-1 study, evaluating ...
THOUSAND OAKS, Calif. , Nov. 5, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the presentation of 10 scientific research abstracts, including the final report of the OSLER -1 study, evaluating the long-term safety and efficacy of Repatha ® (evolocumab) in patients wi
Read more →AMGNAmgen And Provention Bio Announce Co-Development Collaboration In Celiac Disease Amgen (NASDAQ:AMGN) and Provention Bio, Inc. (NASDAQ:PRVB), a clinical-stage biopharmaceutical company focused on immune-mediated diseases, today...
THOUSAND OAKS, Calif. and OLDWICK, N.J. , Nov. 5, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and Provention Bio, Inc. (NASDAQ: PRVB ), a clinical-stage biopharmaceutical company focused on immune-mediated diseases, today announced a licensing and co-development agreement for AMG
Read more →AMGNAmgen To Present New Data Showcasing Extensive Portfolio And Exciting Early Oncology Pipeline At ASH 2018 Amgen (NASDAQ:AMGN) today announced that new clinical data will be presented at the 60th American Society of Hematology (ASH) Annual Meeting &...
THOUSAND OAKS, Calif. , Nov. 1, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that new clinical data will be presented at the 60 th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego , Dec. 1-4, 2018 . Data across an array of malignancies w
Read more →AMGNAmgen Foundation Deepens Commitment To Aspiring Scientists Worldwide By Expanding Amgen Scholars Program The Amgen Foundation today announced the expansion of the Amgen Scholars Program, a hands-on research program that allows undergraduates to spend a...
THOUSAND OAKS, Calif. , Nov. 1, 2018 /PRNewswire/ -- The Amgen Foundation today announced the expansion of the Amgen Scholars Program, a hands-on research program that allows undergraduates to spend a summer at one of many of the world's premier research institutions. The new fou
Read more →AMGNAmgen Reports Third Quarter 2018 Financial Results Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2018. Key results include: Total revenues increased 2 percent versus...
THOUSAND OAKS, Calif. , Oct. 30, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced financial results for the third quarter of 2018. Key results include: "We are in the early stages of launching several new products that offer innovative solutions for patients suffering
Read more →AMGNThird Quarter Product and Pipeline Update
AMGEN REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS THOUSAND OAKS, Calif. (Oct. 30, 2018) - Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2018. Key results include: "We are in the early stages of launching several new products that offer innovati
Read more →AMGNAmgen Announces New FOURIER Analysis Showing Benefit With Repatha® (Evolocumab) In High-Risk Patients With Established Cardiovascular Disease And Chronic Kidney Disease Amgen (NASDAQ:AMGN) today announced a new Repatha cardiovascular outcomes study (FOURIER) analysis evaluating the effects of Repatha® (evolocumab) in ...
THOUSAND OAKS, Calif. , Oct. 26, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced a new Repatha cardiovascular outcomes study (FOURIER) analysis evaluating the effects of Repatha ® (evolocumab) in patients with established cardiovascular disease by kidney function. In l
Read more →AMGNAmgen Announces Webcast Of 2018 Third Quarter Financial Results Amgen (NASDAQ:AMGN) today announced that it will report its third quarter 2018 financial results on Tuesday, Oct. 30, 2018, after the close of the...
THOUSAND OAKS, Calif. , Oct. 26, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will report its third quarter 2018 financial results on Tuesday, Oct. 30, 2018 , after the close of the U.S. financial markets. The announcement will be followed by a conference ca
Read more →AMGNAmgen Makes Repatha® (Evolocumab) Available In The US At A 60 Percent Reduced List Price Amgen (NASDAQ: AMGN) today announced that it is making Repatha® (evolocumab), an innovative biologic medicine for people with high cholesterol who...
THOUSAND OAKS, Calif. , Oct. 24, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it is making Repatha ® (evolocumab), an innovative biologic medicine for people with high cholesterol who are at risk for heart attacks and strokes, available at a reduced list price
Read more →AMGNFirst Head-to-Head Trial of a TNF Inhibitor Versus Methotrexate Monotherapy in Psoriatic Arthritis Shows ENBREL® (Etanercept) Monotherapy and Combination Therapy Both Superior to Methotrexate Amgen (NASDAQ:AMGN) today announced that positive results from the Phase 3 SEAM-PsA study comparing the efficacy of Enbrel® (etanercept) monotherapy...
THOUSAND OAKS, Calif. , Oct. 24, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that positive results from the Phase 3 SEAM-PsA study comparing the efficacy of Enbrel ® (etanercept) monotherapy and ENBREL plus methotrexate to methotrexate monotherapy in patients with
Read more →AMGNAmgen Announces 2018 Fourth Quarter Dividend Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.32 per share dividend for the fourth quarter of 2018. The dividend will ...
THOUSAND OAKS, Calif. , Oct. 23, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that its Board of Directors declared a $1.32 per share dividend for the fourth quarter of 2018. The dividend will be paid on Dec. 7, 2018 , to all stockholders of record as of the close of
Read more →AMGNAmgen Invests £50 Million ($66 Million) In Oxford Nanopore Technologies Amgen (NASDAQ:AMGN) and Oxford Nanopore Technologies Ltd. today announced Amgen's equity investment of £50 million ($66 million) in Oxford Nanopore,...
THOUSAND OAKS, Calif. and OXFORD, England , Oct. 18, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and Oxford Nanopore Technologies Ltd. today announced Amgen's equity investment of £50 million ( $66 million ) in Oxford Nanopore, a privately-owned, UK-based company advancing a new g
Read more →AMGNAmgen Launches AMGEVITA™ (Biosimilar Adalimumab) In Markets Across Europe Amgen (NASDAQ:AMGN) today announced that AMGEVITATM, a biosimilar to adalimumab, will launch in markets across Europe beginning on Oct. 16, 2018....
THOUSAND OAKS, Calif. , Oct. 15, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that AMGEVITA TM , a biosimilar to adalimumab, will launch in markets across Europe beginning on Oct. 16, 2018 . AMGEVITA is the first adalimumab biosimilar to be approved by the European
Read more →AMGNFDA Approves KYPROLIS® (carfilzomib) Once-Weekly 70 mg/m2 In Combination With Dexamethasone (Kd70) For Patients With Relapsed Or Refractory Multiple Myeloma Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) to...
THOUSAND OAKS, Calif. , Oct. 1, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) to expand the Prescribing Information for KYPROLIS ® (carfilzomib) to include a on
Read more →AMGNBLINCYTO® (blinatumomab) Approved In Japan For The Treatment Of Relapsed Or Refractory B-cell Acute Lymphoblastic Leukemia Amgen (NASDAQ:AMGN) today announced that the Japanese Ministry of Health, Labour and Welfare has granted marketing approval for BLINCYTO®...
THOUSAND OAKS, Calif. , Sept. 24, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the Japanese Ministry of Health, Labour and Welfare has granted marketing approval for BLINCYTO ® (blinatumomab) for the treatment of relapsed or refractory B-cell acute lymphoblasti
Read more →AMGNAmgen And Los Angeles County Announce Collaboration To Support Life Science Innovation Hub - BioLA Amgen (NASDAQ:AMGN) and the County of Los Angeles today announced that Amgen has agreed to become a founding sponsor of BioLA, a newly formed...
THOUSAND OAKS, Calif. and LOS ANGELES , Sept. 20, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and the County of Los Angeles today announced that Amgen has agreed to become a founding sponsor of BioLA , a newly formed organization focused on advancing a life science innovation hub
Read more →AMGNWorld's Largest Alzheimer's Survey Reveals Most Adults Believe a Cure Will be Developed in Their Lifetime Amgen (NASDAQ:AMGN), Novartis and Banner Alzheimer's Institute (BAI), in association with Alzheimer's Disease International (ADI), today announced...
THOUSAND OAKS, Calif. , Sept. 17, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ), Novartis and Banner Alzheimer's Institute (BAI), in association with Alzheimer's Disease International (ADI), today announced results from the largest global survey to date investigating perceptions of
Read more →AMGNAmgen To Present At The Bank of America Merrill Lynch Global Healthcare Conference Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 9 a.m. GMT on Friday, Sept. 14, 2018, in London....
THOUSAND OAKS, Calif. , Sept. 11, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 9 a.m. GMT on Friday, Sept. 14, 2018 , in London . David W. Meline , executive vice president and chief financial officer
Read more →AMGNAmgen To Present At The Morgan Stanley Global Healthcare Conference Amgen (NASDAQ: AMGN) will present at the Morgan Stanley Global Healthcare Conference at 9:20 a.m. ET on Wednesday, Sept. 12, 2018, in New York City....
THOUSAND OAKS, Calif. , Sept. 7, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Morgan Stanley Global Healthcare Conference at 9:20 a.m. ET on Wednesday, Sept. 12, 2018 , in New York City . Robert A. Bradway , chairman and chief executive officer at Amgen, will pr
Read more →AMGNTezepelumab Granted Breakthrough Therapy Designation By US FDA For The Treatment Of Patients With Severe Asthma Without An Eosinophilic Phenotype Amgen (NASDAQ: AMGN) and AstraZeneca (NYSE: AZN) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy...
THOUSAND OAKS, Calif. , Sept. 6, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and AstraZeneca (NYSE: AZN ) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tezepelumab in patients with severe asthma without an eosinop
Read more →AMGNAmgen And LabCentral Open Nomination Process For Lab Residency Amgen (NASDAQ: AMGN) and LabCentral today announced that the nomination process to submit proposals to receive an Amgen-sponsored LabCentral Golden...
CAMBRIDGE, Mass. , Sept. 5, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and LabCentral today announced that the nomination process to submit proposals to receive an Amgen-sponsored LabCentral Golden Ticket is open for interested life sciences and biotech startup companies. LabCent
Read more →AMGNEuropean Commission Approves BLINCYTO® (blinatumomab) For Use In Pediatric Patients With Philadelphia Chromosome-Negative Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has approved an expanded indication for BLINCYTO® (blinatumomab) as monotherapy ...
THOUSAND OAKS, Calif. , Aug. 29, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the European Commission (EC) has approved an expanded indication for BLINCYTO ® (blinatumomab) as monotherapy for the treatment of pediatric patients aged one year or older with Phila
Read more →AMGNAmgen Submits Supplemental New Drug Application For KYPROLIS® (carfilzomib) Once-Weekly 70 mg/m2 In Combination With Dexamethasone Amgen (NASDAQ:AMGN) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) to...
THOUSAND OAKS, Calif. , Aug. 27, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) to expand the Prescribing Information for KYPROLIS ® (carfilzomib) to include a
Read more →AMGNAmgen To Present Robust Data Exploring The Impact Of Treatment With Repatha® (evolocumab) Across Patient Subgroups And High-Risk Populations At ESC Congress 2018 Amgen (NASDAQ: AMGN) today announced the upcoming presentation of new Repatha® (evolocumab) analyses, including a late-breaking study evaluating the...
THOUSAND OAKS, Calif. , Aug. 21, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the upcoming presentation of new Repatha ® (evolocumab) analyses, including a late-breaking study evaluating the efficacy of Repatha in patients with metabolic syndrome and established car
Read more →AMGNAmgen Breaks Ground On Next-Generation Biomanufacturing Plant In Rhode Island Amgen (NASDAQ:AMGN) today announced the groundbreaking of its new next-generation biomanufacturing plant that will be constructed at its West...
THOUSAND OAKS, Calif. , July 31, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the groundbreaking of its new next-generation biomanufacturing plant that will be constructed at its West Greenwich, R.I. campus. The new plant is the first-of-its-kind in the U.S. and wil
Read more →AMGNAmgen Announces 2018 Third Quarter Dividend Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.32 per share dividend for the third quarter of 2018. The dividend will...
THOUSAND OAKS, Calif. , July 31, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that its Board of Directors declared a $1.32 per share dividend for the third quarter of 2018. The dividend will be paid on Sept. 7, 2018 , to all stockholders of record as of the close of
Read more →AMGNOne Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.Amgen.com News Release AMGEN ANNOUNCES SUCCESSION PLANS FOR TWO EXECUTIVE OFFICERS THOUSAND OAKS, Calif. (
AMGEN ANNOUNCES SUCCESSION PLANS FOR TWO EXECUTIVE OFFICERS THOUSAND OAKS, Calif. (July 26, 2018) As part of Amgen s (NASDAQ:AMGN) planned executive succession to address upcoming retirements, the Company announced transition plans for two of its executive vice presidents today
Read more →AMGNAmgen Reports Second Quarter 2018 Financial Results Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2018. Key results include: Total revenues increased 4 percent versus...
THOUSAND OAKS, Calif. , July 26, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced financial results for the second quarter of 2018. Key results include: "Amgen's strong performance in the second quarter was driven by double-digit, volume-driven growth from our new and
Read more →AMGNOne Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.amgen.com AMGEN REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS THOUSAND OAKS, Calif. (
AMGEN REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS THOUSAND OAKS, Calif. (July 26, 2018) Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2018. Key results include: Amgen s strong performance in the second quarter was driven by double-digit, volu
Read more →AMGNAmgen Announces Succession Plans For Two Executive Officers As part of Amgen's (NASDAQ:AMGN) planned executive succession to address upcoming retirements, the Company announced transition plans for two of its...
THOUSAND OAKS, Calif. , July 26, 2018 /PRNewswire/ -- As part of Amgen's (NASDAQ: AMGN ) planned executive succession to address upcoming retirements, the Company announced transition plans for two of its executive vice presidents today. After more than 21 years of leadership in
Read more →AMGNAmgen Announces Webcast of 2018 Second Quarter Financial Results Amgen (NASDAQ:AMGN) today announced that it will report its second quarter 2018 financial results on Thursday, July 26, 2018, after the close of the...
THOUSAND OAKS, Calif. , July 24, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will report its second quarter 2018 financial results on Thursday, July 26, 2018 , after the close of the U.S. financial markets. The announcement will be followed by a conference
Read more →AMGNAmgen And Cedars-Sinai Partner For Improved Healthcare Quality Amgen (NASDAQ:AMGN) and Cedars-Sinai Medical Center today announced a partnership to help support the improvement of healthcare quality in the...
THOUSAND OAKS, Calif. and LOS ANGELES , July 19, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and Cedars-Sinai Medical Center today announced a partnership to help support the improvement of healthcare quality in the treatment of multiple therapeutic areas that could include oncolo
Read more →AMGNFormer Major League Baseball (MLB) All-Stars Dave Winfield And Steve Garvey Team Up With Amgen To Launch Myeloma MVP™ And Encourage Patients To Create Their Most Valuable Plan For Managing Multiple Myeloma Amgen (NASDAQ:AMGN) today announced the launch of Myeloma MVPTM, a national campaign to help those affected by multiple myeloma create their Most...
THOUSAND OAKS, Calif. , July 18, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the launch of Myeloma MVP TM , a national campaign to help those affected by multiple myeloma create their M ost V aluable P lan, an individualized approach for managing their disease. Mul
Read more →AMGNAmgen And UCB Resubmit Biologics License Application (BLA) For EVENITY™ (romosozumab) To The US FDA Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced the resubmission of the Biologics License Application (BLA) to the U.S. Food and ...
THOUSAND OAKS, Calif. and BRUSSELS , July 12, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and UCB (Euronext Brussels: UCB) today announced the resubmission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for EVENITY™* (romosozumab), an inv
Read more →AMGNAmgen And Novartis Present New Data Demonstrating Long-Term Efficacy, Safety And Tolerability Of Aimovig™ (erenumab-aooe) In Patients With Chronic And Episodic Migraine Amgen (NASDAQ:AMGN) today announced that the results of two open-label extension (OLE) studies of Aimovig™ (erenumab-aooe) in patients with chronic...
THOUSAND OAKS, Calif. , June 28, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the results of two open-label extension (OLE) studies of Aimovig™ (erenumab-aooe) in patients with chronic and episodic migraine, respectively, will be presented at the 60 th Annual S
Read more →AMGNAmgen And Novartis Highlight Findings From A Large Global Patient Survey Revealing That Worldwide Approximately 60 Percent Of Employed People With Migraine Missed, On Average, A Week Of Work In A Month Amgen (NASDAQ:AMGN) today announced initial findings from a large global migraine patient survey, involving more than 11,000 people from 31...
THOUSAND OAKS, Calif. , June 27, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced initial findings from a large global migraine patient survey, involving more than 11,000 people from 31 countries, including the U.S. The findings, to be presented at the 60th Annual Scien
Read more →AMGNAmgen Announces Top-Line Results From Phase 3 Study Of ABP 710, Biosimilar Candidate To Infliximab Amgen (NASDAQ:AMGN) today announced results from a Phase 3 study evaluating the efficacy and safety of biosimilar candidate ABP 710 compared with...
THOUSAND OAKS, Calif. , June 27, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced results from a Phase 3 study evaluating the efficacy and safety of biosimilar candidate ABP 710 compared with REMICADE ® (infliximab) in patients with moderate-to-severe rheumatoid arthrit
Read more →AMGNAmgen And Health And Benefits Consultant Piper Jordan Partner On First Migraine Project With Employers Amgen (NASDAQ:AMGN) and Piper Jordan, one of the nation's leading health and benefits consulting firms, today announced a unique partnership to help...
THOUSAND OAKS , Calif. and SAN DIEGO, June 27, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and Piper Jordan, one of the nation's leading health and benefits consulting firms, today announced a unique partnership to help improve health and well-being in the workplace for people liv
Read more →AMGNNew Data Show Amgen's Repatha® (evolocumab) Significantly Reduced LDL-C And Non-HDL-C In High-risk Patients With Type 2 Diabetes Amgen (NASDAQ:AMGN) today announced new data that show Repatha® (evolocumab) significantly reduced low-density lipoprotein cholesterol (LDL-C) and...
THOUSAND OAKS, Calif. , June 23, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced new data that show Repatha ® (evolocumab) significantly reduced low-density lipoprotein cholesterol (LDL-C) and non-high density lipoprotein cholesterol (non-HDL-C) in patients with Type 2
Read more →AMGNAmgen Receives European Commission Approval To Add Overall Survival Data To BLINCYTO® (blinatumomab) Label Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has granted a full marketing authorization for BLINCYTO® (blinatumomab) based...
THOUSAND OAKS, Calif. , June 19, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the European Commission (EC) has granted a full marketing authorization for BLINCYTO ® (blinatumomab) based on the overall survival (OS) data from the Phase 3 TOWER study in adult pat
Read more →AMGNFDA Approves Addition Of Positive Overall Survival Data From Phase 3 ASPIRE Trial To KYPROLIS® (carfilzomib) Label Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) to add ...
THOUSAND OAKS, Calif. , June 11, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) to add the positive overall survival (OS) data from the Phase 3 ASPIRE trial to t
Read more →AMGNAmgen To Present At The Goldman Sachs 39th Annual Global Healthcare Conference Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 39th Annual Global Healthcare Conference at 1:20 p.m. PT on Tuesday, June 12, 2018, in Rancho...
THOUSAND OAKS, Calif. , June 7, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Goldman Sachs 39 th Annual Global Healthcare Conference at 1:20 p.m. PT on Tuesday , June 12, 2018, in Rancho Palos Verdes, Calif. Elliott M. Levy , M.D., senior vice president of Resea
Read more →AMGNEuropean Commission Approves Prolia® (denosumab) for Patients With Glucocorticoid-Induced Osteoporosis Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has approved a new indication for Prolia® (denosumab) for the treatment of bone ...
THOUSAND OAKS, Calif. , June 8, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the European Commission (EC) has approved a new indication for Prolia ® (denosumab) for the treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult pa
Read more →AMGNAmgen, Oklahoma Health Care Authority And University of Oklahoma's Pharmacy Management Consultants Partner To Improve Medicaid Outcomes The Oklahoma Health Care Authority (OHCA), Pharmacy Management Consultants (PMC) and Amgen (NASDAQ:AMGN) today announced a new collaborative...
THOUSAND OAKS, Calif. and OKLAHOMA CITY , June 6, 2018 /PRNewswire/ -- The Oklahoma Health Care Authority (OHCA), Pharmacy Management Consultants (PMC) and Amgen (NASDAQ: AMGN ) today announced a new collaborative agreement to help improve clinical outcomes, experience and satisf
Read more →AMGNPhase 3 A.R.R.O.W. Interim Analysis Shows Once-Weekly 70 mg/m2 KYPROLIS® (carfilzomib) Regimen Significantly Extended Progression-Free Survival Versus A Twice-Weekly 27 mg/m2 Regimen In Patients With Relapsed And Refractory Multiple Myeloma Amgen (NASDAQ:AMGN) today announced results from the Phase 3 A.R.R.O.W. trial of a once-weekly KYPROLIS® (carfilzomib) dosing regimen in patients...
THOUSAND OAKS, Calif. , June 1, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced results from the Phase 3 A.R.R.O.W. trial of a once-weekly KYPROLIS ® (carfilzomib) dosing regimen in patients with relapsed and refractory multiple myeloma. In the trial, KYPROLIS administ
Read more →AMGNAmgen And MD Anderson Announce Collaboration To Accelerate Early Stage Treatments For Leukemia, Myelodysplastic Syndromes, Multiple Myeloma, Small-Cell Lung And Other Small-Cell Cancers Amgen (NASDAQ:AMGN) and The University of Texas MD Anderson Cancer Center today announced two multi-year collaboration agreements aimed at...
THOUSAND OAKS, Calif. and HOUSTON , May 31, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and The University of Texas MD Anderson Cancer Center today announced two multi-year collaboration agreements aimed at accelerating development of a variety of Amgen's early-stage oncology ther
Read more →AMGNAmgen Foundation And Harvard Team Up To Offer Free Online Science Education Platform The Amgen Foundation and Harvard University today announced plans to launch a free online science education platform uniquely designed to level the...
THOUSAND OAKS, Calif. and CAMBRIDGE, Mass. , May 30, 2018 /PRNewswire/ -- The Amgen Foundation and Harvard University today announced plans to launch a free online science education platform uniquely designed to level the playing field for aspiring scientists. The LabXchange plat
Read more →AMGNAmgen Enters Groundbreaking Collaboration To Improve Symptom Management During Cancer Treatment Amgen (NASDAQ:AMGN) today announced a groundbreaking collaboration with the National Cancer Institute (NCI), the Federal Communications Commission...
THOUSAND OAKS, Calif. , May 23, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced a groundbreaking collaboration with the National Cancer Institute (NCI), the Federal Communications Commission (FCC) Connect2Health Task Force, the University of Kentucky (UK) Markey Cancer
Read more →AMGNAmgen Announces Voting Results Of Annual Meeting Of Stockholders Amgen (NASDAQ: AMGN) today announced voting results from the Company's Annual Meeting of Stockholders, held in Westlake Village, Calif. Approximately ...
THOUSAND OAKS, Calif. , May 22, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced voting results from the Company's Annual Meeting of Stockholders, held in Westlake Village , Calif. Approximately 90 percent of outstanding shares were represented at the meeting. The dire
Read more →AMGNFDA Approves Prolia® (Denosumab) For Glucocorticoid-Induced Osteoporosis Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the use of Prolia® (denosumab) for the treatment of ...
THOUSAND OAKS, Calif. , May 21, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the U.S. Food and Drug Administration (FDA) has approved the use of Prolia ® (denosumab) for the treatment of glucocorticoid-induced osteoporosis (GIOP) in men and women at high risk o
Read more →AMGNFDA Approves Aimovig™ (erenumab-aooe), A Novel Treatment Developed Specifically For Migraine Prevention Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Aimovig™ (erenumab-aooe) for the preventive...
THOUSAND OAKS, Calif. , May 17, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the U.S. Food and Drug Administration (FDA) has approved Aimovig™ (erenumab-aooe) for the preventive treatment of migraine in adults. Aimovig is a novel therapeutic approach as the fir
Read more →AMGNAmgen Receives European Commission Approval For Repatha® (Evolocumab) To Prevent Heart Attack And Stroke In Adults With Established Cardiovascular Disease Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has approved a new indication in the Repatha® (evolocumab) label for adults...
THOUSAND OAKS, Calif. , May 16, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the European Commission (EC) has approved a new indication in the Repatha ® (evolocumab) label for adults with established atherosclerotic cardiovascular disease (myocardial infarction
Read more →AMGNAmgen To Present At The Bank of America Merrill Lynch 2018 Health Care Conference Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch 2018 Health Care Conference at 10 a.m. PT on Tuesday, May 15, 2018. David W....
THOUSAND OAKS, Calif. , May 10, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Bank of America Merrill Lynch 2018 Health Care Conference at 10 a.m. PT on Tuesday, May 15, 2018 . David W. Meline , executive vice president and chief financial officer at Amgen, and D
Read more →AMGNAmgen Receives Positive CHMP Opinion To Add Overall Survival Results From The Phase 3 ASPIRE Study To KYPROLIS® (carfilzomib) Label Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted ...
THOUSAND OAKS, Calif. , April 30, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending a label variation for KYPROLIS ® (carfilz
Read more →AMGNAmgen Receives Positive CHMP Opinion To Expand Use Of Prolia® (denosumab) To Patients With Glucocorticoid-Induced Osteoporosis Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted ...
THOUSAND OAKS, Calif. , April 27, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the marketing authorization of Prolia ® (denosumab
Read more →AMGNAmgen Reports First Quarter 2018 Financial Results Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2018. Key results include: Total revenues increased 2 percent versus...
THOUSAND OAKS, Calif. , April 24, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced financial results for the first quarter of 2018. Key results include: "Amgen's strong first-quarter performance was driven by our new and recently launched products, all of which deliver
Read more →AMGNAmgen Announces Webcast Of 2018 First Quarter Financial Results Amgen (NASDAQ:AMGN) today announced that it will report its first quarter 2018 financial results on Tuesday, April 24, 2018, after the close of the U....
THOUSAND OAKS, Calif. , April 19, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will report its first quarter 2018 financial results on Tuesday, April 24, 2018 , after the close of the U.S. financial markets. The announcement will be followed by a conference
Read more →AMGNAmgen Presents First-Of-Its-Kind Data At AAN Annual Meeting Reinforcing Robust And Consistent Efficacy Of Aimovig™ (erenumab) For Migraine Patients With Multiple Treatment Failures Amgen (NASDAQ: AMGN) today announced full results from the Phase 3b LIBERTY trial of Aimovig™ (erenumab) in episodic migraine patients who had...
THOUSAND OAKS, Calif. , April 17, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced full results from the Phase 3b LIBERTY trial of Aimovig™ (erenumab) in episodic migraine patients who had previously failed two to four preventive treatments, due to lack of efficacy or t
Read more →AMGNAmgen Announces Rhode Island Will Be Location Of First US Next-Generation Biomanufacturing Plant Amgen (NASDAQ:AMGN) today announced plans to build a new state-of-the-art next-generation biomanufacturing plant at its campus in West Greenwich, R.I....
THOUSAND OAKS, Calif. , April 10, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced plans to build a new state-of-the-art next-generation biomanufacturing plant at its campus in West Greenwich, R.I. The new plant, the first of its kind in the United States (U.S.), will e
Read more →AMGNAmgen To Present New Pre-Clinical Data Showcasing Robust Approach To Evaluating Potential Anti-Cancer Therapies At AACR 2018 Amgen (NASDAQ:AMGN) today announced that new pre-clinical data for several of its novel investigational oncology candidates will be presented at the...
THOUSAND OAKS, Calif. , April 9, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that new pre-clinical data for several of its novel investigational oncology candidates will be presented at the American Association for Cancer Research (AACR) Annual Meeting in Chicago,
Read more →AMGNEuropean Commission Approves Expanded Indication For Amgen's XGEVA® (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has approved an expanded indication for XGEVA® (denosumab) for the prevention...
THOUSAND OAKS, Calif. , April 2, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the European Commission (EC) has approved an expanded indication for XGEVA ® (denosumab) for the prevention of skeletal-related events in adults with advanced malignancies involving b
Read more →AMGNFDA Approves BLINCYTO® (blinatumomab) To Treat Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia In Adults And Children Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application...
THOUSAND OAKS, Calif. , March 29, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for BLINCYTO ® (blinatumomab) for the treatment of adults and children
Read more →AMGNAmgen Receives Positive CHMP Opinion Recognizing That Repatha® (evolocumab) Prevents Heart Attacks And Strokes Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted ...
THOUSAND OAKS, Calif. , March 23, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion to include a new indication in the Repatha ® (evolocum
Read more →AMGNAmgen And Allergan Receive Positive CHMP Opinion For ABP 980 (Biosimilar Herceptin®) For The Treatment Of Three Types Of Cancer Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European...
THOUSAND OAKS, Calif. , March 23, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and Allergan plc. (NYSE: AGN ) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the marketing autho
Read more →AMGNNew Analyses Show Payer Utilization Management Criteria Deny Access To PCSK9 Inhibitors For Patients At The Highest Risk For Subsequent Cardiovascular Events Amgen (NASDAQ: AMGN) today announced data from two new studies exploring barriers to access for PCSK9 inhibitors and the potential consequences of...
THOUSAND OAKS, Calif. , March 9, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced data from two new studies exploring barriers to access for PCSK9 inhibitors and the potential consequences of denying coverage for high-risk patients. The studies will be presented at the
Read more →AMGNAmgen Announces Final Results Of Tender Offer Amgen (NASDAQ: AMGN) today announced the final results of its modified Dutch auction tender offer, which expired at 12:00 Midnight, New York City...
THOUSAND OAKS, Calif. , March 8, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the final results of its modified Dutch auction tender offer, which expired at 12:00 Midnight, New York City time, at the end of Monday, March 5, 2018 . Amgen has accepted for purchase 52
Read more →AMGNAmgen Announces 2018 Second Quarter Dividend Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.32 per share dividend for the second quarter of 2018. The dividend will ...
THOUSAND OAKS, Calif. , March 7, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that its Board of Directors declared a $1.32 per share dividend for the second quarter of 2018. The dividend will be paid on June 8, 2018 , to all stockholders of record as of the close of
Read more →AMGNAmgen To Present At the Cowen and Company 38th Annual Health Care Conference Amgen (NASDAQ:AMGN) will present at the Cowen and Company 38th Annual Health Care Conference at 1:30 p.m. ET on Monday, March 12, 2018, in Boston....
THOUSAND OAKS, Calif. , March 7, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Cowen and Company 38 th Annual Health Care Conference at 1:30 p.m. ET on Monday, March 12, 2018 , in Boston . David W. Meline , executive vice president and chief financial officer at
Read more →AMGNAmgen Announces Preliminary Results Of Tender Offer Amgen (NASDAQ:AMGN) today announced the preliminary results of its modified Dutch auction tender offer, which expired at 12:00 Midnight, New York...
THOUSAND OAKS, Calif. , March 6, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the preliminary results of its modified Dutch auction tender offer, which expired at 12:00 Midnight, New York City time, at the end of March 5, 2018 . Based on the preliminary count by Am
Read more →AMGNAmgen Receives Positive CHMP Opinion For Delivery System Of Neulasta® (pegfilgrastim) Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued...
THOUSAND OAKS, Calif. , Feb. 27, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending a label variation for Neulasta ® (pegfilgra
Read more →AMGNAmgen To Present New Data From Repatha® (evolocumab) Clinical Trials At ACC.18 Amgen (NASDAQ: AMGN) today announced new data from the Repatha® (evolocumab) clinical trial program to be featured at the American College of...
THOUSAND OAKS, Calif. , Feb. 26, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced new data from the Repatha ® (evolocumab) clinical trial program to be featured at the American College of Cardiology's 67th Annual Scientific Session (ACC.18) in Orlando, Fla. , March 10-1
Read more →AMGNAmgen Receives Positive Opinion Expanding Use Of XGEVA® (denosumab) To Cover Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma In Europe Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted ...
THOUSAND OAKS, Calif. , Feb. 23, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion to expand the current indication for XGEVA ® (denosumab
Read more →AMGNAmgen Announces FDA Advisory Committee Meeting To Review Potential New Use Of BLINCYTO® (blinatumomab) Amgen (NASDAQ:AMGN) today announced that the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) will review data...
THOUSAND OAKS, Calif. , Feb. 14, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) will review data supporting the BLINCYTO ® (blinatumomab) supplemental Biologics License Applicat
Read more →AMGNAmgen Reports Fourth Quarter And Full Year 2017 Financial Results Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year 2017. Key results include: For the fourth quarter, total...
THOUSAND OAKS, Calif. , Feb. 1, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced financial results for the fourth quarter and full year 2017. Key results include: "With strong volume-driven growth for our recently launched products and a promising new product pipeline,
Read more →AMGNAmgen Receives CHMP Positive Opinion To Add Updated Overall Survival Data To KYPROLIS® (carfilzomib) Label Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted ...
THOUSAND OAKS, Calif. , Jan. 30, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending a label variation for KYPROLIS ® (carfilzo
Read more →AMGNAmgen Announces Webcast of 2017 Fourth Quarter and Full Year Financial Results Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2017 financial results on Thursday, Feb. 1, 2018, after the...
THOUSAND OAKS, Calif. , Jan. 29, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will report its fourth quarter and full year 2017 financial results on Thursday, Feb. 1, 2018 , after the close of the U.S. financial markets. The announcement will be followed by
Read more →AMGNAmgen Reports Aimovig™ (Erenumab) Met All Primary And Secondary Endpoints In Unique Phase 3b Study In Episodic Migraine Patients Who Have Failed Multiple Prior Preventive Treatments Amgen (NASDAQ:AMGN) today announced positive results from the Phase 3b LIBERTY study assessing the efficacy and safety of Aimovig™ (erenumab) 140 mg...
THOUSAND OAKS, Calif. , Jan. 22, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced positive results from the Phase 3b LIBERTY study assessing the efficacy and safety of Aimovig™ (erenumab) 140 mg in patients with episodic migraine who had experienced two to four previous
Read more →AMGNEuropean Commission Approves Amgen And Allergan's MVASI® (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer Amgen (NASDAQ: AMGN) and Allergan plc. (NYSE: AGN) today announced that the European Commission (EC) has granted marketing authorization for MVASI®...
THOUSAND OAKS, Calif. , Jan. 18, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and Allergan plc. (NYSE: AGN ) today announced that the European Commission (EC) has granted marketing authorization for MVASI ® (biosimilar bevacizumab). MVASI is the first biosimilar bevacizumab approve
Read more →AMGNOverall Survival Analysis From KYPROLIS® (Carfilzomib) Phase 3 ASPIRE Trial Published in the Journal of Clinical Oncology Amgen (NASDAQ:AMGN) today announced that the Journal of Clinical Oncology published positive overall survival (OS) findings from the final analysis...
THOUSAND OAKS, Calif. , Jan. 17, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the Journal of Clinical Oncology published positive overall survival (OS) findings from the final analysis of the Phase 3 ASPIRE trial, which demonstrated that the addition of KYPROLI
Read more →AMGNEuropean Medicines Agency Accepts Filing For EVENITY™ (Romosozumab) Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced that the European Medicines Agency (EMA) has accepted the Marketing...
THOUSAND OAKS, Calif. and BRUSSELS , Jan. 7, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and UCB (Euronext Brussels: UCB) today announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for EVENITY™* (romosozumab) for the treatme
Read more →AMGNFDA Approves XGEVA® (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application...
THOUSAND OAKS, Calif. , Jan. 5, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for XGEVA ® (denosumab) to expand the currently approved indication for t
Read more →AMGNAmgen To Present At The 36th Annual J.P. Morgan Healthcare Conference Amgen (NASDAQ: AMGN) will present at the 36th Annual J.P. Morgan Healthcare Conference at 8:30 a.m. PT on Tuesday, Jan. 9, 2018, in San Francisco....
THOUSAND OAKS, Calif. , Jan. 4, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the 36 th Annual J.P. Morgan Healthcare Conference at 8:30 a.m. PT on Tuesday , Jan. 9, 2018, in San Francisco . Robert A. Bradway , chairman and chief executive officer at Amgen, will pres
Read more →AMGNAmgen Teams Up With Cambridge Biotech Community To Select Two Startups To Receive Golden Tickets At LabCentral Amgen (NASDAQ:AMGN) and LabCentral today announced that Kernal Biologics Inc. and QurAlis have won the Amgen Golden Ticket at LabCentral. The two...
As one of LabCentral's platinum sponsors, Amgen can nominate up to two early-stage companies annually to take up residence in LabCentral's Kendall Square facilities in Cambridge, Mass. The Golden Ticket represents one year of bench space for one scientist, including benefit of La
Read more →AMGNAmgen Announces 15 Percent Increase In 2018 First Quarter Dividend Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.32 per share dividend for the first quarter of 2018. The dividend will...
THOUSAND OAKS, Calif. , Dec. 12, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that its Board of Directors declared a $1 .32 per share dividend for the first quarter of 2018. The dividend will be paid on March 8, 2018 , to all stockholders of record as of the close o
Read more →AMGNAmgen Foundation Pledges Up To $500,000 In Relief To Victims Of The Southern California Wildfires Amgen (NASDAQ:AMGN) today announced that the Amgen Foundation has pledged $500,000 to support victims of the Southern California wildfires. Of this...
THOUSAND OAKS, Calif. , Dec. 11, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the Amgen Foundation has pledged $500,000 to support victims of the Southern California wildfires. Of this commitment, $200,000 will be directed to the United Way of Ventura County to
Read more →AMGNKYPROLIS® (carfilzomib) Extended Overall Survival In Patients With Relapsed Or Refractory Multiple Myeloma In Phase 3 ASPIRE Trial Amgen (NASDAQ: AMGN) today announced new results showing the positive overall survival (OS) findings from the final analysis of the Phase 3 ASPIRE...
THOUSAND OAKS, Calif. , Dec. 11, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced new results showing the positive overall survival (OS) findings from the final analysis of the Phase 3 ASPIRE trial. The study met the key secondary endpoint of OS, demonstrating that the
Read more →AMGNNew Data To Be Presented At ASH 2017 Underscore Amgen's Commitment To Improving Lives And Changing Outcomes For Patients With Difficult-To-Treat Blood Cancers Amgen (NASDAQ:AMGN) today announced that new clinical data and analyses from 33 abstracts, including six oral presentations, evaluating approved...
THOUSAND OAKS, Calif. , Dec. 7, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that new clinical data and analyses from 33 abstracts, including six oral presentations, evaluating approved medicines and investigational immuno-oncology agents from the Company's robust h
Read more →AMGNAmgen To Webcast Investor Call At ASH 2017 Amgen (NASDAQ:AMGN) will host a webcast call for the investment community at the 59th American Society of Hematology (ASH) Annual Meeting &...
THOUSAND OAKS, Calif. , Dec. 6, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will host a webcast call for the investment community at the 59 th American Society of Hematology (ASH) Annual Meeting & Exposition on Saturday, Dec. 9, 2017 , at 11:30 a.m. ET. David M. Reese, M.D., senio
Read more →AMGNFDA Approves Amgen's Repatha® (evolocumab) To Prevent Heart Attack And Stroke Amgen (NASDAQ: AMGN) today announced that following priority review of its supplemental Biologics License Application, the U.S. Food and Drug...
THOUSAND OAKS, Calif. , Dec. 1, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that following priority review of its supplemental Biologics License Application, the U.S. Food and Drug Administration (FDA) approved Repatha ® (evolocumab) as the first PCSK9 inhibitor to
Read more →AMGNAimovig™ (erenumab) Phase 3 STRIVE Data Published In The New England Journal Of Medicine Demonstrate Significant, Sustained Efficacy In Migraine Prevention Amgen (NASDAQ: AMGN) today announced that the New England Journal of Medicine (NEJM) published positive results from the six-month Phase 3 STRIVE...
THOUSAND OAKS, Calif. , Nov. 29, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the New England Journal of Medicine (NEJM) published positive results from the six-month Phase 3 STRIVE study evaluating Aimovig™ (erenumab) versus placebo for the prevention of episo
Read more →AMGNAmgen To Present At The Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference Amgen (NASDAQ:AMGN) will present at the Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference on Thursday, Nov. 30, 2017, in Boston, beginning at ...
THOUSAND OAKS, Calif. , Nov. 27, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference on Thursday, Nov. 30, 2017 , in Boston , beginning at 9:30 a.m. ET . Elliott M. Levy , M.D., senior vice president of Global D
Read more →AMGNEstudo mostra que Repatha® (evolocumabe) reduz pela metade o risco relativo de eventos cardiovasculares em pacientes com doença arterial periférica A Amgen, biofarmacêutica focada no desenvolvimento de medicamentos para doenças de difícil tratamento, apresentou durante o congresso da American...
THOUSAND OAKS, Calif. , Nov. 23, 2017 /PRNewswire/ -- A Amgen, biofarmacêutica focada no desenvolvimento de medicamentos para doenças de difícil tratamento, apresentou durante o congresso da American Heart Association (AHA), cinco novas análises de subgrupo do estudo de desfechos
Read more →AMGNAmgen Launches The ENBREL Mini™ Single-Dose Prefilled Cartridge With AutoTouch™ Reusable Autoinjector That Is Ergonomically Designed For Patients Amgen (NASDAQ:AMGN) announced that the ENBREL Mini™ with AutoTouch™ is now available in the United States (U.S.). Awarded the Arthritis Foundation...
THOUSAND OAKS, Calif. , Nov. 17, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) announced that the ENBREL Mini™ with AutoTouch™ is now available in the United States (U.S.). Awarded the Arthritis Foundation Ease of Use SM Commendation, this new and innovative delivery system provides
Read more →AMGNNew Analyses Presented At AHA 2017 Show Repatha® (evolocumab) Significantly Reduced Cardiovascular Events In Patients With Peripheral Artery Disease And In Patients With A History Of Heart Attacks Amgen (NASDAQ:AMGN) today announced five new subgroup analyses from the Repatha® (evolocumab) cardiovascular outcomes study (FOURIER) that showed the ...
THOUSAND OAKS, Calif. , Nov. 13, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced five new subgroup analyses from the Repatha ® (evolocumab) cardiovascular outcomes study (FOURIER) that showed the addition of Repatha to statin therapy improved clinical outcomes with sig
Read more →AMGNAmgen And Allergan Receive Positive CHMP Opinion For ABP 215 (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European...
THOUSAND OAKS, Calif. , Nov. 10, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and Allergan plc. (NYSE: AGN ) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the Marketing Author
Read more →AMGNAmgen Receives Positive CHMP Opinion To Expand Use Of Nplate® (romiplostim) In Pediatric Patients With Chronic Immune Thrombocytopenic Purpura Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted ...
THOUSAND OAKS, Calif. , Nov. 10, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion to expand the current indication for Nplate ® (romiplos
Read more →AMGNAmgen Announces New Analyses Of High-Risk Patient Subgroups From Repatha® (evolocumab) Cardiovascular Outcomes Study At AHA Scientific Sessions 2017 Amgen (NASDAQ: AMGN) today announced new analyses will be presented from the Repatha® (evolocumab) cardiovascular outcomes study, including analyses...
THOUSAND OAKS, Calif. , Nov. 6, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced new analyses will be presented from the Repatha ® (evolocumab) cardiovascular outcomes study, including analyses investigating the efficacy of Repatha in high-risk patients with peripheral
Read more →AMGNAmgen And Novartis Announce Expanded Collaboration With Banner Alzheimer's Institute In Pioneering Prevention Program Amgen (NASDAQ:AMGN) and Novartis today announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial – the...
THOUSAND OAKS, Calif. , Nov. 2, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and Novartis today announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial – the Alzheimer's Prevention Initiative (API) Generation Study 2. This trial follo
Read more →AMGNKirin-Amgen Joint Venture To Become Wholly-Owned Subsidiary Of Amgen Amgen (NASDAQ:AMGN) today announced that Amgen and Kirin Holdings (Kirin) have agreed that Kirin-Amgen, a joint venture between the two companies,...
THOUSAND OAKS, Calif. , Oct. 30, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that Amgen and Kirin Holdings (Kirin) have agreed that Kirin-Amgen, a joint venture between the two companies, will redeem Kirin's shares in the joint venture and, as a result, Kirin-Amgen
Read more →AMGNAmgen Reports Third Quarter 2017 Financial Results Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2017. Key results include: Total revenues decreased 1 percent versus...
THOUSAND OAKS, Calif. , Oct. 25, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced financial results for the third quarter of 2017. Key results include: "We are seeing strong, volume-driven growth in our recently launched products, as we also effectively manage the life
Read more →AMGNAward-Winning Journalist And Cancer Survivor Joan Lunden Partners With Amgen To Launch 'At Home With Joan' To Empower Patients Battling Cancer Amgen (NASDAQ:AMGN) today announced the launch of At Home with Joan, a campaign led by breast cancer survivor and advocate Joan Lunden. This campaign ...
THOUSAND OAKS, Calif. , Oct. 24, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the launch of At Home with Joan , a campaign led by breast cancer survivor and advocate Joan Lunden . This campaign aims to empower patients diagnosed with cancer to be active participants
Read more →AMGNAmgen Announces Appointment Of Wanda M. Austin To Board Of Directors Amgen (NASDAQ:AMGN) today announced the appointment of Wanda M. Austin to its Board of Directors, effective upon the December Board and committee...
THOUSAND OAKS, Calif. , Oct. 24, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the appointment of Wanda M. Austin to its Board of Directors, effective upon the December Board and committee meetings. Dr. Austin will serve as a member of the Board's Audit Committee and
Read more →AMGNAmgen Announces 2017 Fourth Quarter Dividend Amgen (NASDAQ: AMGN) today announced that its Board of Directors declared a $1.15 per share dividend for the fourth quarter of 2017. The dividend...
THOUSAND OAKS, Calif. , Oct. 24, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that its Board of Directors declared a $1.15 per share dividend for the fourth quarter of 2017. The dividend will be paid on Dec. 8, 2017 , to all stockholders of record as of the close of
Read more →AMGNPhase 3 A.R.R.O.W. Study Of Once-Weekly KYPROLIS® (Carfilzomib) Regimen Meets Primary Endpoint Of Progression-Free Survival In Relapsed And Refractory Multiple Myeloma Patients Amgen (NASDAQ: AMGN) today announced top-line results of the Phase 3 A.R.R.O.W. trial, which showed KYPROLIS® (carfilzomib) administered once-weekly...
THOUSAND OAKS, Calif. , Oct. 23, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced top-line results of the Phase 3 A.R.R.O.W. trial, which showed KYPROLIS ® (carfilzomib) administered once-weekly at the 70 mg/m 2 dose with dexamethasone allowed relapsed and refractory mu
Read more →AMGNAmgen Announces Webcast of 2017 Third Quarter Financial Results Amgen (NASDAQ:AMGN) today announced that it will report its third quarter financial results on Wednesday, Oct. 25, 2017, after the close of the U.S....
THOUSAND OAKS, Calif. , Oct. 20, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will report its third quarter financial results on Wednesday, Oct. 25, 2017 , after the close of the U.S. financial markets. The announcement will be followed by a conference call
Read more →AMGNAmgen And Boston Children's Hospital Enter A Collaboration To Find New Genes And Drug Targets For Severe Pain Syndromes Amgen (NASDAQ:AMGN) and Boston Children's Hospital today announced that they have entered into a neuroscience research collaboration aimed at...
CAMBRIDGE, Mass. , Oct. 16, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and Boston Children's Hospital today announced that they have entered into a neuroscience research collaboration aimed at identifying novel pain targets based on human genetic analyses. The one-year collaborat
Read more →AMGNAmgen Foundation Awards Khan Academy $3 Million To Support Development Of Free Comprehensive Biology Lessons The Amgen Foundation today announced a three-year, $3 million grant to Khan Academy to develop comprehensive new biology lessons. The Amgen...
THOUSAND OAKS, Calif. and MOUNTAIN VIEW, Calif. , Oct. 12, 2017 /PRNewswire/ -- The Amgen Foundation today announced a three-year, $3 million grant to Khan Academy to develop comprehensive new biology lessons. The Amgen Foundation is the exclusive sponsor of Khan Academy's biolog
Read more →AMGNFDA Accepts Supplemental Biologics License Application For Prolia® (Denosumab) In Glucocorticoid-Induced Osteoporosis Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License...
THOUSAND OAKS, Calif. , Oct. 9, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for Prolia ® (denosumab) for the treatment of patients with gl
Read more →AMGNFirst Randomized Study To Evaluate IMLYGIC® (Talimogene Laherparepvec), An Oncolytic Viral Therapy, In Combination With A Checkpoint Inhibitor Published In The Journal Of Clinical Oncology Amgen (NASDAQ:AMGN) today announced that the Journal of Clinical Oncology has published positive results from the IMLYGIC® (talimogene laherparepvec) ...
THOUSAND OAKS, Calif. , Oct. 5, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the Journal of Clinical Oncology has published positive results from the IMLYGIC ® (talimogene laherparepvec) Phase 2 '264 study. The study met its primary endpoint of objective respon
Read more →AMGNAmgen And CytomX Therapeutics Announce Strategic Collaboration In Immuno-Oncology Amgen (NASDAQ:AMGN) and CytomX Therapeutics, Inc., (NASDAQ:CTMX) today announced that the companies have entered into a strategic collaboration in...
THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif. , Oct. 3, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and CytomX Therapeutics, Inc., (NASDAQ: CTMX ) today announced that the companies have entered into a strategic collaboration in immuno-oncology. The companies will co-devel
Read more →AMGNAmgen And AbbVie Agree To Settlement Allowing Commercialization Of AMGEVITA™ Amgen (NASDAQ:AMGN) today announced that it has reached a global settlement with AbbVie to resolve all pending litigation regarding...
THOUSAND OAKS, Calif. , Sept. 28, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it has reached a global settlement with AbbVie to resolve all pending litigation regarding AMGEVITA™/AMJEVITA™, a biosimilar to AbbVie's Humira ® (adalimumab). Under terms of the agr
Read more →AMGNAmgen And Simcere Announce Strategic Collaboration To Co-Develop And Commercialize Biosimilars In China Amgen (NASDAQ: AMGN) and Simcere Pharmaceutical Group today announced the execution of an exclusive agreement to co-develop and commercialize four...
THOUSAND OAKS, Calif. and NANJING , China , Sept. 26, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and Simcere Pharmaceutical Group today announced the execution of an exclusive agreement to co-develop and commercialize four biosimilars in China . The collaboration includes undiscl
Read more →AMGNAmgen Provides Update On Hurricane Maria Amgen (NASDAQ:AMGN) today provided an update on Hurricane Maria's impact on the Company's manufacturing facilities in Puerto Rico. The safety of the...
THOUSAND OAKS, Calif. , Sept. 25, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today provided an update on Hurricane Maria's impact on the Company's manufacturing facilities in Puerto Rico. The safety of the more than 2,000 Amgen colleagues and their families on the island remains
Read more →AMGNAmgen Foundation Pledges Up To $5 Million To Hurricane Maria Relief Efforts Amgen (NASDAQ:AMGN) today announced that the Amgen Foundation has pledged $3 million to support urgent Hurricane Maria relief efforts in Puerto Rico. ...
THOUSAND OAKS, Calif. , Sept. 22, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the Amgen Foundation has pledged $3 million to support urgent Hurricane Maria relief efforts in Puerto Rico . The Foundation also has committed up to an additional $2 million for lon
Read more →AMGNNew FOURIER Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With Diabetes Amgen (NASDAQ:AMGN) today announced that a new analysis of the cardiovascular outcomes study (FOURIER) demonstrated that lowering low-density...
THOUSAND OAKS, Calif. , Sept. 15, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that a new analysis of the cardiovascular outcomes study (FOURIER) demonstrated that lowering low-density lipoprotein cholesterol (LDL-C) levels with Repatha ® (evolocumab) significantly
Read more →AMGNFDA Approves Amgen And Allergan's MVASI™ (bevacizumab-awwb) For The Treatment Of Five Types Of Cancer Amgen (NASDAQ: AMGN) and Allergan plc. (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved MVASI™...
THOUSAND OAKS, Calif. , Sept. 14, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and Allergan plc. (NYSE: AGN ) today announced that the U.S. Food and Drug Administration (FDA) has approved MVASI™ (bevacizumab-awwb) for all eligible indications of the reference product, Avastin ® (be
Read more →AMGNEVENITY™ (romosozumab) ARCH Study Results Published In The New England Journal Of Medicine Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced detailed results from the Phase 3 ARCH study showing that 12 months of EVENITY™* ...
THOUSAND OAKS, Calif. and BRUSSELS , Sept. 11, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and UCB (Euronext Brussels: UCB) today announced detailed results from the Phase 3 ARCH study showing that 12 months of EVENITY™* (romosozumab) followed by alendronate was superior in reduci
Read more →AMGNAmgen To Present At The Bank of America Merrill Lynch Global Healthcare Conference Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 9:45 a.m. GMT on Thursday, Sept. 14, 2017, in...
THOUSAND OAKS, Calif. , Sept. 11, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 9:45 a.m. GMT on Thursday, Sept. 14, 2017 , in London . David W. Meline , executive vice president and chief financial of
Read more →AMGNAmgen And Allergan Present Phase 3 Data On Biosimilar Trastuzumab Candidate ABP 980 At The European Society For Medical Oncology 2017 Congress Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced data from a Phase 3 study evaluating the efficacy and safety of ABP 980, a...
THOUSAND OAKS, Calif. and DUBLIN , Sept. 9, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and Allergan plc. (NYSE: AGN ) today announced data from a Phase 3 study evaluating the efficacy and safety of ABP 980, a Herceptin ® (trastuzumab) biosimilar, compared with the originator prod
Read more →AMGNAmgen Highlights The Latest EVENITY™ (Romosozumab) And Prolia® (Denosumab) Research At The American Society For Bone And Mineral Research Annual Meeting Amgen (NASDAQ:AMGN) today announced that 19 scientific abstracts will highlight the latest scientific research on EVENITY™* (romosozumab) and Prolia® ...
THOUSAND OAKS, Calif. , Sept. 8, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that 19 scientific abstracts will highlight the latest scientific research on EVENITY™* (romosozumab) and Prolia ® (denosumab) at this year's Annual Meeting of the American Society for Bon
Read more →AMGNNew Data Demonstrate Aimovig™ (erenumab) Reduced Monthly Migraine Days In Patients Who Failed Previous Preventive Therapies Amgen (NASDAQ: AMGN) today announced new data in patients with high unmet need, providing further evidence of the efficacy of Aimovig™* (erenumab)...
THOUSAND OAKS, Calif. , Sept. 7, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced new data in patients with high unmet need, providing further evidence of the efficacy of Aimovig™* (erenumab) for migraine prevention. Aimovig is the first and only investigational biologi
Read more →AMGNAmgen To Present At The Morgan Stanley Global Healthcare Conference Amgen (NASDAQ:AMGN) will present at the Morgan Stanley Global Healthcare Conference at 9:10 a.m. ET on Tuesday, Sept. 12, 2017, in New York City....
THOUSAND OAKS, Calif. , Sept. 7, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Morgan Stanley Global Healthcare Conference at 9:10 a.m. ET on Tuesday, Sept. 12, 2017 , in New York City . Robert A. Bradway , chairman and chief executive officer at Amgen, will pres
Read more →AMGNTezepelumab Significantly Reduced Asthma Exacerbations For A Broad Population Of Patients With Severe Uncontrolled Asthma Amgen (NASDAQ:AMGN) and AstraZeneca (NYSE:AZN) today announced results from the PATHWAY Phase 2b trial of tezepelumab that showed a significant...
THOUSAND OAKS, Calif. , Sept. 6, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and AstraZeneca (NYSE: AZN ) today announced results from the PATHWAY Phase 2b trial of tezepelumab that showed a significant reduction in the annual asthma exacerbation rate compared with placebo in pati
Read more →AMGNEuropean Commission Approves Expanded Use Of Mimpara® (Cinacalcet) For The Treatment Of Secondary Hyperparathyroidism In Children With End-Stage Renal Disease On Dialysis Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has granted Marketing Authorization of a pediatric formulation (granules in...
THOUSAND OAKS, Calif. , Aug. 31, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the European Commission (EC) has granted Marketing Authorization of a pediatric formulation (granules in capsule for opening) of Mimpara ® (cinacalcet) for the treatment of secondary
Read more →AMGNLong-Term Analysis Of Phase 3 Head-To-Head Study Confirms KYPROLIS® (Carfilzomib) Regimen Extends Overall Survival In Patients With Relapsed Multiple Myeloma Amgen (NASDAQ: AMGN) today announced positive results from a post-hoc analysis requested by the U.S. Food and Drug Administration (FDA) of the Phase...
THOUSAND OAKS, Calif. , Aug. 30, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced positive results from a post-hoc analysis requested by the U.S. Food and Drug Administration (FDA) of the Phase 3 head-to-head ENDEAVOR trial, which followed patients for at least three ye
Read more →AMGNFDA Accepts Amgen's Filing Of A Supplemental New Drug Application To Add Overall Survival Results To KYPROLIS® (Carfilzomib) Label Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental New Drug Application...
THOUSAND OAKS, Calif. , Aug. 30, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental New Drug Application (sNDA) based on the overall survival (OS) data from the Phase 3 head-to-head EN
Read more →AMGNEl tratamiento con CARFILZOMIB mejora significativamente la supervivencia de pacientes con mieloma múltiple recurrente Amgen (NASDAQ: AMGN) anunció resultados positivos del análisis final del estudio de Fase 3 'ASPIRE'. El estudio logró los criterios de valoración...
THOUSAND OAKS, California , 30 de agosto de 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) anunció resultados positivos del análisis final del estudio de Fase 3 'ASPIRE'. El estudio logró los criterios de valoración secundarios, demostrando que carfilzomib con lenalidomida y dexameta
Read more →AMGNNew Virtual Histology Sub-Study Evaluates Impact Of Repatha® (Evolocumab) On Coronary Artery Plaque Composition Amgen (NASDAQ:AMGN) today announced results from an exploratory virtual histology sub-study of the Repatha® (evolocumab) GLAGOV Phase 3 coronary...
THOUSAND OAKS, Calif. , Aug. 29, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced results from an exploratory virtual histology sub-study of the Repatha ® (evolocumab) GLAGOV Phase 3 coronary intravascular ultrasound imaging trial that looked at coronary artery plaque c
Read more →AMGNNew Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With History Of Stroke Amgen (NASDAQ:AMGN) today announced that a new analysis showed lowering low-density lipoprotein cholesterol (LDL-C) levels with Repatha® (evolocumab) ...
THOUSAND OAKS, Calif. , Aug. 29, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that a new analysis showed lowering low-density lipoprotein cholesterol (LDL-C) levels with Repatha ® (evolocumab) reduced the risk of cardiovascular events in a sub-group of patients with
Read more →AMGNNew Repatha® (evolocumab) Analysis Demonstrates Cardiovascular Outcomes Efficacy And Safety Of Achieving Very Low LDL-C Levels Amgen (NASDAQ:AMGN) today announced a new analysis from the Repatha® (evolocumab) cardiovascular outcomes study (FOURIER) that showed a statistically ...
THOUSAND OAKS, Calif. , Aug. 28, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced a new analysis from the Repatha ® (evolocumab) cardiovascular outcomes study (FOURIER) that showed a statistically significant relationship between lower achieved low-density lipoprotein c
Read more →AMGNAmgen Foundation Expands The Amgen Biotech Experience, Bringing Total Program Reach To 900,000 High School Students By 2020 The Amgen Foundation today announced it will expand the Amgen Biotech Experience (ABE) to reach nearly 900,000 high school students by 2020. For...
THOUSAND OAKS, Calif. , Aug. 24, 2017 /PRNewswire/ -- The Amgen Foundation today announced it will expand the Amgen Biotech Experience (ABE) to reach nearly 900,000 high school students by 2020. For nearly 30 years, ABE has empowered high school science teachers to implement real
Read more →AMGNOverall Survival Analysis From KYPROLIS® (carfilzomib) Phase 3 Endeavor Trial Published In The Lancet Oncology Amgen (NASDAQ:AMGN) today announced that results from an overall survival (OS) analysis of the Phase 3 head-to-head ENDEAVOR trial were published...
THOUSAND OAKS, Calif. , Aug. 23, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that results from an overall survival (OS) analysis of the Phase 3 head-to-head ENDEAVOR trial were published online first in The Lancet Oncology. Data showed that KYPROLIS ® (carfilzomib)
Read more →AMGNNew Economic Analysis Based On Repatha® (Evolocumab) Outcomes Data Published In JAMA Cardiology Amgen (NASDAQ:AMGN) today announced results from a new Repatha® (evolocumab) economic analysis published in the Journal of the American Medical...
THOUSAND OAKS, Calif. , Aug. 23, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced results from a new Repatha ® (evolocumab) economic analysis published in the Journal of the American Medical Association (JAMA) Cardiology. The study identifies the clinical and economic c
Read more →AMGNAmgen To Present New Data From The Repatha® (Evolocumab) Cardiovascular Outcomes Study At ESC Congress 2017 Amgen (NASDAQ:AMGN) today announced that new data from the Repatha® (evolocumab) clinical trial program, including three late-breaking scientific...
THOUSAND OAKS, Calif. , Aug. 21, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that new data from the Repatha ® (evolocumab) clinical trial program, including three late-breaking scientific sessions, will be presented at the European Society of Cardiology (ESC) Congr
Read more →AMGNRepatha® (Evolocumab) Phase 3 Cognitive Function Study Results Published In The New England Journal Of Medicine Amgen (NASDAQ:AMGN) today announced that the New England Journal of Medicine (NEJM) published results from the Repatha® (evolocumab) cognitive...
THOUSAND OAKS, Calif. , Aug. 16, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the New England Journal of Medicine ( NEJM ) published results from the Repatha ® (evolocumab) cognitive function trial (EBBINGHAUS), which was conducted in a subset of patients enrol
Read more →AMGNAmgen And Allergan Submit Biosimilar Biologics License Application For ABP 980 To US Food And Drug Administration Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug...
THOUSAND OAKS, Calif. , July 31, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and Allergan plc. (NYSE: AGN ) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ABP 980, a biosimilar candidate to Herceptin ® (tr
Read more →AMGNAmgen Submits Supplemental Biologics License Application For Prolia® (denosumab) In Glucocorticoid-Induced Osteoporosis Amgen (NASDAQ:AMGN) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration...
THOUSAND OAKS, Calif. , July 31, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Prolia ® (denosumab) for the treatment of patients with glucocortic
Read more →AMGNAmgen Announces 2017 Third Quarter Dividend Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.15 per share dividend for the third quarter of 2017. The dividend will...
THOUSAND OAKS, Calif. , July 28, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that its Board of Directors declared a $1.15 per share dividend for the third quarter of 2017. The dividend will be paid on Sept. 8, 2017 , to all stockholders of record as of the close of
Read more →AMGNFDA Grants Priority Review For Amgen's Supplemental Biologics License Application For Repatha® (evolocumab) To Include Data On Reducing Risk Of Cardiovascular Events Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review for Amgen's supplemental Biologics...
THOUSAND OAKS, Calif. , July 27, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review for Amgen's supplemental Biologics License Application (sBLA) for Repatha ® (evolocumab), a PCSK9 inhibitor. If
Read more →AMGNAmgen Reports Second Quarter 2017 Financial Results Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2017. Key results include: Total revenues increased 2 percent versus...
THOUSAND OAKS, Calif. , July 25, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced financial results for the second quarter of 2017. Key results include: "Our continued solid performance this quarter is yet another indication that we are on track to deliver on our long-
Read more →AMGNFDA Accepts Biologics License Application For Aimovig™ (erenumab) Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA)...
THOUSAND OAKS, Calif. , July 20, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for Aimovig™ (erenumab) for the prevention of migraine in patients experien
Read more →AMGNAmgen Announces Webcast of 2017 Second Quarter Financial Results Amgen (NASDAQ:AMGN) today announced that it will report its second quarter financial results on Tuesday, July 25, 2017, after the close of the U.S....
THOUSAND OAKS, Calif. , July 20, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will report its second quarter financial results on Tuesday, July 25, 2017 , after the close of the U.S. financial markets. The announcement will be followed by a conference call w
Read more →AMGNAmgen And UCB Provide Update On Regulatory Status Of EVENITY™ (romosozumab) In The US Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response...
THOUSAND OAKS, Calif. and BRUSSELS , July 16, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and UCB (Euronext Brussels: UCB) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for the Biologics License Application (BLA) for EVENITY
Read more →AMGNAmgen Submits Regulatory Applications In US And Europe To Include Overall Survival Data In KYPROLIS® (Carfilzomib) Label Amgen (NASDAQ:AMGN) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) and a ...
THOUSAND OAKS, Calif. , July 14, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) and a variation to the marketing application to the European Medicines Agency (E
Read more →AMGNAmgen And Allergan To Discuss Data Supporting Biologics License Application For ABP 215, A Biosimilar Candidate To Avastin® (bevacizumab) Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced that the Companies will discuss data supporting the ABP 215 Biologics License...
THOUSAND OAKS, Calif. , July 13, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and Allergan plc. (NYSE: AGN ) today announced that the Companies will discuss data supporting the ABP 215 Biologics License Application (BLA) with the Oncologic Drugs Advisory Committee (ODAC) of the U.S
Read more →AMGNSecond Phase 3 Study Shows KYPROLIS® (Carfilzomib) Regimen Significantly Improves Overall Survival In Patients With Relapsed Multiple Myeloma Amgen (NASDAQ:AMGN) today announced positive results from the final analysis of the Phase 3 ASPIRE trial. The study met the key secondary endpoint of ...
THOUSAND OAKS, Calif. , July 12, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced positive results from the final analysis of the Phase 3 ASPIRE trial. The study met the key secondary endpoint of overall survival (OS), demonstrating that KYPROLIS ® (carfilzomib), lenali
Read more →AMGNFDA Grants Full Approval for BLINCYTO® (blinatumomab) to Treat Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia in Adults and Children Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application...
THOUSAND OAKS, Calif. , July 11, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for BLINCYTO ® (blinatumomab) to include overall survival (OS) data from
Read more →AMGNAmgen And QB3@953 Announce Winners Of The Amgen Golden Ticket Amgen (NASDAQ: AMGN) and QB3@953 today announced that Darmiyan and Enable Biosciences have won the Amgen Golden Ticket at QB3@953. Each company...
SAN FRANCISCO , July 11, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and QB3@953 today announced that Darmiyan and Enable Biosciences have won the Amgen Golden Ticket at QB3@953. Each company receives one year of lab space at the QB3@953 life sciences incubator, additional facilit
Read more →AMGNFDA Approves Vectibix® (Panitumumab) For Use In Wild-Type RAS Metastatic Colorectal Cancer Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application...
THOUSAND OAKS, Calif. , June 29, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Vectibix ® (panitumumab) for patients with wild-type RAS (defined as
Read more →AMGNAmgen Receives Positive CHMP Opinion To Expand Use Of Mimpara® (cinacalcet) For The Treatment Of Secondary Hyperparathyroidism In Certain Children With End-Stage Renal Disease On Dialysis Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted ...
THOUSAND OAKS, Calif. , June 23, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the Marketing Authorization of a pediatric formulat
Read more →AMGNAmgen To Present New Data At 22nd Congress of the European Hematology Association Amgen (NASDAQ: AMGN) today announced that new clinical data and analyses from its hematology portfolio will be presented at the 22nd Congress of the...
THOUSAND OAKS, Calif. , June 21, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that new clinical data and analyses from its hematology portfolio will be presented at the 22 nd Congress of the European Hematology Association (EHA) in Madrid, June 22-25, 2017. Key data
Read more →AMGNFDA Accepts Amgen's Supplemental Biologics License Application To Expand Indication For XGEVA® (denosumab) To Include Multiple Myeloma Patients Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted the XGEVA® (denosumab) supplemental Biologics...
THOUSAND OAKS, Calif. , June 19, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the U.S. Food and Drug Administration (FDA) has accepted the XGEVA ® (denosumab) supplemental Biologics License Application (sBLA) that seeks to expand the currently approved indicati
Read more →AMGNAmgen Presents Erenumab Data At The 59th Annual Scientific Meeting of the American Headache Society Amgen (NASDAQ:AMGN) today announced that it will present 19 scientific abstracts at the 59th Annual Scientific Meeting of the American Headache...
THOUSAND OAKS, Calif. , June 8, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will present 19 scientific abstracts at the 59 th Annual Scientific Meeting of the American Headache Society (AHS) held June 8-11 in Boston . These include a new analysis from a piv
Read more →AMGNAmgen To Present At The Goldman Sachs 38th Annual Global Healthcare Conference Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 38th Annual Global Healthcare Conference at 2:40 p.m. PT on Tuesday, June 13, 2017, in Rancho...
THOUSAND OAKS, Calif. , June 8, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Goldman Sachs 38 th Annual Global Healthcare Conference at 2:40 p.m. PT on Tuesday, June 13, 2017 , in Rancho Palos Verdes, Calif. Sean E. Harper , M.D., executive vice president of Res
Read more →AMGNAmgen And Allergan Announce FDA Advisory Committee Meeting To Review ABP 215, A Biosimilar Candidate To Bevacizumab Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE: AGN) today announced that the Oncologic Drugs Advisory Committee of the U.S. Food and Drug...
THOUSAND OAKS, Calif. , June 7, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and Allergan plc. (NYSE: AGN ) today announced that the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) will review data supporting the Biologics License Application (BLA)
Read more →AMGNAmgen Submits Regulatory Applications For Repatha® (evolocumab) Cardiovascular Outcomes Data In US And Europe Amgen (NASDAQ:AMGN) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration...
THOUSAND OAKS, Calif. , June 5, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) and a variation to the marketing authorization to the European Medicines
Read more →AMGNAmgen Presents New Data From Phase 3 XGEVA® (Denosumab) Study In Patients With Multiple Myeloma At ASCO 2017 Amgen (NASDAQ:AMGN) today announced new data from the XGEVA® (denosumab) Phase 3 '482 study, the largest international multiple myeloma trial ever...
THOUSAND OAKS, Calif. , June 4, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced new data from the XGEVA ® (denosumab) Phase 3 '482 study, the largest international multiple myeloma trial ever conducted. The study met its primary endpoint, demonstrating XGEVA is non-inf
Read more →AMGNAmgen Presents New Phase 2 Data On IMLYGIC® (Talimogene Laherparepvec) Investigational Combination At ASCO 2017 Amgen (NASDAQ:AMGN) today announced new data from the Phase 2 '264 study that demonstrated IMLYGIC® (talimogene laherparepvec) in combination with...
THOUSAND OAKS, Calif. , June 3, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced new data from the Phase 2 '264 study that demonstrated IMLYGIC ® (talimogene laherparepvec) in combination with the immune checkpoint inhibitor YERVOY ® (ipilimumab)* more than doubled obje
Read more →AMGNAmgen Showcases A Legacy Of Science, Innovation And Collaboration In Cambridge When Amgen (NASDAQ:AMGN) purchased a vacant parcel of land in the heart of Kendall Square in Cambridge, Mass. 25 years ago, the area was far from the ...
CAMBRIDGE, Mass. , June 2, 2017 /PRNewswire/ -- When Amgen (NASDAQ: AMGN ) purchased a vacant parcel of land in the heart of Kendall Square in Cambridge, Mass. 25 years ago, the area was far from the thriving biotechnology hub it has since become. In 2001, Amgen, a biotechnology
Read more →AMGNAmgen And UCB Announce Top-Line Phase 3 Data From Active-Comparator Study Of EVENITY™ (Romosozumab) In Postmenopausal Women With Osteoporosis Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced that the EVENITY™* (romosozumab) ARCH study met both primary endpoints and the...
THOUSAND OAKS, Calif. and BRUSSELS , May 21, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and UCB (Euronext Brussels: UCB) today announced that the EVENITY™* (romosozumab) ARCH study met both primary endpoints and the key secondary endpoint. At the primary analysis, treatment with
Read more →AMGNRepatha® (Evolocumab) Reduced Cardiovascular Events In Patients With Baseline LDL-C Levels Below Current Targets Amgen (NASDAQ:AMGN) today announced new data from the Repatha® (evolocumab) cardiovascular outcomes trial (FOURIER), which showed that Repatha...
THOUSAND OAKS, Calif. , May 20, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced new data from the Repatha ® (evolocumab) cardiovascular outcomes trial (FOURIER), which showed that Repatha consistently and safely reduced cardiovascular events in patients with establishe
Read more →AMGNAmgen Announces Voting Results of Annual Meeting of Stockholders Amgen (NASDAQ:AMGN) today announced voting results from the Company's Annual Meeting of Stockholders, held in Westlake Village, Calif. Approximately...
THOUSAND OAKS, Calif. , May 19, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced voting results from the Company's Annual Meeting of Stockholders, held in Westlake Village , Calif. Approximately 90 percent of outstanding shares were represented at the meeting. The dire
Read more →AMGNAmgen Submits Biologics License Application To The FDA For Erenumab Amgen (NASDAQ:AMGN) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for...
THOUSAND OAKS, Calif. , May 18, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for erenumab to prevent migraine. Erenumab is specifically designed to prevent migrain
Read more →AMGNAmgen To Present At The Bank Of America Merrill Lynch 2017 Health Care Conference Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch 2017 Health Care Conference at 8 a.m. PT on Wednesday, May 17, 2017. David W....
THOUSAND OAKS, Calif. , May 12, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Bank of America Merrill Lynch 2017 Health Care Conference at 8 a.m. PT on Wednesday, May 17, 2017 . David W. Meline , executive vice president and chief financial officer at Amgen, will
Read more →AMGNBLINATUMOMAB mejoró significativamente la supervivencia global en pacientes con leucemia linfoblástica aguda de precursores de células B en comparación con quimioterapia Amgen (NASDAQ: AMGN) anunció los resultados publicados en el New England Journal of Medicine sobre el estudio de Fase 3 TOWER que evaluó la eficacia...
THOUSAND OAKS, California , 4 de mayo de 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) anunció los resultados publicados en el New England Journal of Medicine sobre el estudio de Fase 3 TOWER que evaluó la eficacia de BLINATUMOMAB en comparación con la terapia estándar de tratamient
Read more →AMGNAmgen And Harvard Pilgrim Agree To First Cardiovascular Outcomes-Based Refund Contract For Repatha® (Evolocumab) Amgen (NASDAQ:AMGN) today announced from the World Medical Innovation Forum™ focused on cardiovascular disease that Harvard Pilgrim, a health...
THOUSAND OAKS, Calif. , May 2, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced from the World Medical Innovation Forum™ focused on cardiovascular disease that Harvard Pilgrim , a health services company providing healthcare coverage for nearly 2.7 million customers in
Read more →AMGNAmgen To Participate In The 2017 World Medical Innovation Forum™ Focused On Cardiovascular Disease Amgen (NASDAQ:AMGN) today announced plans to participate in the World Medical Innovation Forum™ focused on cardiovascular disease held May 1-3, 2017, ...
THOUSAND OAKS, Calif. , April 27, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced plans to participate in the World Medical Innovation Forum™ focused on cardiovascular disease held May 1-3, 2017 , in Boston . The World Medical Innovation Forum is a global gathering of
Read more →AMGNAmgen Reports First Quarter 2017 Financial Results Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2017. Key results include: Total revenues decreased 1 percent versus...
THOUSAND OAKS, Calif. , April 26, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced financial results for the first quarter of 2017. Key results include: "We are well positioned for the long term with our newer products demonstrating volume growth around the world and o
Read more →AMGNAmgen Announces Expanded Commercial Collaboration With Novartis For Erenumab In Migraine Amgen (NASDAQ:AMGN) today announced an expanded commercial collaboration with Novartis for erenumab, which is being investigated for the prevention...
THOUSAND OAKS, Calif. , April 24, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced an expanded commercial collaboration with Novartis for erenumab, which is being investigated for the prevention of migraine. This expanded commercial collaboration builds on a global neur
Read more →AMGNAmgen Announces Webcast Of 2017 First Quarter Financial Results Amgen (NASDAQ:AMGN) today announced that it will report its first quarter financial results on Wednesday, April 26, 2017, after the close of the U.S. ...
THOUSAND OAKS, Calif. , April 21, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will report its first quarter financial results on Wednesday, April 26, 2017 , after the close of the U.S. financial markets. The announcement will be followed by a conference cal
Read more →AMGNAmgen Launches Neulasta® (pegfilgrastim) Onpro® NARRATIVES Amgen (NASDAQ: AMGN) today announced the launch of Neulasta® (pegfilgrastim) Onpro® NARRATIVES, an online media resource about the value of a cancer...
THOUSAND OAKS, Calif. , April 18, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the launch of Neulasta ® (pegfilgrastim) Onpro ® NARRATIVES, an online media resource about the value of a cancer care team that provides comprehensive support for patients receiving stro
Read more →AMGNEstudio clínico comparativo cara a cara fase 3 demostró que carfilzomib mejoró significativamente la supervivencia global en comparación con bortezomib en pacientes con mieloma múltiple recurrente o refractario Amgen (NASDAQ:AMGN) anunció resultados positivos de supervivencia global (OS, por sus siglas en inglés) de un análisis intermedio del estudio cara a...
THOUSAND OAKS, California , 6 de abril de 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) anunció resultados positivos de supervivencia global (OS, por sus siglas en inglés) de un análisis intermedio del estudio cara a cara Fase 3 ENDEAVOR. El estudio cumplió con el criterio de valora
Read more →AMGNREPATHA demonstrou em estudos inéditos evitar 20% dos eventos cardiovasculares em pacientes de alto risco com segurança Durante o congresso do Colégio Americano de Cardiologia (ACC), que aconteceu de 17 a 19 de março deste ano, a biofarmacêutica Amgen, apresentou os...
SÃO PAULO, 6 de abril de 2017 /PRNewswire/ -- Durante o congresso do Colégio Americano de Cardiologia (ACC), que aconteceu de 17 a 19 de março deste ano, a biofarmacêutica Amgen, apresentou os resultados de dois estudos com seu medicamento Repatha ® que ajudaram a estabelecer uma
Read more →AMGNAmgen Submits Applications In The US And Europe To Expand Current Indication For XGEVA® (denosumab) To Include Patients With Multiple Myeloma Amgen (NASDAQ:AMGN) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration...
THOUSAND OAKS, Calif. , April 4, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) and an application for a variation to the marketing authorization to th
Read more →AMGNAmgen And UCB Report New Data At ENDO 2017 Examining The Option Of A Second Course Of Treatment With EVENITY™ (romosozumab) Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced results from the fourth year of a Phase 2 study showing the efficacy and safety...
THOUSAND OAKS, Calif. and BRUSSELS , April 1, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and UCB (Euronext Brussels: UCB) today announced results from the fourth year of a Phase 2 study showing the efficacy and safety of a second course of treatment with EVENITY™* (romosozumab),
Read more →AMGNAmgen To Highlight New Preclinical Data At The American Association For Cancer Research (AACR) Annual Meeting Amgen (NASDAQ:AMGN) today announced that new preclinical data from its oncology portfolio will be presented at the American Association for Cancer...
THOUSAND OAKS, Calif. , March 31, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that new preclinical data from its oncology portfolio will be presented at the American Association for Cancer Research (AACR) Annual Meeting from April 1-5, 2017 , in Washington, D.C. Th
Read more →AMGNEstudio de resultados demuestra que evolocumab reduce el colesterol LDL a niveles sin precedentes sin afectar la función cognitiva y reduce el riesgo de eventos cardiovasculares Amgen (NASDAQ:AMGN) anunció los resultados del estudio de eventos cardiovasculares FOURIER realizado en 27,564 pacientes, que demostró por primera...
THOUSAND OAKS, California , 30 de marzo de 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) anunció los resultados del estudio de eventos cardiovasculares FOURIER realizado en 27,564 pacientes, que demostró por primera vez que reducir al máximo los niveles de colesterol de lipoproteína
Read more →AMGNJournal Of Clinical Oncology Publishes Data On BLINCYTO® (Blinatumomab) In High-Risk Patients With Philadelphia Chromosome-Positive B-Cell Precursor Acute Lymphoblastic Leukemia Amgen (NASDAQ:AMGN) today announced that the Journal of Clinical Oncology published results from the Phase 2, open-label ALCANTARA study evaluating...
THOUSAND OAKS, Calif. , March 29, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the Journal of Clinical Oncology published results from the Phase 2, open-label ALCANTARA study evaluating the efficacy and safety of BLINCYTO ® (blinatumomab) in patients with Phila
Read more →AMGNFDA Grants Priority Review For Amgen's BLINCYTO® (blinatumomab) Supplemental Biologics License Application Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the supplemental Biologics...
THOUSAND OAKS, Calif. , March 29, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the supplemental Biologics License Application (sBLA) for BLINCYTO ® (blinatumomab) to include overall su
Read more →AMGNAmgen Awards Three Golden Tickets for LabCentral Residency Amgen (NASDAQ:AMGN) and LabCentral announced that Cocoon Biotech, Torus Therapeutics, and Holobiome are the winners of Golden Ticket awards....
CAMBRIDGE, Mass. , March 28, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and LabCentral announced that Cocoon Biotech, Torus Therapeutics, and Holobiome are the winners of Golden Ticket awards. Sponsored by Amgen, the Golden Ticket awards underwrite the cost of a lab bench for a s
Read more →AMGNEuropean Commission Approves AMGEVITA™ (Biosimilar Adalimumab) For The Treatment Of Certain Inflammatory Diseases Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has granted marketing authorization for AMGEVITA™ (biosimilar adalimumab1) in...
THOUSAND OAKS, Calif. , March 23, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the European Commission (EC) has granted marketing authorization for AMGEVITA™ (biosimilar adalimumab 1 ) in all available indications. AMGEVITA is authorized for the treatment of ce
Read more →AMGNAnalyses Of PCSK9 Inhibitor Prescription Rejection Rates Demonstrate Significant Access Barriers For Appropriate Patients Amgen (NASDAQ:AMGN) today announced new data from two studies that showed that for appropriate patients (on-label) in the U.S., the majority of...
THOUSAND OAKS, Calif. , March 19, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced new data from two studies that showed that for appropriate patients (on-label) in the U.S., the majority of prescription claims for PCSK9 inhibitors, such as Repatha ® (evolocumab), were
Read more →AMGNLowering LDL Levels With Repatha® (Evolocumab) Did Not Adversely Affect Cognitive Function In Landmark Phase 3 Study Amgen (NASDAQ:AMGN) today announced detailed results from the Repatha® (evolocumab) cognitive function trial (EBBINGHAUS) evaluating the impact on...
THOUSAND OAKS, Calif. , March 18, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced detailed results from the Repatha ® (evolocumab) cognitive function trial (EBBINGHAUS) evaluating the impact on cognitive function in 1,974 patients enrolled in the Repatha cardiovascular
Read more →AMGNLandmark Outcomes Study Shows That Repatha® (Evolocumab) Decreases LDL-C To Unprecedented Low Levels And Reduces Risk Of Cardiovascular Events With No New Safety Issues Amgen (NASDAQ:AMGN) today announced that the 27,564-patient Repatha® (evolocumab) cardiovascular outcomes study, FOURIER, established for the first...
THOUSAND OAKS, Calif. , March 17, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the 27,564-patient Repatha ® (evolocumab) cardiovascular outcomes study, FOURIER, established for the first time that maximally reducing low-density lipoprotein cholesterol (LDL-C) l
Read more →AMGNAmgen To Present At The Oppenheimer Global Health Care Conference Amgen (NASDAQ:AMGN) will present at the Oppenheimer Global Health Care Conference at 10:55 a.m. ET on Tuesday, March 21, 2017, in New York City. Sean ...
THOUSAND OAKS, Calif. , March 16, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Oppenheimer Global Health Care Conference at 10:55 a.m. ET on Tuesday, March 21, 2017 , in New York City . Sean E. Harper , M.D., executive vice president of Research and Development
Read more →AMGNRepatha® (Evolocumab) Four-Year Open-Label Follow-Up Study Published In 'JAMA Cardiology' Amgen (NASDAQ:AMGN) today announced that four-year follow-up results from the Repatha® (evolocumab) OSLER-1 study, the longest PCSK9 inhibitor...
THOUSAND OAKS, Calif. , March 14, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that four-year follow-up results from the Repatha ® (evolocumab) OSLER-1 study, the longest PCSK9 inhibitor clinical trial to date, were published in JAMA Cardiology . Repatha, when added
Read more →AMGNAmgen To Webcast Investor Meeting At Upcoming American College Of Cardiology Scientific Sessions Amgen (NASDAQ:AMGN) will host a webcast investor meeting at the American College of Cardiology (ACC.17) Scientific Sessions on Friday, March 17,...
THOUSAND OAKS, Calif. , March 14, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will host a webcast investor meeting at the American College of Cardiology (ACC.17) Scientific Sessions on Friday, March 17, 2017 , at noon ET . Sean E. Harper , M.D., executive vice president of Researc
Read more →AMGNRepatha® (Evolocumab) Demonstrates Reduced Need For Apheresis In Patients With High LDL Cholesterol In Phase 3 Study Amgen (NASDAQ: AMGN) today announced positive top-line results from a Phase 3 study evaluating Repatha® (evolocumab) in patients who were receiving...
THOUSAND OAKS, Calif. , March 13, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced positive top-line results from a Phase 3 study evaluating Repatha ® (evolocumab) in patients who were receiving apheresis to reduce low-density lipoprotein cholesterol (LDL-C). The study
Read more →AMGNAmgen Announces 2017 Second Quarter Dividend Amgen (NASDAQ: AMGN) today announced that its Board of Directors declared a $1.15 per share dividend for the second quarter of 2017. The dividend...
THOUSAND OAKS, Calif. , March 7, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that its Board of Directors declared a $1.15 per share dividend for the second quarter of 2017. The dividend will be paid on June 8, 2017 , to all stockholders of record as of the close of
Read more →AMGNAmgen Highlights Landmark Repatha® (Evolocumab) Cardiovascular Outcomes Study Amongst Data To Be Presented At ACC.17 Amgen (NASDAQ:AMGN) today announced that detailed results of the Repatha® (evolocumab) cardiovascular outcomes trial will be presented, as well as...
THOUSAND OAKS, Calif. , March 6, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that detailed results of the Repatha ® (evolocumab) cardiovascular outcomes trial will be presented, as well as new data from across the cardiovascular portfolio, at the American College o
Read more →AMGNAmgen Presents New Data From Phase 3 XGEVA® (denosumab) Study In Multiple Myeloma Patients At The 16th International Myeloma Workshop Amgen (NASDAQ:AMGN) today announced positive data from the Phase 3 '482 study, the largest international multiple myeloma trial ever conducted. In...
THOUSAND OAKS, Calif. , March 3, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced positive data from the Phase 3 '482 study, the largest international multiple myeloma trial ever conducted. In this study, XGEVA ® (denosumab) met the primary endpoint, demonstrating non-i
Read more →AMGNAmgen Presents Overall Survival Data From KYPROLIS® (carfilzomib) Phase 3 ENDEAVOR Trial At 16th International Myeloma Workshop Amgen (NASDAQ:AMGN) today announced positive results from a planned overall survival (OS) interim analysis of the Phase 3 head-to-head ENDEAVOR trial....
THOUSAND OAKS, Calif. , March 3, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced positive results from a planned overall survival (OS) interim analysis of the Phase 3 head-to-head ENDEAVOR trial. The study met the key secondary endpoint of OS, demonstrating that patien
Read more →AMGNAmgen To Present At The Cowen And Company 37th Annual Health Care Conference Amgen (NASDAQ:AMGN) will present at the Cowen and Company 37th Annual Health Care Conference at 11:20 a.m. ET on Wednesday, March 8, 2017, in Boston. ...
THOUSAND OAKS, Calif. , March 2, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Cowen and Company 37 th Annual Health Care Conference at 11:20 a.m. ET on Wednesday, March 8, 2017 , in Boston . Anthony C. Hooper , executive vice president of Global Commercial Opera
Read more →AMGNBLINCYTO® (blinatumomab) Significantly Improved Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Compared To Chemotherapy Amgen (NASDAQ:AMGN) today announced the New England Journal of Medicine published results from the Phase 3 TOWER study evaluating the efficacy of...
THOUSAND OAKS, Calif. , March 1, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the New England Journal of Medicine published results from the Phase 3 TOWER study evaluating the efficacy of BLINCYTO ® (blinatumomab) versus standard of care (SOC) chemotherapy in high-r
Read more →AMGNAmgen To Present New KYPROLIS® (Carfilzomib) And XGEVA® (Denosumab) Data At The 16th International Myeloma Workshop Amgen (NASDAQ:AMGN) today announced that new data from the KYPROLIS® (carfilzomib) and XGEVA® (denosumab) clinical development programs will be...
THOUSAND OAKS, Calif. , March 1, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that new data from the KYPROLIS ® (carfilzomib) and XGEVA ® (denosumab) clinical development programs will be presented at the 16 th International Myeloma Workshop (IMW), March 1-4, 2017 ,
Read more →AMGNPhase 3 Head-to-Head Trial Showed KYPROLIS® (Carfilzomib) Significantly Improved Overall Survival Compared To Velcade® (Bortezomib) In Relapsed Or Refractory Multiple Myeloma Patients Amgen (NASDAQ:AMGN) today announced positive results from a planned overall survival (OS) interim analysis of the Phase 3 head-to-head ENDEAVOR trial....
THOUSAND OAKS, Calif. , Feb. 28, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced positive results from a planned overall survival (OS) interim analysis of the Phase 3 head-to-head ENDEAVOR trial. The study met the key secondary endpoint of OS, demonstrating that patien
Read more →AMGNRepatha® (Evolocumab) Receives European Commission Approval For New 420 mg Single-Dose Delivery Option Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has adopted a decision to change the Repatha® (evolocumab) marketing...
"Amgen is committed to advancing care and improving the lives of patients with cardiovascular disease," said Sean E. Harper , M.D., executive vice president of Research and Development at Amgen. "We are proud to bring this dosing alternative to patients in Europe , providing anot
Read more →AMGNAmgen Submits Supplemental Biologics License Application For BLINCYTO® (Blinatumomab) In Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia Amgen (NASDAQ:AMGN) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration...
THOUSAND OAKS, Calif. , Feb. 14, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for BLINCYTO ® (blinatumomab) to include overall survival (OS) data fro
Read more →AMGNAmgen anuncia que evolocumab disminuyó significativamente el riesgo de eventos cardiovasculares en el estudio FOURIER Amgen (NASDAQ: AMGN) anunció que el estudio FOURIER, en el que se evaluó la eficacia de evolocumab para reducir el riesgo de eventos cardiovasculares ...
THOUSAND OAKS, California , 8 de febrero de 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) anunció que el estudio FOURIER, en el que se evaluó la eficacia de evolocumab para reducir el riesgo de eventos cardiovasculares en pacientes con enfermedad cardiovascular aterosclerótica clíni
Read more →AMGNFDA Approves Amgen's Parsabiv™ (Etelcalcetide), First New Treatment In More Than A Decade For Secondary Hyperparathyroidism In Adult Patients On Hemodialysis Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Parsabiv™ (etelcalcetide) for the treatment of...
THOUSAND OAKS, Calif. , Feb. 7, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the U.S. Food and Drug Administration (FDA) has approved Parsabiv™ (etelcalcetide) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney diseas
Read more →AMGNAmgen Announces Appointment of Charles M. Holley Jr. to Board of Directors Amgen (NASDAQ:AMGN) today announced the appointment of Charles M. Holley Jr. to the Amgen Board of Directors. Mr. Holley will serve as a member of...
THOUSAND OAKS, Calif. , Feb. 3, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the appointment of Charles M. Holley Jr. to the Amgen Board of Directors. Mr. Holley will serve as a member of the Audit Committee and the Corporate Responsibility and Compliance Committee
Read more →AMGNAmgen Reports Fourth Quarter And Full Year 2016 Financial Results Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2016. Key results include: For the fourth quarter,...
THOUSAND OAKS, Calif. , Feb. 2, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced financial results for the fourth quarter and full year of 2016. Key results include: "We finished the year with strong operating performance," said Robert A. Bradway , chairman and chief e
Read more →AMGNAmgen Announces Repatha® (Evolocumab) Significantly Reduced The Risk Of Cardiovascular Events In FOURIER Outcomes Study Amgen (NASDAQ:AMGN) today announced that the FOURIER trial evaluating whether Repatha® (evolocumab) reduces the risk of cardiovascular events in...
THOUSAND OAKS, Calif. , Feb. 2, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the FOURIER trial evaluating whether Repatha ® (evolocumab) reduces the risk of cardiovascular events in patients with clinically evident atherosclerotic cardiovascular disease (ASCVD)
Read more →AMGNAmgen Announces Webcast of 2016 Fourth Quarter and Full Year Financial Results Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2016 financial results on Thursday, Feb. 2, 2017, after the...
THOUSAND OAKS, Calif. , Jan. 30, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will report its fourth quarter and full year 2016 financial results on Thursday, Feb. 2, 2017 , after the close of the U.S. financial markets. The announcement will be followed by
Read more →AMGNAmgen Receives Positive CHMP Opinion For ABP 501 (Biosimilar Adalimumab) For The Treatment Of Certain Inflammatory Diseases Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted ...
THOUSAND OAKS, Calif. , Jan. 27, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the Marketing Authorization of ABP 501 (biosimilar
Read more →AMGNStudy Results Published in the Journal of the American Medical Association Show Amgen's Parsabiv™ (Etelcalcetide) Significantly Reduced Serum Parathyroid Hormone in Adults With Secondary Hyperparathyroidism on Hemodialysis Amgen (NASDAQ:AMGN) today announced the Journal of the American Medical Association (JAMA) publication of findings from three Phase 3 studies of...
THOUSAND OAKS, Calif. , Jan. 10, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the Journal of the American Medical Association ( JAMA ) publication of findings from three Phase 3 studies of Parsabiv™ (etelcalcetide), an investigational intravenous calcimimetic agent
Read more →AMGNAmgen Statement on January 9, 2017, U.S. District Court Decision Amgen (NASDAQ:AMGN) issued the following statement regarding the U.S. District Court of Delaware's denial of Sanofi and Regeneron's motion to stay...
THOUSAND OAKS, Calif. , Jan. 9, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) issued the following statement regarding the U.S. District Court of Delaware's denial of Sanofi and Regeneron's motion to stay the injunction pending the appeal in the ongoing PCSK9 patent litigation: Tod
Read more →AMGNAmgen And DaVita Enter Into New Sourcing And Supply Agreement Amgen (NASDAQ:AMGN) today announced it has entered into a six-year Sourcing and Supply Agreement with DaVita Inc. This is a continuation of Amgen's...
THOUSAND OAKS, Calif. , Jan. 9, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced it has entered into a six-year Sourcing and Supply Agreement with DaVita Inc. This is a continuation of Amgen's long-term relationship with DaVita that is focused on serving dialysis patien
Read more →AMGNAmgen and Immatics Enter Strategic Collaboration to Develop Novel Bispecific Cancer Immunotherapies Amgen (NASDAQ:AMGN) and Immatics Biotechnologies GmbH, a leading company in the field of cancer immunotherapy, today announced a research...
THOUSAND OAKS, Calif. and TUEBINGEN, Germany , Jan. 9, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and Immatics Biotechnologies GmbH, a leading company in the field of cancer immunotherapy, today announced a research collaboration and exclusive license agreement to develop next-ge
Read more →AMGNCourt Grants Permanent Injunction For Infringement Of Amgen's Repatha® Patents Amgen (NASDAQ:AMGN) today announced that the United States District Court in Delaware granted Amgen's request for a permanent injunction prohibiting...
Amgen has the ability to supply all potential Repatha patients and will work to ensure a smooth transition for patients who wish to switch to Repatha. About Repatha ® (evolocumab) Repatha ® (evolocumab) is a human monoclonal antibody that inhibits proprotein convertase subtilisi
Read more →AMGNAmgen To Present At The 35th Annual J.P. Morgan Healthcare Conference Amgen (NASDAQ:AMGN) will present at the 35th Annual J.P. Morgan Healthcare Conference at 2 p.m. PT on Monday, Jan. 9, 2017, in San Francisco. Robert...
THOUSAND OAKS, Calif. , Jan. 4, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the 35 th Annual J.P. Morgan Healthcare Conference at 2 p.m. PT on Monday, Jan. 9, 2017 , in San Francisco . Robert A. Bradway , chairman and chief executive officer at Amgen, will present
Read more →AMGNAmgen Announces 15 Percent Increase In 2017 First Quarter Dividend Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.15 per share dividend for the first quarter of 2017. The dividend will...
THOUSAND OAKS, Calif. , Dec. 20, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that its Board of Directors declared a $1.15 per share dividend for the first quarter of 2017. The dividend will be paid on March 8, 2017 , to all stockholders of record as of the close of
Read more →AMGNAmgen And UCB Announce Submission Of Application For Investigational Osteoporosis Medication Romosozumab In Japan Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced that an application seeking marketing approval of romosozumab for the treatment...
THOUSAND OAKS, Calif. and BRUSSELS , Dec. 19, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and UCB (Euronext Brussels: UCB) today announced that an application seeking marketing approval of romosozumab for the treatment of osteoporosis for those at high risk of fracture has been su
Read more →AMGNNew Repatha® (evolocumab) Dose Delivery Option Receives Positive CHMP Opinion Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted ...
THOUSAND OAKS, Calif. , Dec. 16, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for an extension to the marketing authorization of a ne
Read more →AMGNAmgen To Present At The Citi 2016 Global Healthcare Conference Amgen (NASDAQ: AMGN) will present at the Citi 2016 Global Healthcare Conference at 10:15 a.m. ET on Wednesday, Dec. 7, 2016, in New York City. David...
THOUSAND OAKS, Calif. , Dec. 1, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Citi 2016 Global Healthcare Conference at 10:15 a.m. ET on Wednesday, Dec. 7, 2016 , in New York City . David W. Meline , executive vice president and chief financial officer at Amgen,
Read more →AMGNAmgen Announces Presentation Of New Data In Acute Lymphoblastic Leukemia, Multiple Myeloma And Immune Thrombocytopenia At ASH 2016 Amgen (NASDAQ:AMGN) today announced new data will be presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH), ...
THOUSAND OAKS, Calif. , Nov. 30, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced new data will be presented at the 58 th Annual Meeting and Exposition of the American Society of Hematology (ASH), Dec. 3 – 6, 2016, in San Diego . "The totality of data for our medicines
Read more →AMGNThe Lancet Publishes Results From COSMIC-HF Trial Showing Omecamtiv Mecarbil Significantly Improved Cardiac Function In Patients With Chronic Heart Failure Amgen (NASDAQ:AMGN) and Cytokinetics, Inc. (NASDAQ:CYTK) today announced The Lancet published results from a Phase 2 clinical trial evaluating...
THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif. , Nov. 30, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and Cytokinetics, Inc. (NASDAQ: CYTK ) today announced The Lancet published results from a Phase 2 clinical trial evaluating omecamtiv mecarbil in patients with chronic hea
Read more →AMGNAmgen Announces Erenumab Significantly Reduces Monthly Migraine Days In Patients With Episodic Migraine In Second Phase 3 Study Amgen (NASDAQ:AMGN) today announced positive top-line results for erenumab from a global Phase 3, randomized, double-blind, placebo-controlled STudy...
THOUSAND OAKS, Calif. , Nov. 16, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced positive top-line results for erenumab from a global Phase 3, randomized, double-blind, placebo-controlled ST udy to evaluate the efficacy and safety of erenumab in mig R a I ne pre VE nti
Read more →AMGNRepatha® (Evolocumab) Regresses Atherosclerosis In Patients With Coronary Artery Disease Amgen (NASDAQ:AMGN) today announced that adding Repatha® (evolocumab) to optimized statin therapy resulted in statistically significant regression of ...
THOUSAND OAKS, Calif. , Nov. 15, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that adding Repatha ® (evolocumab) to optimized statin therapy resulted in statistically significant regression of atherosclerosis in patients with coronary artery disease (CAD). The detai
Read more →AMGNAmgen And Allergan Submit Biosimilar Biologics License Application For ABP 215 To U.S. Food And Drug Administration Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug...
THOUSAND OAKS, Calif. , Nov. 15, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and Allergan plc. (NYSE: AGN ) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ABP 215, a biosimilar candidate to Avastin ® (beva
Read more →AMGNNew 'Ten To Watch' List Highlights Top Amgen Scholars Poised To Impact The Future Of Science And Medicine In recognition of the Amgen Scholars Program's 10th anniversary, the Amgen Foundation announced the Ten To Watch, a list highlighting the best and...
THOUSAND OAKS, Calif. , Nov. 14, 2016 /PRNewswire/ -- In recognition of the Amgen Scholars Program 's 10 th anniversary, the Amgen Foundation announced the Ten To Watch, a list highlighting the best and brightest up-and-comers in science and medicine. Selected from more than 3,00
Read more →AMGNResults From Phase 3 BRIDGE Study Show Romosozumab Significantly Increases Bone Mineral Density In Men With Osteoporosis Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced results from the Phase 3 BRIDGE study showing that in men with osteoporosis, the ...
THOUSAND OAKS, Calif. and BRUSSELS , Nov. 12, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and UCB (Euronext Brussels: UCB) today announced results from the Phase 3 BRIDGE study showing that in men with osteoporosis, the investigational agent romosozumab resulted in significant bon
Read more →AMGNEuropean Commission Approves Parsabiv™ (etelcalcetide) For The Treatment Of Secondary Hyperparathyroidism In Adults On Hemodialysis Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has granted marketing authorization for Parsabiv™ (etelcalcetide) for the...
THOUSAND OAKS, Calif. , Nov. 11, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the European Commission (EC) has granted marketing authorization for Parsabiv™ (etelcalcetide) for the treatment of secondary hyperparathyroidism (sHPT) in adult patients with chronic
Read more →AMGNAmgen Announces Collaboration With Janssen To Co-Fund Studies With KYPROLIS® (Carfilzomib) And DARZALEX® (Daratumumab) In Patients With Multiple Myeloma Amgen (NASDAQ:AMGN) today announced a collaboration with Janssen Biotech, Inc. to evaluate the combination of Amgen's KYPROLIS® (carfilzomib) and...
THOUSAND OAKS, Calif. , Nov. 10, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced a collaboration with Janssen Biotech, Inc. to evaluate the combination of Amgen's KYPROLIS ® (carfilzomib) and Janssen's DARZALEX ® (daratumumab) in multiple clinical studies in patients w
Read more →AMGNAmgen To Webcast Investor Meeting At Upcoming American Heart Association Scientific Sessions 2016 Amgen (NASDAQ:AMGN) will host a webcast investor meeting at the American Heart Association (AHA) Scientific Sessions 2016 on Tuesday, Nov. 15, 2016,...
THOUSAND OAKS, Calif. , Nov. 10, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will host a webcast investor meeting at the American Heart Association (AHA) Scientific Sessions 2016 on Tuesday, Nov. 15, 2016 , at 7 p.m. CT . Sean E. Harper , M.D., executive vice president of Research
Read more →AMGNData To Be Presented At ACR/ARHP 2016 Annual Meeting Show Amgen's Ongoing Commitment To Therapies For Patients With Serious Inflammatory And Bone Diseases Amgen (NASDAQ:AMGN) today announced that it will present data from multiple studies related to Enbrel® (etanercept), Prolia® (denosumab) and...
THOUSAND OAKS, Calif. , Nov. 7, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will present data from multiple studies related to Enbrel ® (etanercept), Prolia ® (denosumab) and AMJEVITA ™ (adalimumab-atto), as well as investigational candidates, including ABP
Read more →AMGNFDA Approves Expanded Use Of ENBREL® (etanercept) To Treat Children With Chronic Moderate-To-Severe Plaque Psoriasis Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application...
THOUSAND OAKS, Calif. , Nov. 4, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the expanded use of ENBREL ® (etanercept), making it the first and on
Read more →AMGNAmgen To Present At The Credit Suisse 25th Annual Healthcare Conference Amgen (NASDAQ: AMGN) will present at the Credit Suisse 25th Annual Healthcare Conference at 9 a.m. MT on Tuesday, Nov. 8, 2016, in Scottsdale, Ariz....
THOUSAND OAKS, Calif. , Nov. 3, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Credit Suisse 25 th Annual Healthcare Conference at 9 a.m. MT on Tuesday, Nov. 8, 2016 , in Scottsdale, Ariz. David W. Meline , executive vice president and chief financial officer at A
Read more →AMGNAmgen Appoints Lori Johnston As Senior Vice President, Human Resources Amgen (NASDAQ:AMGN) today announced the appointment of Lori Johnston to senior vice president, Human Resources, effective Dec. 9, 2016. Johnston will ...
THOUSAND OAKS, Calif. , Nov. 2, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the appointment of Lori Johnston to senior vice president, Human Resources, effective Dec. 9, 2016 . Johnston will be responsible for overseeing the global Human Resources function and rep
Read more →AMGNAmgen Highlights Repatha® (Evolocumab) GLAGOV Imaging Study Amongst Data To Be Presented At AHA Scientific Sessions 2016 Amgen (NASDAQ:AMGN) today announced that it will present detailed results from the Phase 3 coronary intravascular imaging trial, the GLAGOV (GLobal...
THOUSAND OAKS, Calif. , Oct. 31, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will present detailed results from the Phase 3 coronary intravascular imaging trial, the GLAGOV ( GL obal A ssessment of Plaque Re G ression with a PCSK9 Antib O dy as Measured by
Read more →AMGNAmgen Reports Third Quarter 2016 Financial Results Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2016. Key results include: Revenues increased 2 percent versus the...
THOUSAND OAKS, Calif. , Oct. 27, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced financial results for the third quarter of 2016. Key results include: "Our business is performing well and our double-digit earnings per share growth reflects the progress we have made th
Read more →AMGNAmgen To Invest In Israel-Based eHealth Ventures Amgen (Europe) GmbH, an affiliate of Amgen Inc. (NASDAQ:AMGN) (collectively, Amgen ) today announced an investment in eHealth Ventures, an...
ZUG, Switzerland , Oct. 25, 2016 /PRNewswire/ -- Amgen ( Europe ) GmbH, an affiliate of Amgen Inc. (NASDAQ: AMGN ) (collectively, "Amgen") today announced an investment in eHealth Ventures, an Israel -based digital health incubator. The investment reflects Amgen's commitment to s
Read more →AMGNAmgen Announces Webcast Of 2016 Third Quarter Financial Results Amgen (NASDAQ:AMGN) today announced that it will report its third quarter financial results on Thursday, Oct. 27, 2016, after the close of the U.S....
THOUSAND OAKS, Calif. , Oct. 24, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will report its third quarter financial results on Thursday, Oct. 27, 2016 , after the close of the U.S. financial markets. The announcement will be followed by a conference call w
Read more →AMGNAmgen Announces Positive Top-Line Results From XGEVA® (Denosumab) Phase 3 Trial For Delay Of Bone Complications In Multiple Myeloma Patients Amgen (NASDAQ:AMGN) today announced that a Phase 3 study evaluating XGEVA® (denosumab) versus zoledronic acid met the primary endpoint of...
THOUSAND OAKS, Calif. , Oct. 20, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that a Phase 3 study evaluating XGEVA ® (denosumab) versus zoledronic acid met the primary endpoint of non-inferiority (hazard ratio = 0.98, 95 percent CI, 0.85 - 1.14) in delaying the tim
Read more →AMGNAmgen Announces 2016 Fourth Quarter Dividend Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.00 per share dividend for the fourth quarter of 2016. The dividend will ...
THOUSAND OAKS, Calif. , Oct. 14, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that its Board of Directors declared a $1.00 per share dividend for the fourth quarter of 2016. The dividend will be paid on Dec. 8, 2016 , to all stockholders of record as of the close of
Read more →AMGNAmgen Announces Appointment Of Ellen J. Kullman To Board Of Directors Amgen (NASDAQ:AMGN) today announced the appointment of Ellen J. Kullman to the Amgen Board of Directors, effective Oct. 14, 2016. Ms. Kullman will...
THOUSAND OAKS, Calif. , Oct. 14, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the appointment of Ellen J. Kullman to the Amgen Board of Directors, effective Oct. 14 , 2016. Ms. Kullman will serve as a member of the Audit Committee and the Governance and Nominating C
Read more →AMGNNew Retrospective Analyses Confirm Vectibix® (Panitumumab) Treatment Provided Survival Benefit Over Chemotherapy With Or Without Bevacizumab In Metastatic Colorectal Cancer Patients With Tumors Of Left-Sided Origin Amgen (NASDAQ:AMGN) today announced results from new retrospective analyses of key studies with Vectibix® (panitumumab) in metastatic colorectal...
THOUSAND OAKS, Calif. , Oct. 10, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced results from new retrospective analyses of key studies with Vectibix ® (panitumumab) in metastatic colorectal cancer (mCRC) patients. The retrospective analysis of the PEAK study in mCRC p
Read more →AMGNNew Amgen Data In Melanoma And Metastatic Colorectal Cancer To Be Presented At The European Society For Medical Oncology 2016 Congress Amgen (NASDAQ:AMGN) today announced that new data on IMLYGIC® (talimogene laherparepvec) in combination with an immune checkpoint inhibitor and...
THOUSAND OAKS, Calif. , Oct. 5, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that new data on IMLYGIC ® (talimogene laherparepvec) in combination with an immune checkpoint inhibitor and results from retrospective analyses on Vectibix ® (panitumumab) will be presente
Read more →AMGNAmgen To Participate In Citi Biotech R&D Conference Call Amgen (NASDAQ:AMGN) will participate in a call hosted by Citi at 8 a.m. PT on Friday, Oct. 7, 2016. Sean E. Harper, M.D., executive vice president of ...
THOUSAND OAKS, Calif. , Oct. 4, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will participate in a call hosted by Citi at 8 a.m. PT on Friday, Oct. 7, 2016 . Sean E. Harper , M.D., executive vice president of Research and Development (R&D) at Amgen, will discuss recent developments
Read more →AMGNStudy Results Published In Journal of Clinical Oncology Show BLINCYTO® (blinatumomab) Induced Complete Remission In Heavily Pretreated Pediatric Patients With Philadelphia Chromosome-Negative Relapsed Or Refractory B-cell Precursor Acute Lymphoblastic Leukemia Amgen (NASDAQ:AMGN) today announced that the Journal of Clinical Oncology (JCO) published results from the Phase 1/2 '205 single-arm trial evaluating ...
THOUSAND OAKS, Calif. , Oct. 3, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the Journal of Clinical Oncology ( JCO ) published results from the Phase 1/2 '205 single-arm trial evaluating BLINCYTO ® (blinatumomab) in pediatric patients with Philadelphia chromos
Read more →AMGNAmgen And Arrowhead Pharmaceuticals Announce Two Cardiovascular Collaborations Amgen (NASDAQ: AMGN) and Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced two license and collaboration agreements to develop and...
THOUSAND OAKS, Calif. and PASADENA, Calif. , Sept. 29, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR ) today announced two license and collaboration agreements to develop and commercialize RNA interference (RNAi) therapies for cardiov
Read more →AMGNAmgen Announces Erenumab Significantly Reduces Monthly Migraine Days In Patients With Episodic Migraine In First Phase 3 Study Amgen (NASDAQ:AMGN) today announced positive top-line results for erenumab (AMG 334) from A Phase 3, RandomIzed, double-blind, placebo-controlled...
THOUSAND OAKS, Calif. , Sept. 28, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced positive top-line results for erenumab (AMG 334) from A Phase 3, R andom I zed, double-blind, placebo-controlled S tudy to E valuate the efficacy and safety of erenumab in migraine preven
Read more →AMGNAmgen Announces Top-Line Results From Phase 3 KYPROLIS® (Carfilzomib) CLARION Study In Newly Diagnosed Multiple Myeloma Patients Amgen (NASDAQ:AMGN) today announced top-line results of the Phase 3 CLARION trial, which evaluated an investigational regimen of KYPROLIS®...
THOUSAND OAKS, Calif. , Sept. 27, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced top-line results of the Phase 3 CLARION trial, which evaluated an investigational regimen of KYPROLIS ® (carfilzomib), melphalan and prednisone (KMP) versus Velcade ® (bortezomib), melpha
Read more →AMGNAmgen Opens Nomination Process For LabCentral Residency Amgen (NASDAQ: AMGN) today announced that the nomination process to submit proposals to receive an Amgen-sponsored LabCentral Golden Ticket is open...
CAMBRIDGE, Mass. , Sept. 26, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the nomination process to submit proposals to receive an Amgen-sponsored LabCentral Golden Ticket is open for interested life-sciences and biotech startup companies in Massachusetts . Lab
Read more →AMGNAmgen And UCB Announce U.S. FDA Acceptance Of Biologics License Application For Romosozumab Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the...
THOUSAND OAKS, Calif. and BRUSSELS , Sept. 26, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and UCB (Euronext Brussels: UCB) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for romosozumab, an investig
Read more →AMGNFDA Approves Amgen's AMJEVITA™ (Adalimumab-Atto) For Treatment Of Seven Inflammatory Diseases Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved AMJEVITA™ (adalimumab-atto) across all eligible...
THOUSAND OAKS, Calif. , Sept. 23, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the U.S. Food and Drug Administration (FDA) has approved AMJEVITA™ (adalimumab-atto) across all eligible indications of the reference product, Humira ® (adalimumab). AMJEVITA is the
Read more →AMGNAmgen anuncia resultados preliminares positivos do estudo de imagem GLAGOV de fase 3 com Repatha (evolocumabe) Amgen (NASDAQ:AMGN) anunciou hoje que o estudo de Fase 3 GLAGOV (GLobal Assessment of Plaque ReGression with a PCSK9 AntibOdy as Measured by...
SÃO PAULO, 22 de setembro de 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) anunciou hoje que o estudo de Fase 3 GLAGOV ( GL obal A ssessment of Plaque Re G ression with a PCSK9 Antib O dy as Measured by Intra V ascular Ultrasound [Avaliação Global de Regressão de Placas com um Antic
Read more →AMGNAmgen Announces Positive Top-Line Results From Phase 3 GLAGOV Imaging Study Of Repatha® (Evolocumab) Amgen (NASDAQ:AMGN) today announced that the Phase 3 GLAGOV (GLobal Assessment of Plaque ReGression with a PCSK9 AntibOdy as Measured by...
THOUSAND OAKS, Calif. , Sept. 20, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the Phase 3 GLAGOV ( GL obal A ssessment of Plaque Re G ression with a PCSK9 Antib O dy as Measured by Intra V ascular Ultrasound) trial evaluating the effect of Repatha ® (evolocuma
Read more →AMGNResults From Phase 3 FRAME Study Of Romosozumab Showed Significant Reductions In Both New Vertebral And Clinical Fractures In Postmenopausal Women With Osteoporosis Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today announced findings from the FRAME study showing that the investigational agent...
THOUSAND OAKS, Calif. and BRUSSELS , Sept. 18, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and UCB (Euronext Brussels: UCB) today announced findings from the FRAME study showing that the investigational agent romosozumab significantly reduced the incidence of new vertebral fractur
Read more →AMGNAmgen Receives Positive CHMP Opinion For Parsabiv™ (Etelcalcetide) For The Treatment Of Secondary Hyperparathyroidism In Adult Patients With Chronic Kidney Disease On Hemodialysis Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted ...
THOUSAND OAKS, Calif. , Sept. 16, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the Marketing Authorization of Parsabiv™ (etelcalc
Read more →AMGNAmgen Presents Positive Data At EHMTIC 2016 Demonstrating Erenumab Significantly Reduces Monthly Migraine Days In Patients With Chronic Migraine Amgen (NASDAQ:AMGN) today announced detailed global Phase 2 results showing erenumab demonstrated a statistically significant reduction in monthly...
THOUSAND OAKS, Calif. , Sept. 15, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced detailed global Phase 2 results showing erenumab demonstrated a statistically significant reduction in monthly migraine days compared with placebo in patients with chronic migraine. The d
Read more →AMGNAmgen To Webcast Investor Call Amgen (NASDAQ:AMGN) today announced that the Company will host a webcast call for the investment community on Monday, Sept. 19, 2016, at 8:30 a.m. PT....
THOUSAND OAKS, Calif. , Sept. 14, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the Company will host a webcast call for the investment community on Monday, Sept. 19, 2016 , at 8:30 a.m. PT . Sean E. Harper , M.D., executive vice president of Research and Develo
Read more →AMGNAmgen to Present at the Bank of America Merrill Lynch Global Healthcare Conference Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 9:45 a.m. GMT on Friday, Sept. 16, 2016, in...
THOUSAND OAKS, Calif. , Sept. 13, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 9:45 a.m. GMT on Friday, Sept. 16, 2016 , in London . David W. Meline , executive vice president and chief financial offi
Read more →AMGNAmgen To Present At The Morgan Stanley Global Healthcare Conference Amgen (NASDAQ:AMGN) will present at the Morgan Stanley Global Healthcare Conference at 10:30 a.m. ET on Wednesday, Sept. 14, 2016, in New York City....
THOUSAND OAKS, Calif. , Sept. 8, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Morgan Stanley Global Healthcare Conference at 10:30 a.m. ET on Wednesday, Sept. 14, 2016 , in New York City . Robert A. Bradway , chairman and chief executive officer at Amgen, will p
Read more →AMGNAmgen to Highlight 19 Abstracts on Osteoporosis Disease State and Treatment at American Society for Bone and Mineral Research Annual Meeting Amgen (NASDAQ:AMGN) today announced that it will present data from multiple studies for its investigational agent romosozumab and for Prolia®...
THOUSAND OAKS, Calif. , Sept. 7, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will present data from multiple studies for its investigational agent romosozumab and for Prolia ® (denosumab) at the Annual Meeting of the American Society for Bone and Mineral Re
Read more →AMGNAmgen Obtains Global Development And Commercial Rights From Boehringer Ingelheim For Investigational BiTE® Immuno-Oncology Drug For Multiple Myeloma Amgen (NASDAQ:AMGN) and Boehringer Ingelheim today announced that Amgen has acquired global development and commercial rights from Boehringer...
THOUSAND OAKS, Calif. and INGELHEIM, Germany , Sept. 1, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and Boehringer Ingelheim today announced that Amgen has acquired global development and commercial rights from Boehringer Ingelheim for BI 836908 (AMG 420), a bispecific T cell enga
Read more →AMGNAmgen And Servier Extend Omecamtiv Mecarbil Collaboration In Chronic Heart Failure Amgen (NASDAQ:AMGN) and Servier today announced an advancement in their cardiovascular collaboration, with Servier's decision to exercise its option...
Under the terms of the agreement, Servier will make a $10 million option exercise payment, as well as future milestone and royalty payments, to Amgen. Servier will assume a share of the development costs. "We are very pleased to strengthen our collaboration with Servier and for
Read more →AMGNFDA Approves BLINCYTO® (blinatumomab) For Use In Pediatric Patients With Philadelphia Chromosome-Negative Relapsed Or Refractory B-cell Precursor Acute Lymphoblastic Leukemia Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application...
THOUSAND OAKS, Calif. , Sept. 1, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for BLINCYTO ® (blinatumomab) to include new data supporting the treatme
Read more →AMGNAmgen Announces Positive Top-Line Results From Phase 3 Study Of Prolia® (Denosumab) In Patients Receiving Glucocorticoid Therapy Amgen (NASDAQ: AMGN) today announced positive top-line results from the primary analysis conducted in a Phase 3 randomized, double-blind,...
THOUSAND OAKS, Calif. , Aug. 29, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced positive top-line results from the primary analysis conducted in a Phase 3 randomized, double-blind, double-dummy, active-controlled study evaluating the safety and efficacy of Prolia ® (d
Read more →AMGNNew Repatha® (evolocumab) Analyses Show Efficacy And Safety Across Risk Groups In Results Presented At ESC Congress 2016 Amgen (NASDAQ:AMGN) today announced data presented at the European Society of Cardiology (ESC) Congress 2016 showing Repatha® (evolocumab)...
THOUSAND OAKS, Calif. , Aug. 28, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced data presented at the European Society of Cardiology (ESC) Congress 2016 showing Repatha ® (evolocumab) consistently reduced low-density lipoprotein cholesterol (LDL-C) in patients across
Read more →AMGNAmgen Provides Update On Status Of Parsabiv™ (Etelcalcetide) New Drug Application (NDA) Submitted To The U.S. Food And Drug Administration (FDA) Amgen (Nasdaq: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for the New Drug...
THOUSAND OAKS, Calif. , Aug. 24, 2016 /PRNewswire/ -- Amgen (Nasdaq: AMGN ) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for the New Drug Application (NDA) for Parsabiv ™ (etelcalcetide) for the treatment of secondary hype
Read more →AMGNNew Data Add To Understanding Of Repatha® (Evolocumab) In Multiple Patient Populations Amgen (NASDAQ:AMGN) today announced that it will present 11 abstracts at the upcoming European Society of Cardiology (ESC) Congress 2016, being held...
THOUSAND OAKS, Calif. , Aug. 22, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will present 11 abstracts at the upcoming European Society of Cardiology (ESC) Congress 2016, being held Aug. 27-31 in Rome . Abstracts include data evaluating Repatha ® (evolocum
Read more →AMGNREPATHA (evolocumabe): primeiro medicamento de uma classe inédita, para tratar colesterol alto de difícil controle, a ser aprovado pela Anvisa Aprovado pela Anvisa em abril, RepathaTM (evolocumabe), acaba de ser lançado no mercado brasileiro. Trata-se do primeiro medicamento de uma nova...
SÃO PAULO, 18 de agosto de 2016 /PRNewswire/ -- Aprovado pela Anvisa em abril, Repatha TM (evolocumabe), acaba de ser lançado no mercado brasileiro. Trata-se do primeiro medicamento de uma nova classe para tratar colesterol alto de difícil controle: a dos inibidores de PCSK9 (pró
Read more →AMGNAmgen And Advaxis Enter Global Cancer Immunotherapies Collaboration Amgen (NASDAQ:AMGN) and Advaxis, Inc. (NASDAQ:ADXS) today announced a global agreement for the development and commercialization of Advaxis'...
THOUSAND OAKS, Calif. and PRINCETON, N.J. , Aug. 2, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and Advaxis, Inc. (NASDAQ: ADXS ) today announced a global agreement for the development and commercialization of Advaxis' ADXS-NEO, a novel, preclinical investigational cancer immunoth
Read more →AMGNAmgen Reports Second Quarter 2016 Financial Results Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2016. Key results include: Revenues increased 6 percent versus the...
THOUSAND OAKS, Calif. , July 27, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced financial results for the second quarter of 2016. Key results include: "We delivered another strong quarter and are on track to meet or exceed our long-term objectives," said Robert A. Br
Read more →AMGNAmgen Announces Webcast Of 2016 Second Quarter Financial Results Amgen (NASDAQ:AMGN) today announced that it will report its second quarter financial results on Wednesday, July 27, 2016, after the close of the U.S. ...
THOUSAND OAKS, Calif. , July 22, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will report its second quarter financial results on Wednesday, July 27, 2016 , after the close of the U.S. financial markets. The announcement will be followed by a conference call
Read more →AMGNAmgen Announces 2016 Third Quarter Dividend Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.00 per share dividend for the third quarter of 2016. The dividend will...
THOUSAND OAKS, Calif. , July 22, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that its Board of Directors declared a $1.00 per share dividend for the third quarter of 2016. The dividend will be paid on Sept. 8, 2016 , to all stockholders of record as of the close of
Read more →AMGNAmgen And UCB Submit Biologics License Application For Romosozumab To The FDA Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and...
THOUSAND OAKS, Calif. and BRUSSELS , July 22, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and UCB (Euronext Brussels: UCB) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for romosozumab, an investigational mon
Read more →AMGNAmgen And Allergan Announce Top-Line Results From Phase 3 Study Evaluating ABP 980 Compared With Trastuzumab In Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) today announced results from a Phase 3 study evaluating efficacy and safety of ABP 980 compared with...
THOUSAND OAKS, Calif. and DUBLIN , July 21, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and Allergan plc (NYSE: AGN ) today announced results from a Phase 3 study evaluating efficacy and safety of ABP 980 compared with trastuzumab in patients with human epidermal growth factor rec
Read more →AMGNAmgen Announces Settlement Of Securities Litigation Amgen (NASDAQ:AMGN) today announced that it has entered into an agreement with plaintiffs to resolve In re Amgen Inc. Securities Litigation,...
THOUSAND OAKS, Calif. , July 20, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it has entered into an agreement with plaintiffs to resolve In re Amgen Inc. Securities Litigation , CV-07-2536 PSG, a previously disclosed securities class action lawsuit pending in
Read more →AMGNAmgen And Daiichi Sankyo Announce Agreement To Commercialize Biosimilars In Japan Amgen (NASDAQ:AMGN) and Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo; TSE: 4568) today announced the execution of an exclusive...
THOUSAND OAKS, Calif. and TOKYO , July 13, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo; TSE: 4568) today announced the execution of an exclusive agreement to commercialize nine biosimilars in Japan . The deal includes
Read more →AMGNAmgen To Discuss Data Supporting Biologics License Application For ABP 501, A Biosimilar Candidate To Adalimumab Amgen (NASDAQ:AMGN) today announced that the Company will discuss data supporting the ABP 501 Biologics License Application (BLA) with the U.S. Food...
THOUSAND OAKS, Calif. , July 12, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the Company will discuss data supporting the ABP 501 Biologics License Application (BLA) with the U.S. Food and Drug Administration's (FDA) Arthritis Advisory Committee. ABP 501 is a
Read more →AMGNFDA Approves First And Only Single Monthly Injection For A PCSK9 Inhibitor Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the Repatha® (evolocumab) Pushtronex™ system...
THOUSAND OAKS, Calif. , July 11, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the U.S. Food and Drug Administration (FDA) has approved the Repatha ® (evolocumab) Pushtronex ™ system (on-body infusor with prefilled cartridge), a new, monthly single-dose administ
Read more →AMGNEuropean Commission Approves Extended Indication For Amgen's Kyprolis® (Carfilzomib) For The Treatment Of Relapsed Multiple Myeloma Patients Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has approved a variation to the marketing authorization for Kyprolis®...
THOUSAND OAKS, Calif. , July 3, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the European Commission (EC) has approved a variation to the marketing authorization for Kyprolis ® (carfilzomib) to include use in combination with dexamethasone alone for adult patie
Read more →AMGNAmgen Sponsors QB3@953 Incubator For Life Science Startups Amgen (NASDAQ:AMGN) today announced a five-year, platinum sponsorship of the QB3@953 life sciences incubator to accelerate the development of new...
SAN FRANCISCO , June 22, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced a five-year, platinum sponsorship of the QB3@953 life sciences incubator to accelerate the development of new therapies to improve human health. The shared laboratory space at QB3@953 was created
Read more →AMGNAmgen Appoints Esteban Santos Executive Vice President, Operations Amgen (NASDAQ:AMGN) today announced the appointment of Esteban Santos as executive vice president, Operations, effective July 25, 2016, reporting to...
THOUSAND OAKS, Calif. , June 17, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the appointment of Esteban Santos as executive vice president, Operations, effective July 25, 2016 , reporting to Robert A. Bradway , chairman and chief executive officer. Santos will be r
Read more →AMGNAmgen Announces FDA Advisory Committee Meeting To Review ABP 501, A Biosimilar Candidate To Adalimumab Amgen (NASDAQ:AMGN) today announced that the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) will review data supporting...
THOUSAND OAKS, Calif. , June 13, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) will review data supporting the Company's Biologics License Application (BLA) for ABP 501, a biosimilar
Read more →AMGNAmgen Announces Expiration And Final Results Of Senior Notes Exchange Offers Amgen (NASDAQ:AMGN) announced today the expiration and final results of its previously announced seven separate private offers to exchange (each, an...
THOUSAND OAKS, Calif. , June 10, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) announced today the expiration and final results of its previously announced seven separate private offers to exchange (each, an "Exchange Offer" and, collectively, the "Exchange Offers") certain specifie
Read more →AMGNNew Analyses From Pivotal Phase 3 Studies Show Kyprolis® (Carfilzomib) Allows Patients With Relapsed Multiple Myeloma To Live Longer Without Disease Progression Amgen (NASDAQ:AMGN) today announced results from a post-hoc analysis of the pivotal Phase 3 ASPIRE study which highlighted the benefit of continued...
THOUSAND OAKS, Calif. , June 10, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced results from a post-hoc analysis of the pivotal Phase 3 ASPIRE study which highlighted the benefit of continued treatment with Kyprolis ® (carfilzomib) in combination with lenalidomide and
Read more →AMGNBLINCYTO® (Blinatumomab) Improved Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Amgen (NASDAQ:AMGN) today announced new data from a prespecified interim analysis of the Phase 3 TOWER study, in which BLINCYTO® (blinatumomab)...
THOUSAND OAKS, Calif. , June 10, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced new data from a prespecified interim analysis of the Phase 3 TOWER study, in which BLINCYTO ® (blinatumomab) demonstrated an almost two-fold increase in median overall survival (OS) compar
Read more →AMGNAmgen Announces Erenumab (AMG 334) Significantly Reduces Patients' Monthly Migraine Days In Phase 2 Study For The Prevention Of Chronic Migraine Amgen (NASDAQ:AMGN) today announced positive top-line results from the global Phase 2 study evaluating the efficacy and safety of erenumab (AMG 334)...
THOUSAND OAKS, Calif. , June 8, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced positive top-line results from the global Phase 2 study evaluating the efficacy and safety of erenumab (AMG 334) in chronic migraine prevention. The study met its primary endpoint of change
Read more →AMGNNew National Survey Sheds Light On How To Better Engage Students In Science Education The Amgen Foundation and Change the Equation (CTEq) today announced results of a survey conducted to better understand what motivates U.S. high...
THOUSAND OAKS , Calif. and WASHINGTON , June 7, 2016 /PRNewswire/ -- The Amgen Foundation and Change the Equation (CTEq) today announced results of a survey conducted to better understand what motivates U.S. high school students to study science, technology, engineering and math
Read more →AMGNNew Phase 3 Secondary Analysis Shows Progression-Free Survival Benefit In Early Relapsing Multiple Myeloma Patients Treated With Kyprolis® (Carfilzomib)-Based Regimen Amgen (NASDAQ:AMGN) today announced data from a secondary analysis of the pivotal Phase 3 ASPIRE trial that showed Kyprolis® (carfilzomib) for...
THOUSAND OAKS, Calif. , June 6, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced data from a secondary analysis of the pivotal Phase 3 ASPIRE trial that showed Kyprolis ® (carfilzomib) for Injection in combination with lenalidomide and dexamethasone (KRd) improved progr
Read more →AMGNAmgen Announces Launch Of KYPROLIS® (carfilzomib) CENTRAL, An Online News Resource Demonstrating The Impact Of Relapsed Multiple Myeloma On The Lives Of Patients And Caregivers Amgen (NASDAQ:AMGN) today announced the launch of KYPROLIS CENTRAL, an online media resource about the impact of living with relapsed or refractory...
THOUSAND OAKS, Calif. , June 3, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the launch of KYPROLIS CENTRAL, an online media resource about the impact of living with relapsed or refractory multiple myeloma. Intended to drive awareness of a rare blood cancer that is
Read more →AMGNAmgen To Present At The Goldman Sachs 37th Annual Global Healthcare Conference Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 37th Annual Global Healthcare Conference at 1:20 p.m. PT on Tuesday, June 7, 2016, in Rancho...
THOUSAND OAKS, Calif. , June 3, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Goldman Sachs 37 th Annual Global Healthcare Conference at 1:20 p.m. PT on Tuesday, June 7, 2016 , in Rancho Palos Verdes, Calif. Sean E. Harper , M.D., executive vice president of Rese
Read more →AMGNAmgen Receives Positive CHMP Opinion To Extend Indication Of Kyprolis® (Carfilzomib) For The Treatment Of Relapsed Multiple Myeloma Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a...
THOUSAND OAKS, Calif. , May 27, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion to extend the current indication for Kyprolis ® (carfilzomib)
Read more →AMGNKyprolis® (Carfilzomib) Demonstrates Economic Value In Relapsed Or Refractory Multiple Myeloma Manuscript Published In Journal of Medical Economics Amgen (NASDAQ:AMGN) today announced that the Kyprolis Global Economic Model (K-GEM)1 has been published in the Journal of Medical Economics showing...
THOUSAND OAKS, Calif. , May 26, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the Kyprolis Global Economic Model (K-GEM) 1 has been published in the Journal of Medical Economics showing that in the United States (U.S.), Kyprolis ® (carfilzomib) in combination wi
Read more →AMGNAmgen Announces Early Tender Results Of Senior Notes Exchange Offers Amgen (NASDAQ: AMGN) announced today the early tender results of its previously announced seven separate private offers to exchange (each, an...
THOUSAND OAKS, Calif. , May 25, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) announced today the early tender results of its previously announced seven separate private offers to exchange (each, an "Exchange Offer" and, collectively, the "Exchange Offers") certain specified series
Read more →AMGNAmgen Announces Pricing Terms Of Senior Notes Exchange Offers Amgen (NASDAQ:AMGN) announced today the pricing terms of its previously announced seven separate private offers to exchange (each, an Exchange...
THOUSAND OAKS, Calif. , May 25, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) announced today the pricing terms of its previously announced seven separate private offers to exchange (each, an "Exchange Offer" and, collectively, the "Exchange Offers") certain specified series of its
Read more →AMGNAmgen Highlights Data To Be Presented At 21st Congress Of The European Hematology Association Amgen (NASDAQ: AMGN) today announced it will present new data from its oncology portfolio at the 21st Congress of the European Hematology Association ...
THOUSAND OAKS, Calif. , May 19, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced it will present new data from its oncology portfolio at the 21 st Congress of the European Hematology Association (EHA), June 9-12, 2016 , in Copenhagen . Key data to be presented include s
Read more →AMGNAmgen Data To Be Presented At ASCO 2016 Demonstrates More Insights Into Treatment Options For Patients Amgen (NASDAQ:AMGN) today announced that new clinical data from across the oncology portfolio, including Kyprolis® (carfilzomib), IMLYGIC®...
THOUSAND OAKS, Calif. , May 18, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that new clinical data from across the oncology portfolio, including Kyprolis ® (carfilzomib), IMLYGIC ® (talimogene laherparepvec), Vectibix ® (panitumumab) and Neulasta ® (pegfilgrastim)
Read more →AMGNAmgen's Breakaway from Cancer® Public Service Announcement Delivers Message That Education, Resources And Hope Are Essential In The Fight Against Cancer Amgen (NASDAQ:AMGN) today debuted a new public service announcement (PSA) featuring Breakaway from Cancer® ambassador Patrick Dempsey in an effort to ...
THOUSAND OAKS, Calif. , May 17, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today debuted a new public service announcement (PSA) featuring Breakaway from Cancer ® ambassador Patrick Dempsey in an effort to increase awareness of the importance of education and support services ava
Read more →AMGNAmgen Commences Exchange Offers for Certain Series of Outstanding Senior Notes from Exchange Eligible Holders Amgen (NASDAQ:AMGN) announced today the commencement of seven separate private offers to exchange (each, an Exchange Offer and, collectively, the...
THOUSAND OAKS, Calif. , May 12, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) announced today the commencement of seven separate private offers to exchange (each, an "Exchange Offer" and, collectively, the "Exchange Offers") certain specified series of its outstanding senior notes (
Read more →AMGNHall of Fame Quarterback Joe Montana and Amgen Team Up to Launch Breakaway from Heart Disease™ to Make Heart Health a Priority Amgen (NASDAQ:AMGN) today announced the launch of the Breakaway from Heart Disease™ campaign to help make heart health a priority. Hall of Fame...
THOUSAND OAKS, Calif. , May 11, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the launch of the Breakaway from Heart Disease ™ campaign to help make heart health a priority. Hall of Fame quarterback Joe Montana , the American Heart Association and Schwinn are joining
Read more →AMGNPlatelet BioGenesis Wins Amgen Golden Ticket For LabCentral Amgen (NASDAQ: AMGN) and LabCentral announced today that Platelet BioGenesis is an Amgen's 2016 winner of the highly competitive Golden Ticket award, ...
CAMBRIDGE, Mass. , May 9, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and LabCentral announced today that Platelet BioGenesis is an Amgen's 2016 winner of the highly competitive Golden Ticket award, which underwrites the cost of a lab bench for a Platelet BioGenesis scientist in L
Read more →AMGNAmgen To Present At The Bank Of America Merrill Lynch 2016 Health Care Conference Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch 2016 Health Care Conference at 2:20 p.m. PT on Wednesday, May 11, 2016, in Las...
THOUSAND OAKS, Calif. , May 6, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Bank of America Merrill Lynch 2016 Health Care Conference at 2:20 p.m. PT on Wednesday, May 11, 2016 , in Las Vegas . David W. Meline , executive vice president and chief financial offic
Read more →AMGNFDA Grants Priority Review For Amgen's Supplemental Biologics License Application For BLINCYTO® (Blinatumomab) Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the supplemental Biologics...
THOUSAND OAKS, Calif. , May 3, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the supplemental Biologics License Application (sBLA) for BLINCYTO ® (blinatumomab) to include new data supp
Read more →AMGNAmgen's First Quarter 2016 Revenues Increased 10 Percent To $5.5 Billion And Adjusted Earnings Per Share (EPS) Increased 17 Percent To $2.90 Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2016. Key results include: Total revenues increased 10 percent versus...
THOUSAND OAKS, Calif. , April 28, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced financial results for the first quarter of 2016. Key results include: "We are off to a strong start in 2016 delivering results for the year and laying groundwork for our long-term growth
Read more →AMGNAmgen To Participate In The 2016 World Medical Innovation Forum™ On Cancer Amgen (NASDAQ:AMGN) today announced plans to participate in the World Medical Innovation Forum™ on cancer held April 25-27, 2016, in Boston. The...
THOUSAND OAKS, Calif. , April 25, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced plans to participate in the World Medical Innovation Forum ™ on cancer held April 25-27, 2016 , in Boston . The World Medical Innovation Forum is a global gathering of senior corporate, i
Read more →AMGNAmgen Announces Webcast Of 2016 First Quarter Financial Results Amgen (NASDAQ:AMGN) today announced that it will report its first quarter financial results on Thursday, April 28, 2016, after the close of the U.S....
THOUSAND OAKS, Calif. , April 25, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will report its first quarter financial results on Thursday, April 28, 2016 , after the close of the U.S. financial markets. The announcement will be followed by a conference call
Read more →AMGNNplate® (Romiplostim) Study In The Lancet Shows Significant Increase In Durable Platelet Response Among Children With Immune Thrombocytopenia Amgen (NASDAQ:AMGN) today announced that The Lancet published results from a Phase 3 randomized, double-blind, placebo-controlled study of Nplate®...
THOUSAND OAKS, Calif. , April 19, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that The Lancet published results from a Phase 3 randomized, double-blind, placebo-controlled study of Nplate ® (romiplostim) in children with symptomatic immune thrombocytopenia (ITP). T
Read more →AMGNPositive Efficacy And Tolerability Study Of Repatha® (evolocumab) In Statin-Intolerant Patients Published In Journal of the American Medical Association Amgen (NASDAQ:AMGN) today announced new detailed data from the Phase 3 GAUSS-3 (Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin...
THOUSAND OAKS, Calif. , April 3, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced new detailed data from the Phase 3 GAUSS-3 ( G oal A chievement After U tilizing an Anti-PCSK9 Antibody in S tatin Intolerant S ubjects-3) trial evaluating Repatha ® (evolocumab) in patien
Read more →AMGNAmgen And UCB Present Positive Data At ENDO 2016 Comparing Romosozumab With Teriparatide Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today announced detailed Phase 3 results showing the investigational agent romosozumab...
THOUSAND OAKS, Calif. and BRUSSELS , April 1, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and UCB (Euronext Brussels: UCB) today announced detailed Phase 3 results showing the investigational agent romosozumab demonstrated a statistically significant increase in hip bone mineral d
Read more →AMGNAmgen To Present Repatha® (Evolocumab) Data At ACC.16 Amgen (NASDAQ:AMGN) today announced that it will present 19 abstracts related to its cardiovascular portfolio, including new detailed data evaluating ...
THOUSAND OAKS, Calif. , March 21, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will present 19 abstracts related to its cardiovascular portfolio, including new detailed data evaluating Repatha ® (evolocumab) in patients with high cholesterol who cannot toler
Read more →AMGNAmgen And UCB Announce Positive Top-Line Results From Phase 3 Study Evaluating Romosozumab In Men With Osteoporosis Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today announced positive top-line results for romosozumab from the pivotal Phase 3...
THOUSAND OAKS, Calif. , and BRUSSELS , March 20, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and UCB (Euronext Brussels: UCB) today announced positive top-line results for romosozumab from the pivotal Phase 3 place B o-cont R olled study evaluat I ng the efficacy an D safety of ro
Read more →AMGNAmgen Wins Patent Case On Repatha® (Evolocumab) Amgen (NASDAQ:AMGN) today announced that a Delaware jury delivered a verdict in Amgen's favor in a trial on the validity of two Amgen patents that...
THOUSAND OAKS, Calif. , March 16, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that a Delaware jury delivered a verdict in Amgen's favor in a trial on the validity of two Amgen patents that describe and claim monoclonal antibodies to proprotein convertase subtilisin
Read more →AMGNFDA Accepts Amgen's Supplemental Biologics License Application For The Expanded Use Of Enbrel® (Etanercept) To Treat Pediatric Patients With Chronic Severe Plaque Psoriasis Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Amgen's supplemental Biologics License...
THOUSAND OAKS, Calif. , March 10, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Amgen's supplemental Biologics License Application (sBLA) for the expanded use of Enbrel ® (etanercept) to treat p
Read more →AMGNAmgen To Present At The Cowen And Company 36th Annual Health Care Conference Amgen (NASDAQ:AMGN) will present at the Cowen and Company 36th Annual Health Care Conference at 9:20 a.m. ET on Tuesday, March 8, 2016, in Boston....
THOUSAND OAKS, Calif. , March 3, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Cowen and Company 36 th Annual Health Care Conference at 9:20 a.m. ET on Tuesday, March 8, 2016 , in Boston . Sean E. Harper , M.D., executive vice president of Research and Developmen
Read more →AMGNAmgen Announces 2016 Second Quarter Dividend Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.00 per share dividend for the second quarter of 2016. The dividend will ...
THOUSAND OAKS, Calif. , March 2, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that its Board of Directors declared a $1.00 per share dividend for the second quarter of 2016. The dividend will be paid on June 8, 2016 , to all stockholders of record as of the close of
Read more →AMGNAmgen Submits Supplemental Biologics License Application For BLINCYTO® (Blinatumomab) Amgen (NASDAQ:AMGN) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration...
THOUSAND OAKS, Calif. , March 1, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for BLINCYTO ® (blinatumomab) to include new data supporting the treatm
Read more →AMGNAmgen And UCB Announce Positive Top-Line Results From The Phase 3 Study Of Romosozumab In Postmenopausal Women With Osteoporosis Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced top-line results from the Phase 3 placebo-controlled FRActure study in...
THOUSAND OAKS, Calif. and BRUSSELS , Feb. 22, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and UCB (Euronext Brussels: UCB) today announced top-line results from the Phase 3 placebo-controlled FRActure study in postmenopausal woMen with ostEoporosis (FRAME). These data showed FRAME
Read more →AMGNPhase 3 Study Demonstrates Aranesp® (Darbepoetin Alfa) Reduces Red Blood Cell Transfusions In Patients With Myelodysplastic Syndrome (MDS) Amgen (NASDAQ:AMGN) today announced that the randomized, double-blind, placebo-controlled Phase 3 Aranesp® (darbepoetin alfa) ARCADE trial met its...
THOUSAND OAKS, Calif. , Feb. 15, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the randomized, double-blind, placebo-controlled Phase 3 Aranesp ® (darbepoetin alfa) ARCADE trial met its primary endpoint of reducing the incidence of red blood cell transfusions in
Read more →AMGNAmgen To Present At The Leerink Partners 5th Annual Global Healthcare Conference Amgen (NASDAQ:AMGN) will present at the Leerink Partners 5th Annual Global Healthcare Conference at 9:15 a.m. ET on Wednesday, Feb. 10, 2016, in New...
THOUSAND OAKS, Calif. , Feb. 5, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Leerink Partners 5 th Annual Global Healthcare Conference at 9:15 a.m. ET on Wednesday, Feb. 10, 2016 , in New York City . David W. Meline , executive vice president and chief financial
Read more →AMGNPhase 3 Study of BLINCYTO® (Blinatumomab) Met Primary Endpoint Of Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Amgen (NASDAQ:AMGN) today announced that the results of a prespecified interim analysis showed that the primary endpoint of improved overall survival ...
THOUSAND OAKS, Calif. , Feb. 4, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the results of a prespecified interim analysis showed that the primary endpoint of improved overall survival was met in the Phase 3 TOWER study. The randomized, open-label TOWER study
Read more →AMGNAmgen Announces Positive Top-Line Results From Phase 3 GAUSS-3 Trial Of Repatha® (Evolocumab) In Statin-Intolerant Patients With High Cholesterol Amgen (NASDAQ:AMGN) today announced that the Phase 3 GAUSS-3 (Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant...
THOUSAND OAKS, Calif. , Feb. 4, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the Phase 3 GAUSS-3 ( G oal A chievement After U tilizing an Anti-PCSK9 Antibody in S tatin Intolerant S ubjects-3) trial evaluating Repatha ® (evolocumab) in patients with high choles
Read more →AMGNAmgen's 2015 Revenues Increased 8 Percent To $21.7 Billion And Adjusted Earnings Per Share (EPS) Increased 19 Percent To $10.38 Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2015. Key results include: For the fourth quarter,...
THOUSAND OAKS, Calif. , Jan. 28, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced financial results for the fourth quarter and full year of 2015. Key results include: "2015 was an exceptional year for Amgen with six innovative new launches, strong financial performance
Read more →AMGNFDA Accepts Amgen's Biosimilar Biologics License Application For ABP 501 Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Amgen's Biologics License Application...
THOUSAND OAKS, Calif. , Jan. 25, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Amgen's Biologics License Application (BLA) for ABP 501, a biosimilar candidate to Humira ® (adalimumab). "If appr
Read more →AMGNAmgen Announces Webcast of 2015 Fourth Quarter and Full Year Financial Results Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2015 financial results on Thursday, Jan. 28, 2016, after the ...
THOUSAND OAKS, Calif. , Jan. 25, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will report its fourth quarter and full year 2015 financial results on Thursday, Jan. 28, 2016 , after the close of the U.S. financial markets. The announcement will be followed by
Read more →AMGNVectibix® (panitumumab) And Best Supportive Care Improves Overall Survival Compared To Best Supportive Care In Chemorefractory KRAS And RAS Wild-Type Metastatic Colorectal Cancer Amgen (NASDAQ: AMGN) today announced the presentation of detailed results of a Phase 3 study with Vectibix® (panitumumab) and best supportive care...
THOUSAND OAKS, Calif. , Jan. 23, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the presentation of detailed results of a Phase 3 study with Vectibix ® (panitumumab) and best supportive care (BSC) compared to BSC alone. The study met its primary endpoint, demonstratin
Read more →AMGNAmgen's Repatha® (Evolocumab) Approved As First PCSK9 Inhibitor In Japan For The Treatment Of High Cholesterol Amgen (NASDAQ:AMGN) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the cholesterol-lowering medication...
THOUSAND OAKS, Calif. , Jan. 21, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the cholesterol-lowering medication Repatha ® (evolocumab) Injection, the first proprotein convertase subtilisin/kexin
Read more →AMGNFDA Approves New Kyprolis® (Carfilzomib) Combination Therapy For The Treatment Of Patients With Relapsed Or Refractory Multiple Myeloma Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) of...
Experience the interactive Multimedia News Release here: http://www.multivu.com/players/English/74140510-kyprolis-endeavor-expanded-approval/ . "Kyprolis is the only approved therapy for relapsed multiple myeloma with proven efficacy as a single agent, doublet and triplet combin
Read more →AMGNAmgen To Present At The 34th Annual J.P. Morgan Healthcare Conference Amgen (NASDAQ:AMGN) will present at the 34th Annual J.P. Morgan Healthcare Conference at 8 a.m. PT on Tuesday, Jan. 12, 2016, at the Westin St....
THOUSAND OAKS, Calif. , Jan. 7, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the 34 th Annual J.P. Morgan Healthcare Conference at 8 a.m. PT on Tuesday, Jan. 12, 2016 , at the Westin St. Francis in San Francisco . Robert A. Bradway , chairman and chief executive off
Read more →AMGNEuropean Commission Approves Amgen's IMLYGIC™ (talimogene laherparepvec) As First Oncolytic Immunotherapy In Europe Amgen (NASDAQ:AMGN) today announced that the European Commission has approved the use of IMLYGIC™ (talimogene laherparepvec) for the treatment of...
THOUSAND OAKS, Calif. , Dec. 18, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the European Commission has approved the use of IMLYGIC ™ (talimogene laherparepvec) for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic
Read more →AMGNAmgen Announces 27 Percent Increase In 2016 First Quarter Dividend Amgen (NASDAQ: AMGN) today announced that its Board of Directors declared a $1.00 per share dividend for the first quarter of 2016. The dividend will ...
THOUSAND OAKS, Calif. , Dec. 15, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that its Board of Directors declared a $1.00 per share dividend for the first quarter of 2016. The dividend will be paid on March 8, 2016 , to all stockholders of record as of the close of
Read more →AMGNAmgen Reacquires All Product Rights To Prolia® (denosumab), XGEVA® (denosumab) And Vectibix® (panitumumab) From GSK In 48 Countries Amgen (NASDAQ:AMGN) today announced that it has entered into a definitive agreement with GSK to reacquire all of its remaining rights to Prolia®...
THOUSAND OAKS, Calif. , Dec. 14, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it has entered into a definitive agreement with GSK to reacquire all of its remaining rights to Prolia ® (denosumab), XGEVA ® (denosumab) and Vectibix ® (panitumumab) in 48 countries
Read more →AMGNAmgen Presents Data From Three Trials Evaluating BLINCYTO® (blinatumomab) In Acute Lymphoblastic Leukemia At ASH 2015 Amgen (NASDAQ:AMGN) today announced that new data from three Phase 2 trials support the efficacy and safety of BLINCYTO® (blinatumomab) in adults...
THOUSAND OAKS, Calif. , Dec. 7, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that new data from three Phase 2 trials support the efficacy and safety of BLINCYTO ® (blinatumomab) in adults with acute lymphoblastic leukemia (ALL). These data were presented today in or
Read more →AMGNNew Analyses Presented At ASH 2015 Demonstrate The Potential Of Kyprolis® (Carfilzomib) As Backbone Therapy In Multiple Myeloma Amgen (NASDAQ:AMGN) today announced the presentation of new key data evaluating Kyprolis® (carfilzomib) -based regimens in patients with relapsed...
THOUSAND OAKS, Calif. , Dec. 5, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the presentation of new key data evaluating Kyprolis ® (carfilzomib) -based regimens in patients with relapsed multiple myeloma. The data showed Kyprolis in combination with dexamethasone s
Read more →AMGNPivotal Head-To-Head ENDEAVOR Study Results Published in The Lancet Oncology Demonstrate Superiority of Kyprolis® (carfilzomib) Combination Over Velcade® (bortezomib) Combination Amgen (NASDAQ:AMGN) today announced that The Lancet Oncology published results from the pivotal Phase 3 head-to-head ENDEAVOR study comparing...
THOUSAND OAKS, Calif. , Dec. 5, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that The Lancet Oncology published results from the pivotal Phase 3 head-to-head ENDEAVOR study comparing Kyprolis ® (carfilzomib) plus dexamethasone to Velcade ® (bortezomib) plus dexameth
Read more →AMGNAmgen Submits Application In Europe To Expand Indication Of Kyprolis® (carfilzomib) For The Treatment Of Relapsed Multiple Myeloma Amgen (NASDAQ:AMGN) today announced the submission to the European Medicines Agency (EMA) of a Variation to the Marketing Authorization Application...
THOUSAND OAKS, Calif. , Dec. 5, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the submission to the European Medicines Agency (EMA) of a Variation to the Marketing Authorization Application (MAA) to expand the indication for Kyprolis ® (carfilzomib) in combination wi
Read more →AMGNAmgen And Merck Announce Cancer Immunotherapy Collaboration For Patients With Non-Hodgkin Lymphoma Amgen (NASDAQ:AMGN) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced a cancer immunotherapy collaboration to...
THOUSAND OAKS, Calif. and KENILWORTH, N.J. , Dec. 4, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and Merck (NYSE: MRK ), known as MSD outside the United States and Canada , today announced a cancer immunotherapy collaboration to support a Phase 1b/3 study investigating BLINCYTO ®
Read more →AMGNAmgen's First Biosimilar Marketing Authorization Application Submitted To European Medicines Agency For ABP 501 Amgen (NASDAQ:AMGN) today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ABP 501, ...
THOUSAND OAKS, Calif. , Dec. 4, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ABP 501, a biosimilar candidate to Humira ® (adalimumab). Amgen believes this submis
Read more →AMGNAmgen's First Biosimilar Biologics License Application For ABP 501 Submitted To U.S. Food And Drug Administration Amgen (NASDAQ:AMGN) today announced the submission of a Biologics License Application (BLA) with the United States (U.S.) Food and Drug...
THOUSAND OAKS, Calif. , Nov. 25, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the submission of a Biologics License Application (BLA) with the United States (U.S.) Food and Drug Administration (FDA) for ABP 501, a biosimilar candidate to Humira ® (adalimumab). Amgen
Read more →AMGNEuropean Commission Approves Amgen's BLINCYTO® (blinatumomab) for the Treatment of Adults with Philadelphia Chromosome-Negative Relapsed or Refractory B-precursor Acute Lymphoblastic Leukemia Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has granted conditional marketing authorization for BLINCYTO® (blinatumomab)...
THOUSAND OAKS, Calif. , Nov. 24, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the European Commission (EC) has granted conditional marketing authorization for BLINCYTO ® (blinatumomab) for the treatment of adults with Philadelphia chromosome-negative (Ph-) rela
Read more →AMGNAmgen Announces Repatha® Preferred Position On CVS Health Commercial Formularies Amgen (NASDAQ: AMGN) today announced that CVS Health will provide preferred access to Repatha® (evolocumab) through its CVS/caremark commercial...
THOUSAND OAKS, Calif. , Nov. 23, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that CVS Health will provide preferred access to Repatha ® (evolocumab) through its CVS/caremark commercial formularies. "Ensuring access to Repatha for appropriate patients is among Amge
Read more →AMGNEuropean Commission Approves Kyprolis® (carfilzomib) For Combination Use In The Treatment Of Patients With Relapsed Multiple Myeloma Amgen (NASDAQ: AMGN) today announced the European Commission (EC) granted marketing authorization for Kyprolis® (carfilzomib) in combination with...
THOUSAND OAKS, Calif. , Nov. 19, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the European Commission (EC) granted marketing authorization for Kyprolis ® (carfilzomib) in combination with lenalidomide and dexamethasone for the treatment of adult patients with multip
Read more →AMGNAmgen to Present IMLYGIC™ (Talimogene Laherparepvec) Data at the 2015 International Congress of the Society for Melanoma Research Amgen (NASDAQ:AMGN) today announced that the Company will present eight IMLYGICTM (talimogene laherparepvec) abstracts, including data from the Phase ...
THOUSAND OAKS, Calif. , Nov. 16, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the Company will present eight IMLYGIC TM (talimogene laherparepvec) abstracts, including data from the Phase 3 trial and new data from its Phase 1b combination trial with Merck's ant
Read more →AMGNAmgen Presents Detailed Results From Phase 3 Study Demonstrating Clinical Equivalence Of Biosimilar Candidate ABP 501 With Adalimumab Amgen (NASDAQ:AMGN) today presented detailed findings from a head-to-head Phase 3 study comparing the safety, efficacy and immunogenicity of...
THOUSAND OAKS, Calif. , Nov. 9, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today presented detailed findings from a head-to-head Phase 3 study comparing the safety, efficacy and immunogenicity of biosimilar candidate ABP 501 with adalimumab in patients with moderate-to-severe rhe
Read more →AMGNAmgen And Cytokinetics Announce Late-Breaking Presentation Of COSMIC-HF Trial At AHA Scientific Sessions 2015 Amgen (NASDAQ: AMGN) and Cytokinetics Incorporated (NASDAQ: CYTK) today announced the presentation of data from the expansion phase of COSMIC-HF...
THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif. , Nov. 8, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and Cytokinetics Incorporated (NASDAQ: CYTK ) today announced the presentation of data from the expansion phase of COSMIC-HF ( C hronic O ral S tudy of M yosin Activation to
Read more →AMGNAmgen Presents Detailed Data Comparing Etelcalcetide With Cinacalcet In Patients With Secondary Hyperparathyroidism Receiving Hemodialysis Amgen (NASDAQ:AMGN) today presented the findings from a head-to-head Phase 3 study comparing intravenous etelcalcetide (AMG 416) with oral cinacalcet ...
THOUSAND OAKS, Calif. , Nov. 7, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today presented the findings from a head-to-head Phase 3 study comparing intravenous etelcalcetide (AMG 416) with oral cinacalcet for the treatment of secondary hyperparathyroidism (SHPT) in adult patients
Read more →AMGNFDA Accepts Amgen's New Drug Application For Novel Intravenous Calcimimetic Etelcalcetide Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Amgen's New Drug Application (NDA) for...
THOUSAND OAKS, Calif. , Nov. 6, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Amgen's New Drug Application (NDA) for etelcalcetide (formerly AMG 416) for the treatment of secondary hyperparathyr
Read more →AMGNKey Data For Amgen Medicines In Relapsed Multiple Myeloma And Acute Lymphoblastic Leukemia To Be Presented At ASH 2015 Amgen (NASDAQ:AMGN) today announced that a number of important abstracts from the Company's oncology portfolio, including Kyprolis® (carfilzomib) for ...
THOUSAND OAKS, Calif. , Nov. 5, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that a number of important abstracts from the Company's oncology portfolio, including Kyprolis ® (carfilzomib) for Injection, BLINCYTO ® (blinatumomab), Nplate ® (romiplostim) and Neulasta
Read more →AMGNAmgen To Present At The Credit Suisse 24th Annual Healthcare Conference Amgen (NASDAQ:AMGN) will participate at the Credit Suisse 24th Annual Healthcare Conference on Tuesday, Nov. 10, 2015, in Scottsdale, Ariz.,...
THOUSAND OAKS, Calif. , Nov. 5, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will participate at the Credit Suisse 24 th Annual Healthcare Conference on Tuesday, Nov. 10, 2015 , in Scottsdale, Ariz. , beginning at 8 a.m. MT . David W. Meline , executive vice president and chief fin
Read more →AMGNAmgen Highlights Data To Be Presented At 2015 American College Of Rheumatology And Association For Rheumatology Health Professionals Annual Meeting Amgen (NASDAQ:AMGN) today announced that it will present key results from several studies related to Enbrel® (etanercept) and ABP 501, an adalimumab...
THOUSAND OAKS, Calif. , Nov. 4, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will present key results from several studies related to Enbrel ® (etanercept) and ABP 501, an adalimumab biosimilar candidate, at the American College of Rheumatology (ACR) and Ass
Read more →AMGNAmgen To Highlight Cardiovascular Portfolio At American Heart Association Scientific Sessions 2015 Amgen (NASDAQ:AMGN) today announced that it will present 14 abstracts at the American Heart Association (AHA) Scientific Sessions 2015, from Nov....
THOUSAND OAKS, Calif. , Nov. 2, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will present 14 abstracts at the American Heart Association (AHA) Scientific Sessions 2015, from Nov. 7–11 in Orlando, Fla. New data analyses evaluating Repatha ™ (evolocumab), an i
Read more →AMGNAmgen's Third Quarter 2015 Revenues Increased 14 Percent To $5.7 Billion And Adjusted Earnings Per Share (EPS) Increased 18 Percent To $2.72 Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2015. Key results include: Total revenues increased 14 percent versus...
THOUSAND OAKS, Calif. , Oct. 28, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced financial results for the third quarter of 2015. Key results include: "We delivered record revenues, adjusted earnings and cash flow in the third quarter, while improving our operating ma
Read more →AMGNAmgen and Cytokinetics Announce Positive Top-Line Results From COSMIC-HF, A Phase 2 Trial of Omecamtiv Mecarbil in Patients With Chronic Heart Failure Amgen (NASDAQ:AMGN) and Cytokinetics Incorporated (NASDAQ:CYTK) today announced that data from the expansion phase of COSMIC-HF (Chronic Oral Study...
THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif. , Oct. 27, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and Cytokinetics Incorporated (NASDAQ: CYTK ) today announced that data from the expansion phase of COSMIC-HF ( C hronic O ral S tudy of M yosin Activation to I ncrease C o
Read more →AMGNFDA Approves IMLYGIC™ (Talimogene Laherparepvec) As First Oncolytic Viral Therapy In The US Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application for IMLYGIC™...
THOUSAND OAKS, Calif. , Oct. 27, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application for IMLYGIC ™ (talimogene laherparepvec), a genetically modified oncolytic viral therapy ind
Read more →AMGNAmgen Receives CHMP Positive Opinion For IMLYGIC™ (Talimogene Laherparepvec) Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European...
THOUSAND OAKS, Calif. , Oct. 23, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion recommending that IMLYGIC™ (
Read more →AMGNAmgen Announces Webcast of 2015 Third Quarter Financial Results Amgen (NASDAQ:AMGN) today announced that it will report its third quarter financial results on Wednesday, Oct. 28, 2015, after the close of the U.S....
THOUSAND OAKS, Calif. , Oct. 23, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will report its third quarter financial results on Wednesday, Oct. 28, 2015 , after the close of the U.S. financial markets. The announcement will be followed by a conference call
Read more →AMGNAmgen Foundation Announces New $4 Million Commitment to Bring Hands-On Biotechnology Labs to Secondary School Students The Amgen Foundation announced today that it will invest more than $4 million to support and strengthen the Amgen Biotech Experience program across...
THOUSAND OAKS, Calif. , Oct. 21, 2015 /PRNewswire/ -- The Amgen Foundation announced today that it will invest more than $4 million to support and strengthen the Amgen Biotech Experience program across the United States , Puerto Rico , United Kingdom and Ireland . The Amgen Biote
Read more →AMGNAmgen Announces 2015 Fourth Quarter Dividend Amgen (NASDAQ:AMGN) announced that its Board of Directors today declared a $0.79 per share dividend for the fourth quarter of 2015. The dividend will ...
THOUSAND OAKS, Calif. , Oct. 14, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) announced that its Board of Directors today declared a $0.79 per share dividend for the fourth quarter of 2015. The dividend will be paid on Dec. 7, 2015 , to all stockholders of record as of the close of
Read more →AMGNAmgen And LabCentral Announce 2015 Golden Ticket Winners Amgen (NASDAQ: AMGN) and LabCentral announced today that Novopyxis, Inc. and Cocoon Biotech, Inc. are Amgen's 2015 selection for Golden Ticket...
CAMBRIDGE, Mass. , Oct. 13, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and LabCentral announced today that Novopyxis, Inc. and Cocoon Biotech, Inc. are Amgen's 2015 selection for Golden Ticket winners, which supply each company with lab space at LabCentral. LabCentral is an innov
Read more →AMGNNew Data Show Consistent Safety Profile For Up To 10 Years With Prolia® (Denosumab) In Postmenopausal Women With Osteoporosis Amgen (NASDAQ:AMGN) today announced results from a seven-year, single-arm, open-label extension of the three-year randomized, double-blind,...
THOUSAND OAKS, Calif. , Oct. 12, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced results from a seven-year, single-arm, open-label extension of the three-year randomized, double-blind, placebo-controlled, multicenter, international Phase 3 F racture R eduction E valuat
Read more →AMGNNew Exploratory Analysis Showed Romosozumab Increased Estimated Bone Strength More Than Teriparatide Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today presented additional findings from an exploratory sub-study of the previously reported...
THOUSAND OAKS, Calif. and BRUSSELS , Oct. 12, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and UCB (Euronext Brussels: UCB) today presented additional findings from an exploratory sub-study of the previously reported romosozumab Phase 2 trial. 1 The findings were presented today in
Read more →AMGNNew Data Show Greater Bone Mineral Density Gains With Prolia® (Denosumab) Compared With Zoledronic Acid Amgen (NASDAQ:AMGN) today announced findings from a randomized, double-blind, double-dummy, multicenter Phase 4 study showing that Prolia®...
THOUSAND OAKS, Calif. , Oct. 11, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced findings from a randomized, double-blind, double-dummy, multicenter Phase 4 study showing that Prolia ® (denosumab) achieved greater gains in bone mineral density (BMD) than the intravenou
Read more →AMGNAmgen To Give 23 Presentations On Osteoporosis Disease And Treatment At American Society For Bone And Mineral Research Annual Meeting Amgen (NASDAQ: AMGN) today announced that it will present data from multiple studies for Prolia® (denosumab) and investigational molecule romosozumab ...
THOUSAND OAKS, Calif. , Oct. 6, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will present data from multiple studies for Prolia ® (denosumab) and investigational molecule romosozumab at the annual meeting of the American Society for Bone and Mineral Research
Read more →AMGNAmgen Announces Repatha™ Co-Preferred Position on Express Scripts National Formulary Amgen (NASDAQ: AMGN) today announced that Express Scripts will provide access to Repatha™ (evolocumab) through its national formulary. Ensuring...
THOUSAND OAKS, Calif. , Oct. 6, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that Express Scripts will provide access to Repatha™ (evolocumab) through its national formulary. "Ensuring access to Repatha for appropriate patients is among Amgen's highest priorities,"
Read more →AMGNAmgen To Present At The Barclays Biosimilars Symposium Amgen (NASDAQ:AMGN) will present at the Barclays Biosimilars Symposium at 8 a.m. ET on Wednesday, Oct. 7, 2015, in New York City. Scott Foraker, vice ...
THOUSAND OAKS, Calif. , Oct. 2, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Barclays Biosimilars Symposium at 8 a.m. ET on Wednesday, Oct. 7, 2015 , in New York City . Scott Foraker , vice president and general manager of Biosimilars at Amgen, will present at t
Read more →AMGNAmgen Receives CHMP Positive Opinions For Two New Treatment Options For Patients With Blood Cancer In Europe Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted...
THOUSAND OAKS, Calif. , Sept. 25, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted positive opinions recommending marketing authorization for: "We are pleased
Read more →AMGNAmgen To Present New Kyprolis® (carfilzomib) Data At 15th International Myeloma Workshop Amgen (NASDAQ:AMGN) today announced the presentation of several studies evaluating Kyprolis® (carfilzomib) for Injection, a next-generation...
THOUSAND OAKS, Calif. , Sept. 23, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the presentation of several studies evaluating Kyprolis ® (carfilzomib) for Injection, a next-generation proteasome inhibitor, at the 15 th International Myeloma Workshop (IMW), from Sept
Read more →AMGNAmgen And Allergan Announce Positive Top-line Results From Phase 3 Study of Biosimilar Candidate ABP 215 Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced a Phase 3 study of biosimilar candidate ABP 215 met its primary and secondary...
THOUSAND OAKS, Calif. and DUBLIN , Sept. 23, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and Allergan plc. (NYSE: AGN ) today announced a Phase 3 study of biosimilar candidate ABP 215 met its primary and secondary endpoints. The study evaluated the efficacy and safety of ABP 215 c
Read more →AMGNFDA Grants Priority Review for Amgen's Supplemental New Drug Application for Expanded Labeling of Kyprolis® (Carfilzomib) in Relapsed Multiple Myeloma Amgen (NASDAQ: AMGN) today announced the U.S. Food and Drug Administration (FDA) has accepted for priority review the supplemental New Drug...
THOUSAND OAKS, Calif. , Sept. 18, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the U.S. Food and Drug Administration (FDA) has accepted for priority review the supplemental New Drug Application (sNDA) of Kyprolis ® (carfilzomib) for Injection for patients with relap
Read more →AMGNAmgen To Acquire Privately-Held Dezima Pharma Amgen (NASDAQ:AMGN) and Dezima Pharma B.V. (Dezima) today announced that the companies have entered into a definitive acquisition agreement under...
THOUSAND OAKS, Calif. and NAARDEN, Netherlands , Sept. 16, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and Dezima Pharma B.V. (Dezima) today announced that the companies have entered into a definitive acquisition agreement under which Amgen will acquire Dezima, a privately-held, N
Read more →AMGNAmgen And Xencor Announce Strategic Collaboration In Cancer Immunotherapy And Inflammation Amgen (NASDAQ:AMGN) and Xencor, Inc. (Xencor) (NASDAQ:XNCR) announced today that the two companies have entered into a research and license agreement ...
THOUSAND OAKS , Calif. and MONROVIA, Calif. , Sept. 16, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and Xencor, Inc. (Xencor) (NASDAQ: XNCR ) announced today that the two companies have entered into a research and license agreement to develop and commercialize novel therapeutics i
Read more →AMGNAmgen To Present At The Bank Of America Merrill Lynch Global Healthcare Conference Amgen (NASDAQ: AMGN) will participate in the Bank of America Merrill Lynch Global Healthcare Conference on Friday, Sept. 18, 2015, in London,...
THOUSAND OAKS, Calif. , Sept. 15, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will participate in the Bank of America Merrill Lynch Global Healthcare Conference on Friday, Sept. 18, 2015 , in London , beginning at 9 a.m. Greenwich Mean Time. David W. Meline , executive vice presid
Read more →AMGNAmgen Highlights Key Clinical Data To Be Presented At European Cancer Congress 2015 Amgen (NASDAQ:AMGN) today announced it will present data from its oncology portfolio and pipeline at the European Cancer Congress 2015 (ECC 2015),...
THOUSAND OAKS, Calif. , Sept. 14, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced it will present data from its oncology portfolio and pipeline at the European Cancer Congress 2015 (ECC 2015), Sept. 25 - 29, 2015 , in Vienna . "Amgen is excited to be sharing clinical
Read more →AMGNAmgen Submits Application To FDA For New Delivery Option For Monthly Administration Of Repatha™ (Evolocumab) Amgen (NASDAQ:AMGN) today announced the submission of an application to the U.S. Food and Drug Administration (FDA) seeking approval of a...
THOUSAND OAKS, Calif. , Sept. 11, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the submission of an application to the U.S. Food and Drug Administration (FDA) seeking approval of a single-dosing option for the monthly administration of Repatha TM (evolocumab) Inject
Read more →AMGNAmgen To Present At The Morgan Stanley Global Healthcare Conference Amgen (NASDAQ:AMGN) will participate in the Morgan Stanley Global Healthcare Conference on Wednesday, Sept. 16, 2015, at the Grand Hyatt New York in...
THOUSAND OAKS, Calif. , Sept. 11, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will participate in the Morgan Stanley Global Healthcare Conference on Wednesday, Sept. 16, 2015 , at the Grand Hyatt New York in New York City , beginning at 9:55 a.m. ET . Robert A. Bradway , chairman
Read more →AMGNAmgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency Amgen (NASDAQ: AMGN) today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) via the...
THOUSAND OAKS, Calif. , Sept. 2, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) via the centralized procedure for etelcalcetide (formerly AMG 416) for the treatment of
Read more →AMGNAmgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs Amgen (NASDAQ:AMGN) today announced a neuroscience collaboration with Novartis in the areas of Alzheimer's disease and migraine. The collaboration...
THOUSAND OAKS, Calif. , Sept. 1, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced a neuroscience collaboration with Novartis in the areas of Alzheimer's disease and migraine. The collaboration accelerates Amgen's potential entry into Alzheimer's disease by teaming up wi
Read more →AMGNAmgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today announced top-line results from the STRUCTURE trial (STudy evaluating effect of...
THOUSAND OAKS, Calif. and BRUSSELS , Sept. 1, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and UCB (Euronext Brussels: UCB) today announced top-line results from the STRUCTURE trial (STudy evaluating effect of RomosozUmab Compared with Teriparatide in postmenopaUsal women with oste
Read more →AMGNFDA Approves Amgen's New Cholesterol-Lowering Medication Repatha™ (evolocumab) Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved a new cholesterol-lowering medication, Repatha™...
THOUSAND OAKS, Calif. , Aug. 27, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the U.S. Food and Drug Administration (FDA) has approved a new cholesterol-lowering medication, Repatha ™ (evolocumab) Injection. Repatha is a human monoclonal antibody that inhibits
Read more →AMGNAmgen To Present New Long-Term Repatha™ (Evolocumab) Data Analysis At ESC Congress 2015 Amgen (NASDAQ:AMGN) today announced that it will present six abstracts at the upcoming ESC Congress 2015, organized by the European Society of...
THOUSAND OAKS, Calif. , Aug. 25, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will present six abstracts at the upcoming ESC Congress 2015, organized by the European Society of Cardiology, being held Aug. 29 – Sept. 2 in London . Data will be presented evalu
Read more →AMGNAmgen Submits New Drug Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) Amgen (NASDAQ: AMGN) today announced the submission of a New Drug Application (NDA) with the United States Food and Drug Administration (FDA) for...
THOUSAND OAKS, Calif. , Aug. 25, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the submission of a New Drug Application (NDA) with the United States Food and Drug Administration (FDA) for etelcalcetide (formerly AMG 416) for the treatment of secondary hyperparathyroi
Read more →AMGNAmgen And University Of California, Berkeley Announce Multi-Year Partnership To Assist Cancer Patient Advocacy Organizations In Measuring Effectiveness Of Programs Amgen (NASDAQ:AMGN) and the Center for Social Sector Leadership at the University of California (UC), Berkeley's Haas School of Business today...
THOUSAND OAKS , Calif. and BERKELEY, Calif. , Aug. 18, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and the Center for Social Sector Leadership at the University of California (UC), Berkeley's Haas School of Business today announced a multi-year partnership to offer a graduate-leve
Read more →AMGNAmgen Announces Appointment Of Fred Hassan To Board Of Directors Amgen (NASDAQ: AMGN) today announced the appointment of Fred Hassan, partner and managing director of Warburg Pincus LLC, to the Amgen Board of...
THOUSAND OAKS, Calif. , July 30, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the appointment of Fred Hassan , partner and managing director of Warburg Pincus LLC, to the Amgen Board of Directors. "We are pleased to welcome Fred Hassan and the deep, global experien
Read more →AMGNAmgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2015. Key results include: Total revenues increased 4 percent versus...
THOUSAND OAKS, Calif. , July 30, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced financial results for the second quarter of 2015. Key results include: "Focused execution with our growth products drove record revenues in the second quarter, and expense discipline furt
Read more →AMGNAmgen Announces 2015 Third Quarter Dividend Amgen (NASDAQ:AMGN) announced that its Board of Directors today declared a $0.79 per share dividend for the third quarter of 2015. The dividend will...
THOUSAND OAKS, Calif. , July 28, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) announced that its Board of Directors today declared a $0.79 per share dividend for the third quarter of 2015. The dividend will be paid on Sept. 8, 2015 , to all stockholders of record as of the close of
Read more →AMGNEuropean Commission Approves Amgen's New Cholesterol-Lowering Medication Repatha(TM) (evolocumab), The First PCSK9 Inhibitor To Be Approved In The World, For Treatment Of High Cholesterol Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has granted marketing authorization for Repatha™ (evolocumab), the first...
THOUSAND OAKS, Calif. , July 21, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the European Commission (EC) has granted marketing authorization for Repatha ™ (evolocumab), the first proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor to be approved i
Read more →AMGNAmgen Announces Webcast of 2015 Second Quarter Financial Results Amgen (NASDAQ:AMGN) today announced that it will report its second quarter financial results on Thursday, July 30, 2015, after the close of the U.S....
THOUSAND OAKS, Calif. , July 27, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will report its second quarter financial results on Thursday, July 30, 2015 , after the close of the U.S. financial markets. The announcement will be followed by a conference call
Read more →AMGNFDA Approves Kyprolis® (carfilzomib) For Combination Use In The Treatment Of Patients With Relapsed Multiple Myeloma Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for...
THOUSAND OAKS, Calif. , July 24, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for Kyprolis ® (carfilzomib) for Injection in combination with Revlimid ® (lenalidomi
Read more →AMGNAmgen Submits Supplemental New Drug Application For Kyprolis® (Carfilzomib) In Relapsed Multiple Myeloma Amgen (NASDAQ:AMGN) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for...
THOUSAND OAKS, Calif. , July 23, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for Kyprolis ® (carfilzomib) for Injection to seek an expanded indication for th
Read more →AMGNAmgen Announces Positive BLINCYTO® (blinatumomab) Phase 2 Study Results In Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Cell Precursor Acute Lymphoblastic Leukemia Amgen (NASDAQ:AMGN) today announced the top-line results of a Phase 2 open-label, single-arm, multicenter trial to evaluate the efficacy and safety...
THOUSAND OAKS, Calif. , July 16, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the top-line results of a Phase 2 open-label, single-arm, multicenter trial to evaluate the efficacy and safety of BLINCYTO ® (blinatumomab) in adults with relapsed or refractory Philadelp
Read more →AMGNAmgen Presents Open-Label Extension Data From Ongoing Phase 2 Study Of AMG 334 In The Prevention Of Episodic Migraine Amgen (NASDAQ: AMGN) today announced positive interim results from its open-label extension of the global Phase 2, double-blind, placebo-controlled...
THOUSAND OAKS, Calif. , June 19, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced positive interim results from its open-label extension of the global Phase 2, double-blind, placebo-controlled study evaluating the safety and efficacy of AMG 334 for the prevention of epi
Read more →AMGNResults From Phase 3 Trial Show Vectibix® (Panitumumab) Improves Overall Survival In Chemorefractory Wild-Type KRAS Metastatic Colorectal Cancer Versus Best Supportive Care Amgen (NASDAQ: AMGN) today announced that a Phase 3 study evaluating Vectibix® (panitumumab) and best supportive care (BSC) met its primary endpoint, ...
THOUSAND OAKS, Calif. , June 18, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that a Phase 3 study evaluating Vectibix ® (panitumumab) and best supportive care (BSC) met its primary endpoint, demonstrating a statistically significant improvement in overall survival
Read more →AMGNAmgen To Discuss Details Of Repatha™ (Evolocumab) Biologics License Application For The Treatment Of High Cholesterol Amgen (NASDAQ: AMGN) today announced that the Company will discuss the data supporting the RepathaTM (evolocumab) Biologics License Application (BLA) ...
THOUSAND OAKS, Calif. , June 10, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the Company will discuss the data supporting the Repatha TM (evolocumab) Biologics License Application (BLA) for the treatment of high cholesterol with the U.S. Food and Drug Administ
Read more →AMGNAmgen To Present At The Goldman Sachs Global Healthcare Conference Amgen (NASDAQ: AMGN) will present at the Goldman Sachs Global Healthcare Conference at 8:40 a.m. PT on Thursday, June 11, 2015, at the Terranea...
THOUSAND OAKS, Calif. , June 8, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Goldman Sachs Global Healthcare Conference at 8:40 a.m. PT on Thursday, June 11, 2015 , at the Terranea Resort in Rancho Palos Verdes, Calif. Sean E. Harper , executive vice president o
Read more →AMGNAmgen Completes Enrollment In Large Cardiovascular Outcomes Trial Of Repatha™ (Evolocumab) In Patients With High Cholesterol And Clinically Evident Cardiovascular Disease Amgen (NASDAQ: AMGN) today announced the completion of patient enrollment in the FOURIER outcomes trial designed to evaluate whether treatment with...
THOUSAND OAKS, Calif. , June 5, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the completion of patient enrollment in the FOURIER outcomes trial designed to evaluate whether treatment with Repatha TM (evolocumab) in combination with statin therapy compared to placebo
Read more →AMGNAmgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab Amgen (NASDAQ: AMGN) today announced a collaboration with Roche on a Phase 1b study to evaluate the safety and efficacy of talimogene laherparepvec,...
THOUSAND OAKS, Calif. , June 2, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced a collaboration with Roche on a Phase 1b study to evaluate the safety and efficacy of talimogene laherparepvec, Amgen's investigational oncolytic immunotherapy, in combination with Roche's
Read more →AMGNAmgen Presents Phase 3 Data At ASCO Showing Prolia® (Denosumab) Significantly Reduced Bone Fractures In Breast Cancer Patients Receiving Aromatase Inhibitors Amgen (NASDAQ: AMGN) today announced results from a randomized, double-blind, placebo-controlled, multicenter Phase 3 study evaluating the treatment...
THOUSAND OAKS, Calif. , June 1, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced results from a randomized, double-blind, placebo-controlled, multicenter Phase 3 study evaluating the treatment effect of adjuvant Prolia ® (denosumab), 60 mg once every six months, therapy
Read more →AMGNAmgen Initiates Phase 3 Study Evaluating Once-Weekly Kyprolis® (carfilzomib) in Patients With Relapsed And Refractory Multiple Myeloma Amgen (NASDAQ:AMGN) today announced the initiation of the ARROW trial, a global Phase 3 study evaluating the benefit of Kyprolis® (carfilzomib) for...
THOUSAND OAKS, Calif. , May 31, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the initiation of the ARROW trial, a global Phase 3 study evaluating the benefit of Kyprolis ® (carfilzomib) for Injection administered once-weekly with dexamethasone versus the current U.S
Read more →AMGNAmgen And Merck Announce Expansion Of Collaboration To Support Studies Of Talimogene Laherparepvec In Combination With KEYTRUDA® (Pembrolizumab) In Patients With Head And Neck Cancer Amgen (NASDAQ: AMGN) and Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, today announced an expanded collaboration to evaluate the...
THOUSAND OAKS, Calif. and KENILWORTH, N.J. , May 29, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and Merck (NYSE: MRK ), known as MSD outside the U.S. and Canada , today announced an expanded collaboration to evaluate the efficacy and safety of talimogene laherparepvec, Amgen's in
Read more →AMGNAmgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease Amgen (NASDAQ: AMGN) today announced pooled data from two pivotal Phase 3, global, randomized, placebo-controlled trials evaluating AMG 416, a novel...
THOUSAND OAKS, Calif. , May 29, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced pooled data from two pivotal Phase 3, global, randomized, placebo-controlled trials evaluating AMG 416, a novel calcimimetic, for the treatment of secondary hyperparathyroidism (SHPT) in pa
Read more →AMGNAmgen Launches Program To Further Advance Basic Biology Research Amgen (NASDAQ: AMGN) today announced the creation of a catalog of qualified tools and reagents available to academic institutions to help further...
THOUSAND OAKS, Calif. , May 28, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the creation of a catalog of qualified tools and reagents available to academic institutions to help further research and advance basic discoveries in biology, as well as deepen relationshi
Read more →AMGNAmgen To Present At The Jefferies 2015 Global Healthcare Conference Amgen (NASDAQ: AMGN) will present at the Jefferies 2015 Global Healthcare Conference at 10:30 a.m. ET on Monday, June 1, 2015, at the Grand Hyatt New ...
THOUSAND OAKS, Calif. , May 27, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Jefferies 2015 Global Healthcare Conference at 10:30 a.m. ET on Monday, June 1, 2015 , at the Grand Hyatt New York in New York City . Arvind Sood , vice president of Investor Relations
Read more →AMGNAmgen To Advance Understanding Of The Treatment Of Blood Cancers At 20th Congress of European Hematology Association (EHA) Amgen (NASDAQ:AMGN) today announced that it will present data from multiple Kyprolis® (carfilzomib) for Injection, BLINCYTO® (blinatumomab),...
THOUSAND OAKS, Calif. , May 27, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will present data from multiple Kyprolis ® (carfilzomib) for Injection, BLINCYTO ® (blinatumomab), oprozomib and Nplate ® (romiplostim) studies at the 20 th Congress of the Europea
Read more →AMGNPivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma Amgen (NASDAQ: AMGN) today announced the publication of primary results from the Phase 3 OPTiM study in the Journal of Clinical Oncology (JCO). The...
THOUSAND OAKS, Calif. , May 26, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the publication of primary results from the Phase 3 OPTiM study in the Journal of Clinical Oncology ( JCO ) . The data published in JCO , which were previously presented at the Annual Meeti
Read more →AMGNAmgen Receives Positive CHMP Opinion For Use Of Repatha™ (Evolocumab) For The Treatment Of High Cholesterol Amgen (NASDAQ: AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has...
THOUSAND OAKS, Calif. , May 22, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the marketing authorization of Repatha ™ (evolocumab
Read more →AMGNAmgen to terminate participation in co-development and commercialization of brodalumab Amgen (NASDAQ:AMGN) today announced the Company has commenced termination of its participation in the co-development and commercialization of...
"During our preparation process for regulatory submissions, we came to believe that labeling requirements likely would limit the appropriate patient population for brodalumab," said Sean E. Harper , M.D., executive vice president of Research and Development at Amgen. About the A
Read more →AMGNAmgen Appoints Jonathan P. Graham Senior Vice President, General Counsel And Secretary Amgen (NASDAQ: AMGN) today announced the appointment of Jonathan P. Graham as senior vice president, general counsel and secretary, effective July...
THOUSAND OAKS, Calif. , May 18, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the appointment of Jonathan P. Graham as senior vice president, general counsel and secretary, effective July 13, 2015 . He will be responsible for Amgen's legal operations, reporting to Ro
Read more →AMGNAmgen Presents First Phase 2 Data For AMG 334 In The Prevention Of Episodic Migraine Amgen (NASDAQ:AMGN) today announced the first results from its global Phase 2, double-blind, placebo-controlled study evaluating the efficacy and...
THOUSAND OAKS, Calif. , May 15, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the first results from its global Phase 2, double-blind, placebo-controlled study evaluating the efficacy and safety of AMG 334 for the prevention of episodic migraine. The study met its pr
Read more →AMGNAmgen Announces Voting Results of Annual Meeting of Stockholders Amgen (NASDAQ: AMGN) today announced voting results from the Company's Annual Meeting of Stockholders, held in Westlake Village, Calif. Approximately ...
THOUSAND OAKS, Calif. , May 14, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced voting results from the Company's Annual Meeting of Stockholders, held in Westlake Village , Calif. Approximately 89 percent of outstanding shares were represented at the meeting. The dire
Read more →AMGNAmgen Data At ASCO 2015 Highlight Oncology Pipeline And Portfolio Amgen (NASDAQ: AMGN) today announced that data at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) will showcase the...
THOUSAND OAKS, Calif. , May 13, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that data at the 51 st Annual Meeting of the American Society of Clinical Oncology (ASCO) will showcase the Company's continued efforts across both pipeline and marketed products, including
Read more →AMGNAmgen's Breakaway From Cancer® Announces Winners Of Its Nationwide Search For Champions In The Fight Against Cancer Amgen (NASDAQ: AMGN) today announced the 10 Breakaway from Cancer® Champions selected from a nationwide search for survivors, patients, caregivers...
THOUSAND OAKS, Calif. , May 12, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the 10 Breakaway from Cancer ® Champions selected from a nationwide search for survivors, patients, caregivers and advocates who have inspired those affected by cancer. These extraordinary
Read more →AMGNAmgen To Present AMG 334 Data At 17th Congress of the International Headache Society Amgen (NASDAQ:AMGN) today announced it will be presenting data for its calcitonin gene-related peptide (CGRP) receptor inhibitor AMG 334 at the 17th...
THOUSAND OAKS, Calif. , May 11, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced it will be presenting data for its calcitonin gene-related peptide (CGRP) receptor inhibitor AMG 334 at the 17th Congress of the International Headache Society (IHC 2015) in Valencia, Spain
Read more →AMGNAmgen To Present At The Deutsche Bank 40th Annual Healthcare Conference Amgen (NASDAQ: AMGN) will present at the Deutsche Bank 40th Annual Healthcare Conference at 8 a.m. ET on Thursday, May 7, 2015, at the...
THOUSAND OAKS, Calif. , May 4, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Deutsche Bank 40th Annual Healthcare Conference at 8 a.m. ET on Thursday, May 7, 2015 , at the InterContinental in Boston . Anthony C. Hooper , executive vice president of Global Commerc
Read more →AMGNAmgen Announces FDA Advisory Committee Meeting To Review Repatha™ (Evolocumab) As A Treatment For High Cholesterol Amgen (NASDAQ: AMGN) today announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the U.S. Food and Drug Administration...
THOUSAND OAKS, Calif. , April 29, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the U.S. Food and Drug Administration (FDA) will review data supporting the Company's Biologics License Applicati
Read more →AMGNAmgen To Discuss Details Of The Biologics License Application For Talimogene Laherparepvec For Patients With Metastatic Melanoma Amgen (NASDAQ:AMGN) today announced that the Company will discuss the data supporting the Biologics License Application (BLA) for talimogene...
THOUSAND OAKS, Calif. , April 29, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the Company will discuss the data supporting the Biologics License Application (BLA) for talimogene laherparepvec monotherapy for the treatment of patients with injectable regionally
Read more →AMGNAmgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 Amgen (NASDAQ: AMGN) today announced financial results for the first quarter of 2015. Key results include: Total revenues increased 11 percent versus ...
THOUSAND OAKS, Calif. , April 21, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced financial results for the first quarter of 2015. Key results include: "With solid execution in the first quarter, Amgen achieved strong sales and earnings growth and demonstrated substan
Read more →AMGNAmgen Announces Webcast Of 2015 First Quarter Financial Results Amgen (NASDAQ: AMGN) today announced that it will report its first quarter financial results on Tuesday, April 21, 2015, after the close of the U.S....
THOUSAND OAKS, Calif. , April 16, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will report its first quarter financial results on Tuesday, April 21, 2015 , after the close of the U.S. financial markets. The announcement will be followed by a conference call
Read more →AMGNFDA Approves Corlanor® (ivabradine) To Reduce The Risk Of Hospitalization For Worsening Heart Failure In Patients With Chronic Heart Failure Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has granted approval of Corlanor® (ivabradine), an oral...
THOUSAND OAKS, Calif. , April 15, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the U.S. Food and Drug Administration (FDA) has granted approval of Corlanor ® (ivabradine), an oral medication indicated to reduce the risk of hospitalization for worsening heart fa
Read more →AMGNEuropean Commission Approves Amgen's Vectibix® (panitumumab) As First-Line Treatment In Combination With FOLFIRI Chemotherapy For Metastatic Colorectal Cancer Amgen (NASDAQ: AMGN) today announced that the European Commission approved a new use of Vectibix® (panitumumab) as first-line treatment in...
THOUSAND OAKS, Calif. , April 6, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the European Commission approved a new use of Vectibix ® (panitumumab) as first-line treatment in combination with FOLFIRI for the treatment of adult patients with wild-type (WT) RAS
Read more →AMGNFDA Grants Amgen Priority Review for Kyprolis® (Carfilzomib) Supplemental New Drug Application for the Treatment of Relapsed Multiple Myeloma Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) of...
THOUSAND OAKS, Calif. , March 30, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) of Kyprolis ® (carfilzomib) for Injection for the treatment of patients with rel
Read more →AMGNAmgen To Present At The Goldman Sachs Key Debates In Biosimilars Conference Amgen (NASDAQ: AMGN) will present at the Goldman Sachs Key Debates in Biosimilars conference at 9:05 a.m. ET on Thursday, April 2, 2015, at the...
THOUSAND OAKS, Calif. , March 30, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Goldman Sachs Key Debates in Biosimilars conference at 9:05 a.m. ET on Thursday, April 2, 2015 , at the Goldman Sachs Conference Center in New York City . Scott Foraker , vice preside
Read more →AMGNCancer Survivor Joan Lunden Named 2015 Honorary Breakaway From Cancer® Champion And Joins Nationwide Search For Ten Champions In The Fight Against Cancer Amgen (NASDAQ:AMGN) today announced that breast cancer survivor Joan Lunden has been named 2015 Honorary Breakaway from Cancer® Champion as part of a ...
THOUSAND OAKS, Calif. , March 26, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that breast cancer survivor Joan Lunden has been named 2015 Honorary Breakaway from Cancer ® Champion as part of a nationwide search to identify 10 Champions who have made a positive impa
Read more →AMGNAmgen To Webcast Investor Call At the 73rd Annual Meeting of the American Academy of Dermatology Amgen (NASDAQ:AMGN) will host a webcast call for the investment community at the 73rd Annual Meeting of the American Academy of Dermatology (AAD) on...
THOUSAND OAKS, Calif. , March 23, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will host a webcast call for the investment community at the 73 rd Annual Meeting of the American Academy of Dermatology (AAD) on Monday, March 23, 2015 , at 1 p.m. PT . The webcast will begin one hour l
Read more →AMGNAmgen Submits Application For Investigational LDL Cholesterol-Lowering Medication Repatha™ (evolocumab) In Japan Amgen (NASDAQ: AMGN) today announced that an application seeking marketing approval of RepathaTM (evolocumab) for the treatment of high cholesterol...
THOUSAND OAKS, Calif. , March 20, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that an application seeking marketing approval of Repatha TM (evolocumab) for the treatment of high cholesterol has been submitted for review to the Ministry of Health, Labour and Welfare
Read more →AMGNAmgen To Present 10 Abstracts From Its Dermatology Portfolio At The 73rd Annual Meeting Of The American Academy Of Dermatology Amgen (NASDAQ:AMGN) today announced that it will present data from multiple brodalumab and Enbrel® (etanercept) studies at the 73rd Annual Meeting of ...
THOUSAND OAKS, Calif. , March 17, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will present data from multiple brodalumab and Enbrel ® (etanercept) studies at the 73 rd Annual Meeting of the American Academy of Dermatology (AAD) in San Francisco , March 20-2
Read more →AMGNAmgen Publishes Safety Analysis Of Investigational Cholesterol-Lowering Medication Repatha™ (evolocumab) In The New England Journal of Medicine Amgen (NASDAQ: AMGN) today announced one-year data from prespecified exploratory endpoints of adjudicated cardiovascular events in the Phase 2...
THOUSAND OAKS, Calif. , March 15, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced one-year data from prespecified exploratory endpoints of adjudicated cardiovascular events in the Phase 2 (OSLER-1) and Phase 3 (OSLER-2) open-label extension studies of Repatha ™ (evoloc
Read more →AMGNNew Detailed Data From Phase 3 Study Show Amgen's Repatha™ (Evolocumab) In Combination With Statins Reduced LDL-C By 67-76 Percent Compared To Placebo In Japanese Patients With High Cardiovascular Risk And High Cholesterol Amgen (NASDAQ:AMGN) today announced new detailed data from the Phase 3 YUKAWA-2 study evaluating Repatha™ (evolocumab), a novel investigational...
THOUSAND OAKS, Calif. , March 14, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced new detailed data from the Phase 3 YUKAWA-2 study evaluating Repatha™ (evolocumab), a novel investigational cholesterol-lowering medication, in Japanese patients with high cardiovascular
Read more →AMGNAmgen Announces 2015 Second Quarter Dividend Amgen (NASDAQ:AMGN) announced that its Board of Directors today declared a $0.79 per share dividend for the second quarter of 2015. The dividend will ...
THOUSAND OAKS, Calif. , March 4, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) announced that its Board of Directors today declared a $0.79 per share dividend for the second quarter of 2015. The dividend will be paid on June 5, 2015 , to all stockholders of record as of the close of
Read more →AMGNAmgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data Amgen (NASDAQ:AMGN) today announced that it will present 15 abstracts, including data evaluating RepathaTM (evolocumab), an investigational...
THOUSAND OAKS, Calif. , March 2, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will present 15 abstracts, including data evaluating Repatha TM (evolocumab), an investigational cholesterol-lowering medication, and Corlanor ® (ivabradine), an investigational dr
Read more →AMGNAmgen Announces Launch Of New Neulasta® (Pegfilgrastim) Delivery Kit Amgen (NASDAQ: AMGN) today announced that the Neulasta® (pegfilgrastim) Delivery Kit is now available in the United States (U.S.). The Neulasta...
THOUSAND OAKS, Calif. , March 2, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the Neulasta ® (pegfilgrastim) Delivery Kit is now available in the United States (U.S.). The Neulasta Delivery Kit includes a specially designed single-use prefilled syringe co-packa
Read more →AMGNPhase 3 Head-to-Head ENDEAVOR Study Demonstrates Superiority Of Kyprolis® (carfilzomib) Over Velcade® (bortezomib) In Patients With Relapsed Multiple Myeloma Amgen (NASDAQ: AMGN) and its subsidiary Onyx Pharmaceuticals, Inc., today announced the results from a planned interim analysis showing that the...
THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif. , March 1, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and its subsidiary Onyx Pharmaceuticals, Inc., today announced the results from a planned interim analysis showing that the Phase 3 head-to-head clinical trial ENDEAVOR eva
Read more →AMGNAmgen Receives Positive CHMP Opinion For Use Of Vectibix® (panitumumab) As First-Line Treatment In Combination With FOLFIRI Chemotherapy For Advanced Colorectal Cancer Amgen (NASDAQ: AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a...
THOUSAND OAKS, Calif. , Feb. 27, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion to extend the marketing authorization for Vectibix ® (panit
Read more →AMGNAmgen Announces The European Medicines Agency Acceptance Of Kyprolis® (Carfilzomib) Marketing Authorization Application For The Treatment Of Relapsed Multiple Myeloma Amgen (NASDAQ: AMGN) and its subsidiary Onyx Pharmaceuticals, Inc., today announced that the European Medicines Agency (EMA) has accepted the...
THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif. , Feb. 26, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and its subsidiary Onyx Pharmaceuticals, Inc., today announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) of Kyprol
Read more →AMGNAmgen Announces Positive Results From Head-To-Head Study Comparing The Efficacy And Safety Of AMG 416 With Cinacalcet In Patients With Secondary Hyperparathyroidism Receiving Hemodialysis Amgen (NASDAQ: AMGN) today announced results from the head-to-head Phase 3 study comparing AMG 416 with cinacalcet for the treatment of secondary...
THOUSAND OAKS, Calif. , Feb. 25, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced results from the head-to-head Phase 3 study comparing AMG 416 with cinacalcet for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) receiv
Read more →AMGNAmgen To Present At The Cowen And Company 35th Annual Health Care Conference Amgen (NASDAQ: AMGN) will present at the Cowen and Company 35th Annual Health Care Conference at 2:50 p.m. ET on Monday, March 2, 2015, at the Boston ...
THOUSAND OAKS, Calif. , Feb. 25, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Cowen and Company 35 th Annual Health Care Conference at 2:50 p.m. ET on Monday, March 2, 2015 , at the Boston Marriott Copley Place in Boston . David W. Meline , executive vice presid
Read more →AMGNAmgen Announces FDA Advisory Committees To Review Talimogene Laherparepvec For The Treatment Of Patients With Metastatic Melanoma Amgen (NASDAQ: AMGN) announced today that the Cellular, Tissue and Gene Therapies Advisory Committee (CTGTAC) and the Oncologic Drugs Advisory...
THOUSAND OAKS, Calif. , Feb. 11, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) announced today that the Cellular, Tissue and Gene Therapies Advisory Committee (CTGTAC) and the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA) will jointly revie
Read more →AMGNAmgen Announces Positive Top-Line Results From Phase 3 Study Evaluating The Efficacy And Safety Of Biosimilar Candidate ABP 501 Compared With Adalimumab In Patients With Moderate-To-Severe Rheumatoid Arthritis Amgen (NASDAQ: AMGN) today announced a Phase 3 study evaluating the efficacy and safety of biosimilar candidate ABP 501 compared with Humira®...
THOUSAND OAKS, Calif. , Feb. 3, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced a Phase 3 study evaluating the efficacy and safety of biosimilar candidate ABP 501 compared with Humira ® (adalimumab) in patients with moderate-to-severe rheumatoid arthritis met its prima
Read more →AMGNAmgen, The Familial Hypercholesterolemia Foundation And Stanford Medicine Launch FIND FH™ Initiative To Improve Diagnosis And Care For People With Familial Hypercholesterolemia Amgen (NASDAQ: AMGN), The Familial Hypercholesterolemia Foundation and Stanford Medicine today announced the launch of the FIND (FLAG, IDENTIFY,...
THOUSAND OAKS , Calif., SOUTH PASADENA , Calif. and PALO ALTO, Calif. , Jan. 29, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ), The Familial Hypercholesterolemia Foundation and Stanford Medicine today announced the launch of the FIND ( F LAG, I DENTIFY, N ETWORK, D ELIVER) FH ™ init
Read more →AMGNAmgen Submits Applications In The US And Europe For Kyprolis® (carfilzomib) For The Treatment Of Relapsed Multiple Myeloma Amgen (NASDAQ:AMGN) and its subsidiary Onyx Pharmaceuticals, Inc., today announced the submission of a supplemental New Drug Application (sNDA) to...
THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif. , Jan. 27, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and its subsidiary Onyx Pharmaceuticals, Inc., today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) a
Read more →AMGNAmgen's 2014 Revenues Increased 7 Percent To $20.1 Billion And Adjusted Earnings Per Share (EPS) Increased 14 Percent To $8.70 Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2014. Key results include: For the fourth quarter,...
THOUSAND OAKS, Calif. , Jan. 27, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced financial results for the fourth quarter and full year of 2014. Key results include: "2014 was an outstanding year for Amgen," said Robert A. Bradway , chairman and chief executive office
Read more →AMGNAmgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2014 financial results on Tuesday, Jan. 27, 2015, after the...
THOUSAND OAKS, Calif. , Jan. 22, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will report its fourth quarter and full year 2014 financial results on Tuesday, Jan. 27, 2015 , after the close of the U.S. financial markets. The announcement will be followed by
Read more →AMGNAmgen Presents New Data Supporting First-Line Use Of Vectibix® (Panitumumab) In Combination With FOLFOX In Patients With Wild-Type RAS Metastatic Colorectal Cancer Amgen (NASDAQ:AMGN) today announced new data from the Phase 2 PEAK and Phase 3 PRIME studies that support the first-line use of Vectibix®...
THOUSAND OAKS, Calif. , Jan. 15, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced new data from the Phase 2 PEAK and Phase 3 PRIME studies that support the first-line use of Vectibix ® (panitumumab) in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen,
Read more →AMGNAmgen and MD Anderson Announce Agreement to Develop BiTE® Therapies for Myelodysplastic Syndrome Amgen (NASDAQ: AMGN) and The University of Texas MD Anderson Cancer Center today announced a research collaborative agreement focusing on Amgen's...
THOUSAND OAKS, Calif. and HOUSTON , Jan. 12, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and The University of Texas MD Anderson Cancer Center today announced a research collaborative agreement focusing on Amgen's bispecific T cell engager (BiTE ® ) antibody constructs, an immunot
Read more →AMGNAmgen To Present At The 33rd Annual J.P. Morgan Healthcare Conference Amgen (NASDAQ: AMGN) will present at the 33rd Annual J.P. Morgan Healthcare Conference at 9:30 a.m. PT on Tuesday, Jan. 13, 2015, at the Westin St....
THOUSAND OAKS, Calif. , Jan. 8, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the 33 rd Annual J.P. Morgan Healthcare Conference at 9:30 a.m. PT on Tuesday, Jan. 13, 2015 , at the Westin St. Francis in San Francisco . Robert A. Bradway , chairman and chief executive
Read more →AMGNAmgen and Kite Pharma Announce Strategic Cancer Immunotherapy Collaboration to Advance the Application of Novel Chimeric Antigen Receptor (CAR) T Cell Therapies Amgen (NASDAQ:AMGN) and Kite Pharma (NASDAQ:KITE) announced today that the two companies have entered into a strategic research collaboration and...
THOUSAND OAKS, Calif. and SANTA MONICA, Calif. , Jan. 5, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and Kite Pharma (NASDAQ: KITE ) announced today that the two companies have entered into a strategic research collaboration and license agreement to develop and commercialize the n
Read more →AMGNAmgen Announces 30 Percent Increase In 2015 First Quarter Dividend Amgen (NASDAQ: AMGN) today announced that its Board of Directors declared a $0.79 per share dividend for the first quarter of 2015. The dividend will ...
THOUSAND OAKS, Calif. , Dec. 17, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that its Board of Directors declared a $0.79 per share dividend for the first quarter of 2015. The dividend will be paid on March 6, 2015 , to all stockholders of record as of the close of
Read more →AMGNAmgen And AstraZeneca To Present Results From Phase 3 AMAGINE-1™ Study Evaluating Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis Amgen (NASDAQ: AMGN) and AstraZeneca (NYSE: AZN) today announced that additional results from AMAGINE-1TM, a pivotal, multi-arm Phase 3 trial...
THOUSAND OAKS, Calif. and LONDON , Dec. 11, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and AstraZeneca (NYSE: AZN ) today announced that additional results from AMAGINE-1 TM , a pivotal, multi-arm Phase 3 trial evaluating two doses of brodalumab in patients with moderate-to-sever
Read more →AMGNAmgen Presents Data From Pivotal Phase 2 Study Of BLINCYTO™ (blinatumomab) Immunotherapy In Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia Amgen (NASDAQ: AMGN) today announced that new data from a pivotal Phase 2 study evaluating BLINCYTO™ (blinatumomab) for the treatment of adult...
THOUSAND OAKS, Calif. , Dec. 8, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that new data from a pivotal Phase 2 study evaluating BLINCYTO ™ (blinatumomab) for the treatment of adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (A
Read more →AMGNFDA Approves Amgen's XGEVA® (Denosumab) For The Treatment Of Hypercalcemia Of Malignancy Refractory To Bisphosphonate Therapy Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for XGEVA® (denosumab) for the...
THOUSAND OAKS, Calif. , Dec. 8, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for XGEVA ® (denosumab) for the treatment of hypercalcemia of malignancy (HCM) refractory to bisphosphonate th
Read more →AMGNNew Trial Initiated Evaluating Amgen's Talimogene Laherparepvec In Combination With Merck's Anti-PD-1 Therapy KEYTRUDA® (Pembrolizumab) For Advanced Melanoma Amgen (NASDAQ: AMGN) today announced the initiation of a trial of talimogene laherparepvec, an investigational oncolytic immunotherapy, in...
THOUSAND OAKS, Calif. , Dec. 8, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the initiation of a trial of talimogene laherparepvec, an investigational oncolytic immunotherapy, in combination with an investigational use of Merck's U.S. Food and Drug Administration (F
Read more →AMGNAmgen And Onyx Announce Detailed Results From Phase 3 ASPIRE Study Of Kyprolis® (Carfilzomib) In Patients With Relapsed Multiple Myeloma Amgen (NASDAQ: AMGN) and its subsidiary Onyx Pharmaceuticals, Inc., announced today results of the Phase 3 ASPIRE (CArfilzomib, Lenalidomide, and...
THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif. , Dec. 6, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and its subsidiary Onyx Pharmaceuticals, Inc., announced today results of the Phase 3 ASPIRE (C A rfilzomib, Lenalidomide, and Dexametha S one versus Lenalidomide and Dexame
Read more →AMGNAmgen Announces New Data From Phase 2 BLINCYTO™ (blinatumomab) Immunotherapy Study In Patients With Acute Lymphoblastic Leukemia And Minimal Residual Disease Amgen (NASDAQ:AMGN) today announced new data from the Phase 2 BLAST study which evaluated the bispecific T cell engager (BiTE®) immunotherapy...
THOUSAND OAKS, Calif. , Dec. 6, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced new data from the Phase 2 BLAST study which evaluated the bispecific T cell engager (BiTE ® ) immunotherapy BLINCYTO™ (blinatumomab) in patients with minimal residual disease (MRD) positive
Read more →AMGNAmgen To Webcast Investor Meeting At Upcoming American Society of Hematology (ASH) 56th Annual Meeting And Exposition Amgen (NASDAQ: AMGN) will host a webcast investor meeting at the American Society of Hematology (ASH) 56th Annual Meeting and Exposition on Monday,...
THOUSAND OAKS, Calif. , Dec. 3, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will host a webcast investor meeting at the American Society of Hematology (ASH) 56 th Annual Meeting and Exposition on Monday, Dec. 8 , at noon PT . Sean E. Harper , M.D., executive vice president of Rese
Read more →AMGNActriz Adamari López y Amgen lanzan Quimioterapia: Mitos y Realidades sitio web y recursos en Español Hoy Amgen (NASDAQ:AMGN) lanzo Quimioterapia: Mitos y Realidades, una extensión en Español de Chemotheraphy: Myths or Facts™, una iniciativa para...
THOUSAND OAKS, California , 3 de diciembre de 2014 /PRNewswire-HISPANIC PR WIRE/ -- Hoy Amgen (NASDAQ: AMGN ) lanzo Quimioterapia: Mitos y Realidades , una extensión en Español de Chemotheraphy: Myths or Facts™ , una iniciativa para pacientes con cáncer y sus cuidadores, presenta
Read more →AMGNActress Adamari López And Amgen Launch Spanish-Language Chemotherapy: Myths Or Facts™ Website And Resources Amgen (NASDAQ: AMGN) today launched Quimioterapia: Mitos y Realidades, a Spanish-language extension of the Chemotherapy: Myths or FactsTM awareness...
THOUSAND OAKS, Calif. , Dec. 3, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today launched Quimioterapia: Mitos y Realidades , a Spanish-language extension of the Chemotherapy: Myths or Facts TM awareness initiative for cancer patients and their caregivers, featuring actress and E
Read more →AMGNFDA Approves BLINCYTO™ (Blinatumomab) Immunotherapy for the Treatment of Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has granted approval of BLINCYTO™ (blinatumomab) for the...
THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif. , Dec. 3, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the U.S. Food and Drug Administration (FDA) has granted approval of BLINCYTO ™ (blinatumomab) for the treatment of patients with Philadelphia chromosome
Read more →AMGNAmgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis Amgen (NASDAQ: AMGN) and AstraZeneca (NYSE: AZN) today announced that AMAGINE-2TM, a pivotal, multi-arm Phase 3 trial evaluating two doses of...
THOUSAND OAKS, Calif. and LONDON , Nov. 25, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and AstraZeneca (NYSE: AZN ) today announced that AMAGINE-2 TM , a pivotal, multi-arm Phase 3 trial evaluating two doses of brodalumab in more than 1,800 patients with moderate-to-severe plaque
Read more →AMGNAmgen Announces Termination Of All Amgen-Sponsored Clinical Studies Of Rilotumumab In Advanced Gastric Cancer Amgen (NASDAQ:AMGN) today announced the termination of all Amgen-sponsored clinical studies of rilotumumab in advanced gastric cancer, including the...
"While we are disappointed with these results, we will work with lead investigators to further analyze the data in order to help inform future research and therapies in this area," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "There is
Read more →AMGNAmgen Presents Long-Term Data Showing Efficacy And Safety Of Investigational Cholesterol-Lowering Medication Evolocumab Across Lipid And LDL-C Levels Amgen (NASDAQ:AMGN) today announced new data from three separate analyses of Phase 2 and 3 studies evaluating evolocumab, a novel investigational...
THOUSAND OAKS, Calif. , Nov. 18, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced new data from three separate analyses of Phase 2 and 3 studies evaluating evolocumab, a novel investigational low-density lipoprotein cholesterol (LDL-C)-lowering medication. Data from one
Read more →AMGNAmgen To Present At The Jefferies Global Healthcare Conference Amgen (NASDAQ: AMGN) will participate at the Jefferies Global Healthcare Conference on Wednesday, Nov. 19, 2014, in London, beginning at 8:40 a.m....
THOUSAND OAKS, Calif. , Nov. 14, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will participate at the Jefferies Global Healthcare Conference on Wednesday, Nov. 19, 2014 , in London , beginning at 8:40 a.m. GMT . Arvind Sood , vice president of Investor Relations at Amgen, will pres
Read more →AMGNThe Amgen Foundation Expands Amgen Scholars Program to 17 Top Educational Institutions Worldwide The Amgen Foundation today announced that the Amgen Scholars Program is expanding its presence with new host institutions in the U.S., Europe, and,...
THOUSAND OAKS, Calif. , Nov. 12, 2014 /PRNewswire/ -- The Amgen Foundation today announced that the Amgen Scholars Program is expanding its presence with new host institutions in the U.S., Europe , and, for the first time, Japan . A signature Foundation initiative, the Amgen Scho
Read more →AMGNAmgen To Webcast Investor Call At Upcoming American Heart Association Scientific Sessions Amgen (NASDAQ:AMGN) will host a webcast call for the investment community at the American Heart Association (AHA) Scientific Sessions 2014 on...
THOUSAND OAKS, Calif. , Nov. 12, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will host a webcast call for the investment community at the American Heart Association (AHA) Scientific Sessions 2014 on Tuesday, Nov. 18 , at 6 p.m. CT . Rob Scott , M.D., vice president of Global Devel
Read more →AMGNAmgen To Highlight New Data For Investigational Cholesterol-Lowering Medication Evolocumab Amgen (NASDAQ:AMGN) today announced that it will present 13 abstracts at the upcoming American Heart Association (AHA) Scientific Sessions 2014 being ...
THOUSAND OAKS, Calif. , Nov. 12, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will present 13 abstracts at the upcoming American Heart Association (AHA) Scientific Sessions 2014 being held Nov. 15-19 in Chicago , including data from studies evaluating evoloc
Read more →AMGNAmgen And AstraZeneca Announce Positive Results From Second Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis Amgen (NASDAQ: AMGN) and AstraZeneca (NYSE: AZN) today announced that AMAGINE-3TM, a pivotal, multi-arm Phase 3 trial evaluating two doses of...
THOUSAND OAKS, Calif. and LONDON , Nov. 11, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and AstraZeneca (NYSE: AZN ) today announced that AMAGINE-3 TM , a pivotal, multi-arm Phase 3 trial evaluating two doses of brodalumab in more than 1,800 patients with moderate-to-severe plaque
Read more →AMGNFDA Accepts Amgen's Biologics License Application For LDL Cholesterol-Lowering Medication Evolocumab Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Amgen's Biologics License Application...
THOUSAND OAKS, Calif. , Nov. 10, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Amgen's Biologics License Application (BLA) for evolocumab for the treatment of high cholesterol. Evolocumab is an
Read more →AMGNAmgen To Present At The Credit Suisse Annual Healthcare Conference Amgen (NASDAQ: AMGN) will participate at the Credit Suisse Annual Healthcare Conference on Tuesday, Nov. 11, 2014, at The Arizona Biltmore in...
THOUSAND OAKS, Calif. , Nov. 6, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will participate at the Credit Suisse Annual Healthcare Conference on Tuesday, Nov. 11, 2014 , at The Arizona Biltmore in Phoenix , beginning at 8:30 a.m. MT . David W. Meline , executive vice president an
Read more →AMGNAmgen Highlights New Data In The Treatment Of Blood Cancers At ASH 2014 Amgen (NASDAQ:AMGN) and its subsidiary, Onyx Pharmaceuticals, Inc., today announced that more than 50 abstracts from the Company's oncology and...
THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif. , Nov. 6, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and its subsidiary, Onyx Pharmaceuticals, Inc., today announced that more than 50 abstracts from the Company's oncology and hematology portfolios have been accepted for pres
Read more →AMGNAmgen Announces Top-Line Secondary Endpoint Results Of Phase 3 Trebananib TRINOVA-1 Trial In Patients With Recurrent Ovarian Cancer Amgen (NASDAQ:AMGN) today announced the top-line secondary endpoint results of overall survival from the Phase 3 TRINOVA-1 trial in women with...
THOUSAND OAKS, Calif. , Nov. 4, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the top-line secondary endpoint results of overall survival from the Phase 3 TRINOVA-1 trial in women with recurrent platinum-resistant ovarian cancer. The study, which evaluated trebananib
Read more →AMGNAmgen Outlines Strategy, Growth Objectives And Capital Allocation Plans Amgen (NASDAQ:AMGN) today outlined the Company's strategy, growth objectives and capital allocation plans, and provided financial guidance for 2015....
NEW YORK , Oct. 28, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today outlined the Company's strategy, growth objectives and capital allocation plans, and provided financial guidance for 2015. Robert A. Bradway , chairman and chief executive officer at Amgen, opened the meeting b
Read more →AMGNAmgen's Third Quarter 2014 Revenues Increased 6 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 19 Percent To $2.30 Amgen (NASDAQ: AMGN) today announced financial results for the third quarter of 2014. Key results include: Total revenues increased 6 percent to...
THOUSAND OAKS, Calif. , Oct. 27, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced financial results for the third quarter of 2014. Key results include: "Our 22 percent adjusted operating income growth reflects strong performance across our business in the third quarter
Read more →AMGNAmgen To Webcast 2014 Business Review Meeting On October 28 Amgen (NASDAQ: AMGN) today announced that it will hold its Business Review Meeting on Tuesday, Oct. 28, 2014, at the Conrad New York, 102 North End...
THOUSAND OAKS, Calif. , Oct. 23, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will hold its Business Review Meeting on Tuesday, Oct. 28, 2014 , at the Conrad New York, 102 North End Avenue, New York City , beginning at 8 a.m. ET . In the meeting, Robert A. B
Read more →AMGNAmgen Announces Webcast of 2014 Third Quarter Financial Results Amgen (NASDAQ: AMGN) today announced that it will report its third quarter financial results on Monday, Oct. 27, 2014, after the close of the U.S....
THOUSAND OAKS, Calif. , Oct. 23, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will report its third quarter financial results on Monday, Oct. 27, 2014 , after the close of the U.S. financial markets. The announcement will be followed by a conference call wit
Read more →AMGNAmgen Statement Regarding Third Point Investment Amgen (NASDAQ: AMGN) issued the following statement with respect to media inquiries concerning Third Point LLC's equity position in Amgen: Amgen...
THOUSAND OAKS, Calif. , Oct. 21, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) issued the following statement with respect to media inquiries concerning Third Point LLC's equity position in Amgen: Amgen maintains an active, engaged dialogue with all shareholders. Amgen has always a
Read more →AMGNAmgen Files Lawsuit Against Sanofi And Regeneron For Patent Infringement Amgen (NASDAQ: AMGN) today announced that it filed a lawsuit in the United States (U.S.) District Court of Delaware against Sanofi, Aventisub LLC,...
THOUSAND OAKS, Calif. , Oct. 17, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it filed a lawsuit in the United States (U.S.) District Court of Delaware against Sanofi, Aventisub LLC, formerly doing business as Aventis Pharmaceuticals Inc. (collectively "Sanofi"
Read more →AMGNAmgen Announces Appointment Of R. Sanders Williams To Board Of Directors Amgen (NASDAQ: AMGN) today announced the appointment of R. Sanders Williams, M.D., president of Gladstone Institutes and Gladstone's Robert W. and...
THOUSAND OAKS, Calif. , Oct. 17, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the appointment of R. Sanders Williams , M.D., president of Gladstone Institutes and Gladstone's Robert W. and Linda L. Mahley Distinguished Professor. "We are pleased to welcome Dr. Sand
Read more →AMGNAmgen Announces 2014 Fourth Quarter Dividend Amgen (NASDAQ: AMGN) announced that its Board of Directors today declared a $0.61 per share dividend for the fourth quarter of 2014. The dividend...
THOUSAND OAKS, Calif. , Oct. 17, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) announced that its Board of Directors today declared a $0.61 per share dividend for the fourth quarter of 2014. The dividend will be paid on Dec. 5, 2014 , to all stockholders of record as of the close of
Read more →AMGNAmgen's BiTE® Immunotherapy Blinatumomab Receives FDA Priority Review Designation In Acute Lymphoblastic Leukemia Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) ...
THOUSAND OAKS, Calif. , Oct. 9, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for the investigational bispecific T cell engager (BiTE ® ) antibody constru
Read more →AMGNAmgen Announces Positive Top-Line Results From Phase 3 Study Evaluating The Efficacy And Safety Of Biosimilar Candidate ABP 501 Compared With Adalimumab In Patients With Moderate-To-Severe Plaque Psoriasis Amgen (NASDAQ:AMGN) today announced its Phase 3 study evaluating efficacy and safety of biosimilar candidate ABP 501 compared with Humira®...
THOUSAND OAKS, Calif. , Oct. 8, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced its Phase 3 study evaluating efficacy and safety of biosimilar candidate ABP 501 compared with Humira ® (adalimumab) in patients with moderate-to-severe plaque psoriasis met its primary end
Read more →AMGNThe Lancet Publishes Two Phase 3 Studies Showing Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL Cholesterol In Patients With Serious Genetic Disorders That Cause High Cholesterol Amgen (NASDAQ:AMGN) today announced The Lancet published data from two Phase 3 studies, RUTHERFORD-2 and TESLA, that showed treatment with...
THOUSAND OAKS, Calif. , Oct. 1, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced The Lancet published data from two Phase 3 studies, RUTHERFORD-2 and TESLA, that showed treatment with evolocumab, a novel investigational low-density lipoprotein cholesterol (LDL-C)-loweri
Read more →AMGNAmgen Announces Moderate-To-Severe Plaque Psoriasis Data To Be Presented At The 23rd Congress Of The European Academy Of Dermatology And Venereology Amgen (NASDAQ:AMGN) today announced that it will present several studies related to brodalumab, Enbrel® (etanercept) and ABP 501 (adalimumab...
THOUSAND OAKS, Calif. , Oct. 1, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will present several studies related to brodalumab, Enbrel ® (etanercept) and ABP 501 (adalimumab biosimilar) at the 23 rd Congress of the European Academy of Dermatology and Venere
Read more →AMGNAmgen to Host Summary Webcast of Kyprolis® (carfilzomib) for Injection Data Presented at The European Society for Medical Oncology (ESMO) 2014 Congress Amgen (NASDAQ: AMGN) and its subsidiary Onyx Pharmaceuticals, Inc. today announced that they will host a summary webcast of Kyprolis® (carfilzomib)...
THOUSAND OAKS, Calif. , Sept. 24, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and its subsidiary Onyx Pharmaceuticals, Inc. today announced that they will host a summary webcast of Kyprolis ® (carfilzomib) for Injection data presented at the European Society for Medical Oncology (
Read more →AMGNAmgen Submits Biologics License Application for Investigational BiTE® Immunotherapy Blinatumomab Amgen (NASDAQ: AMGN) today announced submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking...
THOUSAND OAKS, Calif. , Sept. 22, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval for its investigational bispecific T cell engager (BiTE ® ) antibody co
Read more →AMGNAmgen Announces Results From Several New Exploratory Analyses Evaluating Long-Term Impact Of Treatment With Prolia® (Denosumab) In Postmenopausal Women With Osteoporosis Amgen (NASDAQ:AMGN) today announced results from a new exploratory analysis of the open-label extension study of the pivotal Phase 3 fracture trial,...
THOUSAND OAKS, Calif. , Sept. 15, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced results from a new exploratory analysis of the open-label extension study of the pivotal Phase 3 fracture trial, which found that treatment with Prolia ® (denosumab) for eight years enabl
Read more →AMGNNew Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels:UCB) today announced results from several exploratory analyses of the Phase 2 study evaluating...
THOUSAND OAKS, Calif. and BRUSSELS , Sept. 15, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and UCB (Euronext Brussels:UCB) today announced results from several exploratory analyses of the Phase 2 study evaluating romosozumab in postmenopausal women with low bone mineral density (B
Read more →AMGNAmgen Presents Analyses Of Phase 3 Ivabradine Data For The Treatment Of Chronic Heart Failure Amgen (NASDAQ:AMGN) today announced data from the Phase 3 SHIFT (Systolic Heart failure treatment with the If inhibitor ivabradine Trial) study...
THOUSAND OAKS, Calif. , Sept. 14, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced data from the Phase 3 SHIFT ( S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial) study evaluating ivabradine in patients with chronic heart failure (HF) were pre
Read more →AMGNAmgen Announces 23 Abstracts To Be Presented At The American Society for Bone and Mineral Research 2014 Annual Meeting Amgen (NASDAQ: AMGN) today announced that it will present data from multiple Prolia® (denosumab) and romosozumab study analyses at the American...
THOUSAND OAKS, Calif. , Sept. 10, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will present data from multiple Prolia ® (denosumab) and romosozumab study analyses at the American Society for Bone and Mineral Research (ASBMR) 2014 Annual Meeting being held in
Read more →AMGNAmgen To Present At The Morgan Stanley Global Healthcare Conference Amgen (NASDAQ:AMGN) will participate in the Morgan Stanley Global Healthcare Conference on Wednesday, Sept. 10, 2014, at the Grand Hyatt New York in...
THOUSAND OAKS, Calif. , Sept. 5, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will participate in the Morgan Stanley Global Healthcare Conference on Wednesday, Sept. 10, 2014 , at the Grand Hyatt New York in New York City , beginning at 9:10 a.m. ET . Robert A. Bradway , chairman a
Read more →AMGNAmgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency Amgen (NASDAQ:AMGN) today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) via the...
THOUSAND OAKS, Calif. , Sept. 2, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) via the centralized procedure for talimogene laherparepvec seeking approval for the tre
Read more →AMGNAmgen Announces Positive Top-Line Results From Phase 3 YUKAWA-2 Trial Of Evolocumab In Combination With Statins In Japanese Patients With High Cardiovascular Risk And High Cholesterol Amgen (NASDAQ:AMGN) today announced that the Phase 3 YUKAWA-2 (StudY of LDL-Cholesterol Reduction Using a Monoclonal PCSK9 Antibody in Japanese...
THOUSAND OAKS, Calif. , Aug. 28, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the Phase 3 YUKAWA-2 (Stud Y of LDL-Cholesterol Reduction U sing a Monoclonal PCS K 9 A ntibody in Japanese Patients W ith A dvanced Cardiovascular Risk) study evaluating evolocumab i
Read more →AMGNAmgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA Amgen (NASDAQ: AMGN) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for...
THOUSAND OAKS, Calif. , Aug. 28, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for evolocumab seeking approval for the treatment of high cholesterol. Evolocumab is
Read more →AMGNFDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure Amgen (NASDAQ: AMGN) today announced the U.S. Food and Drug Administration (FDA) has granted priority review designation for ivabradine for the...
THOUSAND OAKS, Calif. , Aug. 27, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the U.S. Food and Drug Administration (FDA) has granted priority review designation for ivabradine for the treatment of chronic heart failure (HF). Ivabradine is an oral drug that inhibits
Read more →AMGNAmgen Announces Positive Top-Line Results From Second Phase 3 Study Of AMG 416 For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease Receiving Hemodialysis Amgen (NASDAQ:AMGN) today announced that a second placebo-controlled Phase 3 study evaluating AMG 416 for the treatment of secondary...
THOUSAND OAKS, Calif. , Aug. 18, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that a second placebo-controlled Phase 3 study evaluating AMG 416 for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD), receiving hemodia
Read more →AMGNAmgen Issues Voluntary Recall of Aranesp® (darbepoetin alfa) (500 mcg) Prefilled Syringes in Several Countries Outside of the United States Due to the Presence of Visible Particulates Amgen (NASDAQ:AMGN) initiated a voluntary recall on June 26, 2014 for nine packaged lots of Aranesp® (darbepoetin alfa) (500 mcg) prefilled syringes...
THOUSAND OAKS, Calif. , Aug. 13, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) initiated a voluntary recall on June 26, 2014 for nine packaged lots of Aranesp ® (darbepoetin alfa) (500 mcg) prefilled syringes from non-U.S. distributors, wholesalers and a number of hospital pharmacie
Read more →AMGNAmgen Announces Top-Line Results From Phase 3 Focus Trial Of Kyprolis® In Patients With Relapsed And Advanced Refractory Multiple Myeloma Amgen (NASDAQ:AMGN) and its subsidiary, Onyx Pharmaceuticals, Inc., today announced that the Phase 3 clinical trial FOCUS (CarFilzOmib for AdvanCed...
THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif. , Aug. 13, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and its subsidiary, Onyx Pharmaceuticals, Inc., today announced that the Phase 3 clinical trial FOCUS (Car F ilz O mib for Advan C ed Refractory M U ltiple Myeloma European
Read more →AMGNAmgen Announces Phase 3 ASPIRE Trial Of Kyprolis® In Patients With Relapsed Multiple Myeloma Met Primary Endpoint Amgen (NASDAQ:AMGN) and its subsidiary, Onyx Pharmaceuticals, Inc., today announced that a planned interim analysis demonstrated that the Phase 3...
THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif. , Aug. 4, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and its subsidiary, Onyx Pharmaceuticals, Inc., today announced that a planned interim analysis demonstrated that the Phase 3 clinical trial ASPIRE (C A rfilzomib, Lenalidom
Read more →AMGNAmgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 Amgen (NASDAQ: AMGN) today announced financial results for the second quarter of 2014. Key results include: Total revenues increased 11 percent to...
THOUSAND OAKS, Calif. , July 29, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced financial results for the second quarter of 2014. Key results include: "Robust growth through the first half of 2014 affirms the underlying strength of our business," said Robert A. Bradw
Read more →AMGNAmgen Announces 2014 Third Quarter Dividend Amgen (NASDAQ: AMGN) announced that its Board of Directors today declared a $0.61 per share dividend for the third quarter of 2014. The dividend will ...
THOUSAND OAKS, Calif. , July 25, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) announced that its Board of Directors today declared a $0.61 per share dividend for the third quarter of 2014. The dividend will be paid on Sept. 5, 2014 , to all stockholders of record as of the close of
Read more →AMGNAmgen Announces Webcast of 2014 Second Quarter Financial Results Amgen (NASDAQ:AMGN) today announced that it will report its second quarter financial results on Tuesday, July 29, 2014, after the close of the U.S....
THOUSAND OAKS, Calif. , July 24, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will report its second quarter financial results on Tuesday, July 29, 2014 , after the close of the U.S. financial markets. The announcement will be followed by a conference call w
Read more →AMGNAmgen Announces Positive Phase 3 Results for AMG 416 for the Treatment of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease Receiving Hemodialysis Amgen (NASDAQ:AMGN) today announced that a Phase 3 study evaluating AMG 416 (formerly known as velcalcetide) for the treatment of secondary...
THOUSAND OAKS, Calif. , July 17, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that a Phase 3 study evaluating AMG 416 (formerly known as velcalcetide) for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD), receiving
Read more →AMGNAmgen Receives FDA Breakthrough Therapy Designation For Investigational BiTE® Antibody Blinatumomab In Acute Lymphoblastic Leukemia Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to investigational...
THOUSAND OAKS, Calif. , July 1, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to investigational bispecific T cell engager (BiTE ® ) antibody blinatumomab, for adults with P
Read more →AMGNAmgen Joins The National Cancer Institute And Research Partners To Help Accelerate Development Of Personalized Treatment Approaches For Squamous Cell Lung Cancer Amgen (NASDAQ:AMGN) announced today that it will collaborate with the National Cancer Institute (NCI), part of the National Institutes of Health, and ...
THOUSAND OAKS, Calif. , June 16, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) announced today that it will collaborate with the National Cancer Institute (NCI), part of the National Institutes of Health, and other public and private sector partners on the Lung Master Protocol (Lung
Read more →AMGNBrodalumab Treatment Improved Clinical Signs And Symptoms In Phase 2 Psoriatic Arthritis Study Published In The New England Journal Of Medicine Amgen (NASDAQ:AMGN) and AstraZeneca today announced that results from a Phase 2 study evaluating brodalumab in 168 patients with psoriatic arthritis...
THOUSAND OAKS, Calif. and LONDON , June 11, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and AstraZeneca today announced that results from a Phase 2 study evaluating brodalumab in 168 patients with psoriatic arthritis were published in The New England Journal of Medicine (NEJM). Th
Read more →AMGNAmgen Appoints David W. Meline Executive Vice President and Chief Financial Officer Amgen (NASDAQ:AMGN) today announced the appointment of David W. Meline as executive vice president and chief financial officer (CFO), effective July...
THOUSAND OAKS, Calif. , June 9, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the appointment of David W. Meline as executive vice president and chief financial officer (CFO), effective July 21, 2014 . He will be responsible for Amgen's finance and investor relations
Read more →AMGNAmgen To Present At The Goldman Sachs Global Healthcare Conference Amgen (NASDAQ:AMGN) will present at the Goldman Sachs Global Healthcare Conference at 1:20 p.m. PT on Wednesday, June 11, 2014, at the Terranea...
THOUSAND OAKS, Calif. , June 6, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Goldman Sachs Global Healthcare Conference at 1:20 p.m. PT on Wednesday, June 11, 2014 , at the Terranea Resort in Rancho Palos Verdes, Calif. Anthony C. Hooper , executive vice preside
Read more →AMGNNew Detailed Phase 3 Data Show Amgen's Novel Investigational Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL Cholesterol In Patients With A Rare And Serious Genetic Disorder That Causes High Cholesterol Amgen (NASDAQ:AMGN) today announced new detailed data from the Phase 3 TESLA study evaluating its novel investigational cholesterol-lowering...
THOUSAND OAKS, Calif. , June 1, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced new detailed data from the Phase 3 TESLA study evaluating its novel investigational cholesterol-lowering medication, evolocumab (AMG 145), in patients with homozygous familial hypercholeste
Read more →AMGNAmgen Highlights Phase 2 Results Of Vectibix® (panitumumab) Versus bevacizumab In Combination With FOLFOX In Patients With Wild-Type RAS (KRAS And NRAS) Metastatic Colorectal Cancer Amgen (NASDAQ:AMGN) today announced results from the Phase 2 PEAK study that reinforce the improved overall survival (OS) benefit of panitumumab...
THOUSAND OAKS, Calif. , May 31, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced results from the Phase 2 PEAK study that reinforce the improved overall survival (OS) benefit of panitumumab (Vectibix ® ) when used in combination with FOLFOX, an oxaliplatin-based chemoth
Read more →AMGNAmgen To Present At The Jefferies 2014 Global Healthcare Conference Amgen (NASDAQ:AMGN) will present at the Jefferies 2014 Global Healthcare Conference at 11:30 a.m. ET on Wednesday, June 4, 2014, at the Grand Hyatt...
THOUSAND OAKS, Calif. , May 30, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Jefferies 2014 Global Healthcare Conference at 11:30 a.m. ET on Wednesday, June 4, 2014 , at the Grand Hyatt New York in New York City . Arvind Sood , vice president of Investor Relatio
Read more →AMGNAmgen To Host Post-American Society of Clinical Oncology (ASCO) Summary Webcast Amgen (NASDAQ:AMGN) today announced that it will hold a post-American Society of Clinical Oncology (ASCO) summary webcast on Tuesday, June 3, 2014,...
THOUSAND OAKS, Calif. , May 29, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will hold a post-American Society of Clinical Oncology (ASCO) summary webcast on Tuesday, June 3, 2014 , at 1 p.m. PT . Sean E. Harper , M.D., executive vice president of Research a
Read more →AMGNAmgen and Onyx Data at ASCO 2014 Highlight Oncology Pipeline and Portfolio Amgen (NASDAQ:AMGN) and its subsidiary Onyx Pharmaceuticals, Inc., today announced data from several studies of both pipeline and marketed products...
THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif. , May 27, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and its subsidiary Onyx Pharmaceuticals, Inc., today announced data from several studies of both pipeline and marketed products will be presented at the 50 th Annual Meeting
Read more →AMGNThe New England Journal Of Medicine Publishes Positive Proof-Of-Concept Data For New Asthma Treatment Amgen (NASDAQ:AMGN) today announced that The New England Journal of Medicine (NEJM) published positive results from a Phase 1 study adding to the...
THOUSAND OAKS, Calif. , May 20, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that The New England Journal of Medicine (NEJM) published positive results from a Phase 1 study adding to the growing body of evidence that inhibiting thymic stromal lymphopoietin (TSLP) co
Read more →AMGNJournal Of The American Medical Association Publishes Phase 3 LAPLACE-2 Study Showing Evolocumab Significantly Reduced LDL Cholesterol In Patients On Statins Regardless Of Statin Dose Amgen (NASDAQ:AMGN) today announced the publication of data from the Phase 3 LAPLACE-2 (LDL-C Assessment with PCSK9 MonoclonaL Antibody Inhibition...
THOUSAND OAKS, Calif. , May 13, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the publication of data from the Phase 3 LAPLACE-2 ( L DL-C A ssessment with P CSK9 Monoclona L A ntibody Inhibition C ombined with Statin Th E rapy-2) study in the Journal of the American
Read more →AMGNAmgen's Breakaway from Cancer® Honors Four California Cancer Survivors During The Ninth Annual Amgen Tour of California Amgen today announced that four individuals who are an inspiration for others affected by cancer have been selected as Breakaway from Cancer®...
THOUSAND OAKS, Calif. , May 12, 2014 /PRNewswire/ -- Amgen today announced that four individuals who are an inspiration for others affected by cancer have been selected as Breakaway from Cancer ® Champions. They will be honored as part of Amgen's Breakaway from Cancer national in
Read more →AMGNAmgen Names Steven K. Galson, Senior Vice President, Global Regulatory Affairs And Safety Amgen (NASDAQ: AMGN) today announced the appointment of Steven K. Galson, M.D., M.P.H., to the position of senior vice president, Global Regulatory...
THOUSAND OAKS, Calif. , May 12, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the appointment of Steven K. Galson , M.D., M.P.H., to the position of senior vice president, Global Regulatory Affairs and Safety, effective May 19 . Galson will report to Sean E. Harper ,
Read more →AMGNAmgen And AstraZeneca Announce Positive Results From Phase 3 Study Of Brodalumab (AMG 827) In Patients With Moderate-to-Severe Plaque Psoriasis Amgen (NASDAQ: AMGN) and AstraZeneca today announced that the Phase 3 AMAGINE-1TM study evaluating brodalumab in patients with moderate-to-severe...
THOUSAND OAKS, Calif. and LONDON , May 9, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and AstraZeneca today announced that the Phase 3 AMAGINE-1 TM study evaluating brodalumab in patients with moderate-to-severe plaque psoriasis met all primary and secondary endpoints for both eva
Read more →AMGNAmgen's First Quarter 2014 Revenues Increased 7 Percent To $4.5 Billion Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2014. Key results include: Total revenues increased 7 percent to...
THOUSAND OAKS, Calif. , April 22, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced financial results for the first quarter of 2014. Key results include: "Strong underlying demand for our products and growth in adjusted operating income make us confident in our full-yea
Read more →AMGNAmgen Announces Webcast of 2014 First Quarter Financial Results Amgen (NASDAQ: AMGN) today announced that it will report its first quarter financial results on Tuesday, April 22, 2014, after the close of the U.S....
THOUSAND OAKS, Calif. , April 17, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will report its first quarter financial results on Tuesday, April 22, 2014 , after the close of the U.S. financial markets. The announcement will be followed by a conference call
Read more →AMGNAmgen Provides Update On Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma Amgen (NASDAQ: AMGN) today announced top-line results from the primary overall survival (OS) analysis of a Phase 3 trial in melanoma, which evaluated ...
THOUSAND OAKS, Calif. , April 4, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced top-line results from the primary overall survival (OS) analysis of a Phase 3 trial in melanoma, which evaluated the efficacy and safety of talimogene laherparepvec for the treatment of un
Read more →AMGNData From Phase 3 Pivotal Studies Show Amgen's Novel Investigational Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL Cholesterol In Statin Intolerant Patients And In Patients On Statins Amgen (NASDAQ: AMGN) today announced new detailed data from two Phase 3 pivotal studies that showed treatment with its novel investigational...
THOUSAND OAKS, Calif. , March 30, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced new detailed data from two Phase 3 pivotal studies that showed treatment with its novel investigational cholesterol-lowering medication, evolocumab (AMG 145), resulted in a statistically
Read more →AMGNNew Detailed Data from Three Phase 3 Pivotal Studies Show Amgen's Novel Investigational Cholesterol-Lowering Medicine Evolocumab Significantly Reduced LDL Cholesterol By 55-66 Percent Compared To Placebo In Patients With High Cholesterol Amgen (NASDAQ: AMGN) today announced new detailed data from three Phase 3 studies that showed treatment with its novel investigational...
THOUSAND OAKS, Calif. , March 29, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced new detailed data from three Phase 3 studies that showed treatment with its novel investigational cholesterol-lowering medication, evolocumab (AMG 145), resulted in a statistically signif
Read more →AMGNAmgen To Webcast Investor Meeting At Upcoming American College of Cardiology's 63rd Annual Scientific Session Amgen (NASDAQ:AMGN) will host a webcast investor meeting at the American College of Cardiology's 63rd Annual Scientific Session (ACC.14) in...
THOUSAND OAKS, Calif. , March 26, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will host a webcast investor meeting at the American College of Cardiology's 63rd Annual Scientific Session (ACC.14) in Washington, D.C. on Sunday, March 30 , at 7 p.m. EDT . Sean E. Harper , M.D., execu
Read more →AMGNPhase 3 Pivotal Data On Amgen's Novel Investigational Cholesterol-Lowering Medicine To Be Featured At The American College of Cardiology's 63rd Annual Scientific Session Amgen (NASDAQ:AMGN) today announced that it will present pivotal Phase 3 data from five clinical studies evaluating evolocumab (AMG 145), an...
THOUSAND OAKS, Calif. , March 24, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will present pivotal Phase 3 data from five clinical studies evaluating evolocumab (AMG 145), an investigational fully human monoclonal antibody that inhibits PCSK9, a protein tha
Read more →AMGNAmgen Announces Positive Top-Line Results From Phase 3 TESLA Trial Of Evolocumab (AMG 145) In Patients With Homozygous Familial Hypercholesterolemia Amgen (NASDAQ:AMGN) today announced that the Phase 3 TESLA (Trial Evaluating PCSK9 Antibody in Subjects with LDL Receptor Abnormalities) trial...
THOUSAND OAKS, Calif. , March 17, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the Phase 3 TESLA ( T rial E valuating PCSK9 Antibody in S ubjects with L DL Receptor A bnormalities) trial evaluating evolocumab met its primary endpoint of the percent reduction fr
Read more →AMGNAmgen's Talimogene Laherparepvec Reduced Size Of Melanoma Tumors In New Phase 3 Retrospective Analysis Amgen (NASDAQ:AMGN) today announced findings from a pre-specified retrospective analysis of patients with metastatic melanoma that showed talimogene...
THOUSAND OAKS, Calif. , March 14, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced findings from a pre-specified retrospective analysis of patients with metastatic melanoma that showed talimogene laherparepvec reduced the size of injected tumors and also non-injected tu
Read more →AMGNAmgen Announces 2014 Second Quarter Dividend Amgen (NASDAQ:AMGN) announced that its Board of Directors today declared a $0.61 per share dividend for the second quarter of 2014. The dividend will ...
THOUSAND OAKS, Calif. , March 5, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) announced that its Board of Directors today declared a $0.61 per share dividend for the second quarter of 2014. The dividend will be paid on June 6, 2014 , to all stockholders of record as of the close of
Read more →AMGNAmgen To Present At The Cowen And Company 34th Annual Healthcare Conference Amgen (NASDAQ:AMGN) will present at the Cowen and Company 34th Annual Healthcare Conference at 2:10 p.m. ET on Monday, Mar. 3, 2014, at the Boston...
THOUSAND OAKS, Calif. , March 1, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Cowen and Company 34 th Annual Healthcare Conference at 2:10 p.m. ET on Monday, Mar. 3, 2014 , at the Boston Marriott Copley Place in Boston . Anthony C. Hooper , executive vice presid
Read more →AMGNAmgen To Present At The RBC Capital Markets' Global Healthcare Conference Amgen (NASDAQ: AMGN) will present at the RBC Capital Markets' Global Healthcare Conference at 4:05 p.m. ET on Wednesday, Feb. 26, 2014, at the New...
THOUSAND OAKS, Calif. , Feb. 21, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the RBC Capital Markets' Global Healthcare Conference at 4:05 p.m. ET on Wednesday, Feb. 26, 2014 , at the New York Palace Hotel in New York City. Arvind Sood , vice president of Investor
Read more →AMGNAmgen And Merck Announce Collaboration To Evaluate Investigational Combination Treatment For Advanced Melanoma Amgen (NASDAQ:AMGN) and Merck, known as MSD outside the United States and Canada, announced today that they have entered into an agreement through a...
THOUSAND OAKS, Calif. , Feb. 5, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and Merck, known as MSD outside the United States and Canada , announced today that they have entered into an agreement through a subsidiary to evaluate the safety and efficacy of talimogene laherparepvec,
Read more →AMGNAmgen Announces Positive Top-Line Results From Phase 3 RUTHERFORD-2 Trial Of Evolocumab (AMG 145) In Patients With Heterozygous Familial Hypercholesterolemia Amgen (NASDAQ:AMGN) today announced that the Phase 3 RUTHERFORD-2 (RedUction of LDL-C with PCSK9 InhibiTion in HEteRozygous Familial...
THOUSAND OAKS, Calif. , Jan. 30, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the Phase 3 RUTHERFORD-2 ( R ed U ction of LDL-C with PCSK9 Inhibi T ion in HE te R ozygous F amilial Hyperch O leste R olemia D isorder Study-2) trial evaluating evolocumab in combin
Read more →AMGNAmgen Announces Positive Top-Line Results From Phase 3 LAPLACE-2 Trial Of Evolocumab (AMG 145) In Combination With Statins In Patients With High Cholesterol Amgen (NASDAQ:AMGN) today announced that the Phase 3 LAPLACE-2 (LDL-C Assessment with PCSK9 MonoclonaL Antibody Inhibition Combined with Statin...
THOUSAND OAKS, Calif. , Jan. 28, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the Phase 3 LAPLACE-2 ( L DL-C A ssessment with P CSK9 Monoclona L A ntibody Inhibition C ombined with Statin Th E rapy-2) trial evaluating evolocumab in combination with statin thera
Read more →AMGNAmgen's 2013 Revenues Increased 8 Percent To $18.7 Billion And Adjusted Earnings Per Share (EPS) Increased 17 Percent To $7.60 Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2013. Key results include: For the fourth quarter,...
THOUSAND OAKS, Calif. , Jan. 28, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced financial results for the fourth quarter and full year of 2013. Key results include: "Amgen delivered financially and strategically in 2013," said Robert A. Bradway , chairman & chief exe
Read more →AMGNAmgen Announces Positive Top-Line Results From Phase 3 GAUSS-2 Trial Of Evolocumab (AMG 145) In Statin Intolerant Patients With High Cholesterol Amgen (NASDAQ:AMGN) today announced that the Phase 3 GAUSS-2 (Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant...
THOUSAND OAKS, Calif. , Jan. 23, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the Phase 3 GAUSS-2 ( G oal A chievement After U tilizing an Anti-PCSK9 Antibody in S tatin Intolerant S ubjects-2) trial evaluating evolocumab in patients with high cholesterol who c
Read more →AMGNAmgen Announces Webcast of 2013 Fourth Quarter and Full Year Financial Results Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2013 financial results on Tuesday, Jan. 28, 2014, after the...
THOUSAND OAKS, Calif. , Jan. 23, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will report its fourth quarter and full year 2013 financial results on Tuesday, Jan. 28, 2014 , after the close of the U.S. financial markets. The announcement will be followed by
Read more →AMGNMass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease Massachusetts General Hospital (MGH), the Broad Institute, and Amgen (NASDAQ:AMGN) announced today that they have launched a strategic collaboration...
THOUSAND OAKS, Calif. , Jan. 15, 2014 /PRNewswire/ -- Massachusetts General Hospital (MGH), the Broad Institute, and Amgen (NASDAQ: AMGN ) announced today that they have launched a strategic collaboration to jointly discover and validate new therapeutic targets and develop novel
Read more →AMGNAmgen To Present At The 32nd Annual J.P. Morgan Healthcare Conference Amgen (NASDAQ:AMGN) will present at the 32nd Annual J.P. Morgan Healthcare Conference at 9:30 a.m. Pacific Standard Time on Tuesday, Jan. 14, 2014,...
THOUSAND OAKS, Calif. , Jan. 9, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the 32 nd Annual J.P. Morgan Healthcare Conference at 9:30 a.m. Pacific Standard Time on Tuesday, Jan. 14, 2014 , at the Westin St. Francis in San Francisco. Robert A. Bradway , chairman an
Read more →AMGNChief Financial Officer Jonathan M. Peacock to Leave Amgen; Company Appoints Michael A. Kelly Acting Chief Financial Officer Amgen (NASDAQ:AMGN) today announced that Jonathan M. Peacock, executive vice president and chief financial officer, is leaving Amgen to pursue...
THOUSAND OAKS, Calif. , Jan. 9, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that Jonathan M. Peacock , executive vice president and chief financial officer, is leaving Amgen to pursue broader career opportunities. Peacock will be stepping down from his role as CFO
Read more →AMGNRomosozumab Phase 2 Data Published In New England Journal Of Medicine Show Significant Increases In Bone Mineral Density At Both Spine And Hip Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels:UCB) today announced results from a Phase 2 trial evaluating romosozumab (AMG 785/CDP7851) in...
THOUSAND OAKS, Calif. and BRUSSELS , Jan. 1, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and UCB (Euronext Brussels:UCB) today announced results from a Phase 2 trial evaluating romosozumab (AMG 785/CDP7851) in postmenopausal women with low bone mineral density (BMD). Published in
Read more →AMGNAmgen Announces Positive Top-Line Results From 52-Week Phase 3 DESCARTES Study Of Evolocumab (AMG 145) In Patients With High Cholesterol Amgen (NASDAQ:AMGN) today announced that the Phase 3 DESCARTES (Durable Effect of PCSK9 Antibody CompARed wiTh PlacEbo Study) study evaluating the...
THOUSAND OAKS, Calif. , Dec. 19, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the Phase 3 DESCARTES ( D urable E ffect of PC S K9 Antibody C omp AR ed wi T h Plac E bo S tudy) study evaluating the long-term 52-week safety and efficacy of evolocumab for the trea
Read more →AMGNAmgen Announces Positive Top-Line Results From Phase 3 MENDEL-2 Trial Of Evolocumab (AMG 145) In Patients With High Cholesterol Amgen (NASDAQ:AMGN) today announced that the Phase 3 MENDEL-2 (Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not...
THOUSAND OAKS, Calif. , Dec. 17, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the Phase 3 MENDEL-2 ( M onoclonal Antibody Against PCSK9 to Reduce E levated LDL-C in Subjects Currently N ot Receiving D rug Therapy for E asing L ipid Levels-2) trial with evolocum
Read more →AMGNAmgen Announces 2014 First Quarter Dividend Amgen (NASDAQ:AMGN) announced that its Board of Directors today declared a $0.61 per share dividend for the first quarter of 2014. The dividend will...
THOUSAND OAKS, Calif. , Dec. 13, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) announced that its Board of Directors today declared a $0.61 per share dividend for the first quarter of 2014. The dividend will be paid on March 7, 2014 , to all stockholders of record as of the close of
Read more →AMGNAmgen To Host Post American Society of Hematology (ASH) Summary Webcast Amgen (NASDAQ:AMGN) and its subsidiary Onyx Pharmaceuticals, Inc. today announced that they will hold a post American Society of Hematology (ASH)...
THOUSAND OAKS, Calif. , Dec. 10, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and its subsidiary Onyx Pharmaceuticals, Inc. today announced that they will hold a post American Society of Hematology (ASH) summary webcast on Wednesday, Dec. 11, 2013 , at 11 a.m. PST . Pablo Cagnoni ,
Read more →AMGNAmgen To Present At The Oppenheimer 24th Annual Healthcare Conference Amgen (NASDAQ:AMGN) will participate at the Oppenheimer 24th Annual Healthcare Conference on Tuesday, Dec. 10, 2013, at the Crowne Plaza in New York...
THOUSAND OAKS, Calif. , Dec. 5, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will participate at the Oppenheimer 24 th Annual Healthcare Conference on Tuesday, Dec. 10, 2013 , at the Crowne Plaza in New York City , beginning at 9:45 a.m. Eastern Standard Time . Arvind Sood , vice p
Read more →AMGNAmgen Announces Evolocumab (AMG 145) Results From First 52-Week Study Of A PCSK9 Inhibitor To Reduce LDL Cholesterol Amgen (NASDAQ:AMGN) today announced results from the Open Label Study of Long TERm Evaluation Against LDL-C (OSLER) trial, a long-term controlled...
THOUSAND OAKS, Calif. , Nov. 19, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced results from the O pen Label S tudy of L ong T ER m Evaluation Against LDL-C (OSLER) trial, a long-term controlled 52-week safety and efficacy study, that showed monthly treatment with evo
Read more →AMGNAmgen Presents Interim Overall Survival Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma Amgen (NASDAQ:AMGN) today announced interim overall survival (OS) results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in...
THOUSAND OAKS, Calif. , Nov. 18, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced interim overall survival (OS) results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-m
Read more →AMGNAmgen To Webcast Investor Meeting At Upcoming American Heart Association Scientific Sessions 2013 Amgen (NASDAQ:AMGN) will host a webcast investor meeting at the American Heart Association (AHA) Scientific Sessions 2013 on Tuesday, Nov. 19, at 7 p....
THOUSAND OAKS, Calif. , Nov. 14, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will host a webcast investor meeting at the American Heart Association (AHA) Scientific Sessions 2013 on Tuesday, Nov. 19 , at 7 p.m. CST . Sean E. Harper , M.D., executive vice president of Research and
Read more →AMGNAmgen to Highlight New Evolocumab (AMG 145) Data at Upcoming American Heart Association Scientific Sessions 2013 Amgen (NASDAQ: AMGN) today announced that it will present new data on evolocumab (AMG 145), an investigational fully human monoclonal antibody that...
THOUSAND OAKS, Calif. , Nov. 12, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will present new data on evolocumab (AMG 145), an investigational fully human monoclonal antibody that inhibits PCSK9, a protein that reduces the liver's ability to remove low-dens
Read more →AMGNAmgen Foundation Commits $2.5 Million In New Grants To Engage 50,000 Students Each Year In The Thrill Of Scientific Inquiry The Amgen Foundation today announced $2.5 million in new grants for the Amgen Biotech Experience, an innovative science education program, bringing...
THOUSAND OAKS, Calif. , Nov. 7, 2013 /PRNewswire/ -- The Amgen Foundation today announced $2.5 million in new grants for the Amgen Biotech Experience, an innovative science education program, bringing the total committed to nearly $8 million since the program's inception in 1990.
Read more →AMGNAmgen Acquires Filgrastim Franchise Rights From Roche In 100 Markets Amgen (NASDAQ:AMGN) today announced that it has entered into a definitive agreement with F. Hoffmann-La Roche ( Roche ) to acquire Roche's rights to...
THOUSAND OAKS, Calif. , Oct. 22, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it has entered into a definitive agreement with F. Hoffmann-La Roche ("Roche") to acquire Roche's rights to filgrastim and pegfilgrastim in approximately 100 markets, effective Jan. 1
Read more →AMGNAmgen's Third Quarter 2013 Revenues Increased 10 Percent To $4.7 Billion And Adjusted Earnings Per Share (EPS) Increased 16 Percent To $1.94 Amgen (NASDAQ:AMGN) today announced results for the third quarter of 2013. Key financial results for the quarter include: Total revenues increased 10 ...
THOUSAND OAKS, Calif. , Oct. 22, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced results for the third quarter of 2013. Key financial results for the quarter include: "We delivered excellent operating performance this quarter," said Robert A. Bradway , chairman and ch
Read more →AMGNAmgen Announces Webcast of 2013 Third Quarter Financial Results Amgen (NASDAQ:AMGN) today announced that it will report its third quarter financial results on Tuesday, Oct. 22, 2013, after the close of the U.S....
THOUSAND OAKS, Calif. , Oct. 17, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will report its third quarter financial results on Tuesday, Oct. 22, 2013 , after the close of the U.S. financial markets. The announcement will be followed by a conference call wi
Read more →AMGNAmgen Announces Appointment Of Greg C. Garland To Board Of Directors Amgen (NASDAQ: AMGN) today announced the appointment of Greg C. Garland, chairman, president and chief executive officer of Phillips 66, to its Board ...
THOUSAND OAKS, Calif. , Oct. 16, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the appointment of Greg C. Garland , chairman, president and chief executive officer of Phillips 66, to its Board of Directors. "We are pleased to welcome Greg Garland to the Amgen Board.
Read more →AMGNAmgen Announces 2013 Fourth Quarter Dividend Amgen (NASDAQ: AMGN) announced that its Board of Directors today declared a $0.47 per share dividend for the fourth quarter of 2013. The dividend...
THOUSAND OAKS, Calif. , Oct. 16, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) announced that its Board of Directors today declared a $0.47 per share dividend for the fourth quarter of 2013. The dividend will be paid on Dec. 6, 2013 , to all stockholders of record as of the close of
Read more →AMGNAmgen Presents Nearly Two Dozen Abstracts From Romosozumab And Prolia® (Denosumab) At ASBMR Amgen (NASDAQ:AMGN) today announced that it will present data from several romosozumab and Prolia® (denosumab) studies at the American Society for...
THOUSAND OAKS, Calif. , Oct. 4, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will present data from several romosozumab and Prolia ® (denosumab) studies at the American Society for Bone and Mineral Research (ASBMR) 2013 Annual Meeting in Baltimore from Oct.
Read more →AMGNAmgen And AstraZeneca Highlight Data To Be Presented At 22nd Congress Of The European Academy Of Dermatology And Venereology Amgen (NASDAQ: AMGN) and AstraZeneca (AZN), with its biologics research and development arm MedImmune, today announced the upcoming presentation of...
THOUSAND OAKS , Calif. and GAITHERSBURG, Md. , Oct. 3, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and AstraZeneca (AZN), with its biologics research and development arm MedImmune, today announced the upcoming presentation of several key studies evaluating brodalumab, a human mono
Read more →AMGNAmgen Successfully Completes Onyx Pharmaceuticals Tender Offer Amgen (NASDAQ:AMGN) today announced that it has successfully completed its previously announced tender offer to purchase all outstanding shares of...
THOUSAND OAKS, Calif. , Oct. 1, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it has successfully completed its previously announced tender offer to purchase all outstanding shares of common stock of Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX ) for $125 per share
Read more →AMGNPhase 3 Trial Comparing Vectibix® (Panitumumab) to Erbitux® (Cetuximab) Meets Primary Endpoint Of Non-Inferiority Of Overall Survival Amgen (NASDAQ:AMGN) today announced detailed results from the Phase 3 ASPECCT ('763) trial comparing Vectibix® (panitumumab) to Erbitux® (cetuximab)...
THOUSAND OAKS, Calif. , Sept. 28, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced detailed results from the Phase 3 ASPECCT ('763) trial comparing Vectibix ® (panitumumab) to Erbitux ® (cetuximab) for the treatment of wild-type KRAS metastatic colorectal cancer in pati
Read more →AMGNAmgen And ShanghaiTech University Announce Plans For Amgen China R&D Center To Open On ShanghaiTech Campus Amgen (NASDAQ: AMGN) and ShanghaiTech University today announced the two organizations have entered into a memorandum of understanding (MOU) to form...
THOUSAND OAKS, Calif. and SHANGHAI , Sept. 24, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and ShanghaiTech University today announced the two organizations have entered into a memorandum of understanding (MOU) to form a strategic partnership for the advancement of biopharmaceutic
Read more →AMGNAmgen and Onyx Pharmaceuticals Announce Early Termination of HSR Waiting Period for Amgen's Acquisition of Onyx Amgen (NASDAQ:AMGN) and Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) today announced that the waiting period under the Hart-Scott-Rodino Antitrust...
THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif. , Sept. 18, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX ) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (HSR), in
Read more →AMGNAmgen Highlights Data To Be Presented At 2013 European Cancer Congress Amgen (NASDAQ: AMGN) today announced that it will present new data from studies of marketed and pipeline products at the 17th ECCO - 38th ESMO - 32nd ...
THOUSAND OAKS, Calif. , Sept. 12, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will present new data from studies of marketed and pipeline products at the 17th ECCO - 38th ESMO - 32nd ESTRO European Cancer Congress happening Sept. 27 to Oct. 1 in Amsterdam .
Read more →AMGNAnalysis Published In New England Journal of Medicine Highlights Discovery Of New Predictive Biomarkers For Vectibix® (Panitumumab) Amgen (NASDAQ:AMGN) today announced the publication of a biomarker analysis of Vectibix® (panitumumab) in combination with FOLFOX, a type of...
THOUSAND OAKS, Calif. , Sept. 11, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the publication of a biomarker analysis of Vectibix ® (panitumumab) in combination with FOLFOX, a type of oxaliplatin-based chemotherapy, for the first-line treatment of patients with met
Read more →AMGNAmgen To Present At The Bank Of America Merrill Lynch Global Healthcare Conference Amgen (NASDAQ:AMGN) will participate in the Bank of America Merrill Lynch Global Healthcare Conference on Friday, Sept. 13, 2013, in London,...
THOUSAND OAKS, Calif. , Sept. 10, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will participate in the Bank of America Merrill Lynch Global Healthcare Conference on Friday, Sept. 13, 2013 , in London , beginning at 1:00 p.m. British Summer Time. Arvind Sood , vice president of Inve
Read more →AMGNAmgen To Present At The Morgan Stanley Global Healthcare Conference Amgen (NASDAQ: AMGN) will participate in the Morgan Stanley Global Healthcare Conference on Wednesday, Sept. 11, 2013, at the Grand Hyatt New York in ...
THOUSAND OAKS, Calif. , Sept. 6, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will participate in the Morgan Stanley Global Healthcare Conference on Wednesday, Sept. 11, 2013 , at the Grand Hyatt New York in New York City , beginning at 8:35 a.m. Eastern Daylight Time . Robert A. B
Read more →AMGNAmgen And Cytokinetics Announce The First Presentation Of Data From Phase 2 ATOMIC-AHF Study Of Omecamtiv Mecarbil Amgen (NASDAQ: AMGN) and Cytokinetics Incorporated (NASDAQ: CYTK) today announced the first presentation of data from the ATOMIC-AHF (Acute Treatment ...
THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif. , Sept. 3, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and Cytokinetics Incorporated (NASDAQ: CYTK ) today announced the first presentation of data from the ATOMIC-AHF ( A cute T reatment with O mecamtiv M ecarbil to I ncrease
Read more →AMGNAmgen Presents Pooled Analysis Showing AMG 145 Significantly Reduced LDL Cholesterol In Over 1,200 Patients Amgen (NASDAQ: AMGN) today announced treatment with AMG 145 resulted in significant reductions in low-density lipoprotein cholesterol (LDL-C), or...
THOUSAND OAKS, Calif. , Aug. 31, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced treatment with AMG 145 resulted in significant reductions in low-density lipoprotein cholesterol (LDL-C), or "bad" cholesterol, of up to 59 percent in an efficacy analysis of pooled data f
Read more →AMGNAmgen To Participate At Citi's 8th Annual Biotech Conference Amgen (NASDAQ:AMGN) will participate at Citi's 8th Annual Biotech Conference on Tuesday, Sept. 3, 2013, in Boston, beginning at 2:00 p.m. Eastern...
THOUSAND OAKS, Calif. , Aug. 30, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will participate at Citi's 8 th Annual Biotech Conference on Tuesday, Sept. 3, 2013 , in Boston , beginning at 2:00 p.m. Eastern Daylight Time . Scott Foraker , vice president and general manager of Biosi
Read more →AMGNAmgen to Highlight New Data at Upcoming ESC Congress 2013 Amgen (NASDAQ:AMGN) today announced that it will present new data on omecamtiv mecarbil, a small molecule cardiac myosin activator that is being...
THOUSAND OAKS, Calif. , Aug. 27, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will present new data on omecamtiv mecarbil, a small molecule cardiac myosin activator that is being studied for the treatment of heart failure in collaboration with Cytokinetics.
Read more →AMGNAmgen To Acquire Onyx Pharmaceuticals For $125 Per Share In Cash Amgen (NASDAQ:AMGN) and Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) today announced that their Boards of Directors have unanimously approved a...
THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif. , Aug. 25, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX ) today announced that their Boards of Directors have unanimously approved a transaction under which Amgen will acquire all of
Read more →AMGNAmgen And Servier Complete Product Collaboration Transaction Amgen (NASDAQ:AMGN) and Servier today announced the early termination of the waiting period under the Hart–Scott–Rodino Antitrust Improvements Act of ...
THOUSAND OAKS , Calif. and SURESNES, France , Aug. 12, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and Servier today announced the early termination of the waiting period under the Hart–Scott–Rodino Antitrust Improvements Act of 1976 in connection with the cardiovascular product c
Read more →AMGNAmgen's Second Quarter 2013 Revenues Increased 5 Percent To $4.7 Billion And Adjusted Earnings Per Share (EPS) Increased 3 Percent To $1.89 Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2013. Key results for the quarter include: Total revenues increased 5 ...
THOUSAND OAKS, Calif. , July 30, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced financial results for the second quarter of 2013. Key results for the quarter include: "We saw solid product trends during the second quarter and are carrying good momentum into the secon
Read more →AMGNAmgen Announces 2013 Third Quarter Dividend Amgen (NASDAQ:AMGN) announced that its Board of Directors today declared a $0.47 per share dividend for the third quarter of 2013. The dividend will...
THOUSAND OAKS, Calif. , July 26, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) announced that its Board of Directors today declared a $0.47 per share dividend for the third quarter of 2013. The dividend will be paid on Sept. 6, 2013 , to all stockholders of record as of the close of
Read more →AMGNAmgen Announces Webcast of 2013 Second Quarter Financial Results Amgen (NASDAQ:AMGN) today announced that it will report its second quarter financial results on Tuesday, July 30, 2013, after the close of the U.S....
THOUSAND OAKS, Calif. , July 25, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will report its second quarter financial results on Tuesday, July 30, 2013 , after the close of the U.S. financial markets. The announcement will be followed by a conference call w
Read more →AMGNThe Lancet Oncology Publishes Results Of XGEVA® (denosumab) In Patients With Giant Cell Tumor Of Bone Amgen (NASDAQ:AMGN) today announced the Lancet Oncology published planned interim results from an international, open-label, Phase 2 clinical trial...
THOUSAND OAKS, Calif. , July 15, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the Lancet Oncology published planned interim results from an international, open-label, Phase 2 clinical trial that is evaluating XGEVA ® (denosumab) in adults and skeletally mature adole
Read more →AMGNAmgen Award For Science Teaching Excellence Honors Outstanding Teachers Amgen is pleased to announce the nine science teachers in the United States, Canada and Puerto Rico who are this year's recipients of the Amgen Award ...
THOUSAND OAKS, Calif. , June 19, 2013 /PRNewswire/ -- Amgen is pleased to announce the nine science teachers in the United States , Canada and Puerto Rico who are this year's recipients of the Amgen Award for Science Teaching Excellence (AASTE). Now in its 21st year, the award re
Read more →AMGNFDA Approves Amgen's XGEVA® (denosumab) For The Treatment Of Giant Cell Tumor Of Bone Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for XGEVA® (denosumab) for the...
THOUSAND OAKS, Calif. , June 13, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for XGEVA ® (denosumab) for the treatment of adults and skeletally mature adolescents with giant cell tumor o
Read more →AMGNAmgen Announces Top-Line Results Of Phase 3 Trebananib (AMG 386) TRINOVA-1 Trial In Recurrent Ovarian Cancer Amgen (NASDAQ: AMGN) today announced that the Phase 3 TRINOVA-1 trial evaluating trebananib plus paclitaxel versus placebo plus paclitaxel in...
THOUSAND OAKS, Calif. , June 12, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the Phase 3 TRINOVA-1 trial evaluating trebananib plus paclitaxel versus placebo plus paclitaxel in recurrent ovarian cancer met its primary endpoint of progression-free survival (PFS
Read more →AMGNAmgen And AstraZeneca Highlight Data To Be Presented At European League Against Rheumatism Annual Meeting Amgen (NASDAQ:AMGN) and AstraZeneca (AZN), with its biologics research and development arm MedImmune, today announced that they will present data...
THOUSAND OAKS, Calif. and GAITHERSBURG, Md. , June 12, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and AstraZeneca (AZN), with its biologics research and development arm MedImmune, today announced that they will present data from a Phase 2 study evaluating brodalumab, a human mono
Read more →AMGNAmgen To Present At The Goldman Sachs 34th Annual Global Healthcare Conference Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 34th Annual Global Healthcare Conference on Tuesday, June 11, 2013, at the Terranea Resort,...
THOUSAND OAKS, Calif. , June 6, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Goldman Sachs 34 th Annual Global Healthcare Conference on Tuesday, June 11, 2013 , at the Terranea Resort, Rancho Palos Verdes, Calif. , beginning at 11:20 a.m. PDT . Jonathan M. Peaco
Read more →AMGNAmgen Presents Positive Results From Talimogene Laherparepvec Phase 3 Study In Patients With Metastatic Melanoma Amgen (NASDAQ: AMGN) today announced detailed results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected...
THOUSAND OAKS, Calif. , June 1, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced detailed results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimu
Read more →AMGNAmgen And Astellas Announce Japan Alliance Amgen (NASDAQ:AMGN), the world's largest independent biotechnology company, and Astellas Pharma Inc. (Tokyo Stock Exchange: 4503, Astellas ), a...
THOUSAND OAKS , Calif. and TOKYO , May 29, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN ), the world's largest independent biotechnology company, and Astellas Pharma Inc. (Tokyo Stock Exchange: 4503, "Astellas"), a leading Tokyo -based global pharmaceutical company, today announced t
Read more →AMGNAmgen To Webcast Investor Meeting At Upcoming American Society Of Clinical Oncology Annual Meeting Amgen (NASDAQ: AMGN) will host a webcast investor meeting at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on Saturday,...
THOUSAND OAKS, Calif. , May 29, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will host a webcast investor meeting at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on Saturday, June 1 at 7:00 p.m. CDT . Sean E. Harper , M.D., executive vice president of
Read more →AMGNAmgen to Present at the Deutsche Bank 38th Annual Healthcare Conference Amgen (NASDAQ:AMGN) will present at the Deutsche Bank 38th Annual Healthcare Conference on Thursday, May 30, 2013, at the Westin Boston Waterfront...
THOUSAND OAKS, Calif. , May 23, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Deutsche Bank 38 th Annual Healthcare Conference on Thursday, May 30, 2013 , at the Westin Boston Waterfront Hotel, Boston , beginning at 9:20 a.m. Eastern Daylight Time . Arvind Sood ,
Read more →AMGNAmgen To Present At The UBS Global Life Sciences Conference Amgen (NASDAQ:AMGN) will participate in the UBS Global Life Sciences Conference on Tuesday, May 21, 2013, at the Sheraton New York Times Square in...
THOUSAND OAKS, Calif. , May 16, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will participate in the UBS Global Life Sciences Conference on Tuesday, May 21, 2013 , at the Sheraton New York Times Square in New York City , beginning at 10:00 a.m. Eastern Daylight Time . Joseph P. Mil
Read more →AMGNNew Analyses Identify Predictive Biomarkers For Vectibix® (Panitumumab) In Patients With Metastatic Colorectal Cancer Amgen (NASDAQ:AMGN) today announced results from three analyses of Vectibix® (panitumumab) in combination with FOLFOX, an oxaliplatin-based...
THOUSAND OAKS, Calif. , May 15, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced results from three analyses of Vectibix ® (panitumumab) in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, as a first-line treatment for metastatic colorectal cancer (mC
Read more →AMGNAmgen Highlights Data To Be Presented At American Society of Clinical Oncology Annual Meeting Amgen (NASDAQ:AMGN) today announced that it will present data from several studies of both pipeline and marketed products at the 2013 American...
THOUSAND OAKS, Calif. , May 15, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will present data from several studies of both pipeline and marketed products at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting from May 31 to June 4 in Chicag
Read more →AMGNAmgen And Zhejiang Beta Pharma Announce Planned Joint Venture In China Amgen (NASDAQ:AMGN) and Zhejiang Beta Pharma Co., Ltd. (Zhejiang Beta Pharma) today announced that the companies have signed an agreement to form a...
THOUSAND OAKS, Calif. and ZHEJIANG, China , May 9, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and Zhejiang Beta Pharma Co., Ltd. (Zhejiang Beta Pharma) today announced that the companies have signed an agreement to form a joint venture to commercialize Amgen's Vectibix ® (panitum
Read more →AMGNAmgen Announces Top-Line Results of Vectibix® (panitumumab) Phase 3 Head-to-Head Study Against Erbitux® (cetuximab) in Metastatic Colorectal Cancer Amgen (NASDAQ:AMGN) today announced that the Phase 3 head-to-head ASPECCT ('763) trial evaluating Vectibix® (panitumumab) versus Erbitux® (cetuximab) ...
THOUSAND OAKS, Calif. , May 7, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the Phase 3 head-to-head ASPECCT ('763) trial evaluating Vectibix ® (panitumumab) versus Erbitux ® (cetuximab) as a single agent for the treatment of chemorefractory metastatic colorect
Read more →AMGNFour Californians Selected as Breakaway from Cancer® Champions to be Honored During Amgen Tour of California Amgen today announced that four individuals who are an inspiration and have made a difference for others affected by cancer have been selected as...
THOUSAND OAKS, Calif. , May 1, 2013 /PRNewswire/ -- Amgen today announced that four individuals who are an inspiration and have made a difference for others affected by cancer have been selected as Breakaway from Cancer ® Champions. They will be honored as part of Amgen's Breakaw
Read more →AMGNAmgen's First Quarter 2013 Revenues Increased 5 Percent To $4.2 Billion And Adjusted Earnings Per Share (EPS) Increased 22 Percent To $1.96 Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2013. Key results for the quarter include: Total revenues increased 5...
THOUSAND OAKS, Calif. , April 23, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced financial results for the first quarter of 2013. Key results for the quarter include: "We are on track to deliver our full-year growth objectives," said Robert A. Bradway , chairman and
Read more →AMGNAmgen Announces Webcast of 2013 First Quarter Financial Results Amgen (NASDAQ:AMGN) today announced that it will report its first quarter financial results on Tuesday, April 23, 2013, after the close of the U.S....
THOUSAND OAKS, Calif. , April 18, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will report its first quarter financial results on Tuesday, April 23, 2013 , after the close of the U.S. financial markets. The announcement will be followed by a conference call
Read more →AMGNAmgen Announces Top-Line Results Of Phase 3 Talimogene Laherparepvec Trial In Melanoma Amgen (NASDAQ:AMGN) today announced top-line results from the Phase 3 trial in melanoma, which evaluated the efficacy and safety of talimogene...
THOUSAND OAKS, Calif. , March 19, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced top-line results from the Phase 3 trial in melanoma, which evaluated the efficacy and safety of talimogene laherparepvec for the treatment of unresected stage IIIB, IIIC or IV melanoma co
Read more →AMGNAmgen Announces 2013 Second Quarter Dividend Amgen (NASDAQ:AMGN) announced that its Board of Directors today declared a $0.47 per share dividend for the second quarter of 2013. The dividend will ...
THOUSAND OAKS, Calif. , March 6, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) announced that its Board of Directors today declared a $0.47 per share dividend for the second quarter of 2013. The dividend will be paid on June 7, 2013 , to all stockholders of record as of the close of
Read more →AMGNAmgen Statement On Government Budget Analysis For Oral-Only Treatments For Dialysis Patients Amgen (NASDAQ:AMGN) notes that an analysis by the Congressional Budget Office released this week shows that, contrary to the implications of past...
THOUSAND OAKS, Calif. , Feb. 22, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) notes that an analysis by the Congressional Budget Office released this week shows that, contrary to the implications of past media reports, keeping oral-only drugs in Medicare Part D would actually achie
Read more →AMGNAmgen Announces Call For Nominations For 2013 Breakaway From Cancer® Champions Amgen (NASDAQ:AMGN) today announced the call for nominations for Breakaway from Cancer® Champions. For the last five years, Amgen has recognized...
THOUSAND OAKS, Calif. , Feb. 8, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the call for nominations for Breakaway from Cancer ® Champions. For the last five years, Amgen has recognized outstanding individuals making a difference for cancer patients and their loved
Read more →AMGNAmgen Outlines Long-Term Strategy Amgen (NASDAQ:AMGN) today outlined the company's long-term strategy during a Business Review meeting with analysts and investors in New York City....
NEW YORK , Feb. 7, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today outlined the company's long-term strategy during a Business Review meeting with analysts and investors in New York City . Robert A. Bradway , chairman and chief executive officer at Amgen, opened the meeting by
Read more →AMGNAmgen To Webcast 2013 Business Review Meeting On February 7 Amgen (NASDAQ:AMGN) today announced that it will hold its Business Review Meeting on Thursday, Feb. 7, 2013, at the Mandarin Oriental Hotel, 80...
THOUSAND OAKS, Calif. , Jan. 31, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will hold its Business Review Meeting on Thursday, Feb. 7, 2013 , at the Mandarin Oriental Hotel, 80 Columbus Circle, New York City , beginning at 8 a.m. Eastern Standard Time . In
Read more →AMGNAmgen Announces Results From Phase 3 PAVES Study Evaluating Neulasta® (pegfilgrastim) In Patients With Colorectal Cancer Amgen (NASDAQ:AMGN) announced today results from Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES), a Phase 3 trial which evaluated Neulasta®...
THOUSAND OAKS, Calif. , Jan. 26, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) announced today results from Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES), a Phase 3 trial which evaluated Neulasta ® (pegfilgrastim) in 845 patients receiving FOLFOX or FOLFIRI and bevacizumab fo
Read more →AMGNAmgen Backs States' Efforts To Enact Biosimilar Legislation That Allows For Substitution And Supports Patient Safety In conjunction with our oncology biosimilars partner Actavis' announcement earlier today of our four oncology biosimilars products, Amgen...
THOUSAND OAKS, Calif. , Jan. 25, 2013 /PRNewswire/ -- In conjunction with our oncology biosimilars partner Actavis' announcement earlier today of our four oncology biosimilars products, Amgen (NASDAQ: AMGN ) today stated that it supports state biosimilars initiatives that focus o
Read more →AMGNAmgen's Full Year 2012 Revenues Increased 11 Percent To $17.3 Billion And Adjusted Earnings Per Share (EPS) Increased 22 Percent To $6.51 Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2012. Key results include: For the full year, total...
THOUSAND OAKS, Calif. , Jan. 23, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced financial results for the fourth quarter and full year of 2012. Key results include: "We achieved strong operating performance in 2012 as we delivered for patients and created value for s
Read more →AMGNAmgen Announces Webcast of 2012 Fourth Quarter and Full Year Financial Results Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2012 financial results on Wednesday, Jan. 23, 2013, after...
THOUSAND OAKS, Calif. , Jan. 18, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will report its fourth quarter and full year 2012 financial results on Wednesday, Jan. 23, 2013 , after the close of the financial markets. The announcement will be followed by a c
Read more →AMGNAmgen Announces Top-Line Results Of Phase 3 Aranesp® (darbepoetin alfa) RED-HF® Trial Amgen (NASDAQ:AMGN) today announced top-line results of the Phase 3 Aranesp® (darbepoetin alfa) RED-HF® (Reduction of Events With Darbepoetin Alfa in ...
THOUSAND OAKS, Calif. , Jan. 16, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced top-line results of the Phase 3 Aranesp ® (darbepoetin alfa) RED-HF ® (Reduction of Events With Darbepoetin Alfa in Heart Failure) Trial. The trial was initiated in 2006, and a total of 2,
Read more →AMGNAmgen To Build State-Of-The-Art Manufacturing Facility In Singapore Amgen (NASDAQ:AMGN) today announced plans to build a new manufacturing facility in the Tuas Biomedical Park area of Singapore. Over the next several...
THOUSAND OAKS, Calif. , Jan. 16, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced plans to build a new manufacturing facility in the Tuas Biomedical Park area of Singapore . Over the next several years, Amgen anticipates investing approximately $200 million to build an
Read more →AMGNAmgen To Present At The 31st Annual J.P. Morgan Global Healthcare Conference Amgen (NASDAQ:AMGN) will present at the 31st Annual J.P. Morgan Global Healthcare Conference at 9:00 a.m. Pacific Standard Time on Tuesday, Jan. 8,...
THOUSAND OAKS, Calif. , Jan. 3, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the 31 st Annual J.P. Morgan Global Healthcare Conference at 9:00 a.m. Pacific Standard Time on Tuesday, Jan. 8, 2013 , at the Westin St. Francis in San Francisco. Robert A. Bradway , chair
Read more →AMGNAmgen Finalizes Agreement Resolving Previously Announced Federal Investigations Amgen (NASDAQ:AMGN) today announced it has finalized a settlement agreement with the U.S. government, 49 states and the District of Columbia related...
THOUSAND OAKS, Calif. , Dec. 19, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced it has finalized a settlement agreement with the U.S. government, 49 states and the District of Columbia related to previously disclosed investigations. Amgen will pay approximately $612
Read more →AMGNAmgen Announces Appointment of Robert A. Eckert to Board of Directors Amgen (NASDAQ: AMGN) today announced the appointment of Robert A. Eckert, former chief executive officer at Mattel, Inc., to its Board of Directors....
THOUSAND OAKS, Calif. , Dec. 13, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the appointment of Robert A. Eckert , former chief executive officer at Mattel, Inc., to its Board of Directors. Mr. Eckert will serve on the Audit and Corporate Responsibility and Complia
Read more →AMGNAmgen Names Robert A. Bradway Chairman of the Board Of Directors Amgen (NASDAQ: AMGN) today announced appointments to its Board of Directors. Robert A. Bradway, chief executive officer, has been appointed chairman...
THOUSAND OAKS, Calif. , Dec. 13, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced appointments to its Board of Directors. Robert A. Bradway , chief executive officer, has been appointed chairman of the Board, and Vance D. Coffman , an Amgen director since 2007, has been
Read more →AMGNAmgen Announces 31 Percent Increase In 2013 First Quarter Dividend And Increase In Its Share Repurchase Authorization Amgen (NASDAQ:AMGN) announced that its Board of Directors today declared a $0.47 per share dividend for the first quarter of 2013. The dividend will...
THOUSAND OAKS, Calif. , Dec. 13, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) announced that its Board of Directors today declared a $0.47 per share dividend for the first quarter of 2013. The dividend will be paid on March 7, 2013 , to all stockholders of record as of the close of
Read more →AMGNAmgen to Acquire deCODE Genetics, a Global Leader in Human Genetics Amgen (NASDAQ:AMGN) and deCODE Genetics today announced that the companies have entered into a definitive agreement under which Amgen will acquire...
THOUSAND OAKS, Calif. and REYKJAVIK, Iceland , Dec. 10, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and deCODE Genetics today announced that the companies have entered into a definitive agreement under which Amgen will acquire deCODE Genetics, a global leader in human genetics, he
Read more →AMGNAmgen Highlights Data To Be Presented At American Society of Hematology Annual Meeting Amgen (NASDAQ:AMGN) today announced that it will present data from several studies at the 54th Annual Meeting of the American Society of Hematology...
THOUSAND OAKS, Calif. , Dec. 5, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will present data from several studies at the 54th Annual Meeting of the American Society of Hematology (ASH) from Dec. 8-11, 2012 , in Atlanta . These include updated results from
Read more →AMGNAmgen To Present At The 24th Annual Piper Jaffray Healthcare Conference Amgen (NASDAQ:AMGN) will present at the 24th Annual Piper Jaffray Healthcare Conference on Wednesday, Nov. 28, 2012, at the New York Palace hotel in...
THOUSAND OAKS, Calif. , Nov. 20, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the 24 th Annual Piper Jaffray Healthcare Conference on Wednesday, Nov. 28, 2012 , at the New York Palace hotel in New York City , beginning at 11:30 a.m. Eastern Standard Time . Arvind So
Read more →AMGNAmgen and Pfizer Highlight Data to be Presented at American College of Rheumatology Meeting Amgen (NASDAQ:AMGN) and Pfizer (NYSE:PFE) today announced that results from several Enbrel® (etanercept) studies will be presented at the American...
THOUSAND OAKS, Calif. and NEW YORK , Nov. 12, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and Pfizer (NYSE: PFE ) today announced that results from several Enbrel ® (etanercept) studies will be presented at the American College of Rheumatology/Association of Rheumatology Health Pr
Read more →AMGNThe Lancet Publication Of LAPLACE-TIMI 57 And MENDEL Studies Showed AMG 145 Significantly Reduced LDL Cholesterol Amgen (NASDAQ:AMGN) today announced that results from the LAPLACE-TIMI 57 and MENDEL Phase 2 studies evaluating AMG 145 in hypercholesterolemic...
THOUSAND OAKS, Calif. , Nov. 6, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that results from the LAPLACE-TIMI 57 and MENDEL Phase 2 studies evaluating AMG 145 in hypercholesterolemic patients with or without statins, respectively, showed that treatment with AMG 14
Read more →AMGNCirculation Publishes Results From RUTHERFORD Study Which Showed AMG 145 Significantly Reduced LDL Cholesterol In Patients With Heterozygous Familial Hypercholesterolemia Amgen (NASDAQ:AMGN) today announced that treatment with AMG 145 in combination with statin therapy, with or without ezetimibe, resulted in a...
THOUSAND OAKS, Calif. , Nov. 5, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that treatment with AMG 145 in combination with statin therapy, with or without ezetimibe, resulted in a reduction in low density lipoprotein cholesterol (LDL-C), or "bad" cholesterol, by u
Read more →AMGNJournal of the American Medical Association Publishes AMG 145 Phase 2 GAUSS Study Showing Significant Reductions In LDL Cholesterol In Statin-Intolerant Patients Amgen (NASDAQ:AMGN) today announced positive results from the AMG 145 Phase 2 GAUSS study, in patients with high cholesterol who cannot tolerate...
THOUSAND OAKS, Calif. , Nov. 5, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced positive results from the AMG 145 Phase 2 GAUSS study, in patients with high cholesterol who cannot tolerate statins. Reductions of up to 51 percent were observed in low density lipoprotein
Read more →AMGNPhase 3 Sensipar®/Mimpara® EVOLVE™ Trial Published In The New England Journal Of Medicine Amgen (NASDAQ: AMGN) today announced results of the Phase 3 EVOLVE™ (EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events) trial,...
THOUSAND OAKS, Calif. , Nov. 3, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced results of the Phase 3 EVOLVE™ (EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events) trial, which evaluated treatment with Sensipar ® /Mimpara ® (cinacalcet) for the reducti
Read more →AMGNAmgen To Present Data From Four Phase 2 Studies At Upcoming American Heart Association Scientific Sessions 2012 Amgen (NASDAQ:AMGN) will present data from four Phase 2 trials of AMG 145, an investigational fully human monoclonal antibody directed against PCSK9, ...
THOUSAND OAKS, Calif. , Nov. 2, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present data from four Phase 2 trials of AMG 145, an investigational fully human monoclonal antibody directed against PCSK9, a protein that reduces the liver's ability to remove low density lipoprotei
Read more →AMGNAmgen To Webcast Investor Meeting At Upcoming American Heart Association Scientific Sessions 2012 Amgen (NASDAQ:AMGN) will host a webcast investor meeting at the American Heart Association (AHA) Scientific Sessions 2012 on Tuesday, Nov. 6, at 7:00 ...
THOUSAND OAKS, Calif. , Nov. 1, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will host a webcast investor meeting at the American Heart Association (AHA) Scientific Sessions 2012 on Tuesday, Nov. 6 , at 7:00 p.m. Pacific Standard Time . Sean E. Harper , M.D., executive vice preside
Read more →AMGNAmgen Supports Assistance for Patients Affected by Hurricane Sandy Amgen and the Amgen Foundation today announced that they will support nonprofit organizations providing medical relief and vital health services for...
THOUSAND OAKS, Calif. , Nov. 1, 2012 /PRNewswire/ -- Amgen and the Amgen Foundation today announced that they will support nonprofit organizations providing medical relief and vital health services for patients affected by Hurricane Sandy. The contribution of $250,000 will suppor
Read more →AMGNAmgen's Third Quarter 2012 Revenues Increased 10 Percent To $4.3 Billion And Adjusted Earnings Per Share (EPS) Increased 19 Percent To $1.67 Amgen (NASDAQ: AMGN) today announced financial results for the third quarter of 2012. Key results for the quarter include: Total revenues increased...
THOUSAND OAKS, Calif. , Oct. 23, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced financial results for the third quarter of 2012. Key results for the quarter include: "We delivered solid growth in revenues and earnings," said Robert A. Bradway , president and CEO at A
Read more →AMGNAmgen Announces Webcast of 2012 Third Quarter Financial Results Amgen (NASDAQ:AMGN) today announced that it will report its third quarter financial results on Tuesday, Oct. 23, 2012, after the close of the U.S....
THOUSAND OAKS, Calif. , Oct. 18, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will report its third quarter financial results on Tuesday, Oct. 23, 2012 , after the close of the U.S. financial markets. The announcement will be followed by a conference call wi
Read more →AMGNAmgen Presents Several Sub-Analyses At ASBMR From The Ongoing Open-Label Extension Study Of The Pivotal Phase 3 Prolia Fracture Trial Amgen (NASDAQ:AMGN) today announced that it has presented data from several Prolia® (denosumab) studies, including data from the open-label extension ...
THOUSAND OAKS, Calif. , Oct. 14, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it has presented data from several Prolia ® (denosumab) studies, including data from the open-label extension study of the pivotal Phase 3 fracture trial, which showed continued incre
Read more →AMGNAmgen Appoints Cynthia Patton Senior Vice President And Chief Compliance Officer Amgen (NASDAQ:AMGN) today announced the appointment of Cynthia M. Patton to senior vice president and chief compliance officer, effective Oct. 22. In ...
THOUSAND OAKS, Calif. , Oct. 12, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the appointment of Cynthia M. Patton to senior vice president and chief compliance officer, effective Oct. 22 . In this role, Patton will report to Robert A. Bradway , president and chief
Read more →AMGNAmgen Announces 2012 Fourth Quarter Dividend Amgen (NASDAQ:AMGN) announced that on Oct. 10, 2012, its Board of Directors declared a $0.36 per share dividend for the fourth quarter of 2012. The...
THOUSAND OAKS, Calif. , Oct. 11, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) announced that on Oct. 10, 2012 , its Board of Directors declared a $0.36 per share dividend for the fourth quarter of 2012. The dividend will be paid on Dec. 7, 2012 , to all stockholders of record as of
Read more →AMGNFDA Approves New Indication For Prolia® (Denosumab) For The Treatment Of Bone Loss In Men With Osteoporosis At High Risk For Fracture Amgen (NASDAQ:AMGN) today announced the U.S. Food and Drug Administration (FDA) approved a new indication for Prolia® (denosumab) as a treatment to...
THOUSAND OAKS, Calif. , Sept. 20, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the U.S. Food and Drug Administration (FDA) approved a new indication for Prolia ® (denosumab) as a treatment to increase bone mass in men with osteoporosis at high risk for fracture. Pro
Read more →AMGNAmgen Names Ray Jordan Senior Vice President, Corporate Affairs Amgen (NASDAQ:AMGN) today announced the appointment of Ray Jordan to the new position of senior vice president, Corporate Affairs, effective October...
THOUSAND OAKS, Calif. , Sept. 10, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the appointment of Ray Jordan to the new position of senior vice president, Corporate Affairs, effective October 1 . Jordan will report directly to Robert A. Bradway , president and chie
Read more →AMGNAmgen To Present At The Bank of America Merrill Lynch Global Healthcare Conference Amgen (NASDAQ:AMGN) will participate in the Bank of America Merrill Lynch Global Healthcare Conference on Thursday, Sept. 13, 2012, in London,...
THOUSAND OAKS, Calif. , Sept. 10, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will participate in the Bank of America Merrill Lynch Global Healthcare Conference on Thursday, Sept. 13, 2012 , in London , beginning at 9:50 a.m. Greenwich Mean Time. Arvind Sood, vice president of Inv
Read more →AMGNAmgen To Present At The Morgan Stanley Global Healthcare Conference Amgen (NASDAQ:AMGN) will present at the Morgan Stanley Global Healthcare Conference on Wednesday, Sept. 12, 2012 at the Grand Hyatt in New York City, ...
THOUSAND OAKS, Calif. , Sept. 7, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Morgan Stanley Global Healthcare Conference on Wednesday, Sept. 12, 2012 at the Grand Hyatt in New York City , beginning at 2:10 p.m. Eastern Daylight Time . Jonathan M. Peacock , exec
Read more →AMGNAmgen To Present At The Baird Healthcare Conference Amgen (NASDAQ:AMGN) will participate in the Baird Healthcare Conference on Thursday, Sept. 6, 2012, at The New York Palace Hotel in New York City,...
THOUSAND OAKS, Calif. , Aug. 31, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will participate in the Baird Healthcare Conference on Thursday, Sept. 6, 2012 , at The New York Palace Hotel in New York City , beginning at 1:24 p.m. Eastern Daylight Time . Arvind Sood , vice president
Read more →AMGNAmgen Announces Termination Of Ganitumab Phase 3 Study For Futility In Metastatic Pancreatic Cancer Amgen (NASDAQ: AMGN) today announced a decision to stop the ganitumab (AMG 479) Phase 3 GAMMA (Gemcitabine and AMG 479 in Metastatic Adenocarcinoma...
The GAMMA study is a randomized, multicenter, double-blind, Phase 3 trial to determine if ganitumab plus gemcitabine improves overall survival, compared to placebo plus gemcitabine, in the first-line treatment of patients with metastatic adenocarcinoma of the pancreas. "These di
Read more →AMGNAmgen's Second Quarter 2012 Revenues Increased 13 Percent To $4.5 Billion And Adjusted Earnings Per Share (EPS) Increased 34 Percent To $1.83 Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2012. Key results for the quarter include: Total revenues increased...
THOUSAND OAKS, Calif. , July 26, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced financial results for the second quarter of 2012. Key results for the quarter include: "I am very pleased with the performance of the business in the first half," said Bob Bradway , CEO a
Read more →AMGNAmgen Announces Webcast of 2012 Second Quarter Financial Results Amgen (NASDAQ:AMGN) today announced that it will report its second quarter financial results on Thursday, July 26, 2012, after the close of the U.S....
THOUSAND OAKS, Calif. , July 23, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will report its second quarter financial results on Thursday, July 26, 2012 , after the close of the U.S. financial markets. The announcement will be followed by a conference call
Read more →AMGNAmgen Announces 2012 Third Quarter Dividend Amgen (NASDAQ:AMGN) announced that its Board of Directors today declared a $0.36 per share dividend for the third quarter of 2012. The dividend will...
THOUSAND OAKS, Calif. , July 19, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) announced that its Board of Directors today declared a $0.36 per share dividend for the third quarter of 2012. The dividend will be paid on Sept. 7, 2012 , to all stockholders of record as of the close of
Read more →AMGNAmgen Completes Acquisition of KAI Pharmaceuticals Amgen (NASDAQ: AMGN) today announced the completion of the acquisition of KAI Pharmaceuticals, a privately held company based in South San Francisco. ...
THOUSAND OAKS, Calif. , July 5, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the completion of the acquisition of KAI Pharmaceuticals, a privately held company based in South San Francisco . The acquisition was initially announced April 10, 2012 and includes KAI's l
Read more →AMGNActress Maura Tierney And Amgen Launch The Chemotherapy: Myths or Facts™ Campaign Amgen (NASDAQ:AMGN) today launched Chemotherapy: Myths or Facts™, an awareness campaign for cancer patients and their caregivers featuring...
THOUSAND OAKS, Calif. , June 25, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today launched Chemotherapy: Myths or Facts™, an awareness campaign for cancer patients and their caregivers featuring Emmy®-nominated actress and breast cancer survivor Maura Tierney . In 2009, Tierney w
Read more →AMGNAmgen Completes Acquisition of Mustafa Nevzat Pharmaceuticals Amgen (NASDAQ: AMGN) today announced the completion of the acquisition of more than 99 percent of the shares of Mustafa Nevzat Pharmaceuticals, a...
THOUSAND OAKS, Calif. , June 12, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the completion of the acquisition of more than 99 percent of the shares of Mustafa Nevzat Pharmaceuticals, a privately held Turkish company. The all-cash transaction significantly expands
Read more →AMGN20th Annual Amgen Award For Science Teaching Excellence Honors Nine Outstanding Teachers Amgen is pleased to announce the nine science teachers in the United States, Canada and Puerto Rico who are this year's recipients of the Amgen Award ...
THOUSAND OAKS, Calif. , June 11, 2012 /PRNewswire/ -- Amgen is pleased to announce the nine science teachers in the United States , Canada and Puerto Rico who are this year's recipients of the Amgen Award for Science Teaching Excellence (AASTE). Now in its 20th year, the award re
Read more →AMGNAmgen Announces Top-Line Results Of Phase 3 Sensipar®/Mimpara® EVOLVE™ Trial Amgen (NASDAQ:AMGN) today announced top-line results of the Phase 3 EVOLVE™ (EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events)...
THOUSAND OAKS, Calif. , June 8, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced top-line results of the Phase 3 EVOLVE™ (EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events) trial, which evaluated Sensipar®/Mimpara® (cinacalcet) for the reduction of the
Read more →AMGNAmgen Announces Voting Results of Annual Meeting of Stockholders Amgen (NASDAQ:AMGN) today announced voting results from the Company's Annual Meeting of Stockholders, held at the Four Seasons Hotel, Westlake...
THOUSAND OAKS, Calif. , May 23, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced voting results from the Company's Annual Meeting of Stockholders, held at the Four Seasons Hotel, Westlake Village , Calif. Approximately 87 percent of outstanding shares were represented a
Read more →AMGNAmgen's BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate Of Complete Response In Adult Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia Amgen (NASDAQ:AMGN) today announced updated results from a Phase 2 study that showed treatment with blinatumomab (AMG 103) helped achieve a high-rate ...
Median Survival 9.0 Months, with a Median Follow-up of 10.7 Months THOUSAND OAKS, Calif. , May 16, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced updated results from a Phase 2 study that showed treatment with blinatumomab (AMG 103) helped achieve a high-rate of comp
Read more →AMGNAnalysis Of Rilotumumab (AMG 102) Data Identifies A Potential Predictive Biomarker For Patients With Gastric Or Gastroesophageal Cancer Amgen (NASDAQ: AMGN) announced today results from an exploratory biomarker analysis evaluating MET expression as a predictor of clinical response to...
THOUSAND OAKS, Calif. , May 16, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) announced today results from an exploratory biomarker analysis evaluating MET expression as a predictor of clinical response to rilotumumab (AMG 102). This analysis, conducted on a previously reported Phas
Read more →AMGNAmgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars Amgen (NASDAQ:AMGN) announced today that Joseph P. Miletich, M.D., Ph.D., senior vice president of Research and Development at Amgen will testify at...
THOUSAND OAKS, Calif. , May 11, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) announced today that Joseph P. Miletich , M.D., Ph.D., senior vice president of Research and Development at Amgen will testify at the United States (U.S.) Food and Drug Administration (FDA) stakeholder hea
Read more →AMGNCancer Support Community Launches National Program to Assist Patients With Cancer, Make Informed Decisions About Care The Cancer Support Community (CSC) and the Amgen Foundation, today announced the launch of Open to Options™, a program designed to bridge the...
To view the multimedia assets associated with this release, please visit: http://www.multivu.com/mnr/48053-cancer-support-community-csc-amgen-foundation-open-to-options The Open to Options program is available through its Cancer Support Helpline at (888) 793-9355, through select
Read more →AMGNAmgen to Present at the Baird Growth Stock Conference Amgen (NASDAQ:AMGN) will present at the Baird Growth Stock conference on Wednesday, May 9, 2012, at the Four Seasons Hotel, Chicago, Ill., beginning...
THOUSAND OAKS, Calif. , May 4, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Baird Growth Stock conference on Wednesday, May 9, 2012 , at the Four Seasons Hotel, Chicago, Ill. , beginning at 8:20 a.m. Central Daylight Time . Arvind Sood , vice president of Invest
Read more →AMGNAmgen to Present at the Deutsche Bank 37th Annual Healthcare Conference Amgen (NASDAQ:AMGN) will present at the Deutsche Bank 37th Annual Healthcare Conference on Tuesday, May 8, 2012, at the InterContinental Hotel,...
THOUSAND OAKS, Calif. , May 3, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Deutsche Bank 37th Annual Healthcare Conference on Tuesday, May 8, 2012 , at the InterContinental Hotel, Boston, Mass. , beginning at 9:20 a.m. Eastern Daylight Time . Arvind Sood , vice
Read more →AMGNFour Californians Selected As Breakaway from Cancer® Champions To Be Honored During Amgen Tour of California Amgen today announced that four individuals who have made a difference for others affected by cancer in their communities have been selected as...
THOUSAND OAKS, Calif. , May 1, 2012 /PRNewswire/ -- Amgen today announced that four individuals who have made a difference for others affected by cancer in their communities have been selected as Breakaway from Cancer ® Champions. They will be honored at the seventh consecutive e
Read more →AMGNAmgen Receives Complete Response Letter From FDA for XGEVA® sBLA for Prevention of Bone Metastases Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for the supplemental...
THOUSAND OAKS, Calif. , April 26, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for the supplemental Biologics License Application (sBLA) for XGEVA® (denosumab) to treat men with c
Read more →AMGNAmgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company Amgen (NASDAQ:AMGN), the world's largest biotechnology company, and Mustafa Nevzat Pharmaceuticals (MN) today announced an agreement under which...
THOUSAND OAKS, Calif. and ISTANBUL , April 25, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN ), the world's largest biotechnology company, and Mustafa Nevzat Pharmaceuticals (MN) today announced an agreement under which Amgen will acquire 95.6 percent of shares in MN, a privately held
Read more →AMGNAmgen's First Quarter 2012 Revenue Increased 9 Percent To $4.0 Billion And Adjusted Earnings Per Share (EPS) Increased 20 Percent To $1.61 Amgen (NASDAQ:AMGN) reported total revenue increased 9 percent during the first quarter of 2012 to $4,048 million versus $3,706 million in the first...
THOUSAND OAKS, Calif. , April 24, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) reported total revenue increased 9 percent during the first quarter of 2012 to $4,048 million versus $3,706 million in the first quarter of 2011. Adjusted earnings per share (EPS) were $1.61 for the fir
Read more →AMGNA Tribute to George Rathmann, Amgen's Founding CEO (1927-2012) Amgen (NASDAQ:AMGN) today announced that George Rathmann, founding CEO of Amgen from 1980 to 1988 and board chairman until 1990, has passed away....
THOUSAND OAKS, Calif. , April 23, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that George Rathmann , founding CEO of Amgen from 1980 to 1988 and board chairman until 1990, has passed away. Recruited by Bill Bowes , one of Amgen's founders, Rathmann possessed the k
Read more →AMGNAmgen Announces Webcast of 2012 First Quarter Financial Results Amgen (NASDAQ: AMGN) today announced that it will report its first quarter financial results on Tuesday, April 24, 2012, after the close of the U.S....
THOUSAND OAKS, Calif. , April 19, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will report its first quarter financial results on Tuesday, April 24, 2012 , after the close of the U.S. financial markets. The announcement will be followed by a conference call
Read more →AMGNAmgen to Acquire Privately Held KAI Pharmaceuticals Amgen (NASDAQ: AMGN) and KAI Pharmaceuticals today announced an agreement under which Amgen will acquire KAI, a privately held pharmaceutical company ...
THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif. , April 10, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and KAI Pharmaceuticals today announced an agreement under which Amgen will acquire KAI, a privately held pharmaceutical company based in South San Francisco. KAI's lead p
Read more →AMGNUCB and Amgen Initiate Sclerostin Antibody Phase 3 Program in Patients With Postmenopausal Osteoporosis UCB (Euronext Brussels: UCB) and Amgen (NASDAQ:AMGN) announced today the start of their sclerostin antibody (CDP7851/AMG 785) Phase 3 clinical trial...
BRUSSELS and THOUSAND OAKS, Calif. , April 4, 2012 /PRNewswire/ -- UCB (Euronext Brussels: UCB) and Amgen (NASDAQ: AMGN ) announced today the start of their sclerostin antibody (CDP7851/AMG 785) Phase 3 clinical trial program for the treatment of postmenopausal osteoporosis. "We
Read more →AMGNAmgen and AstraZeneca Announce Collaboration to Jointly Develop and Commercialize Clinical-Stage Inflammation Portfolio Amgen (NASDAQ:AMGN) and AstraZeneca Plc, today announced an agreement to jointly develop and commercialize five monoclonal antibodies from Amgen's...
THOUSAND OAKS, Calif. and LONDON , April 2, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and AstraZeneca Plc, today announced an agreement to jointly develop and commercialize five monoclonal antibodies from Amgen's clinical inflammation portfolio (AMG 139, AMG 157, AMG 181, AMG 55
Read more →AMGNAmgen Announces Phase 2 Study Results for Brodalumab in Moderate to Severe Plaque Psoriasis Published in the New England Journal of Medicine Amgen (NASDAQ:AMGN) announced today that results from a Phase 2 trial evaluating the safety and efficacy of brodalumab (formerly AMG 827) in 198...
THOUSAND OAKS, Calif. , March 28, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) announced today that results from a Phase 2 trial evaluating the safety and efficacy of brodalumab (formerly AMG 827) in 198 patients with moderate to severe plaque psoriasis were published in the New En
Read more →AMGNAmgen's PCSK9 Inhibitor Reduced LDL Cholesterol up to 81 Percent in Phase 1b Study Amgen (NASDAQ:AMGN) announced today positive results from a Phase 1b clinical study of AMG 145, an investigational PCSK9 inhibitor, in patients with...
THOUSAND OAKS, Calif. , March 25, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) announced today positive results from a Phase 1b clinical study of AMG 145, an investigational PCSK9 inhibitor, in patients with high cholesterol who were taking statins. The study demonstrated that mult
Read more →AMGNAmgen Announces 2012 Second Quarter Dividend Amgen (NASDAQ:AMGN) announced that its Board of Directors today declared a $0.36 per share dividend for the second quarter of 2012. The dividend will ...
THOUSAND OAKS, Calif. , March 15, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) announced that its Board of Directors today declared a $0.36 per share dividend for the second quarter of 2012. The dividend will be paid on June 7, 2012 , to all stockholders of record as of the close o
Read more →AMGNAmgen Completes Tender Offer for Outstanding Shares of Micromet, Inc. Amgen Inc. ( Amgen ) (NASDAQ:AMGN) announced today the expiration of the subsequent offering period of the tender offer (the Offer ) by a wholly...
THOUSAND OAKS, Calif. , March 7, 2012 /PRNewswire/ -- Amgen Inc. ("Amgen") (NASDAQ: AMGN ) announced today the expiration of the subsequent offering period of the tender offer (the "Offer") by a wholly owned subsidiary, "Merger Sub," to acquire all outstanding shares of common st
Read more →AMGNSchwartz Center Receives $500,000 Grant from the Amgen Foundation The Schwartz Center for Compassionate Healthcare, a Boston-based nonprofit dedicated to strengthening the relationship between patients and their...
BOSTON and THOUSAND OAKS, Calif. , March 6, 2012 /PRNewswire/ -- The Schwartz Center for Compassionate Healthcare, a Boston -based nonprofit dedicated to strengthening the relationship between patients and their healthcare providers, today announced it has received a $500,000 gra
Read more →AMGNAmgen Announces Initial Results of Tender Offer for Outstanding Shares of Micromet, Inc. and Commencement of Subsequent Offering Period Amgen ( Amgen ) (NASDAQ: AMGN) announced today that all conditions to the closing of the tender offer (the Offer ) by a wholly owned subsidiary,...
THOUSAND OAKS, Calif. , March 2, 2012 /PRNewswire/ -- Amgen ("Amgen") (NASDAQ: AMGN ) announced today that all conditions to the closing of the tender offer (the "Offer") by a wholly owned subsidiary, "Merger Sub", to acquire all outstanding shares of common stock of Micromet, In
Read more →AMGNAmgen to Present at the Cowen and Company 32nd Annual Healthcare Conference Amgen (NASDAQ:AMGN) will present at the Cowen and Company 32nd Annual Healthcare Conference on Monday, March 5, 2012 at the Boston Marriott Copley...
THOUSAND OAKS, Calif. , Feb. 29, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Cowen and Company 32nd Annual Healthcare Conference on Monday, March 5, 2012 at the Boston Marriott Copley Place, Boston, Mass. , beginning at approximately 2:50 p.m. Eastern Standard
Read more →AMGNAmgen and Micromet Announce Early Termination of HSR Waiting Period for Amgen's Acquisition of Micromet Amgen (NASDAQ: AMGN) and Micromet, Inc. (NASDAQ: MITI) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvement Act...
THOUSAND OAKS, Calif. , Feb. 15, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and Micromet, Inc. (NASDAQ: MITI ) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvement Act of 1976, as amended (HSR), in connection with Amgen's tender offer for Micr
Read more →AMGNAmgen Names Michael Severino, M.D., Senior Vice President, Global Development and Corporate Chief Medical Officer Amgen (NASDAQ:AMGN) today announced that Michael Severino, M.D., has been named senior vice president, Global Development and Corporate Chief Medical ...
THOUSAND OAKS, Calif. , Feb. 14, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that Michael Severino , M.D., has been named senior vice president, Global Development and Corporate Chief Medical Officer, effective immediately. Severino, 46, formerly vice president, Gl
Read more →AMGNAmgen to Present at the Leerink Swann Global Healthcare Conference Amgen (NASDAQ:AMGN) will present at the Leerink Swann Global Healthcare Conference at 9:30 a.m. Eastern Standard Time on Thursday, Feb. 16, 2012, at...
THOUSAND OAKS, Calif. , Feb. 13, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Leerink Swann Global Healthcare Conference at 9:30 a.m. Eastern Standard Time on Thursday, Feb. 16, 2012 , at the Waldorf Astoria Hotel in New York City. Jonathan M. Peacock , executiv
Read more →AMGNAmgen to Discuss Application for New Use of XGEVA® (denosumab) at FDA Oncologic Drugs Advisory Committee Meeting Amgen (NASDAQ: AMGN) will discuss the data from the supplemental Biologics License Application (sBLA) for XGEVA® (denosumab) to treat men with...
THOUSAND OAKS, Calif. , Feb. 8, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will discuss the data from the supplemental Biologics License Application (sBLA) for XGEVA® (denosumab) to treat men with castration-resistant prostate cancer (CRPC) at high risk of developing bone metasta
Read more →AMGNÜbernahme von Micromet Durch Amgen Die Übernahme umfasst auch neuartige Medikamente gegen hämatologische Malignome, die derzeit in klinischen Studien getestet werden. Die...
THOUSAND OAKS , Kalifornien, und ROCKVILLE, Maryland , January 26, 2012 /PRNewswire/ -- Die Übernahme umfasst auch neuartige Medikamente gegen hämatologische Malignome, die derzeit in klinischen Studien getestet werden. Die patentgeschützte BiTE ® -Technologie von Micromet hat
Read more →AMGNAmgen to Acquire Micromet Amgen (NASDAQ:AMGN) and Micromet, Inc. (NASDAQ:MITI) today announced that the companies have entered into a definitive merger agreement under which...
THOUSAND OAKS, Calif. , and ROCKVILLE, Md. , Jan. 26, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and Micromet, Inc. (NASDAQ: MITI ) today announced that the companies have entered into a definitive merger agreement under which Amgen will acquire Micromet, a biotechnology company
Read more →AMGNAmgen's Full Year 2011 Revenue Increased 4 Percent to $15.6 Billion and Adjusted Earnings Per Share (EPS) Increased 2 Percent to $5.33 Amgen (NASDAQ: AMGN) reported total revenue increased 3 percent during the fourth quarter of 2011 to $3,973 million versus $3,841 million in the...
THOUSAND OAKS, Calif. , Jan. 26, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) reported total revenue increased 3 percent during the fourth quarter of 2011 to $3,973 million versus $3,841 million in the fourth quarter of 2010. For the full year 2011, total revenue increased 4 percen
Read more →AMGNAmgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2011 financial results on Thursday, Jan. 26, 2012 after the...
THOUSAND OAKS, Calif. , Jan. 24, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will report its fourth quarter and full year 2011 financial results on Thursday, Jan. 26, 2012 after the close of the financial markets. The announcement will be followed by a conf
Read more →AMGNAmgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference Amgen (NASDAQ:AMGN) will present at the 30th Annual J.P. Morgan Global Healthcare Conference at 10:00 a.m. Pacific Time on Monday, Jan. 9, 2012, at...
THOUSAND OAKS, Calif. , Jan. 4, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the 30th Annual J.P. Morgan Global Healthcare Conference at 10:00 a.m. Pacific Time on Monday, Jan. 9, 2012 , at the Westin St. Francis in San Francisco , Calif. Robert A. Bradway , preside
Read more →AMGNFDA to Review Potential New Use of XGEVA® (Denosumab) at Oncologic Drugs Advisory Committee Meeting Amgen (NASDAQ: AMGN) today announced the U.S. Food and Drug Administration (FDA) has invited the Company to participate in a meeting of the Oncologic ...
THOUSAND OAKS, Calif. , Dec. 29, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the U.S. Food and Drug Administration (FDA) has invited the Company to participate in a meeting of the Oncologic Drugs Advisory Committee (ODAC) on Feb. 8, 2012 to discuss the supplemental
Read more →AMGNAmgen and Watson Announce Collaboration to Develop and Commercialize Oncology Biosimilars Amgen (NASDAQ:AMGN) and Watson Pharmaceuticals, Inc. (NYSE:WPI) announced today that they will collaborate to develop and commercialize, on a...
THOUSAND OAKS, Calif. and PARSIPPANY, N.J. , Dec. 19, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and Watson Pharmaceuticals, Inc. (NYSE: WPI ) announced today that they will collaborate to develop and commercialize, on a worldwide basis, several oncology antibody biosimilar medic
Read more →AMGNKevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012 Kevin W. Sharer, chairman and chief executive officer of Amgen (NASDAQ:AMGN) since 2000, has announced his plan to retire from the Company at the end ...
THOUSAND OAKS, Calif. , Dec. 15, 2011 /PRNewswire/ -- Kevin W. Sharer , chairman and chief executive officer of Amgen (NASDAQ: AMGN ) since 2000, has announced his plan to retire from the Company at the end of 2012, following 20 years of service to Amgen. To facilitate an orderly
Read more →AMGNAmgen Announces 2012 First Quarter Dividend Amgen (NASDAQ: AMGN) announced that its Board of Directors today declared a $0.36 per share dividend for the first quarter of 2012. This represents...
THOUSAND OAKS, Calif. , Dec. 15, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) announced that its Board of Directors today declared a $0.36 per share dividend for the first quarter of 2012. This represents an approximate 29 percent increase from that paid in the previous two quarter
Read more →AMGNAmgen Announces Final Results of Its Tender Offer Amgen (NASDAQ:AMGN) today announced the final results of its modified Dutch auction tender offer, which expired at 12:00 midnight, New York City...
THOUSAND OAKS, Calif. , Dec. 14, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the final results of its modified Dutch auction tender offer, which expired at 12:00 midnight, New York City time, on Wednesday, Dec. 7, 2011 . Amgen has accepted for purchase 83,333,333
Read more →AMGNAmgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim) Amgen (NASDAQ:AMGN) today announced that data from several key Nplate® (romiplostim) studies were presented at the 53rd Annual Meeting and Exposition ...
THOUSAND OAKS, Calif. , Dec. 13, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that data from several key Nplate ® (romiplostim) studies were presented at the 53rd Annual Meeting and Exposition of the American Society of Hematology (ASH), Dec. 10-13, 2011 , in San Di
Read more →AMGNAmgen to Present at the 22nd Annual Oppenheimer Healthcare Conference Amgen (NASDAQ:AMGN) will participate in the Oppenheimer Healthcare Conference on Wednesday, Dec. 14, 2011, at the Waldorf Astoria Hotel in New York...
THOUSAND OAKS, Calif. , Dec. 9, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will participate in the Oppenheimer Healthcare Conference on Wednesday, Dec. 14, 2011 , at the Waldorf Astoria Hotel in New York City , beginning at 1:35 p.m. Eastern Time . Arvind Sood , vice president of
Read more →AMGNAmgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy Amgen (NASDAQ:AMGN) today announced the U.S. Food and Drug Administration (FDA) has modified the requirements of the Nplate® (romiplostim) Risk...
THOUSAND OAKS, Calif. , Dec. 6, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the U.S. Food and Drug Administration (FDA) has modified the requirements of the Nplate® (romiplostim) Risk Evaluation and Mitigation Strategy (REMS) Program. Prescribing physicians, patien
Read more →AMGNEnbrel® (etanercept) Patent Issued Amgen (NASDAQ:AMGN) today issued the following statement: Amgen today announced the issuance of U.S. Patent No. 8,063,182 related to Enbrel®...
THOUSAND OAKS, Calif. , Nov. 22, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today issued the following statement: Amgen today announced the issuance of U.S. Patent No. 8,063,182 related to Enbrel ® (etanercept). This patent is owned by Hoffman-La Roche Inc. ("Roche") and exclusi
Read more →AMGNThe Lancet Publishes Results Demonstrating XGEVA® Significantly Prolonged Bone Metastasis-free Survival in Men With Prostate Cancer Amgen (NASDAQ: AMGN) announced today the publication of results from a Phase 3 trial (the '147 study) that evaluated XGEVA® (denosumab) for use in...
THOUSAND OAKS, Calif. , Nov. 15, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) announced today the publication of results from a Phase 3 trial (the '147 study) that evaluated XGEVA® (denosumab) for use in preventing or delaying the onset of bone metastases in men with nonmetastatic
Read more →AMGNAmgen Announces Plan to Launch Tender Offer and Launch of Senior Notes Offering Amgen (NASDAQ: AMGN) today announced its plan to launch a modified Dutch auction tender offer to purchase up to $5 billion of its common stock, par...
THOUSAND OAKS, Calif. , Nov. 7, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced its plan to launch a modified Dutch auction tender offer to purchase up to $5 billion of its common stock, par value $0.0001 per share ("Common Stock"). Amgen also announced a public offeri
Read more →AMGNProlia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Six Years With Similar Safety Profile Observed in Original Fracture Trial Amgen (NASDAQ: AMGN) today announced positive data from the first three years of the open-label extension study of the pivotal Phase 3 fracture trial ...
THOUSAND OAKS, Calif. , Nov. 5, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced positive data from the first three years of the open-label extension study of the pivotal Phase 3 fracture trial showing that six years of Prolia® (denosumab) treatment in postmenopausal wo
Read more →AMGNTreatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease Amgen (NASDAQ: AMGN) and Pfizer Inc. (NYSE: PFE) today announced results of the second and final period of the PRESERVE trial. PRESERVE is a...
THOUSAND OAKS, Calif. and NEW YORK , Nov. 5, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and Pfizer Inc. (NYSE: PFE ) today announced results of the second and final period of the PRESERVE trial. PRESERVE is a two-period multi-center trial in patients with moderately active rheuma
Read more →AMGNAmgen Appoints Anthony (Tony) Hooper Executive Vice President Global Commercial Operations Amgen (NASDAQ: AMGN) today announced the appointment of Anthony (Tony) Hooper, executive vice president, Global Commercial Operations, effective...
THOUSAND OAKS, Calif. , Oct. 19, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the appointment of Anthony (Tony) Hooper , executive vice president, Global Commercial Operations, effective October 26th . In this role, Hooper will report to Robert A. Bradway , presiden
Read more →AMGNAmgen Announces Webcast of 2011 Third Quarter Financial Results Amgen (NASDAQ: AMGN) today announced that it will report its third quarter financial results on Monday, Oct. 24, 2011 after the close of the U.S....
THOUSAND OAKS, Calif. , Oct. 19, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will report its third quarter financial results on Monday, Oct. 24, 2011 after the close of the U.S. financial markets. The announcement will be followed by a conference call with
Read more →AMGNAmgen Announces 2011 Fourth Quarter Dividend Amgen (NASDAQ: AMGN) announced that its Board of Directors today declared a $0.28 per share dividend for the fourth quarter of 2011. The dividend...
THOUSAND OAKS, Calif. , Oct. 13, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) announced that its Board of Directors today declared a $0.28 per share dividend for the fourth quarter of 2011. The dividend will be paid on Dec. 8, 2011 to all stockholders of record as of the close of b
Read more →AMGNAmgen Highlights Data to be Presented at 2011 European Multidisciplinary Cancer Congress Amgen (NASDAQ: AMGN) announced today that data from XGEVA® (denosumab) and Vectibix® (panitumumab) studies will be presented at the 2011 European...
THOUSAND OAKS, Calif. , Sept. 23, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) announced today that data from XGEVA® (denosumab) and Vectibix® (panitumumab) studies will be presented at the 2011 European Multidisciplinary Cancer Congress, Sept. 23 - 27, 2011 , in Stockholm, Sweden
Read more →AMGNFDA Approves New Indications for Prolia® (Denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) approved two new indications for Prolia® (denosumab) as a...
THOUSAND OAKS, Calif. , Sept. 19, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the U.S. Food and Drug Administration (FDA) approved two new indications for Prolia® (denosumab) as a treatment to increase bone mass in women at high risk for fracture receiving adj
Read more →AMGNProlia® (Denosumab) Phase 2 Extension Study Showed Continued Increase in Bone Mineral Density Over Eight Years of Treatment Amgen (NASDAQ: AMGN) today announced new long-term data showing that Prolia® (denosumab) treatment for up to eight years in postmenopausal women with ...
THOUSAND OAKS, Calif. , Sept. 17, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced new long-term data showing that Prolia® (denosumab) treatment for up to eight years in postmenopausal women with low bone mass or osteoporosis was associated with a continued increase in
Read more →AMGNAmgen to Present at the UBS Global Life Sciences Conference Amgen (NASDAQ: AMGN) will participate in the UBS Global Life Sciences Conference on Tuesday, Sept. 20, 2011, at the Grand Hyatt in New York City,...
THOUSAND OAKS, Calif. , Sept. 15, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will participate in the UBS Global Life Sciences Conference on Tuesday, Sept. 20, 2011 , at the Grand Hyatt in New York City , beginning at 8:30 a.m. Eastern Time . Roger M. Perlmutter, M.D., Ph.D., exec
Read more →AMGNAmgen Staff Volunteer Efforts Result in $5,000 For Each of Their Favorite Nonprofits Each year, thousands of Amgen staff generously devote their personal time, energy and talents to a variety of charitable organizations. To recognize...
THOUSAND OAKS, Calif. , Sept. 15, 2011 /PRNewswire/ -- Each year, thousands of Amgen staff generously devote their personal time, energy and talents to a variety of charitable organizations. To recognize these exceptional efforts, the Amgen Foundation today announced the 11 recip
Read more →AMGNAmgen to Present at the Bank of America Merrill Lynch Global Healthcare Conference Amgen (NASDAQ: AMGN) will participate in the Bank of America Merrill Lynch Global Healthcare Conference on Thursday, Sept. 15, 2011 in London,...
THOUSAND OAKS, Calif. , Sept. 12, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will participate in the Bank of America Merrill Lynch Global Healthcare Conference on Thursday, Sept. 15, 2011 in London , beginning at 11:20 a.m. Greenwich Mean Time. Arvind Sood, vice president of Inve
Read more →AMGNAmgen to Present at the Morgan Stanley Global Healthcare Conference Amgen (NASDAQ: AMGN) will present at the Morgan Stanley Global Healthcare Conference on Tuesday, Sept. 13, 2011 at the Grand Hyatt in New York City,...
THOUSAND OAKS, Calif. , Sept. 8, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Morgan Stanley Global Healthcare Conference on Tuesday, Sept. 13, 2011 at the Grand Hyatt in New York City , beginning at 9:10 a.m. Eastern Time . Jim Daly, senior vice president of No
Read more →AMGNAmgen to Present at the Baird Healthcare Conference Amgen (NASDAQ: AMGN) will participate in the Baird Healthcare Conference on Thursday, Sept. 8, 2011, at The New York Palace Hotel in New York City,...
THOUSAND OAKS, Calif. , Sept. 6, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will participate in the Baird Healthcare Conference on Thursday, Sept. 8, 2011 , at The New York Palace Hotel in New York City , beginning at 10:00 a.m. Eastern Time . Arvind Sood , vice president of Inve
Read more →AMGNAmgen to Present at the Stifel Nicolaus Healthcare Conference Amgen (NASDAQ: AMGN) will present at the Stifel Nicolaus Healthcare Conference on Wednesday, Sept. 7, 2011 at the Four Seasons Hotel, Boston, Mass.,...
THOUSAND OAKS, Calif. , Sept. 2, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Stifel Nicolaus Healthcare Conference on Wednesday, Sept. 7, 2011 at the Four Seasons Hotel, Boston, Mass. , beginning at 8:35 a.m. Eastern Time . Arvind Sood, vice president of Invest
Read more →AMGNAward-Winning Actress Blythe Danner and Amgen Launch Act 2 Reduce Fractures(TM) Educational Campaign Emmy® and Tony® award-winning actress Blythe Danner and Amgen (NASDAQ:AMGN) today launch Act 2 Reduce Fractures™, an educational campaign for women...
THOUSAND OAKS, Calif. , Aug. 25, 2011 /PRNewswire/ -- Emmy® and Tony® award-winning actress Blythe Danner and Amgen (NASDAQ: AMGN ) today launch Act 2 Reduce Fractures™, an educational campaign for women with postmenopausal osteoporosis at increased risk for fractures. Earlier th
Read more →AMGNAmgen Announces PDUFA Date for XGEVA® Supplemental Biologics License Application Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) will target a Prescription Drug User Fee Act (PDUFA) action...
THOUSAND OAKS, Calif. , Aug. 22, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the U.S. Food and Drug Administration (FDA) will target a Prescription Drug User Fee Act (PDUFA) action date of April 26, 2012 for the supplemental Biologics License Application (sBLA
Read more →AMGNAmgen Highlights Data to Be Presented at American Society for Bone and Mineral Research Meeting Amgen (NASDAQ: AMGN) today announced that it will present data from several Prolia® (denosumab) studies, including eight year efficacy and safety...
THOUSAND OAKS, Calif. , Aug. 18, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will present data from several Prolia® (denosumab) studies, including eight year efficacy and safety data from a Phase 2 extension study in women with postmenopausal osteoporosis w
Read more →AMGNAmgen’s Second Quarter 2011 Revenue Increased 4 Percent to $4.0 Billion Amgen (NASDAQ: AMGN) reported total revenue increased 4 percent during the second quarter of 2011 to $3,959 million versus $3,804 million in the...
THOUSAND OAKS, Calif. , July 29, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) reported total revenue increased 4 percent during the second quarter of 2011 to $3,959 million versus $3,804 million in the second quarter of 2010. Total product sales increased 8 percent in the second qu
Read more →AMGNAmgen Announces Webcast of 2011 Second Quarter Financial Results Amgen (NASDAQ: AMGN) today announced that it will report its second quarter financial results on Friday, July 29, 2011 before the opening of the U.S. ...
THOUSAND OAKS, Calif. , July 25, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it will report its second quarter financial results on Friday, July 29, 2011 before the opening of the U.S. financial markets. The announcement will be followed by a conference call w
Read more →AMGNXGEVA® (Denosumab) Granted Marketing Authorization in the European Union Amgen (NASDAQ: AMGN) today announced that the European Commission (EC) has granted marketing authorization for XGEVA® (denosumab) for the prevention...
THOUSAND OAKS, Calif. , July 15, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the European Commission (EC) has granted marketing authorization for XGEVA® (denosumab) for the prevention of skeletal-related events (SREs) (pathological fracture, radiation to bone,
Read more →AMGNAmgen Resolves G-CSF Patent Litigation With Teva Amgen (NASDAQ: AMGN) announced today that the United States (U.S.) District Court in Pennsylvania has entered final judgment and a permanent...
"We are very pleased with this outcome, as it reaffirms the validity of these important patents," said David J. Scott , senior vice president, general counsel and secretary at Amgen. "This closes this matter and allows Amgen to continue to focus on bringing innovative therapies t
Read more →AMGNAmgen and UCB Team Up With NASA on Final Space Shuttle Mission to Conduct Preclinical Test of Sclerostin Antibody on Bone Loss Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) announced today that they are collaborating with the National Aeronautics and Space...
Thousand Oaks, Calif. and BRUSSELS , July 5, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and UCB (Euronext Brussels: UCB) announced today that they are collaborating with the National Aeronautics and Space Administration (NASA) Ames Research Center to conduct a preclinical test of
Read more →AMGNAmgen Submits Application to Expand Indication for XGEVA® (Denosumab) to Prevent or Delay Spread of Prostate Cancer to the Bone Amgen (NASDAQ: AMGN) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration...
THOUSAND OAKS , Calif., June 27, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) to expand the indication for XGEVA® (denosumab) to treat men with castr
Read more →AMGNNotice to Investors Regarding 2011 and 2015 Guidance Today, Amgen (NASDAQ: AMGN) issued the following notice to investors: Amgen reaffirms its guidance for 2011 and 2015. Forward-Looking Statements This ...
THOUSAND OAKS, Calif. , June 24, 2011 /PRNewswire/ -- Today, Amgen (NASDAQ: AMGN ) issued the following notice to investors: Amgen reaffirms its guidance for 2011 and 2015. Forward-Looking Statements This news release contains forward-looking statements that are based on manag
Read more →AMGNAmgen Announces Modifications to U.S. Prescribing Information for Use of Erythropoiesis-Stimulating Agents in Chronic Kidney Disease Amgen (NASDAQ: AMGN) announced today that the U.S. Food and Drug Administration (FDA) has approved modified language in the prescribing information...
THOUSAND OAKS, Calif. , June 24, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) announced today that the U.S. Food and Drug Administration (FDA) has approved modified language in the prescribing information for the use of erythropoiesis-stimulating agents (ESAs), including Aranesp® (
Read more →AMGNAmgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy Amgen (NASDAQ: AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has...
THOUSAND OAKS, Calif. , June 24, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Vectibix® (panitumumab) be approved f
Read more →AMGNTeachers and Schools Across North America Receive $10,000 Amgen Award for Science Teaching Excellence Amgen (NASDAQ: AMGN) today announced the 34 science teachers in the United States, Canada and Puerto Rico who are this year's recipients of the 19th...
THOUSAND OAKS, Calif. , June 21, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced the 34 science teachers in the United States , Canada and Puerto Rico who are this year's recipients of the 19th annual Amgen Award for Science Teaching Excellence. The award recognizes ex
Read more →AMGNData Presented at Two Global Medical Congresses Reinforce Benefit of Enbrel® (etanercept) for Patients with Chronic Inflammatory Conditions Amgen (NASDAQ: AMGN) and Pfizer Inc. (NYSE: PFE) today announced new results from multiple studies of ENBREL, further expanding the body of evidence...
THOUSAND OAKS, Calif. and NEW YORK , May 25, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and Pfizer Inc. (NYSE: PFE ) today announced new results from multiple studies of ENBREL, further expanding the body of evidence supporting the efficacy and safety profile of ENBREL, the most
Read more →AMGNAmgen Receives CHMP Positive Opinion for XGEVA™ (Denosumab) in the European Union Amgen (Nasdaq: AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has...
THOUSAND OAKS, Calif. , May 20, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN ) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended a positive opinion for the marketing authorization of XGEVA™ (denosumab
Read more →AMGNAmgen Announces Voting Results Of Annual Meeting of Stockholders Amgen (NASDAQ: AMGN), today announced results of voting at the Company's Annual Meeting of Stockholders, held at The Fairmont Olympic Hotel in...
SEATTLE , May 20, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN ), today announced results of voting at the Company's Annual Meeting of Stockholders, held at The Fairmont Olympic Hotel in Seattle, Wash. Approximately 86.32 percent of outstanding shares were represented at the meeting.
Read more →AMGNAmgen Oncology Data to be Presented at ASCO Annual Meeting Amgen (NASDAQ: AMGN) today announced that data from studies involving nine Amgen products will be presented at the 2011 American Society of Clinical...
THOUSAND OAKS, Calif. , May 18, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that data from studies involving nine Amgen products will be presented at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting, June 3 - 7, 2011 in Chicago . These studies i
Read more →AMGNPhase 3 Data Demonstrate XGEVA™ (Denosumab) is First Bone Targeted Therapy to Prevent Spread of Cancer to the Bone in Men With Advanced Prostate Cancer Amgen (NASDAQ: AMGN) today announced primary results of a pivotal Phase 3 trial ('147) demonstrating that XGEVA™ (denosumab) significantly increased...
THOUSAND OAKS, Calif. , May 17, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced primary results of a pivotal Phase 3 trial ('147) demonstrating that XGEVA™ (denosumab) significantly increased bone metastasis-free survival for more than four months in men with castrate-
Read more →AMGNAmgen to Webcast Investor Meeting at Upcoming American Urological Association Conference Amgen (NASDAQ: AMGN) will webcast its investor meeting at the upcoming American Urological Association (AUA) Conference on Tuesday, May 17 at 12:00 p....
THOUSAND OAKS, Calif. , May 13, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will webcast its investor meeting at the upcoming American Urological Association (AUA) Conference on Tuesday, May 17 at 12:00 p.m. Eastern Time . Members of Amgen's scientific and management team and a cl
Read more →AMGNPatrick Dempsey Teams up With Breakaway from Cancer® to Help Connect Cancer Patients to Free Resources Patrick Dempsey is speaking out to help connect cancer patients to the free resources available to them via Amgen's Breakaway from Cancer® initiative....
THOUSAND OAKS, Calif. , May 11, 2011 /PRNewswire/ -- Patrick Dempsey is speaking out to help connect cancer patients to the free resources available to them via Amgen's Breakaway from Cancer® initiative. Dempsey first teamed up with Breakaway from Cancer in 2007 to help bring th
Read more →AMGNFive Californians Selected as Breakaway from Cancer® Champions to be Honored During Amgen Tour of California Amgen today announced that five inspirational cancer survivors who have made a difference for others affected by cancer in their communities have...
THOUSAND OAKS, Calif. , May 10, 2011 /PRNewswire/ -- Amgen today announced that five inspirational cancer survivors who have made a difference for others affected by cancer in their communities have been selected as Breakaway from Cancer Champions as part of Amgen's Breakaway fro
Read more →AMGNAmgen to Present at the Deutsche Bank 36th Annual Healthcare Conference Amgen (Nasdaq: AMGN) will present at the Deutsche Bank 36th Annual Healthcare Conference on Tuesday, May 3, 2011 at the InterContinental, Boston,...
THOUSAND OAKS, Calif. , April 28, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN ) will present at the Deutsche Bank 36th Annual Healthcare Conference on Tuesday, May 3, 2011 at the InterContinental, Boston, Mass. , beginning at 9:20 a.m. Eastern Time . Senior Vice President of North A
Read more →AMGNAmgen Outlines Strategy, Growth Objectives and Capital Allocation Plans Amgen (NASDAQ: AMGN) today outlined the Company's strategy, capital allocation plans and provided financial guidance for 2015 during a meeting with...
NEW YORK , April 21, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today outlined the Company's strategy, capital allocation plans and provided financial guidance for 2015 during a meeting with investors in New York . Kevin Sharer , chairman & CEO opened the meeting by outlining ke
Read more →AMGNAmgen and UCB Announce Positive Phase 2 Results of AMG 785/CDP7851 in Patients With Postmenopausal Osteoporosis (PMO) Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) announced today positive top-line results from their Phase 2 clinical study comparing...
THOUSAND OAKS, Calif. and BRUSSELS , April 21, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) and UCB (Euronext Brussels: UCB) announced today positive top-line results from their Phase 2 clinical study comparing sclerostin-antibody AMG 785/CDP7851 to placebo in postmenopausal women
Read more →AMGNAmgen’s First Quarter 2011 Revenue Increased 3 Percent to $3.7 Billion Amgen (NASDAQ: AMGN) reported adjusted earnings per share (EPS) of $1.34 for the first quarter of 2011, an increase of 3 percent compared to $1.30...
THOUSAND OAKS, Calif. , April 20, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) reported adjusted earnings per share (EPS) of $1.34 for the first quarter of 2011, an increase of 3 percent compared to $1.30 for the first quarter of 2010. Adjusted net income decreased 2 percent to $1,
Read more →AMGNAmgen to Webcast 2011 Business Review Meeting on April 21 Amgen (Nasdaq: AMGN) today announced that it will hold its Business Review Meeting on Thursday, April 21, 2011 at the Mandarin Oriental Hotel, 80...
THOUSAND OAKS, Calif. , April 14, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN ) today announced that it will hold its Business Review Meeting on Thursday, April 21, 2011 at the Mandarin Oriental Hotel, 80 Columbus Circle, New York City , beginning at 8 a.m. Eastern Time . In the mee
Read more →AMGNAmgen Announces Webcast of 2011 First Quarter Financial Results Amgen (NASDAQ: AMGN) today announced that it plans to report its first quarter financial results on Wednesday, April 20, 2011 after the close of the...
THOUSAND OAKS, Calif. , April 13, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that it plans to report its first quarter financial results on Wednesday, April 20, 2011 after the close of the U.S. financial markets. The announcement will be followed by a conference c
Read more →AMGNAmgen Establishes Commercial Operations in Brazil Amgen (NASDAQ: AMGN), the world's largest biotechnology company, announced today the expansion of its operations in Brazil, including the acquisition ...
THOUSAND OAKS, Calif. , April 8, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN ), the world's largest biotechnology company, announced today the expansion of its operations in Brazil , including the acquisition of Bergamo, a privately-held Brazilian pharmaceutical company. Amgen has a
Read more →AMGNTop-Line Results Announced of Pivotal Phase 3 Motesanib Trial in Advanced Non-Squamous Non-Small Cell Lung Cancer Patients Amgen (Nasdaq: AMGN), Millennium: The Takeda Oncology Company, and Takeda Pharmaceutical Company Limited (TSE: 4502) today announced top-line results ...
THOUSAND OAKS, Calif. , CAMBRIDGE, Mass. and OSAKA, Japan , March 30, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN ), Millennium: The Takeda Oncology Company, and Takeda Pharmaceutical Company Limited (TSE: 4502) today announced top-line results from the MONET1 pivotal Phase 3 trial
Read more →AMGNAmgen to Appeal CHMP Opinion on Vectibix® (Panitumumab) Use With Chemotherapy in Metastatic Colorectal Cancer in Europe Amgen (Nasdaq: AMGN) announced today that it has submitted a request to the European Medicines Agency (EMA) for a re-examination of the negative...
THOUSAND OAKS, Calif. , March 30, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN ) announced today that it has submitted a request to the European Medicines Agency (EMA) for a re-examination of the negative opinion issued in March by the Committee For Medicinal Products for Human Use (
Read more →AMGNProlia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Five Years of Treatment With Similar Safety Profile Observed in Pivotal Trial Amgen (Nasdaq: AMGN) today announced new long-term data showing that during the fourth and fifth years of Prolia® (denosumab) treatment,...
THOUSAND OAKS, Calif. , March 23, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN ) today announced new long-term data showing that during the fourth and fifth years of Prolia® (denosumab) treatment, postmenopausal women with osteoporosis receiving Prolia continued with further, statist
Read more →AMGNTreatment With Prolia® (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to Alendronate Amgen (Nasdaq: AMGN) today announced new data that showed postmenopausal women with osteoporosis had significantly greater adherence, compliance, and ...
THOUSAND OAKS, Calif. , March 23, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN ) today announced new data that showed postmenopausal women with osteoporosis had significantly greater adherence, compliance, and persistence during Prolia® (denosumab) treatment than during alendronate t
Read more →AMGNAmgen Statement on CHMP Opinion on Vectibix® (Panitumumab) Use With Chemotherapy in Metastatic Colorectal Cancer Amgen (Nasdaq: AMGN) today issued the following statement: Amgen has received notice that the Committee for Medicinal Products for Human Use (CHMP)...
THOUSAND OAKS, Calif. , March 18, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN ) today issued the following statement: Amgen has received notice that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion for A
Read more →AMGNAmgen Donates $1 Million to Help Japanese Disaster Victims Amgen (Nasdaq: AMGN) today announced that the company will donate $1 million to Japanese disaster relief efforts. Amgen and the Amgen Foundation will ...
THOUSAND OAKS, Calif. , March 14, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN ) today announced that the company will donate $1 million to Japanese disaster relief efforts. Amgen and the Amgen Foundation will distribute the funds to both Direct Relief International and International
Read more →AMGNAmgen Completes Acquisition of BioVex Amgen (Nasdaq: AMGN), today announced the completion of the acquisition of BioVex Group, Inc., a privately held biotechnology company based in...
THOUSAND OAKS, Calif. , March 4, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN ), today announced the completion of the acquisition of BioVex Group, Inc., a privately held biotechnology company based in Woburn, Mass. , with additional operations in Abingdon, UK. The acquisition includ
Read more →AMGNBreakaway From Cancer® Launches Newly-Enhanced Website Offering Comprehensive, Tailored Support for Cancer Patients As part of its ongoing mission to serve cancer patients, Amgen's Breakaway from Cancer® initiative announced the launch of its enhanced website that...
THOUSAND OAKS, Calif. , March 3, 2011 /PRNewswire/ -- As part of its ongoing mission to serve cancer patients, Amgen's Breakaway from Cancer ® initiative announced the launch of its enhanced website that provides cancer patients, survivors, and caregivers a 'one-stop shop' of ess
Read more →AMGNAmgen to Present at the Cowen and Company 31st Annual Healthcare Conference Amgen (Nasdaq: AMGN) will present at the Cowen and Company 31st Annual Healthcare Conference on Tuesday, March 8, 2011 at the Boston Marriott Copley...
THOUSAND OAKS, Calif. , March 3, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN ) will present at the Cowen and Company 31st Annual Healthcare Conference on Tuesday, March 8, 2011 at the Boston Marriott Copley Place, Boston, Mass. , beginning at 8:45 a.m. Eastern Time . James Daly, Amg
Read more →AMGNWorld-Class Professional Golfer Phil Mickelson Launches 'On Course with Phil' for People with Certain Inflammatory Joint and Skin Conditions World-class professional golfer and psoriatic arthritis patient Phil Mickelson today launches On Course with Phil, a disease education program for...
THOUSAND OAKS, Calif. and COLLEGEVILLE, Pa. , March 2, 2011 /PRNewswire/ -- World-class professional golfer and psoriatic arthritis patient Phil Mickelson today launches "On Course with Phil," a disease education program for people with certain chronic inflammatory joint and skin
Read more →AMGNNBPTS and Amgen Foundation Join to Bolster Science Education The National Board for Professional Teaching Standards (NBPTS) and the Amgen Foundation today announced a grant to improve highly-effective science...
THOUSAND OAKS, Calif. and ARLINGTON, Va. , March 1, 2011 /PRNewswire/ -- The National Board for Professional Teaching Standards (NBPTS) and the Amgen Foundation today announced a grant to improve highly-effective science teaching and learning in schools across the country. The Am
Read more →AMGNResults Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer Amgen (Nasdaq: AMGN) today announced the publication of results from a Phase 3 head-to-head trial that compared XGEVA™ (denosumab) to Zometa®...
THOUSAND OAKS, Calif. , Feb. 24, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN ) today announced the publication of results from a Phase 3 head-to-head trial that compared XGEVA ™ (denosumab) to Zometa ® (zoledronic acid) in preventing bone complications called skeletal-related events
Read more →AMGNAmgen to Present at the Citi 2011 Global Healthcare Conference Amgen (Nasdaq: AMGN) will participate in the Citi 2011 Global Healthcare Conference on Tuesday, March 1, 2011, at the Hilton Club New York in New...
THOUSAND OAKS, Calif. , Feb. 24, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN ) will participate in the Citi 2011 Global Healthcare Conference on Tuesday, March 1, 2011 , at the Hilton Club New York in New York City , beginning at 11:30 a.m. Eastern Time . Rolf Hoffmann , senior vice
Read more →AMGNThe Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma Amgen (Nasdaq: AMGN) today announced the publication of results from a pivotal Phase 3 study of 1,776 advanced cancer patients with different types...
THOUSAND OAKS, Calif. , Feb. 22, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN ) today announced the publication of results from a pivotal Phase 3 study of 1,776 advanced cancer patients with different types of solid tumors (not including breast and prostate cancer) or multiple myelom
Read more →AMGNEnbrel® (etanercept) Significantly Improved Scalp Involvement in Patients with Moderate to Severe Plaque Psoriasis Amgen (Nasdaq: AMGN) and Pfizer Inc. (NYSE: PFE) today announced results from a new trial that demonstrated Enbrel® (etanercept) significantly...
THOUSAND OAKS, Calif. and COLLEGEVILLE, Pa. , Feb. 4, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN ) and Pfizer Inc. (NYSE: PFE ) today announced results from a new trial that demonstrated Enbrel® (etanercept) significantly improved scalp involvement in adult patients with moderate t
Read more →AMGNAmgen to Acquire BioVex, a Privately Held Biotechnology Company Headquartered in Woburn, Mass Amgen (Nasdaq: AMGN) and BioVex Group, Inc. today announced that the companies have entered into a definitive acquisition agreement under which Amgen ...
THOUSAND OAKS, Calif. and WOBURN, Mass. , Jan. 24, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN ) and BioVex Group, Inc. today announced that the companies have entered into a definitive acquisition agreement under which Amgen has agreed to acquire BioVex Group, Inc., a privately hel
Read more →AMGNAmgen’s Fourth Quarter 2010 Adjusted Earnings Per Share Increased 11 Percent to $1.17; Full Year 2010 Adjusted Earnings Per Share Increased 6 Percent to $5.21 Amgen (Nasdaq: AMGN) reported adjusted earnings per share (EPS) of $1.17 for the fourth quarter of 2010, an increase of 11 percent compared to $1.05...
THOUSAND OAKS, Calif. , Jan. 24, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN ) reported adjusted earnings per share (EPS) of $1.17 for the fourth quarter of 2010, an increase of 11 percent compared to $1.05 for the fourth quarter of 2009. Adjusted net income increased 4 percent to $
Read more →AMGNAmgen Announces Webcast of 2010 Fourth Quarter and Full Year Financial Results Amgen (Nasdaq: AMGN) today announced that it plans to report its fourth quarter and full year financial results on Monday, Jan. 24, 2011 after the...
THOUSAND OAKS, Calif. , Jan. 24, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN ) today announced that it plans to report its fourth quarter and full year financial results on Monday, Jan. 24, 2011 after the close of the financial markets. The announcement will be followed by a confere
Read more →AMGNBoehringer Ingelheim to Purchase Amgen's Fremont (California) Facility Amgen Inc. (Nasdaq: AMGN) and Boehringer Ingelheim today announced they have signed an agreement under which Boehringer Ingelheim will acquire...
THOUSAND OAKS, Calif. and INGELHEIM, Germany , Jan. 18, 2011 /PRNewswire/ -- Amgen Inc. (Nasdaq: AMGN ) and Boehringer Ingelheim today announced they have signed an agreement under which Boehringer Ingelheim will acquire Amgen's rights in and substantially all assets at Amgen's F
Read more →AMGNSensipar® Patents Upheld By District Court A U.S. District Court in Delaware today granted an injunction preventing Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals Industries Ltd., and...
THOUSAND OAKS, Calif. , Jan. 7, 2011 /PRNewswire/ -- A U.S. District Court in Delaware today granted an injunction preventing Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals Industries Ltd., and Barr Laboratories, Inc. from commercializing generic versions of Amgen's (Nasdaq
Read more →AMGNAmgen to Present at the 29th Annual JP Morgan Healthcare Conference Amgen (Nasdaq: AMGN) will present at the 29th Annual JP Morgan Global Healthcare Conference at 8:00 a.m. Pacific Time on Tuesday, Jan. 11, 2011, at...
THOUSAND OAKS, Calif. , Jan. 6, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN ) will present at the 29th Annual JP Morgan Global Healthcare Conference at 8:00 a.m. Pacific Time on Tuesday, Jan. 11, 2011 , at the Westin St. Francis in San Francisco, Calif. Amgen Chairman and CEO Kevin
Read more →AMGNAmgen and Xencor Enter Option Deal to Co-Develop Xencor's Novel Antibody for Autoimmune Diseases Amgen (Nasdaq: AMGN) and Xencor, Inc. announced today that they will collaborate to develop XmAb®5871, an Fc- engineered monoclonal antibody dually...
THOUSAND OAKS, Calif. and MONROVIA, Calif. , Jan. 6, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN ) and Xencor, Inc. announced today that they will collaborate to develop XmAb ® 5871, an Fc- engineered monoclonal antibody dually targeting CD19 and CD32b. XmAb5871 is currently in late
Read more →AMGNTeach For America and the Amgen Foundation Renew Partnership to Improve Math and Science Education in Urban and Rural Schools Teach For America and the Amgen Foundation today announced the renewal of their partnership to advance math and science education in America's...
THOUSAND OAKS, Calif. and NEW YORK , Dec. 16, 2010 /PRNewswire/ -- Teach For America and the Amgen Foundation today announced the renewal of their partnership to advance math and science education in America's underserved public schools. Under this partnership, the Amgen Foundati
Read more →AMGNXGEVA™ (Denosumab) Significantly Improved Bone Metastasis-Free Survival in Men With Prostate Cancer Amgen (Nasdaq: AMGN) today announced top-line results from a Phase 3 trial evaluating XGEVA™ (denosumab) versus placebo in 1,432 men with...
THOUSAND OAKS, Calif. , Dec. 13, 3010 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN ) today announced top-line results from a Phase 3 trial evaluating XGEVA™ (denosumab) versus placebo in 1,432 men with castrate-resistant prostate cancer. The trial, known as the '147 study, demon
Read more →AMGNAmgen Presents New XGEVA™ (Denosumab) Breast Cancer Skeletal-Related Event Prevention Data at SABCS Amgen (Nasdaq: AMGN) today announced results from new analyses comparing XGEVA™ (denosumab), the first new treatment for advanced cancer patients...
THOUSAND OAKS, Calif. , Dec. 10, 2010 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN ) today announced results from new analyses comparing XGEVA™ (denosumab), the first new treatment for advanced cancer patients with bone metastases in nearly a decade to prevent skeletal-related e
Read more →AMGNThree Innovative Ideas Receive $10,000 Prizes in Patients | Choices | Empowerment Competition The Amgen Foundation and Ashoka's Changemakers today announced three winners for the Patients | Choices | Empowerment competition. Each winner will...
THOUSAND OAKS, Calif. and WASHINGTON , Dec. 8, 2010 /PRNewswire/ -- The Amgen Foundation and Ashoka's Changemakers today announced three winners for the Patients | Choices | Empowerment competition. Each winner will receive a $10,000 cash prize and was selected by the public for
Read more →AMGNAmgen to Present at Deutsche Bank's 2010 BioFEST Amgen (Nasdaq: AMGN) will participate in Deutsche Bank's 2010 BioFEST on Wednesday, Dec. 15, 2010, at the Four Seasons in Boston, beginning at 10:00...
THOUSAND OAKS, Calif. , Dec. 8, 2010 /PRNewswire/ -- Amgen (Nasdaq: AMGN ) will participate in Deutsche Bank's 2010 BioFEST on Wednesday, Dec. 15, 2010 , at the Four Seasons in Boston , beginning at 10:00 a.m. Eastern Time . Roy Baynes , M.D., Ph.D., vice president of Global Deve
Read more →AMGNAmgen's Nplate® Maintains Platelet Counts for More Than Five Years in Adults With Chronic ITP Amgen Inc. (Nasdaq: AMGN) today announced the final results from a 5-year open-label extension study investigating the long-term efficacy and safety...
ORLANDO, Fla. , Dec. 5, 2010 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN ) today announced the final results from a 5-year open-label extension study investigating the long-term efficacy and safety of Nplate® (romiplostim) in adult chronic immune (idiopathic) thrombocytope
Read more →AMGNAmgen Highlights Data to Be Presented at American Society of Hematology Annual Meeting Amgen (Nasdaq: AMGN) today announced that it will present data from several key Nplate® (romiplostim) studies at the 52nd Annual Meeting and...
THOUSAND OAKS, Calif. , Dec. 2, 2010 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN ) today announced that it will present data from several key Nplate® (romiplostim) studies at the 52nd Annual Meeting and Exposition of the American Society of Hematology (ASH), Dec. 4-7, 2010 , in
Read more →AMGNFDA Approves Amgen's XGEVA™ (Denosumab) for the Prevention of Skeletal-Related Events in Patients with Bone Metastases from Solid Tumors Amgen Inc. (Nasdaq: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved XGEVA™ (denosumab), the first and only RANK...
THOUSAND OAKS, Calif. , Nov. 18, 2010 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN ) today announced that the U.S. Food and Drug Administration (FDA) has approved XGEVA™ (denosumab), the first and only RANK Ligand inhibitor for the prevention of skeletal-related events (SRE
Read more →AMGNAmgen Foundation and Ashoka's Changemakers Announce Finalists in Patients | Choices | Empowerment Competition The Amgen Foundation and Ashoka's Changemakers today announced ten finalists in the Patients | Choices | Empowerment competition and launched public...
THOUSAND OAKS, Calif. and WASHINGTON , Nov. 17, 2010 /PRNewswire/ -- The Amgen Foundation and Ashoka's Changemakers today announced ten finalists in the Patients | Choices | Empowerment competition and launched public online voting in search of the best innovative solutions that
Read more →AMGNCall for Applications: The Amgen Award for Science Teaching Excellence Amgen (Nasdaq: AMGN) today announced that it now invites applications for its 19th annual Amgen Award for Science Teaching Excellence (AASTE). This...
THOUSAND OAKS, Calif. , Nov. 16, 2010 /PRNewswire/ -- Amgen (Nasdaq: AMGN ) today announced that it now invites applications for its 19th annual Amgen Award for Science Teaching Excellence (AASTE). This award is designed to recognize and honor extraordinary science teachers at th
Read more →AMGNAmgen Scholars Undergraduate Summer Research Program Begins Phase 2 Today, Amgen Scholars, the signature initiative of the Amgen Foundation, moves into its second phase of what has become a $34 million program to...
THOUSAND OAKS, Calif. , Nov. 10, 2010 /PRNewswire/ -- Today, Amgen Scholars , the signature initiative of the Amgen Foundation , moves into its second phase of what has become a $34 million program to advance science learning and inspire the next generation of scientists. To vie
Read more →AMGNAmgen Foundation Recognizes Outstanding Staff Volunteers and Contributes $55,000 to Their Favorite Local Nonprofits Amgen today announced the 11 recipients of the Amgen Excellence in Volunteering Awards. Launched this year by the Amgen Foundation, the Awards...
THOUSAND OAKS, Calif. , Nov. 11, 2010 /PRNewswire/ -- Amgen today announced the 11 recipients of the Amgen Excellence in Volunteering Awards. Launched this year by the Amgen Foundation, the Awards recognize staff in the United States (U.S.) and Puerto Rico who are making a differ
Read more →AMGNStudy Published in New England Journal of Medicine Shows Nplate® Significantly Reduces Treatment Failure and Splenectomy Rate in Patients With Chronic ITP Amgen Inc. (Nasdaq: AMGN) today announced the publication of results from the first open-label study to compare Nplate® (romiplostim) treatment to...
THOUSAND OAKS, Calif. , Nov. 10, 2010 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN ) today announced the publication of results from the first open-label study to compare Nplate ® (romiplostim) treatment to standard of care therapies (SOC) in non-splenectomized adult patien
Read more →AMGNAmgen to Present at 19th Annual Credit Suisse Healthcare Conference Amgen (Nasdaq: AMGN) will participate in the 19th Annual Credit Suisse Healthcare Conference on Friday, Nov. 12, 2010, at the Biltmore Hotel in...
THOUSAND OAKS, Calif. , Nov. 9, 2010 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN ) will participate in the 19th Annual Credit Suisse Healthcare Conference on Friday, Nov. 12, 2010 , at the Biltmore Hotel in Phoenix, Ariz. , beginning at 8:30 a.m. Mountain Time . Jonathan M. Pea
Read more →AMGNPublished Results Show Denosumab Superior to Zometa® in Delaying or Preventing Bone Complications in Patients With Bone Metastases From Advanced Breast Cancer Amgen (Nasdaq: AMGN) today announced the publication of results from a pivotal Phase 3 study of 2,046 patients which compared denosumab with Zometa®...
THOUSAND OAKS, Calif. , Nov. 8, 2010 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN ) today announced the publication of results from a pivotal Phase 3 study of 2,046 patients which compared denosumab with Zometa® (zoledronic acid) in delaying or preventing skeletal-related events
Read more →AMGNAmgen, Pfizer, and World-Class Professional Golfer Phil Mickelson Announce Partnership Amgen Inc. (Nasdaq: AMGN), Pfizer Inc. (NYSE: PFE) and world-class professional golfer Phil Mickelson, have entered into a partnership to share...
THOUSAND OAKS, Calif. , and COLLEGEVILLE, Pa. , Nov. 6, 2010 /PRNewswire/ -- Amgen Inc. (Nasdaq: AMGN ), Pfizer Inc. (NYSE: PFE ) and world-class professional golfer Phil Mickelson , have entered into a partnership to share Phil's experience with his diagnosis of psoriatic arthri
Read more →AMGNProlia™ (denosumab) Receives Best New Drug Honor at Scrip Awards Amgen (Nasdaq: AMGN) is pleased to announce that it has won the Best New Drug award for Prolia™ (denosumab), a novel treatment approved in the United ...
THOUSAND OAKS, Calif. , Nov. 5, 2010 /PRNewswire/ -- Amgen (Nasdaq: AMGN ) is pleased to announce that it has won the Best New Drug award for Prolia™ (denosumab), a novel treatment approved in the United States (U.S.) for women with postmenopausal osteoporosis at high risk for fr
Read more →AMGNAmgen Foundation Awards $4.5 Million Grant to MLA Partner Schools to Invest in LA's Promise The Amgen Foundation will grant $4.5 million over the next three years to MLA Partner Schools (MLA) to invest in LA's Promise – an endeavor to...
LOS ANGELES and THOUSAND OAKS, Calif. , Nov. 3, 2010 /PRNewswire/ -- The Amgen Foundation will grant $4.5 million over the next three years to MLA Partner Schools (MLA) to invest in "LA's Promise" – an endeavor to prepare thousands of children from one South Los Angeles community
Read more →AMGNAmgen to Provide Testimony at FDA Hearing on Biosimilars Amgen (Nasdaq: AMGN) Senior Vice President of Research and Development Joe Miletich, M.D., Ph.D., will urge members of a U.S. Food and Drug...
THOUSAND OAKS, Calif. , Nov. 1, 2010 /PRNewswire/ -- Amgen (Nasdaq: AMGN ) Senior Vice President of Research and Development Joe Miletich , M.D., Ph.D., will urge members of a U.S. Food and Drug Administration (FDA) panel charged with implementing a pathway for biosimilars to est
Read more →AMGNAmgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year Amgen (Nasdaq: AMGN) reported revenue unchanged for the third quarter of 2010 at $3,816 million versus $3,812 million for the third quarter of 2009....
THOUSAND OAKS, Calif. , Oct. 25 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN ) reported revenue unchanged for the third quarter of 2010 at $3,816 million versus $3,812 million for the third quarter of 2009. Adjusted net income decreased 14 percent to $1,313 million for the thir
Read more →AMGNBreakaway From Cancer® Launches 'Striking the Balance' Podcast Series to Inspire Action and Change Across the Cancer Continuum Amgen announced today the launch of the Breakaway from Cancer® initiative's Striking the Balance podcast series. The series presents the best...
THOUSAND OAKS, Calif. , Oct. 20 /PRNewswire/ -- Amgen announced today the launch of the Breakaway from Cancer ® initiative's "Striking the Balance" podcast series. The series presents the best moments from a dynamic, first-of-its-kind roundtable event held with Amgen's four nonpr
Read more →AMGNAmgen Announces Webcast of 2010 Third Quarter Financial Results Amgen (Nasdaq: AMGN) today announced that it plans to report its third quarter financial results on Monday, Oct. 25, 2010 after the close of the...
THOUSAND OAKS, Calif. , Oct. 20 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN ) today announced that it plans to report its third quarter financial results on Monday, Oct. 25, 2010 after the close of the financial markets. The announcement will be followed by a conference call wi
Read more →AMGNAmgen to Review Results From TREAT and Propose Updates to ESA Labeling for Chronic Renal Failure Patients at an FDA Advisory Committee Meeting Today Amgen (Nasdaq: AMGN) will review the results from TREAT (the Trial to Reduce Cardiovascular Events with Aranesp® Therapy) and will discuss how these...
THOUSAND OAKS, Calif. , Oct. 18 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN ) will review the results from TREAT (the Trial to Reduce Cardiovascular Events with Aranesp® Therapy) and will discuss how these results inform the appropriate use of erythropoiesis-stimulating agents
Read more →AMGNAmgen Highlights Data to Be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting Amgen (Nasdaq: AMGN) today announced that results from several Prolia™ (denosumab) studies, as well as analyses of the growing global burden of...
THOUSAND OAKS, Calif. , Oct. 14 /PRNewswire/ -- Amgen (Nasdaq: AMGN ) today announced that results from several Prolia™ (denosumab) studies, as well as analyses of the growing global burden of osteoporosis, will be presented at the 2010 American Society for Bone and Mineral Resea
Read more →AMGNIntegrated Analysis Demonstrates That Denosumab Delays the Onset of Bone Complications Compared to Zometa® Amgen (Nasdaq: AMGN) today announced results from two integrated analyses of head-to-head pivotal Phase 3 trials comparing denosumab to Zometa®...
THOUSAND OAKS, Calif. , Oct. 10 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN ) today announced results from two integrated analyses of head-to-head pivotal Phase 3 trials comparing denosumab to Zometa® (zoledronic acid), the current standard of care in the prevention of skeletal
Read more →AMGNUpdated AMG 386 Data Demonstrate Promising Antitumor Activity in Patients With Recurrent Ovarian Cancer Amgen (Nasdaq: AMGN) today announced AMG 386, combined with paclitaxel, demonstrated antitumor activity in a randomized Phase 2 trial involving 161...
THOUSAND OAKS, Calif. , Oct. 9 /PRNewswire/ -- Amgen (Nasdaq: AMGN ) today announced AMG 386, combined with paclitaxel, demonstrated antitumor activity in a randomized Phase 2 trial involving 161 patients with recurrent ovarian cancer. The updated results, now including data on o
Read more →AMGNAmgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress Amgen (Nasdaq: AMGN) today announced that results from several important studies from the Company's oncology portfolio will be presented at the 35th...
THOUSAND OAKS, Calif. , Oct. 5 /PRNewswire/ -- Amgen (Nasdaq: AMGN ) today announced that results from several important studies from the Company's oncology portfolio will be presented at the 35th European Society for Medical Oncology (ESMO) Congress, Oct. 8-12, 2010 , in Milan,
Read more →AMGNTwo Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology Amgen (Nasdaq: AMGN) today announced that results from the PRIME '203' and '181' pivotal Phase 3 trials evaluating Vectibix® (panitumumab) in...
THOUSAND OAKS, Calif. , Oct. 4 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN ) today announced that results from the PRIME '203' and '181' pivotal Phase 3 trials evaluating Vectibix® (panitumumab) in combination with chemotherapy (FOLFOX or FOLFIRI) as a first and second-line tre
Read more →AMGNAmgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) Amgen (Nasdaq: AMGN) announced today that certain lots of EPOGEN® and PROCRIT® (Epoetin alfa) vials are being voluntarily recalled from specialty...
THOUSAND OAKS, Calif. , Sept. 24 /PRNewswire/ -- Amgen (Nasdaq: AMGN ) announced today that certain lots of EPOGEN® and PROCRIT® (Epoetin alfa) vials are being voluntarily recalled from specialty distributors, wholesalers, pharmacies and healthcare providers as a precaution. The
Read more →AMGNAmgen and Pfizer Introduce 'Psophisticated Style: A Guide to Everyday Style and Psoriasis™' Hosted by Tim Gunn Amgen and Pfizer today announced the launch of Psophisticated Style: A Guide to Everyday Style and Psoriasis™, an online resource, providing a...
NEW YORK , Sept. 22 /PRNewswire/ -- Amgen and Pfizer today announced the launch of "Psophisticated Style: A Guide to Everyday Style and Psoriasis™," an online resource, providing a wealth of style advice specifically for people with psoriasis. Hosted by Tim Gunn , mentor to the d
Read more →AMGNAmgen to Present at the UBS Global Life Sciences Conference Amgen (Nasdaq: AMGN) will participate in the UBS Global Life Sciences Conference on Wednesday, Sept. 22, 2010, at the Grand Hyatt in New York City,...
THOUSAND OAKS, Calif. , Sept. 20 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN ) will participate in the UBS Global Life Sciences Conference on Wednesday, Sept. 22, 2010 , at the Grand Hyatt in New York City , beginning at 9:00 a.m. Eastern Time . Roger M. Perlmutter, M.D., Ph.D.
Read more →AMGNAmgen to Present at the Bank of America Merrill Lynch Global Healthcare Conference Amgen (Nasdaq: AMGN) will participate in the Bank of America Merrill Lynch Global Healthcare Conference on Thursday, Sept. 16, 2010, in London,...
THOUSAND OAKS, Calif. , Sept. 14 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN ) will participate in the Bank of America Merrill Lynch Global Healthcare Conference on Thursday, Sept. 16, 2010 , in London , beginning at 9:50 a.m. Greenwich Mean Time. Amgen executives Rolf Hoffmann
Read more →AMGNAmgen to Present at the Baird Healthcare Conference Amgen (Nasdaq: AMGN) will participate in the Baird Healthcare Conference on Wednesday, Sept. 15, 2010, at the St. Regis New York in New York City,...
THOUSAND OAKS, Calif. , Sept. 13 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN ) will participate in the Baird Healthcare Conference on Wednesday, Sept. 15, 2010 , at the St. Regis New York in New York City , beginning at 12:15 p.m. Eastern Time . Roy Baynes , M.D., Ph.D., vice p
Read more →AMGNAmgen Announces Top-Line Results of Phase 3 Head and Neck Cancer Trial Amgen (Nasdaq: AMGN) today announced top-line results from a randomized Phase 3 trial evaluating Vectibix® (panitumumab) as a first-line treatment in ...
THOUSAND OAKS, Calif. , Aug. 11 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN ) today announced top-line results from a randomized Phase 3 trial evaluating Vectibix® (panitumumab) as a first-line treatment in patients with recurrent and/or metastatic squamous cell head and neck c
Read more →Competitive Position
How AMGN ranks across every disease it competes inCompetitive Position is a premium feature
See how AMGN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial